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ABSTRACT
 
Excessive neutrophilic inflammation of the airways in response to infection is characteristic 
for patients with CF. There is also an important but not fully understood role for platelets. 
Previous studies established increased copper levels in the circulation and in the sputum in 
CF. Inhaled tobramycin was suggested to have an anti-inflammatory effect beyond 
eradicating Pseudomonas aeruginosa. This study tested the hypothesis that tobramycin 
has anti-inflammatory and anti-oxidant efficacy due to its ability to bind copper into a 
copper-tobramycin complex. 
A copper-tobramycin complex was synthesised and the UV-VIS spectrum analysed. 
Neutrophil migration through a TNF-α-stimulated human lung microvascular endothelial 
cell layer towards thrombin-activated platelets was measured. The role of CFTRinh-172 on 
neutrophil transendothelial migration was assessed. Endothelial tobramycin uptake and 
CFTR expression were assessed using immunocytochemistry. Endothelial oxidative stress 
was measured using a fluorescent indicator. Neutrophils were stimulated to measure 
reactive oxygen species (ROS) production and neutrophil elastase (NE) activity, 
spectrophotometrically. 
Platelet and endothelium-derived NAP-2 and IL-8, respectively, contributed to neutrophil 
transendothelial migration. Copper-tobramycin was shown to be more effective than 
tobramycin in limiting migration of neutrophils. Both, tobramycin and copper-tobramycin 
accumulated in endothelial cells via a heparan sulphate-dependent mechanism, decreased 
intracellular ROS and increased endothelial surface CFTR expression. CFTRinh-172 failed to 
create an inflammatory profile in endothelium. Copper-tobramycin decreased extracellular 
superoxide released by activated neutrophils, and displaced NE from sites of encryption, 
making it more susceptible to inhibition by α1-antitrypsin.  
The antibiotic tobramycin was demonstrated to be a multi-potent drug with additional 
anti-inflammatory and anti-oxidant properties. These effects, desirable in CF treatment, 
are due to copper binding. 
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CHAPTER 1 
GENERAL INTRODUCTION 
 
1.1. PATHOGENIC MECHANISMS OF CYSTIC FIBROSIS 
1.1.1. EPIDEMIOLOGY OF CYSTIC FIBROSIS 
Cystic fibrosis (CF) is the most common life-shortening autosomal recessive disorder in 
the white population, affecting approximately 1 in 2,500 live births. It is also reported 
in other racial groups, but less frequently. There are over 9,000 people with cystic 
fibrosis in the United Kingdom (UK CF Registry, 2011; Hamosh et al, 1998). The 
progress during the past two decades in the diagnosis and treatment of affected 
individuals has resulted in improved survival (FitzSimmons, 1993). The predicted mean 
survival for babies born in the 21st century is now over 50 years (Dodge et al, 2007).  
1.1.2. THE GENETIC DEFECT 
CF is caused by mutations in a single gene, located on the long arm of chromosome 7. 
In 1989, Kerem et al, Riordan et al and Rommens et al identified this mutation and its 
protein product called the cystic fibrosis transmembrane conductance regulator 
(CFTR). CFTR is a member of a family of adenosine triphosphate (ATP)-binding cassette 
transport proteins (Hyde, 1990). It contains two nucleotide-binding domains that bind 
and hydrolyze ATP, two dual sets of membrane-spanning domains that form the 
channel, and a central regulatory (R) domain. The R domain, unique to CFTR, is highly 
charged with numerous phosphorylation sites for protein kinases A or C (Figure 1.1, 
over) (Chang et al, 1994). Studies have established that the CFTR functions not only as 
a chloride ion channel but is also a regulator of outwardly rectifying chloride channels 
(ORCC) (Schwiebert et al, 1995), sodium channels (Stutts et al, 1995), and renal outer 
medullary K+ channel (ROMK) or other inwardly rectifying K+ channels (McNicholas et 
al, 1997). Moreover, it transports ATP (Schwiebert et al, 1995), bicarbonate (Tang et al, 
2009) and GSH (Linsdell & Hanrahan, 1998). 
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Figure 1.1. The structure of CFTR. CFTR protein forms chloride-permeable channel in the apical 
membrane of many cell types. Chloride passage is regulated by two membrane-spanning domains, two 
nucleotide-binding domains and the regulatory domain due to ATP binding and hydrolysis (Welsh & 
Smith, 1995). 
CFTR-mediated Cl- secretion and epithelial sodium channel (ENaC)-mediated Na+ 
absorption are coordinated to maintain airway surface liquid (ASL) at a depth allowing 
cilia to beat effectively and move the mucus across the epithelial cell surface. Two 
defects in this process arise from the absence of CFTR protein and/or its function in CF 
airway epithelium. Firstly, the decreased permeability of CF epithelia results in reduced 
Cl- secretion and therefore less salt on the apical surface. Consequently, a reduced 
level of water enters the lumen. Secondly, in the absence of CFTR negative regulation, 
ENaC activity is removed, which results in an unregulated and inappropriate 
absorption of salt, and therefore water from ASL. The overlying mucus consequently 
becomes dehydrated and it is followed by the arrest of mucociliary clearance (Figure 
1.2, over) (Clunes & Boucher, 2007). 
Over 1800 different mutations of the CFTR gene have been reported to the CF Genetic 
Analysis Consortium database (www.genet.sickkids.on.ca/cftr/). 
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Figure 1.2. Normal and CF airway, respectively. Defects in CFTR cause reduced chloride secretion into 
airways and enhanced sodium reabsorption, resulting in dehydrated airway secretions and mucostasis 
with accumulation of mucus plugs (Zhang et al, 2009). 
The various mutations can be grouped into six distinct classes (I-VI) that include the 
absence of synthesis (class I), defective protein maturation and premature degradation 
(class II), disordered regulation, including diminished ATP binding and hydrolysis (class 
III), defective chloride conductance or channel gating (class IV), a reduced number of 
CFTR transcripts due to a promoter or splicing abnormality (class V) and accelerated 
turnover from the cell surface (class VI) (Figure 1.3, over) (Rowe et al, 2005). Different 
mutations determine varying effects on CFTR function resulting in different 
phenotypes of this disease (Tsui & Durie, 1992). The most common mutation is 
deletion of three base pairs, which determines the loss of phenylalanine at amino acid 
position 508 (ΔF508). It occurs in 91.5% CF patients in the UK (UK CF Registry, 2011). 
The disease manifests by abnormalities in exocrine gland functions resulting in altered 
ion composition and increased viscosity of epithelial secretions in the sweat ducts, 
salivary glands, small intestine, pancreatic exocrine gland ducts, biliary tract, vas 
deferens and respiratory tract. Although CF is a multi-organ disease, the major cause 
of morbidity and mortality in CF is due to pulmonary disease (Welsh, 1995). 
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Figure 1.3. Classification of the CFTR mutations. Six classes of CF-related gene mutations are compared 
to the normal CFTR maturation pathway. A wild-type CFTR is transcribed into messenger RNA (mRNA) 
followed by posttranslational modifications including folding, glycosylation and trafficking via the Golgi 
apparatus to the cell membrane, where it functions as a chloride channel. Class I mutations, such as 
G542X, contain premature stop mutations that generate truncated mRNA. Class II mutations, with the 
most common ΔF508, are misfolded and unable to proceed to the endoplasmic reticulum, they are then 
ubiquitinated and degraded. Class III mutations, exemplified by G551D, reach the cell membrane but the 
channel is not properly activated. Class IV mutations, such as R347P, produce fully activated cell surface 
channels but with decreased chloride conductance. Class V mutations result in reduced abundance of 
CFTR, like incorrect splicing with the mutation 3849 + 10 kb C→T. Class VI mutation is characterised by 
lowered stability of functional but unstable CFTR in the apical membrane (Rowe et al, 2005).
 
1.1.3. PULMONARY INFECTION 
The CF lung is normal at birth and during the first months of life (Sturgess & Imrie, 
1982). However, shortly after birth, many patients become infected with bacteria and 
develop airway inflammation. Infections with Staphylococcus aureus, Haemophilus 
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influenza and Streptococcus pneumoniae predominate in younger patients, while the 
onset of chronic Pseudomonas aeruginosa infection is delayed (Koch & Hoiby, 1993). 
Chronic P. aeruginosa infection is closely associated with progressive pulmonary 
deterioration in most CF patients.   
Several hypotheses have been proposed to explain CF lung susceptibility to infection 
with P. aeruginosa. Some investigators suggest that the elevated salt level in the CF 
ASL renders human β-defensin-1 nonfunctional, eliminating the bacterial activity of the 
respiratory epithelium (Goldman et al, 1997). A second hypothesis claims a failure of 
the respiratory epithelial cells in the CF lungs to ingest bacteria. Indeed, CFTR has been 
proposed to function as a receptor increasing clearance of P. aeruginosa. Lack of CFTR 
could directly impair host defense allowing for P.  aeruginosa retention at the 
endobronchial surface (Schroeder et al, 2002; Pier et al, 1996).  A third possibility is 
that Pseudomonas abundantly adheres to epithelial cells in the CF airway due to the 
abnormal surface properties of the cells, thus leading to infection. P. aeruginosa pilin, 
the protein responsible for P. aeruginosa binding, recognizes and binds to the cell 
surface glycolipid asialo ganglioside M1. Asialo ganglioside M1 is present at high levels 
in CF airway epithelial cells as a consequence of CFTR dysfunction (Saiman & Prince, 
1993; Saiman et al, 1992).  
P. aeruguinosa isolated from the lower respiratory tract is commonly initially non-
mucoid. Persistence of this organism usually coincides with increased expression of 
bacterial genes coding for production of alginate (uronic acid, which is a polymer of 
mannuronic acid and guluronic acid) under hypoxic conditions. P. aeruginosa grow in 
mucoid macrocolonies, embedded in a biofilm of alginate, which protects the organism 
from neutrophils and antibiotics and contributes to the establishment of chronic 
infection (Pedersen, 1992). Most of the recurrent episodes of worsening pulmonary 
symptoms termed exacerbations are due to bacterial infections (Hoiby, 1982). Beside 
P. aeruginosa identified in the sputa of the majority of CF patients, other typical CF 
organisms include Staphylococcus aureus, Haemophilus influenzae, and Burkholderia 
cepacia. The late stages of lung disease may be accompanied by the presence of less 
common organisms such as Stenotrophomonas maltophilia, Alcaligenes xiloxidants, 
Mycobacterium avium complex or Mycobacterium abscessus (Coutinho et al, 2008). 
Acute infection caused by chlamydia and mycoplasma enhance progression of 
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bacterial infection (Petersen et al, 1981). Also, virus infection is now implicated in 
exacerbation and increased susceptibility to bacteria in CF due to increased production 
of pro-inflammatory cytokines by epithelial cells compared to control or deficiency in 
antiviral innate immune responses in CF cells (Singanayagamn et al, 2012). 
Pulmonary infection rarely spreads outside the respiratory tract in CF patients (Hoiby, 
1982). However, the inflammatory response fails to eradicate it from the airways, 
eventually causing irreversible damage to the airways and lung parenchyma (reviewed 
by De Rose, 2002).   
1.1.4. PULMONARY INFLAMMATION 
CF is characterized by bronchial inflammation leading to bronchial wall thickening, 
bronchiectasis and lung tissue fibrosis. However, alveolar inflammation with 
remodeling has been also described in end-stage CF lungs (Ulrich et al, 2010). 
Pulmonary disease in patients with CF is dominated by an excessive neutrophilic 
inflammatory response to infection of the airways. Polymorphonuclear neutrophils 
(PMNs) were preferentially detected in the CF surface epithelium, where the epithelial 
damage is frequently described. A significantly increased T cell population was 
observed in the CF bronchiolar epithelium and parenchyma together with intense 
morphological alterations. A high number of B cells in CF lung samples were also 
found, suggesting interactions between T and B cells and their activation, leading to 
distal tissue remodelling. Plasma cells, macrophages and mast cells were located in the 
lamina propria and not significantly increased in CF compared to non-CF tissues 
(Hubeau et al, 2001). Additionally, the study of O`Sullivan et al (2006) established 
increased number of blood circulating platelets. 
The presence of microorganisms activates epithelial and macrophage synthesis and 
release of several cytokines (Bonfield et al, 1995). Both LPS and N-formyl-methionyl-
leucyl-phenylalanine (fMLP) synergistically induce the inflammatory response via 
multiple signaling pathways in vivo and in vitro. For instance, TLR4 and nuclear 
transcription factor-kappa B (NF-κB) signaling pathways are involved in the synergistic 
induction of pro-inflammatory cytokine, tumor necrosis factor-α (TNF-α) (Chen et al, 
2009).  
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Cells migrating within tissues can navigate through complex arrays of 
chemoattractants in a sequential manner (Foxman et al, 1999). In a consequence, 
PMNs migrate sequentially through the endothelial cell (EC) layer into the interstitial 
space followed by a transepithelial migration into the alveolar air space (Reutershan et 
al, 2005). 
IL-8 is the major neutrophil chemoattractant in the CF airways. Noah et al (1997) have 
shown that IL-8 levels are markedly increased in children with CF compared with non-
CF children with the same level of bacterial infection of the lower airways. The 
concentration of IL-8 is increased in the sputum, bronchoalveolar lavage fluid (BALF), 
and serum of CF patients, even during stable clinical conditions and the IL-8 
concentration in BALF positively correlates with the percentage of neutrophils in BALF 
(Dean et al, 1993).  
IL-8 binds with high affinity to two CXC chemokine receptors on PMNs, CXCR1 and 
CXCR2 (Lee et al, 1992), but neutrophils in the blood also respond to a concentration 
gradient of IL-8 bound to EC surfaces (Rot, 1992). In vitro studies have shown that 
glycosaminoglycan (GAG) side chains of proteoglycans (PGs) acts as IL-8 binding sites 
on human EC. In particular, the heparan sulphate (HS) side chains associated with 
syndecan-1, -2 and -4 bind IL-8 and are obligatory for successful migration of normal 
human neutrophils across the endothelium (Halden et al, 2004, Marshall et al, 2003, 
Kaneider et al, 2002). Binding to the GAGs may protect IL-8 from elastase-mediated 
degradation and prolong its half-life in the inflamed lung (Hoogewerf et al, 1997). 
Expression of HSPGs on the endothelium in bronchial tissue from patients with CF is 
increased compared to non-CF controls (Solic et al, 2005). Plasminogen activator 
inhibitor-1 (PAI-1), which stabilizes endothelial gradients of IL-8 and enhances cell 
migration was also reported to be increased in CF sputa and correlated negatively with 
pulmonary function (Xiao et al, 2005; Marshall et al, 2003). Previous studies 
demonstrated that chemokines, including IL-8, form dimers and higher order oligomers 
when bound to HS on EC surfaces, which increase the local concentration of 
chemokines for presentation to specific receptors on neutrophils in the circulation 
(Hoogewerf et al, 1997). It is also possible that tissue-derived IL-8 binds to the Duffy 
antigen on the endothelial cells of postcapillary venules and indicates a way for the 
chemokine transfer to the luminal surface of the endothelium. Indeed, Duffy protein 
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may be a necessary EC component for controlled leukocyte migration during 
inflammation. It was shown that in cultured human endothelial cells, Duffy protein can 
be induced by TNF-α and in the mouse by LPS (Chaudhuri et al, 2003).  
Other neutrophil chemoattractants, such as leukotriene B4 (LTB4), fMLP, and platelet 
activating factor (PAF) induced neutrophil migration through not only epithelial, but 
also endothelial cells in a dose-dependent fashion (Casale et al, 1992). Lipoxygenase 
products, 5-hydroperoxy-eicosatetraenoic acid (5-HPETE) or 5-hydroxy-
eicosatetraenoic acid (5-HETE) beside LTB4, were shown to be chemotactic for 
neutrophils (Nagy et al, 1982). Additionally, epithelial cell neutrophil activating 
peptide-78 (ENA-78), previously thought to be exclusively a product of epithelium, is 
expressed by endothelium in inflamed human lung and other tissues as well as by 
cultured ECs. ENA-78 acts in concert with IL-8 to induce PMN adhesiveness to ECs 
(Imaizumi et al, 1997). Another chemokine, neutrophil-activating peptide-2 (NAP-2) 
displays 53 % identity with ENA-78. ENA-78 and NAP-2 bind to CXCR1 with low affinity, 
whereas CXCR2 binds all CXC chemokines with high affinity (Ahuja & Murphy, 1996). 
Significantly increased concentrations of other pro-inflammatory cytokines, namely IL-
1, TNF-α, IL-6, IL-17 and IL-22 have been measured in CF sputum and BALF, and are 
known to extend airway inflammation (Aujla et al, 2008; Bonfield et al, 1995; 
McAllister et al, 1995). The synthesis of these cytokines is via activation of NF-ĸB by 
cellular interaction with bacterial LPS and proinflammatory cytokines, such as IL-1 or 
TNF-α. CF BALF was demonstrated to be deficient in the anti-inflammatory cytokine IL-
10, which presumably contributes to the excessive inflammatory response in CF 
compared to normal (Berger, 2002). Interestingly, it has been noted that the CFTR 
protein downregulates the expression of Regulated upon Activation, Normal T cell 
Expressed and Secreted (RANTES) chemokine, in contrast to IL-8 and monocyte 
chemoattractant-1 (MCP-1). Moreover, the absence of RANTES expression in CF may 
determine a dysregulated chemotaxis of lymphocytes into the CF lung (Schweibert et 
al, 1999). In contrast, a recent study by Scapa et al (2011) presented upregulation of 
RANTES in nasal polyps from patients with CF. 
High levels of chemoattractants and pro-inflammatory cytokines are a prerequisite for 
activated neutrophils to continue to accumulate in the airways. Neutrophils in sputum 
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release massive amounts of active proteases, mainly elastase, which overhelm local 
antiprotease defences including α1-antitrypsin (α1-AT), normally found in the blood, 
and secretory leukoprotease inhibitor (SLPI), locally made by epithelium. As CF has 
been characterized by defective neutrophil apoptosis (Moriceau et al, 2010), necrosing 
neutrophils are the major source of long-stranded deoxyribonucleic acid (DNA), which 
is responsible for the high viscosity of CF sputum and further impairs mucociliary 
clearance (Berger, 2002). Moreover, senescent and dead neutrophils were reported to 
release DNA, which compose neutrophil extracellular traps (NETs) binding the active 
serine proteases in CF sputum (Dubois et al, 2012). 
Neutrophil elastase (NE) directly contributes to tissue damage by degrading structural 
proteins, such as elastin, collagen type I – IV, fibronectin and proteoglycans (Janoff et 
al, 1979). Elastase can cause prolongation of the inflammatory process by degrading 
complement component C3 and releasing C5a, a potent chemoattractant for 
neutrophils (Fick et al, 1986). Neutrophil recruitment may be further augmented by 
the effect of elastase on the epithelium to synthesise and secrete IL-8 (Nakamura et al, 
1992). NE can cause a reduced ciliary beat frequency of the respiratory epithelium and 
directly damage the epithelial cells (Amitani et al, 1991). As elastase is a potent 
stimulator of airway gland serous cells, bacterial colonisation could be facilitated by 
excessive mucus production (Sommerhoff et al, 1990). Elastase may inactivate several 
components of the immune system (immunoglobulins, immune complexes, 
complement components and neutrophil cell surface receptors), thus interfering with 
the ability of neutrophils to opsonise and eliminate bacterial pathogens. The 
augmented amount of free elastase in the airways of CF patients is also related to 
inactivation of the two main physiological protease inhibitors, α1-AT and SLPI (Birrer et 
al, 1994; Berger et al, 1989). 
The effect of the exaggerated neutrophil-dominated inflammation is to generate a 
chronic burden of reactive oxygen species (ROS) in the respiratory tract of CF patients. 
High sputum levels of extracellular myeloperoxidase (MPO), a PMN-derived enzyme, 
which converts hydrogen peroxide into HOCl, have been reported in CF patients and 
inversely correlated with lung function (Witko-Sarsat et al, 1994). CF patients with an 
acute pulmonary exacerbation were shown to have abnormally high concentrations of 
H2O2 in exhaled air, which decrease during intravenous antibiotic treatment (Jobsis et 
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al, 2000). Higher concentrations of oxidation products have also been detected in the 
plasma of CF patients in comparison to control subjects (Brown & Kelly, 1994). 
Moreover, levels of glutathione, the major local lung antioxidant, are reduced in the 
epithelial lining fluid as well as in the plasma of CF patients as a result of defective 
CFTR. Its deficiency predisposes patients with CF to oxidative tissue damage (Roum et 
al, 1993).  
The inflammatory response to the infection in CF is excessive and persistent and sets 
the stage for a vicious cycle of airway obstruction, infection and inflammation that 
ultimately leads to lung damage and the progression of CF lung disease (Figure 1.4) 
(Konstan & Berger, 1997). However, the airway remodeling might be not only a 
consequence of repeated cycles of infection and inflammation, but also changes 
specific to CF, resulting from CFTR, or a protective responses to both of them. Indeed, 
CF airways have been characterized with the opposite structural changes in airway 
remodeling leading to narrowing of the small airways. Bronchiectasis, which is 
commonly defined as local and irreversible bronchial dilation by degradation of the 
bronchial tissue matrix have been observed together with widespread fibrotic changes 
described, especially in end-stage CF (Regamey et al, 2011). 
 
 
 
Figure 1.4. The excessive inflammatory response in the cystic fibrosis (CF) lung. A basic genetic defect 
leads to airway infection and uncontrolled inflammatory response, which both contribute to a persistent 
polymorphonuclear neutrophil (PMN) influx. This influx is maintained by chemoattractants released by 
PMNs themselves and interleukin (IL)-8 production induced by high quantity of elastase in the airways. 
PMNs release reactive oxygen species and proteolytic enzymes, which cause structural damage. The 
accelerated protease burden also impairs phagocytosis, facilitating the persistence of infection. Hence, a 
self-perpetuating vicious circle of infection and inflammation is established, leading to irreversible lung 
damage. LTB4: leukotriene B4; DNA: deoxyribonucleic acid (De Rose, 2002).   
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1.1.5. RESOLUTION OF INFLAMMATION 
Several cellular and molecular mechanisms terminate the acute inflammatory 
response. During acute inflammation, after entering the tissues, early-phase 
arachidonic acid-derived prostaglandin, PGE2 switches PMNs biosynthesis from 
leukotriene, LTB4 to lipoxin, LXA4, which promoted resolution (Levy et al, 2001). In 
airway epithelial cells low production of LXA4 has been reported in the airway of CF, 
which could explain the persistent inflammation in this severe airway disease (Karp et 
al, 2004). These events coincide with the biosynthesis, from omega-3 polyunsaturated 
fatty acids, of resolvins and protectins, which shorten the period of neutrophil 
infiltration by initiating apoptosis (Bannenberg et al, 2005). 
Neutrophil recruitment is therefore stopped and removal of infiltrated inflammatory 
cells is engaged, and plays a central role in resolution of inflammation. Inflammatory 
cells undergo apoptosis and efferocytosis (engulfment of apoptotic cells), which is 
likely to represent one of the most primitive forms of phagocytosis (Vandivier et al, 
2006, deCathelineau & Henson, 2003). Indeed, a distinct macrophage subpopulation, 
termed fibroblastic macrophages controls the dynamics of inflammation via phagocytic 
clearance of leukocytes (Hou et al, 2010). However, reduced apoptosis of a number of 
cells, including PMNs (Moriceau et al, 2010) in the airways of CF patients was reported 
and related with the presence of chronic infection rather than CFTR dysfunction. 
However, neutrophils are eliminated even more efficiently in the transepithelial 
pathway, from the apical membrane of mucosal epithelium into the lumen by 
induction of epithelial CD55 (Louis et al, 2005). However, neutrophils in severe chronic 
obstructive pulmonary disease (COPD) exhibit reduced chemotaxis compared to 
neutrophils in mild COPD to the increased number of neutrophil chemoattractants in 
bronchial mucosal tissues. It results in increased attraction and retention of 
neutrophils in the airway wall, and therefore modulates transepithelial egression of 
these cells (reviewed by Persson & Uller, 2011). 
Also, pro-resolution pathways may stimulate the release of anti-inflammatory 
mediators, such as IL-10 (Souza et al, 2007) and transforming growth factor-β1 (TGF-
β1) (Bannenberg et al, 2005). IL-10 deficiency in CF is well reported (Berger, 2002). In 
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addition, TGF-β1-mediated signaling in CF epithelium is altered due to a CF-related 
reduction of protein levels of TGF-β1 signalling molecule Smad-3 (Kelly et al, 2001). 
1.2. CELLULAR CONTRIBUTION TO AIRWAY INFLAMMATION IN CF 
As mentioned in Section 1.1.4, the number of PMNs in the airways, T cells in the tissue 
(Hubeau et al, 2001) and platelets in the blood (O`Sullivan et al, 2006) is raised in CF. 
1.2.1. NEUTROPHILS 
Neutrophils account for 40 – 65 % of white blood cells and are found in the blood at 
concentrations of 3 – 5 x 106 cell/ml. This number can increase up to tenfold during 
infections. Neutrophils have a relatively short life-time in the circulation 
(approximately 8 – 20 hours), but this may be extended to up to several days if the 
cells leave the circulation and enter tissues. In the circulation, they are spherical (about 
10 µm in diameter) with few cytoplasmic extrusions (Edwards, 1994). 
Neutrophils play a crucial role in the immune system, acting as the first line of defense 
against bacterial and fungal infections. These cells use oxygen-dependent and -
independent mechanisms to destroy and remove infectious agents. Oxygen-dependent 
mechanisms involve the intracellular production of ROS, which can be microbiocidal 
(Roos et al, 2003) and oxygen-independent mechanisms, which include the use of lytic 
enzymes and bactericidal peptides (reviewed by Witko-Sarsat et al, 2000). 
The generation of microbiocidal oxidants by neutrophils results from the activation of 
a multiprotein enzyme complex known as the reduced nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase, which catalyses the formation of superoxide 
anion (O2
.-). O2
.- may further dismutate spontaneously to form hydrogen peroxide 
(H2O2) (Figure 1.5). O2
.- and H2O2 can also undergo further reactions to form other ROS. 
For example, MPO in presence of Cl- converts H2O2 to HOCl and further to chloramines. 
(1) NAD(P)H + 2O2 → NAD(P)
+ + H+ + 2O2
.- 
(2) 2H+ + 2O2
.- → H2O2 + O2 
Figure 1.5. The action of NADPH oxidase (1) and further dismutation of superoxide anion (O2
.-
) to 
hydrogen peroxide (H2O2) (2). 
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Together these reduced oxygen products play an essential role in the killing of ingested 
microorganisms (Badwey & Karnowsky, 1980; Babior, 1978). 
Preformed and stored in vesicles, granule proteins of PMNs can be released on 
demand during the inflammatory response. Different granule subsets with specialized 
functions can be distinguished (Borregaard & Cowland, 1997). Secretory vesicles have 
the highest tendency to release their contents, which are delivered to the endothelium 
during the initial interactions of the PMN with the vessel wall. Tertiary granules are 
released during PMN transmigration across the EC layer. Indeed, proteases such as 
MMP-9 allow the PMN to cross the basement membrane (BM) more effectively. 
Primary (azurophilic) and secondary (specific) granule contents are released in the 
extravascular space. Antimicrobial polypeptides in these compartments are important 
in bacterial clearance by direct antimicrobial activity, bacterial opsonisation and 
macrophage activation (Figure 1.6) (Soehnlein et al, 2008; Levy, 2004; Fleischmann et 
al, 1985). 
 
Figure 1.6. Neutrophil effector mechanisms in the inflammatory process. These mechanisms are 
mobilized following phagocytosis of a pathogen. Complement opsonins C3b and C4b are recognized by 
CR1 and CR3, while IgG opsonins are recognized via the immunoglobulin receptors (FcgR). The first 
microbicidal pathway is oxygen-dependent and consists of the production of radical oxygen species 
following NADPH-oxidase complex activation, including superoxide anion (O2
.-
), hydrogen peroxide 
(H2O2), and, via myeloperoxidase, hypochlorous acid (HOCl) and chloramines. The second microbicidal 
pathway is does not depend on oxygen, but on the fusion of granules containing preformed proteins 
with the phagolysosome or release the granules to the extracellular medium. Serine proteases, 
antibiotic proteins and myeloperoxidase are stored in azurophilic granules. Specific granules contain 
metalloproteinases (collagenase and gelatinase) and antimicrobial proteins (lactoferrin and cathelicidin). 
Gelatinase is contained in tertiary granules, also called gelatinase granules (Witko-Sarsat et al, 2000). 
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A novel antimicrobial mechanism of neutrophils has been described by Brinkman et al 
(2004). Neutrophil extracellular traps (NETs) were observed as a highly decondensed 
chromatin structure that is formed and released by activated neutrophils. NETs are 
composed of nuclear DNA with histones, proteases (e.g. elastase) and AMPs. These 
structures bind Gram-positive and Gram-negative bacteria, as well as fungi (Urban et 
al, 2006). A variety of different proinflammatory stimuli have been shown to activate 
the formation of NETs, including H2O2, LPS, the mitogen PMA and IL-8. This active 
process depends on the generation of ROS by NADPH oxidase. During infection, ROS 
formation may contribute to intraphagosomal killing in live neutrophils or NET-
mediated killing post mortem (Fuchs et al, 2007). However, mitochondrial, not nuclear 
DNA release by neutrophils and NET formation do not require neutrophil death and 
also do not limit the lifespan of these cells (Yousefi et al, 2009). 
1.2.2. ENDOTHELIAL CELLS 
An endothelium lines the entire vascular system and is composed of a monolayer of 
endothelial cells. In an adult, the endothelium consists of more than 1 × 1012 cells and 
covers a surface area of more than 1000 m2 (Jaffe, 1987). The maintenance by the 
endothelium of a semi-permeable barrier is particularly important in controlling the 
passage of macromolecules and fluid between the blood and interstitial space.
 
The 
glycocalyx, a negatively charged surface coat of proteoglycans, glycosaminoglycans and 
adsorbed plasma proteins lining the luminal surface of the endothelium, contributes to 
this function (Pries et al, 2000). 
Endothelial cells form a heterogenous cell population that varies not only in different 
organs but also in vessels of different calibres within an organ (Bicknell, 1993). 
Functional studies on in vitro models of lung macro- and micro-vascular ECs show that 
they exhibit unique characteristics. Lung microvascular endothelial cells possess a 
more restrictive barrier than their macrovascular counterparts and exhibit unique 
signalling responses to TNF-α and other agonists (Kelly et al, 1998). Well-defined site 
specific vascular responses are observed in the intact lung (Chetham et al, 1999). The 
pulmonary microcirculation is less permeable to protein and water flux as compared to 
large pulmonary vessels (Parker & Yoshikawa, 2002). In contrast, macrovascular 
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endothelial cells express more endothelial nitric oxide synthase (eNOS) and generate 
more nitric oxide than do microvascular ECs (Stevens et al, 2001; Geiger et al, 1997). 
The vascular endothelium is versatile and multifunctional, having many synthetic and 
metabolic properties. Under basal conditions ECs are broadly involved in maintaining 
the nonthrombogenic blood–tissue barrier by regulating thrombosis, thrombolysis, 
platelet adherence, vascular tone and blood flow. They produce and release many 
vasoactive substances, such as prostacyclin and nitric oxide, which inhibit platelet 
aggregation and cause vasodilation. These mediators are released in response to a 
range of chemical stimuli (thrombin, bradykinin, ADP), as well as changes in 
haemodynamic forces (changes in blood pressure or flow) (Sumpio et al, 2002). 
A critical balance between endothelium-derived relaxing and contracting factors 
maintains vascular homeostasis. A disrupted balance predisposes the vasculature to 
vasoconstriction, leukocyte adherence, platelet activation, mitogenesis, pro-oxidation, 
thrombosis, impaired coagulation, vascular inflammation, and atherosclerosis (Pober 
et al, 2009; Arnout et al, 2006). 
The endothelium plays a key role in immune and inflammatory responses by regulating 
leukocyte, monocyte and lymphocyte movement into tissues. Pulmonary endothelium 
modulates leukocyte function by the expression of adhesion molecules, such as P-
selectin (Bonfanti et al, 1989) and by release of soluble factors including prostacyclin 
(Weksler et al, 1977) and PAF (Bjork et al, 1983). Vascular endothelial cells possess 
unique and specialised storage vesicles, called Weibel-Palade bodies that contain a 
number of proteins important in haemostasis and inflammation. As well as P-selectin, 
these secretory granules contain: von Willebrand Factor (vWF) (Wagner et al, 1982), 
CD63 (Vischer & Wagner, 1993), endothelin (Russel et al, 1998), IL-8 (Utgaard et al, 
1998; Wolff et al, 1998), t-PA (Huber et al, 2002) and PAI-1 (Xiao et al, 2005). 
Vascular endothelium can be affected by a persistent inflammatory state, which can be 
secondary to chronic pulmonary infection, characterised in CF. Romano et al (2001) 
found circulating levels of vWF, t-PA, P-selectin, TNF-α and IL-6 to be significantly 
higher in CF patients. Those results indicate that CF patients exhibit signs of 
endothelial dysfunction/perturbation, which are likely to be related to a persistent 
inflammatory state due to chronic pulmonary infection and may play a role in the 
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progression of the disease. Others have suggested that changes in EC in CF are the 
cause of the increased inflammation (Solic et al, 2005). 
1.2.3. PLATELETS 
Platelets are anucleate fragments of bone marrow megakaryocytes of approximately 1 
– 2 µm in diameter (Dopheide et al, 2002). Daily production of 2.5 x 1011 cells with a 
median life span of 7 – 9 days constitutes a total platelet pool of 2 x 1012 cells in human 
adults. Platelets contain at least three types of morphologically different granules: α-
granules, dense granule and lysosomes. The most abundant α-granules contain 
platelet-derived growth factor, PF-4, coagulation factors V & XIII and fibrinogen. Dense 
bodies contain serotonin, nucleotides (ADP) and calcium, while lysosomes contain 
hydrolytic enzymes (acid hydrolases). α-granules comprise roughly 10 % of the platelet 
volume, which is approximately equal to the surface of the open canalicular system, an 
elaborate system of tunnelling invaginations of the cell membrane unique to the 
platelet (Frojmovic & Milton, 1982; White & Clawson, 1980) (Figure 1.7). 
 
Figure 1.7. The structure of a platelet (Semple, Italiano & Freedman, 2011). 
Platelets were shown to be a linking element between haemostasis, inflammation and 
tissue repair (O`Sullivan & Michelson, 2006). Their physiological role in haemostasis is 
determined by their ability to change shape, aggregate, and release the contents of 
secretory granules in response to specific agonists. Thrombin, epinephrine, adenosine 
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diphosphate (ADP), thromboxane A2 (TXA2), PAF, collagen and other extracellular 
matrix components in the subendothelium are agonists, known to activate platelets 
(Johnson, 1999). Platelets can be also activated by antigens, antigen–antibody 
complexes, microorganisms, and bacterial endotoxins, like LPS from P. aeruginosa. 
Release of mediators stored in platelet granules and de novo platelet synthesis of other 
mediators including cytokines/chemokines, enhance the inflammatory response. 
Platelet-derived histamine and serotonin contribute to increased vascular 
permeability; ADP augments the agonist-induced oxidative burst in PMNs; platelet-
derived growth factor stimulates chemotaxis for monocytes and primes eosinophils to 
produce superoxide anion; PF-4 predispose PMNs to adhere to unstimulated vascular 
endothelium, stimulates the release of histamine from basophils, and induces the 
adherence of eosinophils to vascular walls. Platelet basic protein (PBP) and CTAP III, 
the predominant β-TG variants are secreted by activated platelets. They are inactive 
precursors of NAP-2, which stimulates neutrophil functions, such as chemotaxis, 
adherence and degranulation of lysosomal enzymes. Furthermore, platelets release 
RANTES, which supports the recruitment and adhesion of monocytes and T cells to 
activated endothelium (O`Sullivan & Michelson, 2006). 
Once activated, platelets mediate homeostasis and thrombosis by adhering to the 
vascular wall, recruiting circulating platelets and aggregating to form a thrombus, 
which seals the damaged blood vessel (Johnson, 1999). 
Previous studies demonstrated that CF patients have an increased number of 
circulating platelets, increased platelet activation in response to gram-negative 
infection, and increased release of platelet-derived mediators, many of which can have 
negative pulmonary consequences (O`Sullivan & Michelson, 2006).  Previous studies 
have also shown that CF patients have increased ex vivo platelet aggregability, 
increased release of TXA2, and a blunted response to PGE1-induced inhibition of 
platelet aggregation (O`Sullivan et al, 2005). These studies suggest a link between 
platelet activation and progressive impairment of CF lung function. 
Given their multiple significant roles in inflammation, platelets are a potential 
therapeutic target in patients with CF (O`Sullivan & Michelson, 2006).  Platelets also 
contain micromolar concentrations of copper (Lind et al, 1993). 
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1.3. LEUKOCYTE RECRUITMENT 
Under both normal and pathologic conditions, circulating leukocytes migrate from 
vessels into tissues. In the systemic microcirculation, PMN influx from blood into tissue 
at sites of inflammation, which typically occurs in post-capillary venules, present in 
non-lymphoid tissues. Post capillary venules in secondary lymphoid tissue, called high 
endothelial venules, allow only lymphocytes to migrate into the lymph node 
(Cavender, 1990; Colditz, 1985). 
Leukocyte recruitment across the endothelium requires a multistep cascade of 
adhesive and migratory events, which are mediated by three classes of adhesion 
receptors, selectins, integrins and adhesion receptors of the immunoglobulin 
superfamily. These steps are: the initial selectin-mediated rolling, chemokine-induced 
activation and integrin and adhesion molecule-dependent adherence and subsequent 
transendothelial migration (Figure 1.8) (Ley et al, 2007; Springer, 1994). 
 
Figure 1.8. Multistep process of leukocyte recruitment from the circulation into inflammatory sites. 
Following initial selectin-mediated capture, adhesive interactions between leukocyte and activated 
endothelium are required for transendothelium migration of leukocytes into inflammatory site 
(Ninichuk & Anders, 2008). 
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Rolling interactions are reversible as they are mediated by weak binding between 
transmembrane glycoprotein adhesive molecules called selectins with P-selectin 
glycoprotein ligand (PSGL-1, CD162) and other glycosylated ligands. Selectins are 
expressed by most leukocytes (L-selectin) and inflamed endothelium (E- and P-selectin) 
(McEver, 2002; Bevilacqua & Nelson, 1993). PMNs newly released from bone marrow 
demonstrate higher constitutive expression of L-selectin compared with older, 
circulating PMNs (Matsuba et al, 1997). The activity of metalloprotease is partly 
responsible for the loss or shedding of L-selectin from the surface of PMN. It results in 
active accumulation of L-selectin in the blood (Kishimoto et al, 1995). However, L-
selectin autoproteolysis can also occur after exposure to inflammatory stimuli, such as 
LPS and TNF-α or come from physiological rolling interactions with the vessel wall 
(Walchek et al, 1996). In turn, P-selectin (granule membrane protein-140, CD62P) is 
accumulated in platelet α-granules as well as endothelial Weibel-Palade bodies (Malik 
& Lo, 1996). Within minutes of exposure to ECs, inflammatory mediators, including 
complement products, ROS or various cytokines, P-selectin is mobilized to the cell 
surface, where it may interact with its PMN counterpart, PSGL-1. P-selectin on 
activated ECs can also bind PSGL-1 on monocytes and platelets (McEver & Cummings, 
1997). E-selectin (ELAM-1, CD62) is not stored but its expression and activity on ECs is 
induced in vitro by inflammatory cytokines (Klein et al, 1995). E-selectin mediates slow 
and more stable rolling (Smith et al, 2004). 
After injury or infection, inflammatory cytokines activate the endothelium to express 
adhesion molecules and synthesize chemokines and lipid chemoattractants from both 
luminal and basolateral surfaces (Middleton et al, 1997). Chemoattractants are also 
generated in activated mast cells (IL-1β, IL-4, TNF-α) and platelets (NAP-2, RANTES, 
ENA-78) and delivered to ECs through exocytosis of intracellular granules or circulating 
microparticles. Chemokines can oligomerize and interact with specific, high affinity 
receptors, G protein coupled receptors (GPCRs) that modulate their functions. Many 
chemokines can also bind to GAGs on the EC surface, which is crucial for efficient 
leukocyte recruitment and protection from proteolytic cleavage (Johnson et al, 2005). 
During chemokine-induced activation, the low-affinity, selectin-mediated interaction 
are converted into the high-affinity, integrin-mediated adhesion (Ley et al, 2007). 
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Integrins are heterodimeric transmembrane glycoproteins present on PMNs and other 
blood cells and mediate cell-cell and cell-extracellular matrix adhesions. PMN binding 
to activated endothelium is mediated mainly by two β2-integrins: macrophage 
antigen-1 (MAC-1; αMβ2; CD11b/CD18) and lymphocyte-associated function antigen-1 
(LFA-1; αLβ2; CD11a/CD18) and a β1-integrin, very late activation antigen 4 (VLA-4; 
α4β1) (Luscinskas & Lawler, 1994). LFA-1 was identified as the essential neutrophil 
integrin during transendothelial migration. Indeed, LFA-1 was shown to be sufficient in 
mediating neutrophil emigration in MAC-1-deficient mice (Lu et al, 1997). However, it 
also contributes to neutrophil rolling by stabilizing the transient attachment or 
tethering phase of rolling (Henderson et al, 2001). MAC-1 is exclusive to granulocytes 
and monocytes (Thylen et al, 1992). Already assembled MAC-1 is stored in PMN 
vesicles (Borregaard & Cowland, 1997) and can be rapidly mobilized to the PMN 
surface after exposure to TNF-α and bacterial LPS or fMLP (Altieri & Edgington, 1988). 
Inflammatory stimuli can also promote transcription and translation of MAC-1 genes, 
in order to prolong integrin involvement during inflammation (Wagner & Roth, 2000). 
In contrast, VLA-4 is expressed on most leukocytes and has been shown to mediate 
attachment to ECM proteins and to function as a ligand for the endothelial VCAM-1 
(Elices et al, 1990). 
Although, 5 % of neutrophils were found to use the transcellular route of migration, in 
vitro findings pointed to the predominance of the paracellular route for neutrophils 
(Carman & Springer, 2004). Endothelial junctions represent the major barrier for the 
transmigrating neutrophil for the paracellular pathway. At least two types of junctions 
are involved in transmigration: adherens junctions (zonula adherens) and tight 
junctions (zonula occludens). Additionally, endothelial gap junctions, which are 
communication structures, allow the passage of small molecular weight solutes 
between neighbouring cells (Bazzoni & Dejana, 2004). 
Adherens junctions are formed by VE-cadherins that promotes homophilic cell-cell 
contacts in a calcium-dependent fashion. The link between cell membrane-associated 
VE-cadherin and the actin filaments is mediated by intracellular catenins (Bazzoni & 
Dejana, 2004). VE-cadherin permits the leukocyte passage of leukocytes, as antibodies 
against VE-cadherin increase the permeability of endothelial cell monolayers and the 
rate of neutrophils extravasation in vivo (Gotsch et al, 1997). However, in vitro studies 
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of Shaw et al (2001) indicate that VE-catherin gaps form transiently during diapedesis. 
Few pathways emerged to explain these observations. One of them reports that the 
crucial event promoting leukocyte trafficking is the phosphorylation of tyrosine 
residues 658 and 731 in the cytoplasmic tail of the VE-cadherin as well as Ser 665, 
correlated with the barrier function of VE-cadherin (Potter et al, 2005). Also, 
engagement of ICAM-1 by leukocytes results in tyrosine phosphorylation of VE-
cadherin (Allingham et al, 2007). Signalling events during leukocyte transendothelial 
migration including ROS production is particularly interesting. ROS are generated as a 
signal downstream of ICAM-1 engagement (Wang & Doerschuk, 2000), although the 
production of ROS is known to be a downstream of other EC-leukocyte receptors, such 
as ICAM-3 and VCAM-1 (van Buul et al, 2004; van Watering et al, 1997). HSP27 protein 
activates ROS production in EC and by promoting actin cytoskeleton rearrangement, 
facilitates TEM (Nguyen et al, 2004; Gerthoffer & Gunst, 2001). Moreover, ROS inhibits 
phosphatase activity by reversible oxidation of the catalytic cysteine residue and the 
resulting increase in tyrosine phosphorylated junctional proteins might increase TEM 
as an effect of junctional distruption (Sallee et al, 2006). ROS production is also 
increased by the activity of Rac-1, a component of vascular NADPH oxidase complex. 
Indeed, treatment of ECs with NADPH oxidase inhibitors and ROS scavengers was 
found to block lymphocyte TEM (Matheny et al, 2000). 
Tight junctions form a close intercellular adhesive contact beneath the apical cell 
surface. They contain several transmembrane adhesive proteins of the occludin, 
claudins and junctional adhesion molecules (JAM) families, which are linked 
intracellularly to cytoskeletal signalling molecules (Bazzoni & Dejana, 2004). Members 
of the JAM family (JAM-A, -B, -C) have been shown to interact with leukocyte integrins 
and therefore are implicated in leukocyte transmigration. In particular, JAM-A as a 
ligand for the leukocyte β2-integrin LFA-1, under flow conditions contributed to LFA-1-
dependent transendothelial migration of T cells and neutrophils as well as LFA-1-
mediated arrest of T cells (Ostermann et al, 2002). Also, endothelial JAM-A mediated 
neutrophil extravasation in a liver model for ischemia-reperfusion injury (Khandoga et 
al, 2005). JAM-B was hypothesized to be involved in leukocyte rolling and firm 
adhesion, because it binds to VLA-4 (Ludwig et al, 2009). JAM-C has been described as 
a ligand for the leukocyte integrins MAC1 and αXβ2 (Zen et al, 2004; Santoso et al, 
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2002). Endothelial cell-selective adhesion molecule (ESAM) is another tight junction 
transmembrane protein that is related to JAMs family members. ESAM knockout mice 
decrease neutrophil, but not lymphocyte TEM using in vivo inflammation models. Thus, 
both ESAM and JAM protein functions correlate positively with leukocyte TEM, 
reflecting their role as leukocyte counter-receptors (Wegmann et al, 2006). 
In addition to these transmembrane proteins, there are also intracellular proteins, 
which form a complex on the cytoplasmic side of the plasma membrane underlying the 
tight junction. The zonula occludens components, ZO-1 and ZO-2, are the predominant 
cytoplasmic tight junction proteins in endothelium (Jesaitis et al, 1994; Stevenson et al, 
1986). They link the cytoplasmic domain of occludin to the actin filaments and recruit 
signalling molecules that function during junctional regulation (Schneeberger et al, 
2004; Fanning et al, 1998). 
Platelet endothelial cell adhesion molecule-1 (PECAM-1) is a member of the 
immunoglobulin superfamily, expressed at the intracellular borders of endothelial 
cells, platelets, neutrophils, monocytes and T cells subsets (Newman, 1997). Muller et 
al (1993) show that antibodies specific for PECAM-1 inhibited emigration of monocytes 
or neutrophils across endothelial cell monolayer in a quantitative in vitro assay of TEM. 
In addition, the findings of Sachs and co-workers (2007) provide direct evidence that 
neutrophil-specific CD177 is a heterophilic binding partner of PECAM-1 and their 
mutual interaction may contribute to the neutrophil transmigration. A step in 
diapedesis that is distal to the step mediated by PECAM-1 is controlled by CD99. 
Indeed, cells blocked at the CD99-dependent step are arrested halfway through EC 
contacts (Schenkel et al, 2002).  
However, neutrophils are also able to migrate through a transcellular pore in the 
cytoplasm of the EC close to, but distinct from EC junctions (Feng et al, 1998). 
Interestingly, TNF-α pretreatment or ICAM-1 overexpression resulted in an increase of 
the relative contribution of the transcellular pathway in neutrophil transmigration 
(Yang et al, 2005). Upon leukocyte adhesion, leukocyte attachment induced 
assembling of VCAM-1 and ICAM-1 on the surface of EC. This causes, in turn, local actin 
remodelling and formation of the membrane protrusions around the attached 
leukocyte in a manner dependent on cortactin (Yang et al, 2006b; Barreiro et al, 2002).  
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Cortactin and its tyrosine phosphorylation are required for the clustering of ICAM-1 
around transmigrating neutrophils (Yang et al, 2006a). Moreover, microvascular 
permeability of ECs is regulated by subcellular membranous structures such as 
caveolae, finestrae and vesiculo-vacuolar organelles, which act as a gateway for 
leukocytes through the body of the ECs (Dvorak & Feng, 2001). Leukocyte migration 
begins with the expansion of membrane protrusions into EC. Ligation of ICAM-1 
triggers cytoplasmic signalling mechanisms that lead to the translocation of apical 
ICAM-1 to caveolae and F‑actin-rich regions and to the final transport with caveolin‑1 
to the basal plasma membrane. It causes the formation of channels through which 
leukocytes can migrate (Millan et al, 2006). Molecules involved in cell migration 
through endothelial-cell junctions may also mediate transcellular migration 
(Engelhardt & Wolburg, 2004). 
Leukocytes continue their migration beyond the endothelium, exhibiting motility 
across EC BM and pericytes. Penetration of endothelial BM takes much longer than 
leukocyte migration through the endothelial barrier (Ley et al, 2007).  The endothelial 
BM is composed of protein networks of the vascular laminins, including laminin-8 and 
laminin-10 and collagen type IV, which interacts with nidogen-2 and HSPGs (Hallmann 
et al, 2005). Pericytes are cellular components of capillaries and post-capillary and 
collecting venules in companion to the underlying endothelium. The perycite network 
in most tissues is loosely distributed around endothelial cells and embedded in the BM 
(Hirschi & D`Amore, 1996). 
Interestingly, examination of unstimulated mouse cremasteric venules discovered 
regions of low expression of matrix proteins within the endothelial BM, termed low 
expression regions (LERs). The level of laminin‑10, collagen IV, or other basement-
membrane constituents is there lower than average (Wang et al, 2006; Sixt et al, 
2001). Neutrophil migration through IL‑1β-stimulated cremasteric venules resulted in 
transient enlargement of these sites. Neutrophils migrate specifically at LERs, which 
are co-localized with gaps between neighbouring pericytes and low protein deposition 
within the extracellular matrix (ECM). Besides, a variety of proteases have been related 
to neutrophil transmigration and LER modelling, including matrix metalloproteinase 8 
(MMP8), MMP9 and neutrophil elastase (Reichel et al, 2008; Wang et al, 2006). 
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1.4. LEUKOCYTE RECRUITMENT TO THE LUNG 
PMN trafficking in the pulmonary circulation, which takes place in end-stage CF lungs 
(Ulrich et al, 2010), is distinct to that in the systemic circulation. Due to the small 
diameter of pulmonary capillaries (2 – 15 µm), PMN transit time is increased, allowing 
intimate contact with the capillary endothelium (Doerschuk et al, 1993). About 50 % of 
the capillary segments require PMNs (6 – 8 µm) to stop and change their shape to pass 
through. Hence, the number of PMNs within pulmonary capillary blood is 35 – 100 
times higher compared to large vessels of the systemic vasculature (Doerschuk et al, 
1987).  
The main site of leukocyte migration in the lung is the capillary bed (Reutershan et al, 
2004). During lung injury or inflammation, PMNs migrate to the following lung 
compartments, intravascular, interstitial and intra-alveolar area. PMNs advancing to 
the alveolar airspace induce lung damage, which is associated with an increased 
mortality (Li et al, 2002). Inflammatory challenge, such as IL-8, PAF or TNF-α, sequester 
neutrophils in the pulmonary microvasculature, reducing the systemic to pulmonary 
PMN pool (Drost & MacNee, 2002).  
Selectin-mediated rolling takes place in the pulmonary venules, but most of the 
pulmonary capillaries are too narrow to allow rolling. Also, the involvement of 
selectins may be stimulus-dependent, as they have been shown to be involved in the 
development of lung injury induced by LPS or complement C5a deposited 
intratracheally (Hayashi et al, 1999; Mulligan et al, 1996). In turn, PMN adherence in 
the lung may occur in both CD18-dependent or CD18-independent ways in regard to 
the intrapulmonary stimulus. IL-1, phorbol 12-myristate 13-acetate (PMA) and LPS, 
elicit migration via pathways predominantly mediated by CD18, whereas complement 
factor, IL-8, LTB4, C5a and Gram-positive bacteria recruit PMN mostly independently of 
CD18 (Mackarel et al, 2000; Hellewell et al, 1994; Doerschuk et al, 1990). Moreland et 
al (2002) has shown the dominance of CD18 integrin MAC-1 over LFA-1 in PMN 
recruitment in the lung inhaled LPS model, because antibodies to MAC-1, not to LFA-1 
significantly inhibited neutrophil migration. Moreover, ICAM-1, which is known to 
support CD18-dependent emigration in mice, was involved in neutrophil migration in 
the same model, suggesting that the mechanism of adhesion may be regulated by the 
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expression of endothelial rather than neutrophil adhesion molecules. In addition, VLA-
5 may mediate CD18-independent PMN migration (Burns et al, 2003). 
1.5. CHEMOKINES INVOLVED IN THE INFLAMMATORY PROCESS 
Chemokines are small heparin-binding polypeptides, produced by a variety of cells, 
whose main role is to regulate leukocyte migration during physiological and 
pathological conditions (Oppenheim et al, 1991). Chemokine activity is mediated by 7-
transmembrane spanning GPCRs, which trigger different signalling pathways and gene 
expression changes within the responding cell (Taub et al, 1995). Chemokines are 
classified based on a cysteine motif conserved within their structure. The subgroups 
include CXC, CC, C and CX3C families (Oppenheim et al, 1991). The role of most 
chemokines still needs to be deciphered, however the members of CXC and CC families 
are inflammatory agents (Castellani et al, 2007). 
The CXC family of cytokines, in which the first of two N-terminal cysteines are 
separated by another amino acid residue, induces chemotaxis in PMNs and T-cells, 
whereas the CC chemokine family, in which the first two cysteines are in juxtaposition, 
induces chemotaxis in monocytes, eosinophils, basophils and T cell subpopulations 
(Baggiolini et al, 1994; Schall et al, 1994). Moreover, members of the CXC chemokine 
family are known to be involved in angiogenesis, which has been related to the Glu-
Leu-Arg (ELR) motif at the NH2-terminal cysteine. In general, ELR-positive chemokines, 
bind to PMNs and acts as angiogenic factors and ELR-negative, bind to lymphocytes 
and are angiostatic (Table 1.1) (Strieter et al, 1995). 
CXC chemokines IL-8; PBP → β-TG → CTAP-III → NAP-2; Gro-α; Gro-β; Gro-γ; PF-
4; ENA-78; γ-IP-10; GCP-2; γ-MIG 
CC chemokines MCP-1; MCP-2; MCP-3; MIP-1α; MIP-1β; RANTES; eotaxin; I-309 
C chemokines lymphotactin 
 
Table 1.1. Human chemokines. → indicate N-terminal processing resulting in different biological activity 
(Rot, 1996). 
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1.5.1. INTERLEUKIN-8 (IL-8) 
IL-8 (CXCL8) or neutrophil-activating peptide-1 (NAP-1) is secreted from activated 
monocytes, fibroblasts, endothelial cells and T cells (Strieter et al, 1989; Gregory et al, 
1988; Strieter et al, 1988; Walz et al, 1987) and is a potent chemoattractant for 
neutrophils (Baggiolini et al, 1989; Larsen et al, 1989). IL-8 has the highest specific 
activity as a granulocyte activating protein. In vitro effects on neutrophils include a 
transient increase of intracellular Ca2+ concentration, the release of azurophilic, 
specific and gelatinase granules, respiratory burst, chemotaxis and shape change 
(Baggiloni et al, 1989). 
IL-8 has three binding domains: a high affinity binding domain, which mediates the 
binding to specific receptors on PMNs, the dimer interface, where IL-8 molecules binds 
to each other to form high molecule weight multimers and the GAG-binding domain 
(Kuschert et al, 1998; Hoogewerf et al, 1997; Lee et al, 1992).  
The high-affinity binding domain is located at the N-terminus of IL-8 and it is formed of 
residues 4, 5 and 6, which are absolutely essential for the binding of IL-8 to CXCR1 and 
CXCR2. The C-terminal α-helix is probably important for stabilizing the three-
dimensional structure
 
(Clark-Lewis et al, 1991). The interaction of IL-8 with the high-
affinity receptors mediates neutrophil chemotaxis and activation (Lee et al, 1992). 
Hammond and co-workers (1995) suggested that CXCR1 is involved in mediating IL-8-
induced chemotaxis at the site of inflammation at high IL-8 concentration, while CXCR2 
contributes to the initiation phase of PMN migration, distant from the site of 
inflammation, where IL-8 concentration is at low (pg/ml) level. Additionally, IL-8 binds 
to a Duffy antigen/receptor for chemokines (DARC) on red blood cells, which prevents 
leukocyte stimulation by IL-8 released into the blood (Darbonne et al, 1991).  
A low-affinity binding domain on IL-8, the dimer interface, is a region where IL-8 
molecules bind to each other to form dimers and tetramers. IL-8 exists as a non-
covalent homodimer of 8 kDa (Hassfurther et al, 1994). However, cell surface GAGs 
were shown to induce polymerization of chemokines, increasing their local 
concentration and therefore enhancing IL-8 concentration on the surface of 
endothelial cells in vitro (Hoogewerf et al, 1997). 
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Another low-affinity binding domain on IL-8, the GAG-binding domain is composed of a 
group of basic amino acids located in the C-teminal α-helix and in the proximal loop 
(Kuschert et al, 1998). IL-8 selectively binds to GAGs with an increased affinity:  CS < DS 
< HS < heparin (Kuschert et al, 1999). IL-8 interactions with GAGs enhance neutrophil 
migration and protect IL-8 from damage by lytic enzymes released from the migrating 
cells in vitro (Webb et al, 1993). In the lung, IL-8 binding to GAGs promotes 
dimerization of IL-8, increasing the amount of IL-8 binding to lung tissue in vivo 
(Frevert et al, 2003). 
1.5.2. NEUTROPHIL-ACTIVATING PEPTIDE-2 (NAP-2) 
Neutrophil-activating peptide-2 (NAP-2, CXCL7) is generated during cleavage of the 
connective-tissue-activating peptide III (CTAP-III) and platelet basic protein (PBP). 
CTAP-III constitutes one of several molecular variants of β-thromboglobulin-antigen (β-
TG), a group of chemokines that differ by their degree of N-terminal truncation. Along 
with platelet factor 4 (PF-4, CXCL4), CTAP-III represents the major preformed 
chemokines stored in platelet α-granules and released by exocytosis upon stimulation. 
CTAP-III and PBP are considered as pro-forms of NAP-2, because they do not have the 
capacity to activate neutrophils (Walz & Baggiolini, 1990; Walz & Baggiolini, 1989). 
CTAP-III is converted to its active derivate by limited truncation by enzymatic 
proteolysis and removal of 15 amino acids from the N-terminus of the precursor 
(Brandt et al, 1991). CTAP-III was shown to be rapidly cleaved by chymotrypsin, 
cathepsin G, trypsin and chymase, serine proteases found in neutrophils, monocytes 
and mast cells (Schiemann et al, 2006; Car et al, 1991). 
NAP-2 belongs to the family of ELR-positive chemokines, similar to IL-8, that potently 
activate neutrophils through interaction with CXCR1 and CXCR2 (Petersen et al, 1994). 
NAP-2 stimulates neutrophil chemotaxis almost as potently as IL-8 over a wide range 
of concentrations (Ludwig et al, 1997). NAP-2 was shown to stimulate release of the 
lysosomal and secondary granule enzymes upon cytochalasin-B treatment. Moreover, 
NAP-2-induced degranulation may be considerably enhanced by TNF-α- priming 
(Brandt et al, 1992; Walz & Baggiolini, 1989). NAP-2 up-regulates the adhesion 
molecule MAC-1, but down-regulates the surface expression of L-selectin on 
neutrophils (Detmers et al, 1991). Additionally, NAP-2 and CTAP-III induced CXCR2-
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dependent neutrophil adhesion to human ECs, while only NAP-2 was shown to induce 
transmigration across monolayers of cultured HUVEC (Schenk et al, 2002). 
1.6. PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) 
PAI-1 is a specific serine protease inhibitor of urokinase-type plasminogen activator (u-
PA) and tissue-type plasminogen activator (t-PA). The molecular weight of this 
glycoprotein is around 54 kDa, depending on protein glycosylation at the asparagine 
residues (Asp209 and Asp265) (Gils et al, 2003). The main storage site of non-active 
PAI-1 is platelet α-granules, where it is released to the plasma (Nordenhem & Wiman, 
1997). Under physiological conditions, PAI-1 can be constitutively secreted from a 
number of cells, such as platelets (De Taeye et al, 2005).  
PAI-1 belongs to the serpin superfamily of serine protease inhibitors, which share 
unique structural features, such as a five-stranded β-sheet motif and a flexible reactive 
center loop (RCL). PAI-1 exists in several conformations, including the active and 
inactive forms as well as latent stages and the conformational changes associated with 
the RCL have been linked to the inhibitory function of PAI-1 (Ibarra et al, 2004; Nar et 
al, 2000). The binding of PAI-1 to t-PA and u-PA is mediated by the exosite interactions 
between the surface-exposed variable region-1 or 37-loop of the t-PA and the distal 
RCL of PAI-1 (Figure 1.9) (Ibarra et al, 2004). 
 
 
 
 
Figure 1.9. A model structure of a complex between t-PA 
and PAI-1. The α-helices, β-sheets, and loops are 
depicted in red, yellow, and gray respectively. 
Components of the catalytic triad and the variable region 
1 loop of t-PA, as well as the P1 residue (Arg346) and the 
distal P4′ (Glu350) and P5′ (Glu351) residues of PAI-1 are 
represented as ball-and-stick models (Ibarra et al, 2004). 
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PAI-1 is stabilised by binding to vitronectin, which may prolong its half life in vivo and 
in vitro (Declerk et al, 1988). Also, the protease specificity of PAI-1 toward thrombin is 
substantially increased in the presence of heparin (Ehrlich et al, 1991). PAI-1 is 
involved in the plasminogen activation cascade, where it is a key inhibitor of 
fibrinolysis and proteolysis (Figure 1.10).   
 
 
 
  
 
 
 
Figure 1.10. Plasminogen activation cascade (Wyrzykowska & Kasza, 2009). 
Under pathological conditions, large amounts of PAI-1 are secreted by ECs and other 
cells in response to inflammatory cytokines, such as TNF-α. High PAI-1 plasma levels 
are consistently found in patients with severe sepsis and acute or chronic 
inflammatory diseases, such as atherosclerosis. PAI-1 is upregulated by inflammatory 
cytokines and may therefore be regarded as a marker for an ongoing inflammatory 
process (Binder et al, 2002). A correlation between an increased level of PAI-1 and 
TNF-α was determined in chronic inflammatory diseases, including CF, COPD and 
asthma (Xiao et al, 2005). Other inflammatory mediators, IL-1β and IL-6, were found to 
increase PAI-1 expression by 40 and 30-fold in the HepG2 cell line (Healy & Gelehrter, 
1994). PAI-1 is known to be synthesized in response to numerous factors, such as TGF-
β (Sato et al, 1990), thrombin (Cockell et al, 1995), insulin (Nordt et al, 1994) or 
oxidation products (Dichtl et al, 1999). 
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1.7. COPPER AND ITS DUAL ROLE IN THE HUMAN BODY 
 Copper has two roles in the human body. It is both an essential element required for 
copper-dependent enzyme activity and also a pro-oxidant, contributing to human 
diseases.       
1.7.1. COPPER AS AN ESSENTIAL ELEMENT 
Since the late 1930s, copper has been recognised as an essential trace metal required 
for normal metabolic processes in living organisms. As it is an element, dietary intake 
and absorption are crucial (Linder, 2001).  The level of copper intake that has been 
recommended as safe and adequate is 1.5 – 3 mg/day for adults, but many Western 
diets contain much less than this. Foods are believed to represent the major source for 
higher animals and humans, although water and nutritional supplements can 
contribute considerable quantities of the metal (Failla, 1999).  
The total copper content in the human body is approximately 100 mg and the highest 
concentration is found in the liver, brain, heart and kidneys. However, due to the very 
large masses of muscles and bones, they contain approximately 50 % of the total 
copper in the body. The relatively large amounts of copper in the liver contribute 10 % 
to the total amount of copper in the body (Osterberg, 1980).  
On entering the interstitial fluid and blood plasma from interstitial cells, copper is 
initially bound to albumin and transcuprein in the portal blood and general circulation. 
Most of this bound copper is then rapidly deposited in the liver. About 65 % is bound 
to ceruloplasmin in the liver during its synthesis, but albumin can bind and release 
copper outside the liver. A small amount of plasma copper is also associated with small 
peptides and amino acids. Copper from the blood is distributed into the liver, kidney 
and other tissues (Linder & Hazegh-Azam, 1996).  
The role of copper as a cofactor for important enzymes has been well established. This 
includes cytochrome c oxidase (the terminal enzyme in electron transport and 
respiration), Cu/Zn superoxidase dismutase and ceruloplasmin (which removes 
superoxide and other potentially harmful radicals), as well as tyrosinase (producing 
melanin pigment), lysyl oxidase (which cross-links elastin and collagen), dopamine-
31 
 
monooxygenase (crucial for catecholamine production), and peptidyl glycine α-
amidating monooxygenase (necessary for modification of neuropeptide hormones). 
Most of these enzymes catalyze oxidation/reduction reactions that have molecular 
oxygen as a co-substrate. Indeed, the chemistry of copper makes it an ideal participant 
in redox reactions, as it easily cycles between cuprous Cu+ (Cu I) and cupric Cu2+ (Cu II) 
states (Linder, 2001). In biological systems, including water, copper tends to be in a 
cupric state. At physiological pH, there is little free copper in solution (Linder & 
Hazegh-Azam, 1996). Results from Rae et al (1999) indicate that intracellular free 
copper is limited to less than one free copper ion per cell. Moreover, calculated 
amounts of ionic copper suggested to be present in plasma are 10-18 M. Ionic copper 
has a particularly high affinity for other molecules (ligands) and, in consequence, all 
measurable copper in biological systems exists as complexes and chelates composed of 
copper bonded to organic components (Sorenson, 1987). However, extracellular 
copper is not controlled as tightly and is elevated in some pathological conditions, 
including cancer and inflammation (Linder, 1991). 
In the liver cells, copper is mainly found in the nuclear, granular, microsomal and 
soluble fraction. Under physiological conditions and normal copper intake, the 
microsomal and nuclear fractions contain only minor amounts of copper, about 10 % 
of the total copper. The main part of copper, about 60 %, is found in the soluble 
fraction. In the granular fraction, which includes both mitochondria and the lysosomes, 
there is about 20 % copper (Osterberg, 1980). 
1.7.2. COPPER HOMEOSTASIS 
Although adequate copper levels are essential for normal metabolism, excess copper 
can be toxic to cells. The cellular requirements for copper depend on tightly regulated 
network of proteins such as the copper transporter 1 (CTR1), supporting copper uptake 
across the plasma membrane and the copper chaperones, a collection of proteins that 
deliver copper to specific target enzymes (Figure 1.11, over) (Wang et al, 2011). 
CTR1 primarily mediates copper uptake into eukaryotic cells in mammals. This high 
affinity copper permease is an integral membrane protein that is structurally and 
functionally conserved from yeast to human (Puig et al, 2002; Zhou & Gitschier, 1997). 
A single CTR1 polypeptide contains 3 major domains: an extra-cytoplasmic N-terminus, 
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3 transmembrane helices and cytosolic C-terminal tail. The N-terminal domain, rich in 
Met and His residues, has been implicated in copper binding (Puig et al, 2002). 
 
Figure 1.11. Cellular copper homeostasis. The CTR1 protein plays an important role in copper uptake. 
The copper chaperones COX17 and CCS deliver copper to CCO and SOD1, respectively. Additional copper 
chaperones (SCO1 and SCO2) involved in copper incorporation into CCO is not shown. ATOX1 copper 
chaperone deliver copper to the ATP7A and ATP7B proteins, which then transport copper to copper 
dependent enzymes in the trans-Golgi network. Increased concentrations of copper stimulate the 
endocytosis and degradation of CTR1 and the exocytosis of ATP7A and ATP7B to post-Golgi vesicles or 
the plasma membrane (Wang et al, 2011). 
Once copper enters the cell via CTR1 protein, it can be transported to various distinct 
cellular locations. In eukaryotic cells, copper is delivered and incorporated into specific 
protein targets via the action of copper carrier proteins known as “metallochaperones” 
(Pufhal et al, 1997). One of them, COX17, acts in the delivery of copper to 
mitochondrial cytochrome oxidase (Glerum et al, 1996); ATOX1, escorts copper strictly 
to transport ATPases in the secretory pathway (Lin et al, 1997; Lin & Culotta, 1995); 
while CCS, copper chaperone for superoxide dismutase 1 (SOD), mediates delivery and 
incorporation of copper into cytosolic SOD1 (Culotta et al, 1997).  
The bioavailability of intracellular copper is also regulated by copper exporters, ATP7A 
and ATP7B, whose main role is transporting copper to newly synthesized 
cuproenzymes en route through the secretory pathway and copper export from cells. 
Both transporters are mainly located in the final compartment of the Golgi network. In 
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polarized cells, ATP7A and ATP7B undergo copper stimulated trafficking toward 
opposing membranes: ATP7A to the basolateral membrane and ATP7B to the subapical 
vesicles. Although ATP7A and ATP7B share similar biochemical functions, their tissue 
and developmental expression is different. ATP7A functions in a wide range of tissues 
that play critical roles in copper physiology, including copper absorption from the 
intestine and copper transport into the cerebral spinal fluid and cuproenzymes in the 
Golgi membranes of various tissues. Accordingly, loss of ATP7A function causes a lethal 
disorder of lack of copper called Menkes disease. In contrast, ATP7B is more selectively 
expressed in the liver, kidney, mammary epithelial cells, brain and eyes. Therefore, 
ATP7B mutation results in symptoms of hepatic and neuronal copper toxicosis seen in 
Wilson disease due to its specialized roles in these tissues (Wang et al, 2011). 
1.7.3. COPPER AND OXIDATIVE STRESS 
Unbound Cu (II) in the presence of a reducing agent, such as ascorbate, is reduced to 
Cu (I), which catalyzes Haber-Weiss-Fenton reaction to produce ROS (Figure 1.12) 
(Biaglow et al, 1997). For this reason, copper has been largely involved in the onset of 
oxidative stress (Valko et al, 2005) and in excess of cellular needs, copper can be 
cytotoxic. ROS are responsible for lipid peroxidation in membranes, direct oxidation of 
proteins and cleavage of DNA and RNA molecules (Tapiero et al, 2003).  
(1) Cu2+ + O2
.- → Cu+ + O2 
(2) Cu+ + H2O2  → Cu
2+ + OH- + ·OH 
(3) O2
.- + H2O2 → ·OH + OH
- + O2 
Figure 1.12. The Haber-Weiss-Fenton reaction generates ·OH (hydroxyl radicals) from H2O2 (hydrogen 
peroxide) and superoxide (O2
.-
) (1 and 2). It is followed by the Fenton reaction, which involves reduction 
of cupric ion (Cu
2+
) to cuprous ion (Cu
+
) (2) and net reaction (3). 
The generation and action of ROS are major contributors to the development of a 
variety of pathologies such as ischaemia-reperfusion injury, chronic inflammation, 
Alzheimer`s disease, cancer, depression and aging (Tapiero et al, 2003; Rael et al, 
2007). Generation of ROS was also suggested as a mechanism for the increased IL-8 
secretion by endothelium observed with post-ischaemic reperfusion injury (Bar-Or et 
al, 2003). In inflammation and cancer, plasma copper and ceruloplasmin 
concentrations rise and the rates of synthesis and secretion of ceruloplasmin in the 
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liver are enhanced. This occurs through enhanced transcription of ceruloplasmin 
mRNA in hepatocytes. The increased concentrations of this protein in the circulation 
most likely provide additional extracellular protection from oxygen radicals to cell 
membranes during activation of leukocytes, macrophages and other immune cells that 
release them. In addition, the elevated ceruloplasmin in inflammation would provide 
additional copper for uptake by cells in normal tissues (Linder & Hazegh-Azam, 1996).  
Copper levels are elevated in the circulation and in sputum in CF. Copper levels in 
plasma of adult men with cystic fibrosis are 1205.9 ± 255.4 µg/l (19.14 ± 4.05 µM), 
compared to healthy controls, 808.8 ± 80.0 µg/l (12.84 ± 1.27 µM) (Percival et al, 
1999), while copper in sputum in CF was measured to be in the range 14.5 – 30.1 µg/l 
versus control, 3.0 – 16.4 µg/l (Gray et al, 2010).   
There is evidence implicating transition metals as mediators of inflammation and 
cytotoxity via oxidative mechanisms. Ambient air particles from a variety of locales 
contain ionisable metals and produce ROS in aqueous solution (Frampton et al, 1999). 
Kennedy et al (1998), for instance, studied air pollution particles collected in Provo, 
Utah. They stimulated a human EC line with metals contained in particulates. Zinc, lead 
and ferric ions had no effect on cytokine production, only copper dramatically 
stimulated secretion of the proinflammatory chemokine IL-8. However, Rice et al 
(2001) compared the proinflammatory effects of intratracheally instilled, equimolar, 
soluble forms of six metal sulphates in vivo in rats: vanadium, nickel, copper, iron (II), 
manganese and zinc. Copper was revealed to be the most proinflammatory metal, as it 
consistently induced early (4 hours post-instillation) and high airway neutrophilia even 
at the low dose. Copper was also found to be the most cytotoxic, as indicated by LDH 
activity and total protein concentrations in BALF. Eventually, copper induced 
expression of macrophage inflammatory protein-2 (MIP-2) mRNA at earlier sampling 
times compared to other treatments. Copper also initiates transcription of genes 
coding for fundamental proinflammatory cytokines via an NF-ĸB-dependent pathway 
through production of ROS, which could explain the mechanism contributing to the 
induction of leukocyte influx and cytotoxity by copper (Perschini et al, 2006). 
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1.8. ANTI-COPPER THERAPY 
Anti-copper drugs that have been developed to treat Wilson’s disease, include 
tetrathiomolybdate, zinc, penicillamine, and trientine. Tetrathiomolybdate has proven 
effective in numerous animal models of cancer, retinopathy, fibrosis and inflammation 
and with non-Wilson’s patients, tetrathiomolybdate inhibits angiogenesis, fibrosis and 
inflammation while avoiding clinical copper deficiency (Brewer, 2005). Lowering 
copper levels by a modest amount leaves adequate copper for use by cells to make 
vital copper-containing enzymes, such as cytochrome oxidase. The decrease of the 
copper concentration appears to involve inhibition of several proangiogenic cytokines, 
as well as inhibition of NF-ĸB, a master switch for transcription of many cytokines.  
Bleomycin is a cytostatic drug employed in treatment of cancer, however it can cause 
side effects, such as pulmonary fibrosis, that may progress to fibrosis. 
Tetrathiomolybdate therapy is associated with inhibition of TNF-α expression and 
reduction of TGF-β protein levels in the lungs of bleomycin treated mice as well as 
MCP-1 and smooth muscle function, which have been shown to be important in the 
pathogenesis of fibrosis in the bleomycin model (Brewer et al, 2004). Since 1950, D-
penicillamine has been used as a form of immunosuppression therapy to treat 
rheumatoid arthritis and its effect involves copper chelation.  D-penicillamine reduces 
the number of peripheral blood T cells, inhibits macrophage function, reduces IL-1 and 
rheumatoid factor level and prevents collagen from cross-linking (Brewer, 2005). 
A proinflammatory role for copper has been demonstrated as copper induced IL-8 
synthesis and release from EC, which suggests that copper chelators, such as 
penicillamine may be useful as an anti-inflammatory therapy. Such a mechanism was 
demonstrated using human lung microvascular endothelial cells in cell culture, which 
showed that penicillamine significantly inhibited T cell transendothelial migration in 
response to platelet-derived RANTES (MacGregor et al, 2008, abstract), 
Tobramycin and other aminoglycosides are able to chelate copper (Jezowska-Bojczuk 
et al, 1998). Tobramycin is widely used as antibiotic in the treatment of CF with 
Pseudomonas infection, having an indirect effect on inflammation by reducing the 
bacterial burden. However, the study of Ramsey et al (1999) indicated beneficial anti-
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inflammatory effects of tobramycin beyond antibacterial activity. This project now 
investigates the potential direct anti-inflammatory effects of tobramycin. 
1.9. CURRENT TREATMENT OF CYSTIC FIBROSIS 
Understanding the pathogenesis of CF lung disease may provide opportunities for 
treatment, which resulted in significant improvements in life expectancy and quality of 
life over the past 50 years (Voynow et al, 2005). The successful therapy of CF aims at 
reducing airway obstruction, controlling airway infection and inflammation and 
improving nutritional status (Davis at al, 1996). Nowadays, therapeutic strategies 
targeting the cause of CF disease rather than symptomatic treatment are under 
development. More precise therapies focused on the basic defect, including 
manipulation of ion transport, activation of mutant CFTR and gene therapy are of 
particular interest (Becq et al, 2011). 
1.9.1. REDUCING AIRWAY OBSTRUCTION 
A characteristic feature of CF is the plugging of airways with thick and sticky airway 
secretion, a combination of mucus and pus, which requires a physical clearance 
procedure (Davis, 2006). Daily chest physiotherapy was demonstrated to maintain 
pulmonary function better over 3 years compared with deep breathing and cough 
alone, as shown in a prospective, controlled study by Reisman et al (1988). 
Bronchodilators, such as β-adrenergic agonists or cholinergic blockers are usually used 
prior to chest physiotherapy to dilate small airways and facilitate mucus clearance 
(Davis et al, 1996). Mucolytics increase the expectoration of sputum by reducing its 
viscosity or hypersecretion (Del Donno & Olivieri, 1998). In particular, two mucolytic 
agents, administered by nebulisation are able reduce sputum viscosity in CF, N-
acetylcysteine (NAC) and recombinant human DNase (Pulmozyme). NAC reduces 
disulfide bonds in mucins and decreases sputum viscosity in vitro. Additionally, as an 
antioxidant, NAC may have beneficial effects in the inflamed milieu in the CF airway 
(Voynow et al, 2005; Moldeus et al, 1986). Also, a reduction in viscosity was found in 
purulent sputum incubated in vivo with bovine pancreatic DNase I (Chernick et al, 
1961). It therefore led to the development of inhaled bovine and human recombinant 
DNase I. However, this treatment improved pulmonary function in CF patients with 
only mild lung disease (Geller, 1997) and did not eliminate exacerbations of respiratory 
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symptoms (Fuchs et al, 1994). It was subsequently proposed to add human 
recombinant DNase in hypertonic saline with mannitol and denufosol (Pettit & 
Johnson, 2011). 
1.9.2. TREATMENT OF AIRWAY INFECTION WITH ANTIBIOTICS 
Antibiotics are a key therapy responsible for increased survival and improved quality of 
life in CF. Antibiotics can be grouped by their function into five groups: inhibitors of cell 
wall synthesis, inhibitors of protein synthesis, inhibitors of membrane function, anti-
metabolites and inhibitors of nucleic acid synthesis (Figure 1.13) (Pratt & Cornely, 
2004). Aminoglycosides, which belong to the group of inhibitors of protein synthesis 
are the most common antibiotics prescribed to CF patients. 
 
Figure 1.13. Mechanisms of antibiotic action. Tobramycin acts on the translation process and affects 
protein synthesis by inhibiting the 30S RNA subunit (Pratt & Cornely, 2004). 
Antibiotic therapy is used to treat an acute exacerbation of bronchitis when signs and 
symptoms are consistent with worsening infection (Voynow et al, 2005). However, 
early in CF, most bacteria are susceptible and antibiotics can successfully treat 
infection. Treatment with an anti-staphylococcal agent following the diagnosis of CF 
through newborn screening may lead to reduced colonisation with P. aeruginosa and 
fewer hospitalisation during the first two years of life (Weaver et al, 1994). Indeed, an 
aggressive approach to the early treatment of P. aeruginosa with a combination of 
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inhaled colistin and oral ciprofloxacin resulted in reduced colonisation rates as well as 
better pulmonary function and fewer days of hospitalisation (Frederiksen et al, 1997). 
Inhaled therapy with antibiotics such as tobramycin, colistin, and aztreonam is 
prescribed for long-term treatment to improve lung function by hindering the growth 
of colonized bacteria (McCoy et al, 2008; Westerman et al, 2004; Pai & Nahata, 2001). 
Because of the altered pharmacokinetics of many antibiotics, patients with CF often 
require higher doses and/or more frequent dosing intervals than what is usually 
recommended. In order to minimise complications, the duration of antibiotic therapy 
depends on clinical response and monitoring of adverse effects (Davis et al, 1996). For 
example, inhaled tobramycin is inhibited by sputum components, such as DNA, 
therefore, high concentrations of antibiotics are used with avoiding systemic toxicity. 
Aminoglycoside antibiotics (aminoglycosides) form a large class of clinically important 
antibiotics with an efficacy in particular against Gram-negative bacteria, such as: 
Pseudomonas aeruginosa, Esherichia coli, Proteus species, Klebsiella species and 
Serratia species and Enterobacter species (Spelman et al, 1989). Most of the 
aminoglycosides are naturally occurring substances and are readily obtained from 
actinomycetes of either genus Streptomyces (labelled “-mycin”) or Micromonospora 
(labelled ”-micin”). A key structural feature of the aminoglycoside antibiotics is a 1,3-
diaminocyclohexanetriol termed streptamine or, in case where the 2-hydroxy function 
is deoxygenated as in most aminoglycosides, 2-deoxystreptamine (DOS) (Ring B in the 
structure in Figure 1.14, over). This central position of 2-deoxystreptamine suggests a 
crucial role for the biological activity of aminoglycosides (Busscher et al, 2005). 
There are two classes of aminoglycosides that contain a 2-deoxystreptamine core, the 
4,5- and 4,6-disubstituted 2-deoxystreptamine antibiotics. The 4,5-disubstituted class 
consists of neomycin, paromycin and ribostamycin. The largest group of the 4,6-
disubstituted class consists of kanamycin, gentamycin, tobramycin and amikacin 
(Figure 1.14, over) (Recht et al, 2001). 
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Figure 1.14. Schematic structures of aminoglycosides. (A) neomycin B (R = NH2) and paromomycin (R = 
OH), (B) gentamicin C1 (R1 = R2 = CH3), gentamicin C2 (R1 = CH3; R2 = H), and gentamicin C1A (R1 = R2 = H), 
and (C) kanamycin A (R1 = OH; R2 = OH), kanamycin B (R1 = OH; R2 = NH2), and tobramycin (R1 = H; R2 = 
OH) (Ming, 2003). 
Aminoglycosides carry a positive charge under physiological conditions (pH 7.4). The 
amine groups on ring A are the most basic (pKa ~ 9.6), whereas those on rings B (pKa ~ 
5.6 to ~ 8.8) and ring C (pKa ~ 7.5) are closer to physiological pH (Gokhale et al, 2007). 
The presence of these positively-charged amine groups promotes aminoglycoside 
binding to negatively charged moieties of phospholipids, lipopolysaccharides and outer 
membrane proteins in Gram-negative bacteria. It is thought that binding of 
aminoglycosides causes displacement of Mg2+ and Ca2+ ions linking neighbouring 
lipopolysaccharide molecules. This process damages the outer membrane and 
enhances its permeability. The initial electrostatic surface binding is followed by 
energy-dependent phase I of bacterial uptake. During that phase, only a small quantity 
of antibiotic molecules crosses the cytoplasmic membrane. The binding of antibiotic to 
the interface between smaller (30S) and larger (50S) ribosomal subunits results in 
misreading of mRNA and production of misfolded proteins. Some of these proteins are 
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incorporated in the cytoplasmic membrane, leading to the loss of membrane integrity. 
This is followed by a cascade of events known as energy-dependent phase II uptake. 
During this phase, additional quantities of aminoglycoside are moved across the 
damaged cytoplasmic membrane. Consequently, antibiotics accumulate in the 
cytoplasm and bind to receptors on the 30S subunit of the bacterial ribosome, which 
plays an essential role in providing high-fidelity translocation of genetic material, and 
inhibit ribosomal protein synthesis. Higher concentration of the aminoglycoside dictate 
more rapid onset of energy-dependent phase II uptake and subsequent bacterial death 
(Lode, 1998; reviewed by Vakulenko et al, 2003). 
2-deoxystreptamine-containing aminoglycosides bind to the ribosomal decoding site at 
the internal loop of the 16S RNA that comprises three unpaired adenine residues. Two 
of the adenines (A1492 and A1493) are flexible and may acquire positions inside the 
RNA loop or project into a site at the ribosome that accommodates the hybrid 
between messenger RNA (mRNA) and the A-site-bound transfer RNA (tRNA). Decoding 
of mRNA involves direct contacts between the flexible adenine “sensors” of the 
decoding site and the mRNA-tRNA codon-anticodon hybrid. Aminoglycoside binding at 
the decoding site displaces the flexible adenines from the RNA interior and locks them 
in a “flipped-out” state that closely resembles the conformation during mRNA 
decoding. As a result, the difference between cognate and near-cognate tRNA-mRNA 
interactions is reduced, leading to diminished translational fidelity. Over time, 
accumulation of truncated or inproperly folded proteins leads to bacterial cell death 
(Figure 1.15, over) (Hermann, 2007). 
Several mechanisms have been suggested for bacterial resistance to aminoglycosides. 
The main ones are: decreased antibiotic uptake and accumulation, modification of the 
ribosomal target, efflux of antibiotic or enzymatic modification of aminoglycosides 
(Vakulenko et al, 2003). 
Aminoglycosides could be used in combination with another drug (an 
antipseudomonal penicillin or cephalosporin) to obtain a synergistic effect (a positive 
interaction between two anti-infective drugs that results in greater efficacy than the 
sum of their two individual effects) and to minimise the risk of resistance (Michea-
Hamzehpour et al, 1986; Lode, 1998). 
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Figure 1.15. The decoding site in 16S ribosomal RNA. Secondary structure of the bacterial decoding site 
(left); the aminoglycoside binding site is shown a box; superposition of the crystal structures of three 
aminoglycosides in complex with the bacterial decoding site RNA (right). The structures highlight the 
conserved docking site of the 2-DOS scaffold in the three aminoglycosides and the displacement of the 
flexible adenines A1492 and A1493, which play a key role in the decoding process (Hermann, 2007). 
Aminoglycoside antibiotics do not easily cross normal human biologic membranes in 
physiological conditions and, in consequence, are not absorbed from the 
gastrointestinal tract, because of its poor lipid solubility. Thus they are typically 
administered intravenously, topically, ophthalmologically or intramuscularly. 
Aerosolization may be used when the drug is required in the airways, such as in CF 
(Lode, 1998). 
The killing potential of aminoglycosides is dependent on the concentration and 
increases with increasing levels of the antibiotic. Importantly, aminoglycosides exhibit 
the post-antibiotic effect, which has been classically described as a persistent 
suppression of bacterial growth after a limited exposure to antimicrobial agents 
(Novelli et al, 1995). Aminoglycosides continue to kill bacteria even after the drug has 
been removed (Buntzen et al, 1981). This bactericidal activity of aminoglycosides 
favours one-a-day dosing. High single doses per day are used to maximise peak levels, 
avoiding sustained high levels of the drugs (Gilbert, 1991; Rao et al, 2006). 
Aminoglycosides are excreted almost entirely by glomerular filtration without prior 
metabolisation due to their high polarity and low protein-binding. Nephrotoxicity of 
42 
 
aminoglycosides is associated to the accumulation of small portions of the drug dose in 
the renal cortex followed by mostly reversibly renal impairment (Mingeot-Leclercq, 
1999; Fischel-Ghodsian, 2005). Beside nephrotoxicity, aminoglycosides can cause 
irreversible ototoxicity in a dose-dependent manner that damages hair cells in the 
inner ear. Experimental evidence in animals has indicated that ROS may be one factor 
responsible for the development of aminoglycoside ototoxicity (Bates, 2003). Kalinec 
and co-workers (2005) indicated that the production of ROS in the cochlea during 
aminoglycoside therapy elicits apoptosis of hair cells via a complex signalling pathway. 
General bacterial resistance by compound modifying enzymes and drug toxicity are the 
main limitations of aminoglycoside antibiotic therapy. The poor oral absorption is a 
secondary concern since these antibiotics are used in clinical settings for the treatment 
of closely monitored patients suffering from serious infections. A great number of 
efforts have been made to reduce the resistance and toxicity of aminoglycosides by 
focusing on modifications of the natural products or synthesis of aminoglycoside 
mimetics (Hermann, 2007). 
1.9.3. THERAPIES DIRECTED AT INFLAMMATION 
Antibiotic therapy reduces the inflammatory stimulus, however inflammation 
significantly contributes to the lung destruction in CF. Only few therapies for CF lung 
disease are specifically and directly aimed at reducing inflammation.      
Although studies have not shown any particular benefit of long-term inhaled steroids 
for people with CF, they are used to treat CF patients, who also suffer from asthma or 
allergic bronchopulmonary aspergillosis. They are generally not recommended because 
of the potential for serious side effects including growth retardation in children, 
diabetes, cataracts, osteoporosis and decreased ability to fight lung infections (Davis et 
al, 1996). 
Nonsteroidal anti-inflammatory drugs (NSAIDs) do not carry the same risk of side 
effects, making them more appropriate for long-term use. High concentrations of 
ibuprofen reveal specific activity against neutrophils, such as inhibition of neutrophil 
migration and release of lysosomal enzymes (Davis et al, 1996). In patients with CF, 
high doses of ibuprofen administered orally twice daily inhibited neutrophil 
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recruitment to a mucosal site in vivo (Konstan et al, 2003). A four year trial of 
ibuprofen demonstrated the improvement in lung function in patients 5 to 12 years of 
age, but did not in older patients (Konstan et al, 1995). However, the Cystic Fibrosis 
Foundation recommends ibuprofen as a treatment option for CF patients, who are at 
least 6 years old and have an FEV1 (forced expiratory volume in 1 second) of 60 % or 
greater. 
Azithromycin, a macrolide antibiotic was shown to exhibit anti-inflammatory activity in 
animal and humans. Azithromycin has been shown to affect several pathways of the 
inflammatory process, including neutrophil migration, the oxidative burst in 
phagocytes and the production of proinflammatory cytokines (Legssyer et al, 2006; 
Shinkai et al, 2006; Tsai et al, 2004; Anderson et al, 1996). Two small randomised 
controlled trials  (Southern et al, 2003) as well as three well-designed randomised 
controlled trials have demonstrated a small but significant improvement in respiratory 
function with azithromycin compared with placebo (Southern et al, 2004). 
 
1.10. HYPOTHESIS, AIMS AND OBJECTIVES 
The hypothesis of this study is that tobramycin binds copper to become a copper-
tobramycin complex with anti-oxidant properties, that inhibits neutrophilic and 
endothelial inflammatory responses. 
OBJECTIVES: 
 to study platelet-neutrophil-endothelial cell interactions in the recruitment of 
neutrophils across the blood vessel wall and to determine the role of each cell 
type 
 to investigate the effect of the aminoglycoside antibiotic, tobramycin, and the 
copper-tobramycin complex on transendothelial migration of neutrophils 
 to propose the mechanism of action of the drug 
 
The overall aim of the study is to indicate the therapeutic potential of tobramycin in 
respiratory disorders, such as cystic fibrosis, beyond its known antibacterial role. 
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CHAPTER 2 
CELLULAR COPPER CONTENT AND FORMATION  
OF THE COPPER-TOBRAMYCIN COMPLEX 
 
2.1.   INTRODUCTION    
2.1.1. SUPEROXIDE DISMUTASE 
Superoxide dismutase (SOD) is a blue copper protein, first isolated from bovine 
erythrocytes by Mann and Keilin in 1939. SOD catalyses the conversion of the 
superoxide (O2
.-) to hydrogen peroxide and oxygen, according to the equation:  
              2O2
- + 2H+ → H2O2 + O2 
Superoxide dismutase is widely distributed within mammalian tissues (McCord & 
Fridovich, 1969). There are three different mammalian SODs : intracellular 
copper/zinc-SOD (Cu/Zn-SOD, SOD1), predominantly located in the cell cytoplasm; 
mitochondrial manganese-SOD (Mn-SOD, SOD2), present in the mitochondria and 
cytoplasm of the cells; and extracellular-SOD (EC-SOD, SOD3), located mainly outside 
the cells, where it is bound to matrix proteins, such as collagen and elastin (Marklund, 
1982; Weisiger & Fridovich, 1972; McCord & Fridovich, 1969). 
Intracellular SOD1 has been shown to obtain catalytic copper ion through interaction 
with the cytosolic copper carrier CCS, a copper chaperone for SOD1 (Culotta et al, 
1997). The human CCS metallochaperone harbors a central, polypeptide region, which 
serves in target recognition of SOD1, while smaller segments at the N- and C-terminus 
of CCS facilitate the binding and release of copper into SOD1 (Schmidt et al, 1999). The 
Cu/Zn-SOD structure with its active site is shown in Figure 2.1 (over). The SOD 
molecule is a dimer with a molecular weight of 31,500 Da and it is composed of two 
subunits, each containing a Cu2+ and Zn2+ ion (Keele et al, 1971). The zinc ion is bound 
to three histidine residues and one aspartate residue and the copper atom is bound to 
four histidine residues. The two metal ions are connected via a histidine bridge 
(imidazole ring) (Richardson et al, 1975).  
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Figure 2.1. Human SOD1 structure. The relationship of the two monomers is indicated. Intrasubunit 
disulfide bonds are shown as orange sticks, the metal-binding loops (loop IV and VII) are shown in blue 
and pink, respectively. Copper and zinc ions are shown as cyan and green spheres, respectively 
(Seetharaman et al, 2009). 
 
Superoxide is thought not to bind with the enzyme active site, but is guided near its 
active site using a specific form of electrostatic attraction, referred to as a cationic 
funnel (Livesay et al, 2003). The first superoxide attraction near the enzyme is followed 
by an electron jump from the superoxide to the active site. As a result, the histidine 
bridge breaks, and the copper ion moves slightly away, whereas the rings on the 
copper structure rotate about 20 degrees towards the zinc. The attraction of the 
second superoxide near the active site takes place, when the reduced copper is re-
oxidized. Then, the original electron jumps back to the second superoxide molecule 
along with two protons, and one molecule of hydrogen peroxide is formed (Figure 2.2) 
(Hough & Hasnain, 1999). 
 
Figure 2.2. Dismutation of superoxide by SOD1. Kinetic studies of SOD have indicated that the copper 
ion cycles between the +1 and +2 oxidation states in two irreversible reactions each of which is first 
order with respect to O2
.-
 (Smirnov & Roth, 2006). 
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Previous studies demonstrated that cytokines or oxidative stress had no effect on lung 
Cu/Zn-SOD mRNA or activity in vivo or in vitro, in contrast to SOD2 (Chang et al, 1993; 
Visner et al, 1990). 
Mitochondrial SOD2 forms a homo-tetramer and binds one manganese ion per 
subunit. SOD2 is an important antioxidant enzyme, which catalyzes the conversion of 
superoxide radicals to H2O2 and molecular oxygen in the mitochondria, playing a key 
role in protecting cells against oxidative damage (Weisiger & Fridovich, 1973). 
SOD2 is highly inducible by oxidants and cytokines. Indeed, SOD2 mRNA, protein and 
activity are increased in cultured pulmonary epithelial and endothelial cells, 
fibroblasts, granulocytes and lung adenocarcinoma cells (A549) by oxidants, reducing 
agents, IL-1, TNF-α and LPS (Akashi et al, 1996; Chang et al, 1995; Das et al, 1995;  et 
al, 1990). Moreover, TNF-α was shown to significantly increase SOD2 activity and 
mRNA in a dose- and time-dependent manner (Warner et al, 1991). In contrast, 
peroxynitrite and dexamethasone appeared to inactivate SOD2 (reviewed by Kinnula & 
Crapo, 2003). 
Extracellular SOD3 is also a cuprozinc enzyme with a molecular weight of 135,000 Da, 
genetically related to SOD1, because it shares 40 – 60 % similarity with SOD1 (Zelko et 
al, 2002). A fundamental property of the secretory tetrameric form of SOD3 is its in 
vivo affinity for heparin and analogues, mediating attachment to HSPGs located on cell 
surfaces and in the connective tissue matrix (Sandstorm et al, 1992). 
SOD3 activity has been reported to be remarkably higher in the lung than in other 
organs. Bronchial and alveolar epithelium, epithelial cells lining intrapulmonary 
airways, alveolar macrophages and endothelial cells lining arteries and veins synthesize 
SOD3. Immunohistochemical studies revealed that SOD3 is located in the ECM and 
expressed in airway epithelial cell junctions and around the surface of vascular and 
airway smooth muscle cells (reviewed by Kinnula & Crapo, 2003). 
Direct oxidative stress does not affect SOD3 expression, but it is activated by cytokines, 
such as IFN-γ and TNF-α in alveolar type II pneumocytes and fibroblasts (reviewed by 
Kinnula & Crapo, 2003). Because SOD3 exerts an important protective role in the 
vascular wall, the vasoactive factors, such as histamine, vasopressin, serotonin and 
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heparin markedly increase enzyme levels in the cultured arterial smooth muscle cells. 
Increased concentrations of SOD3 also prevent the degradation of NO by oxygen 
radicals. TGF-β in fibroblasts and platelet-derived growth factor and epidermal growth 
factor in vascular smooth muscle cells downregulate expression and excretion of SOD3 
(Zelko et al, 2002). Moreover, proteolytic removal of the heparin-binding domain of 
SOD3 has been suggested to be important regulatory mechanism in the distribution of 
SOD3 within the ECM (Enghild et al, 1999). 
2.1.2. CATALASE 
Catalase is present in nearly all living organisms. Catalase serves to protect the cell 
from the toxic effects of hydrogen peroxide by decomposing it into molecular oxygen: 
2H2O2 → O2 + 2H2O (Loew, 1990). In Eucaryota, catalase is localized mainly in 
peroxisomes, but a small amount of catalase was also shown in mitochondria, the 
endoplasmic reticulum and cytoplasm (Yamamoto et al, 1988). The highest activity of 
catalase was detected in hepatocytes, kidney, erythrocytes, bone marrow, mucosal 
membranes and the smallest in connective tissue (Aebi et al, 1968). In contrast, human 
vascular smooth muscle cells and endothelial cells lack catalase activity and are 
susceptible to hydrogen peroxide (Shingu et al, 1985). 
All catalases studied so far are tetrameric. Each subunit (molecular weight around 
60,000 Da) is formed by a single polypeptide chain with haem as a prosthetic group at 
the catalytic centre (Deisseroth & Dounce, 1970; Schroeder  et al, 1969). Catalase 
monomers from certain species also contain one tightly bound NADP per subunit. This 
NADP may serve to protect the enzyme from oxidation by its H2O2 substrate (Eaton et 
al, 1995).  
More than 300 catalase sequences from different organisms are now available, divided 
among monofunctional catalases, bifunctional catalase-peroxidases and manganese-
containing catalases (Chelikani et al, 2004). Catalases present specific activities ranging 
from 20,700 to 273,800 units per milligram of protein and maximal turnover rates 
ranging from 54,000 to 833,000 per second. The effective concentrations of common 
catalase inhibitors, cyanide, azide, hydroxylamine, aminotriazole and mercaptoethanol 
varied over a 100- to 1000-fold concentration range and sensitivities to heat 
inactivation also varied (Switala & Loewen, 2002). 
48 
 
2.1.3. SOD MIMETICS 
Low molecular weight SOD mimetics differentiate into organic complexes that chelate 
metal ions and compounds that do not contain metal ions, but also neutralise 
superoxide radicals. It was remarked that certain transient metal complexes, especially 
manganese and copper, react with the superoxide anion radical in the way reminiscent 
of native SODs. The SOD mimetics, which are transient metal complexes distinguish 
three huge groups: metalloporphyrins, salens and macrocyclic metal complexes (Figure 
2.3). SOD mimetics could be also divided into compounds with solely SOD activity 
(group I) and compounds with both SOD and catalase activity (group II) (Wozniak & 
Czyz, 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. Classification of SOD mimetics with regard to their catalytic activity. Green colour identifies 
mimetics with solely SOD activity (group I) and blue – compounds with both SOD and catalase activity 
(group II). The end product of pseudoenzymatic activity of group I SOD mimetics is, according to the 
disproportionation reaction: 2H
+
 +
 
O2
.-
 +
 
O2
.-
 → H2O2 + O2, hydrogen peroxide and superoxide ion. In 
group II SOD mimetics, the second disproportionation follows the first one: H2O2 + H2O2 → 2H2O + O2, 
where hydrogen peroxide is dismutated to water and oxygen. There is a debate, whether mimetics with 
solely SOD activity are safe and do not trigger a cytotoxic level of hydrogen peroxide (modified from 
Wozniak & Czyz, 2008). 
Many metal-containing macrocyclics (group I) inhibit neutrophil infiltration to sites of 
inflammation and release of proinflammatory cytokines (Salvemini et al, 1999), which 
could be attributed to their marked superoxide SOD activity. Current interest in copper 
complexes originates from their potential use as anti-microbial, anti-viral, anti-
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inflammatory and anti-tumor agents as well as enzyme inhibitors, or chemical 
nucleases.  
Cu(II) complexes with non-steroidal anti-inflammatory drugs (NSAIDs) are more active 
than their parent drugs and exhibit reduced gastrointestinal toxicity compared to the 
uncomplexed drug. Further, many of these complexes, including that of copper 
ibuprofenate complex show enhanced anti-inflammatory and anti-ulcerogenic activity 
(Weder et al, 2002).  
Additionally, it has been shown that Cu(II)-curcumin complex possesses SOD activity, 
free radical neutralizing ability and antioxidant potential (Barik et al, 2005), while 
uncomplexed curcumin, a natural polyphenol derived from the plant Curcuma longa, 
has been described in several systems as a potent antioxidant and anti-inflammatory 
agent with anticancer potential (Aggarwal et al, 2003). 
The peptides, Ac-HisValHis-NH2 and Ac-HisValGlyAsp-NH2, related to the active site of 
the Cu/Zn-SOD enzyme formed stable complexes with copper even at low pH, but the 
interactions with zinc resulted in formation of a precipitate, indicating polypeptide 
complex formation (Boka et al, 2004). Both, copper(II)-Ac-HisValHis-NH2 and 
copper(II)-HisValHis systems exhibited catalytic activity toward the dismutation of 
superoxide anion, but the saturated coordination sphere of the metal ions in both 
systems results in low reactivity as compared to the native enzyme. 
All porphyrin SOD mimetics (group II) have low catalytic activity, which is lower than 
1% of the total catalytic activity of native catalase; however it is sufficient to protect 
cells from toxicity of high concentration of hydrogen peroxide. Manganese(III) tetrakis 
(4-benzoic acid) porphiryn (MnTBAP), a metalloporphyrin, is an effective free radical 
scavenger (Faulkner KM et al, 1994). For instance, it inhibited LPS-induced TNF-α 
production by macrophages and therefore decreased inflammation (Tumurkhuu et al, 
2007). Manganese(III) tetrakis (1-methyl-4-pyridyl) porphyrin pentachloride 
(MnTMPyP) is characterized by an easy penetration through the cellular membranes. It 
appeared to be an efficient antioxidant, which decreases release of malonyl 
dialdehyde, a marker of oxidative stress in a global cerebral ischaemia, preventing lipid 
peroxidation and DNA fragmentation induced by anoxia (Sharma & Gupta, 2007). 
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Two commercially available salen-manganese mimetics, EUK-8 and EUK-134 are 
characterized by a great stability and activity of SOD and catalase, scavenging almost 
all known forms of ROS. However, those reactions are reversible being a potential 
source of ROS. Therefore, EUK-8 and especially EUK-134 could contribute to the cell 
damage (Fucassi et al, 2007). 
2.1.4. COPPER(II)-AMINOGLYCOSIDES 
Aminoglycosides form the strongest complexes with Cu2+, compared to iron(III), 
nickel(II), cobalt(II) and zinc(II) (Szczepanik et al, 2004a). Moreover, the chelate 
formation stabilizes Cu2+ coordination to the aminoglycoside ligand (Patwardhan & 
Cowan, 2011). Several aminoglycoside antibiotics bind Cu2+, including gentamicin 
(Jezowska-Bojczuk et al, 1998b),  kanamycin A (Szczepanik et al, 2004a), lincomycin, 
(Jezowska-Bojczuk et al, 2001b),   kasugamycin (Jezowska-Bojczuk &Lesniak, 2001),  
tobramycin (Jezowska-Bojczuk et al, 1998a) and the semi-synthetic, amikacin 
(Jezowska-Bojczuk et al, 2001a). 
The ability of aminoglycosides to coordinate metal ions is primarily governed by sugar 
ring substitutions on the 2-deoxystreptamine ring. Vicinal amine and hydroxyl groups 
within the 2-deoxystreptamine ring can form a potential metal chelating motif. The 
simplest 4-substituted aminoglycoside is neamine, which has 2`-amine and 3`-hydroxyl 
juxtaposed to each other (ring A) and thus can effectively form a metal chelate (Figure 
2.4). Water molecules that complete an octahedral geometry occupy the remaining 
coordination sites around copper (Gokhale et al, 2007, Sreedhara et al, 2000). 
 
Figure 2.4. Cu
2+
-neamine at pH 7.5 (Sreedhara et al, 2000). 
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The proposed structure of the Cu2+-tobramycin complex at physiological pH is 
schematically shown on Figure 2.5, with the central Cu2+ metal ion and a N2O2 
coordination sphere comprising 3”-NH2, 4”-O
-, 4’-OH and 6’-NH2 from rings A and C 
(Jezowska-Bojczuk et al, 1998). 
 
 
Figure 2.5. Cu
2+
-tobramycin complex at physiological pH (Jezowska-Bojczuk et al, 1998). 
The positive charge, which the aminoglycosides carry on their amine functions, 
influences their chemical and therapeutic behaviour. The proton binding abilities of 
amino groups determine their interactions with the negatively charged residues of 
nucleic acids and with biological membranes. Individual aminoglycosides differ from 
each other with the amount of the groups undergoing ionization and not all of them 
are protonated at physiological pH (Kozlowski et al, 2005). 
Szczepanik et al (2004a) tested the effect of the aminoglycoside antibiotic kanamycin A 
on Cu2+ homeostasis. In order to examine whether the drug was capable of disturbing 
the Cu2+ content in blood plasma, the ability of kanamycin A to remove metal ions 
from saturated N-terminal binding site of human serum albumin was tested. The 
formation of an NH2→Cu
2+ charge transfer transition characteristic for the Cu2+ 
complex of aminosugar antibiotics was observed. This fact, simultaneously with the 
decrease of the d–d band intensity of Cu2+-HSA, suggests that under favorable 
conditions Cu2+-aminoglycoside complex formation might be possible in vivo, especially 
in the case of high antibiotic concentrations in plasma, which may occur during 
+ 
+ 
+ 
 3 
52 
 
intravenous or intramuscular injection (Szczepanik et al, 2004a; Jezowska-Bojczuk et al, 
1998a; Jezowska-Bojczuk et al, 1996). 
The oxidative properties of copper centres in metalloproteins are well known.  Also, 
many cupric complexes of aminoglycosides induce the formation of ROS (Szczepanik et 
al, 2004b). Although cyclic volumetric studies indicated that kanamycin A and amikacin 
are redox-inactive, their copper(II) complexes exhibited irreversible reduction and 
oxidation peaks in a wide pH range (Szczepanik et al, 2004b; Jezowska-Bojczuk et al, 
2001a). Among aminoglycoside antibiotic complexes with copper, Cu2+-neomycin B, 
generated hydroxyl radicals most effectively. Indeed, Cu2+-neomycinB has the highest 
charge, because of six amino groups within its complex (Szczepanik et al, 2003).  The 
hydroxyl radical is the most powerful oxidizing agent in biological system. Therefore 
their formation constitutes potential pro-mutagenic and pro-carcinogenic properties 
(Szczepanik et al, 2004b). 
In the presence of H2O2, the Cu(II)-amikacin complex oxidizes 2`-deoxyguanosine to its 
8-oxo derivative. Production of 8-oxo-guanosine suggests that these complexes may 
oxidize nucleobases within DNA molecules and the consecutive impairment of bases 
may lead to deleterious results, such as mutations. This process seems to be pH 
dependent, showing thereby that the complex present around physiological pH is the 
most efficient 2`deoxyguanosine oxidizing agent (Jezowska-Bojczuk et al, 2002). 
However, some physiologically ubiquitous compounds like histidine or ATP appeared 
to disturb complex formation between Cu2+ and aminoglycoside and thus prevent DNA 
from damage. Both amino acid and nucleotides at physiological concentrations were 
found to drastically decrease the amount of strand breakages. Similar observations 
came from the experiment including magnesium ions. The magnesium binding to the 
phosphate residues protects DNA against the complex activity (Sczepanik et al, 2004c). 
In the circulation, Cu(II)-kanamycin A and other copper-aminoglycoside complexes may 
exert influence on blood cells and generate various immune reactions, such as 
cytokine production, which are messenger proteins that regulate a wide variety of 
cellular functions. Szczepanik et al (2004a) demonstrated that Cu(II)-kanamycin A 
complex was able to induce TNF, interferon (IFN) and IL-10 in human peripheral blood 
leukocytes. The effect on the cytokine release was dose and time dependent and an 
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inter-dependence between IL-10 and TNF stimulation was found. In addition, the 
Cu(II)-aminoglycoside system can act as a moderate inducer of TNF-α, IFN-α/β and IL-
10 released from human leukocytes. The research of Szczepanik et al (2004a) suggests 
therefore that in vivo Cu2+ coordination by aminoglycosides may support the pro-
inflammatory process. 
However, so far, tobramycin or Cu(II)-tobramycin complex has not been shown to have 
any pro-inflammatory effect in vivo or in vitro. Conversely, tobramycin has been 
suggested to have an anti-inflammatory effect beyond its known anti-pseudomonal 
activity in the treatment of CF patients (Ramsey et al, 1999). More recently, an anti-
inflammatory role of tobramycin, related to its clinical efficacy as an inhalation therapy 
in chronic Pseudomonas aeruginosa airway infection, was confirmed in vitro by 
Nakamura et al (2011). A high dose of tobramycin (500 µg/ml) was demonstrated to 
decrease MUC5AC gene expression and protein production in NCI-H292 cells 
stimulated by LPS. Moreover, tobramycin complex with copper was shown to possess 
SOD-like activity (Shute & MacGregor, 2009, abstract). 
2.2.   HYPOTHESIS, AIMS AND OBJECTIVES 
It is hypothesized that, in vitro, tobramycin binds copper and becomes a copper-
tobramycin complex. 
The aim of this research is to investigate a potential anti-inflammatory activity of 
tobramycin associated with copper binding. The initial objective was to measure the 
copper level in endothelial cells, neutrophils and platelets. The further objective was to 
prove that tobramycin binds copper in vitro and readily becomes a copper-tobramycin 
complex. Moreover, the SOD and catalase activity of copper-tobramycin was 
investigated. 
2.3. MATERIALS 
Human lung microvascular endothelial cells (HLMVEC) were purchased from Lonza Ltd. 
(Slough, Berkshire, UK), which also supplied endothelial cell culture basal medium,  
growth supplements and trypsin/EDTA and trypsin neutralising solution.  
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75 cm2 culture flasks were obtained from Triple Red Ltd. (Long Crendon, 
Buckinghampshire, UK).  
Greiner-Bio-One Ltd. (Stonehouse, Gloucestershire, UK) provided the following 
consumables for blood collection: Vacuette EDTA K3, lithum heparin tubes, clot 
activator tubes, butterfly needles 23 G x 23 cm, Vacuette holdex holder. 
LymphoprepTM was purchased from Axis Shield Diagnostics Ltd. (Huntington, UK).      
Macrodex TM (Dextran 70, 6 % w/v) was from Baxter Healthcare, Thetford, UK. 
Phosphate buffered saline (PBS), Hank`s Balanced Salt Solution (HBSS), RPMI 1640 and 
distilled water were obtained from GIBCO, Invitrogen Ltd. (Paisley, UK). Invitrogen also 
provided Amplex Red Neuraminidase (Sialidase). 
Trypan blue solution (0.4 %), dimethyl sulphoxide (DMSO), heat inactivated fetal 
bovine serum (FBS), tobramycin sulphate, copper (II) chloride, copper standard for AAS 
(TracecertTM), ammonium nitrate, hydrogen peroxide 30 % (v/v), bovine liver catalase, 
bovine erythrocytes superoxide dismutase, nitro blue tetrazolium (NBT), NADH and 
phenazine methosulphate (PMS) came from Sigma-Aldrich Inc. (Poole, Dorset, UK). 
Copper sulphate, sodium chloride and ethylenediaminetetraacetic acid (EDTA) were 
purchased from Fisher Scientific (Loughborough, Leicestershire, UK). Fisher Scientific 
also provided polypropylene Falcon tubes, 14 ml (17 x 100 mm) capacity, a trace metal 
grade nitric acid and colour-fixed pH indicator sticks.
 
 
Complete mini® protease inhibitor (double strength) was from Roche Ltd. (Wewlyn 
Garden City, Hertfordshire, UK). 
2.4.   METHODS 
2.4.1.   NEUTROPHIL ISOLATION 
Neutrophils were isolated from EDTA-anticoagulated venous blood (18 ml) from 
healthy donors.  Red blood cells (RBCs) were removed by sedimentation by mixing 
blood in a 2:1 ratio with 9 ml of 6 % (v/v) Dextran 70 (Baxter Healthcare) for 45 
minutes. Leukocyte-rich supernatants were underlayered with an equal volume of 
Lymphoprep (Axis Shield Diagnostics) and centrifuged at 450 x g for 30 minutes at 
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room temperature. The upper layers were discarded and RBCs remaining in the 
granulocyte pellet were subjected to hypotonic lysis with 5 ml of 0.2 % NaCl for 45 
seconds, followed by 5 ml 1.6 % NaCl. After centrifugation at 800 x g for 10 minutes at 
40C, hypotonic lysis for 30 seconds was carried out. Neutrophils were pelleted at 200 x 
g for 5 minutes at 40C. Cells were finally re-suspended in appropriate buffer/medium, 
depending on the experiment, HBSS (- Ca/Mg) + 20 mM HEPES, pH 7.4 or RPMI 1640 
containing 2.5 % (v/v) FBS. The cells were then counted using a haemocytometer and 
diluted to the required density. Cell viability was assessed by trypan blue exclusion to 
be above 95 % and purity above 98 %. Contaminating cells were mostly eosinophils 
and rarely monocytes. 
2.4.2.   PLATELET ISOLATION 
Platelets were isolated from 18 ml EDTA-anticoagulated normal venous blood. 
Platelet-rich supernatant was prepared by adding 0.1 volume of 0.15 M NaCl plus       
77 mM EDTA, pH 7.4 to whole blood and centrifuging at 200 x g for 15 minutes at 200C. 
The platelet-rich plasma was harvested and platelets were pelleted at 2500 x g for 15 
minutes at room temperature and the pellet was washed first with PBS (- Ca/Mg) 
containing 10 mM EDTA and secondly with PBS (- Ca/Mg) without EDTA. Cells were 
finally re-suspend in appropriate buffer, counted using trypan blue and 
haemocytometer and diluted to the required cell number. 
2.4.3. PLASMA AND SERUM SAMPLE PREPARATION 
Plasma samples were prepared in lithium-heparin Vacuette tubes by a centrifugation 
at 1300 x g of whole blood. Serum samples were prepared in serum clot activator 
Vacuette tubes and left for clotting for 30 minutes at room temperature. Then the 
samples were centrifuged at 1300 x g for 10 minutes, clear supernatants removed and 
stored at -200C before copper measurement. 
2.4.4. ENDOTHELIAL CELL CULTURE 
Human lung microvascular endothelial cells (HLMVEC) were maintained in culture 
medium consisting of endothelial basal medium (EBM-2), 5 % (v/v) FBS, 0.04 % (v/v) 
hydrocortisone, 0.4 % (v/v) human fibroblastic growth factor (hFGF-2), 0.1 % (v/v) 
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vascular endothelial growth factor (VEGF), 0.1 % (v/v) insulin-like growth factor (R3-
IGF-1), 0.1% (v/v) ascorbic acid, 0.1 % (v/v) human epidermal growth factor (hEGF), 1 % 
(v/v)_gentamycin and amphoteracin B (GA-1000). The cell cultures were maintained at 
370C in 5 % CO2 and 95 % air. Experiments were performed up to passage 10 with cells 
at 90 to 100 % confluence. 
HLMVEC were seeded in 75 cm2 flasks at a density of 5000 cells/cm2. The number of 
flasks was calculated using the following formulas: 
 
    a  no o  cm  that can  e p ated                                             
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For seeding, 10 ml of fresh medium was added to each flask, which was placed into the 
incubator for 5 minutes to warm up. The cryovial with HLMVEC was removed from the 
liquid nitrogen. In a sterile field, the cap was briefly twisted a quarter turn to relieve 
the internal pressure, then re-tightened. Holding the cryovial, the bottom ¾ of the 
cryovial was dipped in a 370C water bath and swirled gently for 1 – 2 minutes until the 
contents were thawed. The cryovial was removed immediately and transferred to a 
sterile field, where the equilibrated flasks were waiting, ready to seed. The cells in the 
cryovial were re-suspended with a gentle, slow and steady up and down pipetting 
motion. An equal amount of cell suspension was dispensed into each flask. The caps 
were replaced and the vessels gently rocked to evenly distribute the cells. Each flask 
was labeled with the cell type and density, medium type, passage number and date. 
The cell density was checked under the microscope and the culture vessels were 
returned to the incubator, where cells were allowed to adhere overnight. 
2.4.4.1. CELL FEEDING 
One day after seeding, the old medium was removed and the same volume of warm 
and fresh growth medium was added per flask. Every other day, the cells were fed with 
a larger volume of medium as they became more confluent: 
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If cells are:                                            Then feed them: 
Under 25 % con   ent…                      1 m  per 5 cm2 (15 ml for T-75)     
From 25 – 45 % con   ent…               1.5 ml per 5 cm2 
Exceeding 45 % con   ence…             2 ml per 5 cm2 
Feeding the cells was continued until 60 – 90 % confluence. 
2.4.4.2. SUBCULTURING 
The cells were subcultured when they were 60 – 90 % confluent and contained many 
mitotic figures throughout the flask. The growth medium was aspirated from all flasks 
and the cells were washed with 5 ml/flask of HBSS (- Ca/Mg). This step allowed 
removing the excess of medium, which contains complex proteins that neutralize 
trypsin.  The cells were covered with 2 ml/flask warmed trypsin/EDTA (Lonza, UK) and 
the flasks left in the incubator for approximately 10 minutes. The flasks were rapped 
against the palm of the hand few times to release the cells from the culture surface. 
The cell layer was examined microscopically. The trypsinization was continued until 
approximately 90 % of the cells were rounded up. Trypsin/EDTA was neutralized with 
an equal volume of warmed trypsin neutralising solution (Lonza, UK) and rinsed 
around. The detached cells were quickly transferred into a sterile 50 ml Falcon tube. 
The flasks were rinsed with 5 ml of HBSS (- Ca/Mg) to collect residual cells. The 
harvested flasks were examined under the microscope to make sure the harvest was 
successful. The harvested cells were pelleted at 220 x g for 5 minutes. After 
centrifugation, the supernatant was discarded and the cell pellet re-suspend in full 
growth medium. To count the cells, 10 µl of the cell suspension was mixed well with   
90 µl trypan blue solution. Then, 10 µl of the mixture was added per chamber of 
haemacytometer. The cell number was calculated using the following formula:  
Cn = n x 10 x 10
4/ml, where:  
n = cell number, 10 = dilution factor, 104 = a constant factor 
2.4.4.3. SUBCULTURING FOR NEW FLASKS 
To subculture for new flasks, the total number of flasks to inoculate was determined 
by using the equation shown in section 2.4.4 as the number of flasks needed depends 
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upon cell yield and seeding density. 1 ml growth medium was transferred for every 5 
cm2 surface area of the flask (15 ml/75 cm2 flask). The vessels were placed into the 
incubator to warm up. The calculated volume of cell suspension was dispensed into 
the prepared flasks. The flasks were gently rocked to promote even distribution and 
placed to the incubator. 
2.4.4.4. SUBCULTURING FOR CRYOPRESERVATION 
To subculture for cryopreservation, a cryopreservation solution was prepared. It 
contained: 80 % (v/v) growth medium, 10 % (v/v) FBS and 10 % (v/v) DMSO. HLMVEC 
were diluted to 2 x 106/ml in cryopreservation solution and splitted into cryogenic vials 
(1 ml/vial). Each vial was labeled with the cell name, cell density, passage number and 
date of subculturing. Cryogenic vials were placed on a polystyrene base in -800C 
freezer for no longer than 12 – 24 hours. The vials were finally transferred to liquid 
nitrogen. 
2.4.5.   COPPER   MEASUREMENT   BY   GRAPHITE   FURNACE  –  ATOMIC   ABSORPTION   
             SPECTROPHOTOMETRY (GF-AAS) 
2.4.5.1. SAMPLE PREPARATION FOR GF-AAS 
HLMVEC were grown in 75 cm2 flasks until confluent and lifted with trypsin/EDTA as 
described in Section 2.4.4.2. The cells from each of three flasks were counted and 
lysed in 1 ml of 1 % (v/v) Triton X-100 in water, containing double strength of protease 
inhibitor (Roche). 
Neutrophils were isolated from healthy donors as described in Section 2.4.1. They 
were re-suspended in HBSS (- Ca/Mg) or RPMI 1640 containing 2.5 % (v/v) FBS at 1 x 
107 cells/ml. 4 and 5 preparations of neutrophil suspensions (1 ml) were made in HBSS      
(- Ca/Mg) and RPMI 1640 with FBS, respectively. 
Platelets were isolated from healthy donors as described in Section 2.4.2 and re-
suspended in PBS (+ Ca/Mg) at a concentration of 1 x 109 cells/ml. Platelets were than 
activated with thrombin in the concentration range 0 – 3 U/ml at 370C for 30 minutes 
in a total volume of 1 ml. The material was centrifuged at 2500 x g for 15 minutes in 
40C. 1 ml supernatants were stored at -800C. The cell pellets were lysed in an equal 
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volume of 1 ml of 1 % (v/v) Triton X-100 in water, containing double strength protease 
inhibitor (Roche). 
2.4.5.2.   SAMPLE DIGESTION 
The digestion system for copper analysis was adapted from Alcock (1987). 1 ml of 
neutrophil suspension at 1 x 107 cells/ml, HLMVEC and platelet lysates were 
transferred into trace metal free polypropylene, round bottomed tubes. HNO3 at 0.1 M 
final concentration was added per 1 ml sample using 10 M stock (10 µl). As sample 
controls, 1 ml of HBSS (- Ca/Mg), PBS (- Ca/Mg), RPMI 1640 with 2.5 % (v/v) FBS, EGM 
and 1 % (v/v) Triton X-100 in water was transferred into trace metal free 
polypropylene, round bottomed tubes (Fisher), followed by addition of 10 µl trace 
metal grade 10 M HNO3. Furthermore, 1 ml of 50 ppb (50 µg/l) copper standard was 
prepared to serve as a copper recovery control. The samples were frozen at -800C and 
freeze-dried. The dried powder was dissolved in 0.5 ml of 30 % (v/v) H2O2 and the 
mixture left to dry at 500C two times. This step was repeated again with 650C drying 
temperature. Then, the dry residue was dissolved in 200 µl of 10 M HNO3 and dried at 
650C. That prepared material was reconstituted in 1 ml of 0.1 M HNO3 before copper 
measurement. 
2.4.5.3. INSTRUMENT SETTINGS 
Thermo Scientific iCE 3300 AA Graphite Furnace - Atomic Absorption Spectrometry 
(GF-AAS) was used to measure the copper concentration in samples including plasma, 
serum, platelets and neutrophils obtained from healthy volunteers. The copper was 
also measured in endothelial cells and cell culture medium and buffers.  
All glassware used for acid, standards and ammonium nitrate preparation and sample 
cups for samples measurement were washed with 0.1 M HNO3 overnight. Working 
standard solutions  were prepared manually in  10 ml  glass volumetric flasks in the 
range 10 – 50 µl/ml in copper free 0.1 M HNO3 (100 – 500 µl/10 ml). Final standard 
solutions were also prepared in 10 ml glass volumetric flasks in the range 10 – 50 µg/l 
in copper free 0.1 M HNO3 using 10 – 50 µl/ml solutions (10 µl/10 ml, 1/1000 dilution). 
Plasma and serum samples were diluted 1/50 and all the other samples were analysed 
after re-constitution in 0.1 M HNO3 without further dilution. 
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All determinations were performed under the following conditions (Table 2.1) 
according to the GF-AAS instruction manual.  The absorbance of each sample was 
measured at a wavelength of 324.8 nm three times. The average number of three 
measurements was calculated when the % of differences did not exceeded 10. 
Ammonium nitrate in 5 g/l concentration was used as a matrix modifier (a substance 
added to enhance sensitivity or repeatability of the measurement).  
SPECTROMETER PARAMETERS 
Wavelength 324.8 nm 
Background Correction Zeeman 
Lamp Current 80 % 
Number Of Resamples 3 
FURNACE PARAMETERS 
Phase Temp [˚C] Time [sec] Ramp [˚C/sec] Gas Flow 
Drying 120 40 10 0.2 L/min 
Ashing 850 20 150 0.2 L/min 
Atomization 2100 3 0 Off 
Cleaning 2500 3 0 0.2 L/min 
SAMPLING PARAMETRES 
Working Volume 10 µL 
Martix Modifier Ammonium Nitrate 
Std Additions Wet-mixed 
CALIBRATION PARAMETRES 
Calibration Mode Standard Additions 
Concentration Units µg/L 
Acceptable Fit 0.995 
 
Table 2.1. The instrumental conditions for copper measurement by GF-AAS. 
The copper level was measured using the standard addition method and the sample 
concentration was calculated by the instrument and expressed in µg/l. Moreover, a fit 
of at least 0.995 was accepted. 
2.4.6. SYNTHESIS OF COPPER-TOBRAMYCIN 
This method was developed from the method described in Sreedhara, Freed & Cowan 
(2000). Tobramycin sulphate (0.025 mmols, 0.1169 g) was dissolved in 5 ml UHQ water 
in a sterile 15 ml Falcon tube on a rota mixer for 5 minutes. Then copper sulphate 
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(0.025 mmols, 0.0624 g) was weighted and added to the solution. The lid was replaced 
firmly and the cap sealed with parafilm and the tube left rotating overnight at room 
temperature. A clear dark blue solution was formed. Because free tobramycin 
interferes in the binding with copper-tobramycin to DNA it is important to remove the 
free, uncomplexed tobramycin from the solution. Ethanol (3.3 ml) was added to a final 
concentration of 40 % (v/v) in the reaction mixture. This precipitated the copper-
tobramycin as a blue solid and left the uncomplexed tobramycin in solution. The blue 
copper-tobramycin precipitate was recovered by centrifugation at 2000 x g for 10 
minutes at 100C. The supernatant was removed and discarded. The precipitate was 
washed in absolute ethanol by adding 5 ml of ethanol to the tube, mixing vigorously to 
break up the pellet and placing on the roller for 3 hours. The precipitate was recovered 
by centrifugation, as before (2000 x g for 10 minutes at 100C) and washed again in 5 ml 
absolute ethanol for 3 hours on the roller. Finally the precipitated copper-tobramycin 
was recovered by centrifugation at 2000 x g for 10 minutes, the supernatant was 
discarded and the pellet dried under vacuum for 1 hour at 300C. 
2.4.7. UV-VIS SPECTROPHOTOMETRY 
The stock solutions of tobramycin, copper-sulphate and copper-tobramycin were 
prepared in double deionised and sterilized water. 12.5 mM tobramycin was prepared 
by dissolving 11.69 mg of tobramycin sulphate (MW 467.51) in 2 ml of water. 12.5 mM 
copper sulphate was prepared by dissolving 6.24 mg copper sulphate pentahydrate 
(MW 249.6) in 2ml water. Copper-tobramycin (MW 531) was prepared with 13.28 mg 
in 2 ml water to obtain 12.5 mM copper-tobramycin stock. Serial 1:2 dilution of 
tobramycin, copper-tobramycin and copper-sulphate were prepared in double 
deionised water from 12.5 mM to 0.024 mM. The pH of stock solutions was measured 
using colour-fixed pH indicator sticks. A wavelength scan was performed on Uvikon 
923 Double Beam UV/VIS Spectrophotometer supplied by NorthStar Scientific Ltd. The 
measurement was carried out using 0.5 cm pathlength quartz cuvettes placed at 370C 
and each reading was subtracted from the water control.  
Copper-tobramycin concentrations were plotted against absorbance values. The molar 
extinction coefficient (ε) was calculated for the maximal absorption wavelength of 
62 
 
λ  50 nm using the Beer-Lambert law. Also, a dissociation constant (KD) and pKD were 
calculated using appropriate formulas. 
2.4.8. MICROPLATE SUPEROXIDE DISMUTASE ASSAY 
The assay was modified from the procedure developed by Ewing & Janero (1995). 
Superoxide dismutase activity of the copper-tobramycin complex (0.001 – 500 µM) 
was determined by using its ability to inhibit the reduction of nitrotetrazolium blue 
(NBT) by superoxide ions generated by the aerobic mixtures of NADH and phenazine 
methosulphate (PMS). The extent of NBT reduction was followed 
spectrophotometrically by measuring the formation of formazan at an absorbance of 
560 nm.  This assay was performed in a 96-well plate with a total reaction volume of 
100 μ . The complete reaction system consisted of 50 μ  NBT, 78 μ  NADH and 3.3 
μ  P S ( ina  concentrations) in 1 x PBS (- Ca/Mg) at pH 7.4 and 25°C. An endpoint 
optical density measurement at 560 nm was obtained after 5 minutes of incubation by 
using MRX Microplate Reader (Dynex Technologies, Chanitlly, VA, USA). For 
comparative purposes, the activity of native superoxide dismutase from bovine 
erythrocytes (200 U/ml) and tobramycin (0.001 – 500 µM) was also measured under 
the same experimental conditions. The assay was performed in triplicate. 
2.4.9. HYDROGEN PEROXIDE ASSAY 
Hydrogen peroxide was detected by Amplex Red Neuraminidase (Sialidase) Assay 
(Molecular Probes). 10 mM stock solution of Amplex Red reagent (Component A) was 
prepared by dissolving the contents of the vial of Amplex Red reagent (0.26 mg) in   
100 µl DMSO (Component B). 1 x working solution of Reaction Buffer was prepared by 
adding 4 ml of 5 x Reaction Buffer stock solution (Component E) to 16 ml of water.   
100 U/ml stock solution of horseradish peroxidase (HRP) was prepared by dissolving 
the contents of the vial of HRP (Component C) in 200 µl of 1 x Reaction Buffer. 20 mM 
H2O2 working solution was prepared by diluting 23 µl of 3 % (v/v) H2O2 into 977 µl 
water. The sample stocks (tobramycin, copper-tobramycin and copper sulphate), were 
prepared 100 x concentrated in water and diluted in 1 x Reaction Buffer. 50 µl of each 
sample was pipetted per well of a 96-well plate. An H2O2 standard curve was prepared 
using 20 mM H2O2 working solution to obtain 200, 100, 50, 25, 12.5, 6.25, 3.125 µM 
H2O2 standards in water. 1 x Reaction Buffer served as blank. 50 µl of each H2O2 
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standard was pipetted per well of a 96-well plate in duplicate. 100 µM Amplex Red 
reagent containing 0.2 U/ml HRP was prepared and 50 µl of this solution was added 
per well to begin the reaction. The plate was incubated at 370C for 30 minutes, 
protected from light. The absorbance was measured at 550 nm. 
2.4.10. A RAPID KINETIC ASSAY FOR CATALASE ACTIVITY 
Catalase activity was measured by the method modified from Beers & Sizer (1952).  
Hydrogen peroxide at 1 M was prepared from 30 % (v/v) hydrogen peroxide stock (8.8 
M) by diluting 0.1 ml stock with 0.78 ml in PBS (- Ca/Mg), pH 7. This was then diluted 
to the final concentration of 10 mM (1/100 dilution). 1000 U/ml of catalase stock was 
prepared in water (1 ml) and diluted to obtain 1, 5 and 10 U/ml final concentrations. 
50 mM stocks of tobramycin, copper tobramycin, copper sulphate (100 µl) were also 
prepared in water to obtain 0.5 mM concentration of appropriate drug in 0.7 ml, the 
total sample volume in the cuvette (1/100 dilution). Additionally, 10 mM MnTBAP 
stock was prepared in TRIS buffer, pH 7.4 (100 µl) to be verified for its catalase activity. 
1 and 50 µM final concentration of MnTBAP was tested. 
The measurement was carried out in auto-rate mode on the Uvikon 923 Double Beam 
UV/VIS Spectrophotometer supplied by North Star Scientific Ltd. in 0.5 cm pathlength 
quartz cuvettes placed at 370C against water as a control. A reading of 10 mM 
hydrogen peroxide solution was followed by a reading of each sample (0.7 ml). The 
samp es  ere scanned immediate   at λ  40 nm every 12 seconds within 2 minutes in 
duplicate.  
2.4.11. STATISTICAL ANALYSIS 
All statistical analyses were performed on GraphPad Prism 4 version 4. The results 
were expressed as average plus/minus SEM. One-way ANOVA and Dunnett`s or 
Tukey`s multiple comparison post hoc test were performed on the data. A paired t-test 
was also used for data analysis where appropriate. The p values less than 0.05 were 
considered as statistically significant. 
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2.5. RESULTS 
2.5.1. DEVELOPMENT OF COPPER ANALYSIS USING THE STANDARD ADDITION METHOD  
           (GF-AAS)  
The concentration of copper in each sample was determined using a standard addition 
method. This method is recommended for instrumental analysis, such as GF-AAS. The 
standard addition method is commonly used to determine the concentration of an 
analyte that is in a complex matrix, like biological fluids. The matrix of blood and cell 
lysates may contain other components that interfere with the analyte signal causing 
inaccuracy in the determined concentration, therefore it is reasonable to apply the 
standard addition method with GF-AAS. 
A separate calibration curve was performed for every sample analysed. To obtain a 
standard addition plot (Figure 2.6) and also determine the sample concentration, the 
instrument was programmed to measure the absorbance signal in three repeat 
measurements of the blank (0.1 M HNO3), the measured sample and the copper 
standard (10 – 50 µg/l). At least three different preparations of each sample have been 
analysed. 
 
 
Figure 2.6. A representative standard addition plot. Blue diamonds represent copper standards (10 – 50 
µg/l), red square is the blank (0.1 M HNO3), which has OD 0.032 and green triangle is the analysed 
sample. The horizontal blue line shows the background subtraction. The sample concentration was 
calculated by using the graph formula: y = 0.0027x + 0.0686, where y = sample OD – blank OD. The 
sample concentration was measured here was 13.16 µg/l (arrow). 
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2.5.2. CELLULAR COPPER LEVELS 
Normal serum and plasma copper levels were measured using GF-AAS and found to 
be 1262.73 ± 211.16 µg/l and 991.08 ± 229.01 µg/l, respectively (n=7).  
The copper level in endothelial cells, platelets and neutrophils was calculated after 
subtraction of the copper concentration measured in medium or buffer that the cells 
were re-suspended in before they underwent the digestion procedure. HLMVEC 
contained 23.37 ± 1.11 ng copper/106 cells (n=3), while platelets contained 14.33 ± 
2.49 ng copper/109 cells (n=8).  The copper level in supernatants of thrombin-
activated platelets was below the level of detection (n=8). Also, the copper 
concentration in neutrophils of healthy volunteers was below the level of control 
medium, HBSS (- Ca/Mg) (n=4) or RPMI 1640 containing 2.5 % (v/v) of FBS (n=5).       
The full growth medium, EGM (containing 5 % v/v FBS), used to grow HLMVEC had 
38.48 ± 1.01 µg/l copper. RPMI 1640 supplemented with 2.5 % (v/v) FBS was found to 
have 23.11 ± 1.98 µg/l copper. 
The buffers that were used in experimental procedures described throughout this 
study were HBSS (- Ca/Mg) and PBS (- Ca/Mg). The level of copper in these buffers was 
very similar and was determined to be: 24.85 ± 1.84 µg/l for HBSS (- Ca/Mg) (n=3) and 
29.30 ± 6.00 µg/l for PBS (- Ca/Mg) (n=3). Moreover, copper concentration was also 
measured in 1 % (v/v) Triton X-100 lysis buffer, which had 6.02 ± 1.12 µg/l copper 
(n=3).  
Furthermore, 50 µg/l (50 ppb) copper standard was prepared and analysed as a 
sample after the freeze-drying and digestion procedure. The measured copper 
concentration was 45.73 ± 2.30 µg/l, which corresponds to 91.45 ± 4.59 % sample 
recovery (n=3). 
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Material Type n Copper [µg/l] 
EGM (5% FBS) 3 38.48 ± 1.01 
RPMI 1640 + 2.5% FBS 3 23.11 ± 1.98 
PBS (- Ca/Mg) 3 29.30 ± 6.00 
HBSS (- Ca/Mg) 3 24.85 ± 1.84 
Triton X-100 in water 3 6.02 ± 1.12 
Serum 7 1262.73 ± 211.16 
Plasma 7 991.08 ± 229.01 
Neutrophils 9 Undetectable levels above medium control 
Platelets 7 14.33 ± 2.49 [ng/109 cells] 
HLMVEC 3 23.37 ± 1.11 [ng/106 cells] 
 
Table 2.2. Summary of the copper concentration in different buffers, media and cells expressed as a 
mean ± SEM. 
2.5.3.    UV - VIS   SPECTRUM   OF   TOBRAMYCIN,  COPPER   SULPHATE   AND   COPPER- 
              TOBRAMYCIN 
In order to investigate whether tobramycin forms a complex with copper sulphate in  
in vitro assay conditions, tobramycin, copper sulphate and copper-tobramycin 
solutions in water in a range of concentrations, were scanned using UV-VIS 
spectrophotometry. The pH of all solutions prepared were measured and the results 
are shown in the table below (Table 2.3). 
Stock solution pH 
Double deionised water 6.5 
Tobramycin 7.5 
Copper-tobramycin 6.0 
Copper sulphate 5.0 
 
Table 2.3. The summary of the pH of 12.5 mM tobramycin, copper sulphate and copper-tobramycin 
stock solutions prepared in double deionised water. 
Figure 2.7 (over) demonstrates a representative UV-VIS wavelength scan of a range of 
tobramycin concentrations (1.5625 – 12.5 mM) measured against water blank. This 
scan was divided into two spectra, in the UV and VIS range (Figure 2.7A and Figure 
2.7B, respectively) and the scale was adjusted for the peaks to be distinct. Tobramycin 
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shows very little absorbance at any wavelength. However, an interesting absorption 
maxima for the two highest tobramycin concentrations, 12.5 mM (absorbance 0.051) 
and 6.25 mM (absorbance 0.008)  ere o ser ed at λ  45 nm. This is the absorbance 
maxima similar to the one, characteristic for copper-tobramycin (see Figure 2.19) and 
it could suggest trace metals contamination of tobramycin with copper. A single peak 
on tobramycin VIS spectrum has not been identified. 
 
 
 
Figure 2.7. UV-VIS spectrum of tobramycin at 37
0
C. A range of tobramycin (1.5625 – 12.5 mM) was 
scanned across 200-900 nm using quartz cuvettes. Representative scans of: A) UV spectrum; B) VIS 
spectrum of tobramycin. 
Copper sulphate in a range of concentrations (0.024 – 12.5 mM) was also scanned 
across the whole spectrum. UV and VIS spectrum of copper sulphate are presented in 
-0.05 
0 
0.05 
0.1 
200 220 240 260 280 300 
12.5 
6.25 
3.125 
1.5625 
Wavelength [nm] 
A
b
so
rb
an
ce
 
Tob [mM] 
A 
λ=245 nm 
-0.05 
-0.03 
-0.01 
0.01 
0.03 
0.05 
600 700 800 900 
12.5 
6.25 
3.125 
1.5625 
Wavelength [nm] 
A
b
so
rb
an
ce
 
Tob [mM] 
B 
68 
 
Figure 2.8A and 2.8B, respectively. No obvious peak can be distinquished on the UV 
spectrum, whereas the VIS spectrum showed peaks with absorbance maxima at λ=812 
nm for 12.5 mM (absorbance 0.068) and 6.5 mM (absorbance 0.035). 
 
 
Figure 2.8. UV-VIS spectrum of a range of copper sulphate at 37
0
C. A range of copper sulphate (0.024 – 
12.5 mM) was scanned across 200-900 nm using quartz cuvettes. Representative scans of: A) UV 
spectrum; B) VIS spectrum of copper sulphate. 
Copper-tobramycin complex synthesized as described in Section 2.4.6, was dissolved in 
water and a wavelength scan of this complex was performed. Figure 2.9A and 2.9B 
(over) demonstrate characteristic peaks for copper-tobramycin in both UV and VIS 
range of the spectrum, respectively. Although, the UV-VIS wavelength scan of copper-
tobramycin was carried out in the concentration range of 0.024 – 12.5 mM, copper-
tobramycin at the concentration of 12.5 mM was excluded from the UV spectrum due 
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to an absorbance above 4 at the absorbance maxima at wavelength λ  50 nm. That 
high absorbance value for the sample could not be measured accurately by the 
instrument, and was outside the linear range for detection of the complex (see Figure 
2.10). 
 
 
Figure 2.9. UV-VIS spectrum of copper-tobramycin at 37
0
C. A range of copper-tobramycin (0.024 – 12.5 
mM) was scanned across 200-900 nm using quartz quvettes. Representative scans of: A) UV spectrum; 
B) VIS spectrum of copper-tobramycin. 
Copper-tobramycin was found to have a distinct profile and a much higher absorbance 
value at λ  50 and λ 706, compared to the same concentration of tobramycin (Figure 
2.7) and copper sulphate alone (Figure 2.8). Moreover, the copper-tobramycin 
complex absorbed much more strongly at the wavelength of λ  50 than at λ 706 nm. 
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For instance, 6.25 mM copper-tobramycin concentration elicited absorbance 3.239 at 
λ  50 nm and on   0.05  a sor ance at λ 706 mn. The dependency of copper-
tobramycin absorbance values on copper-tobramycin concentration are presented in 
Figure 2.10, for a single experiment. 
 
 
Figure 2.10. A Beer-Lambert plot for copper-tobramycin. A) Copper-to ram cin comp e  at λ  50 nm; B) 
Copper-tobramycin comples at λ 706 nm. 
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(6.25 mM final concentration) was monitored every two seconds for 1 minute. The 
same spectrum (Figure 2.9, red line) was obtained. An immediate change of colour 
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from pale to dark blue was observed. This experiment revealed that copper-
to ram cin comp e  is  ormed instant  . The ma ima  a sorption at λ  50 o  copper-
tobramycin (3.356 nm) appeared in 2 seconds and was constant within 1 minute of 
measurement. Furthermore, no change of absorbance or colour of the complex was 
observed within months of keeping the complex at 40C and re-analysing.  
 
By using a the Beer-Lambert law, which is the linear relationship between absorbance 
and concentration of an absorbing species, the extinction coefficient for copper-
tobramycin complex was calculated. The general Beer-Lambert law is usually written 
as: A   λ c,  here: A is the meas red a sor ance, λ is a  a e ength-dependent 
absorptivity coefficient, b is the path length and c is the analyte concentration. When 
working in concentration units of molarity, the Beer-Lambert law is written as: A = εbc, 
 here: ε is the  a e ength-dependent molar extinction coefficient with units of M-1 
cm-1. For the calculations a range of concentrations was used rather than a single 
concentration.  
The extinction coefficient was calculated for the copper-tobramycin complex only at    
λ=250 nm to be 1062 M-1cm-1. However, Heyrovska (1996) shown that the non ideal 
thermodynamic properties of strong electrolytes in aqueous solutions at all 
concentrations are due to partial dissociation and hydration. The degree of 
dissociation of copper-tobramycin complex was calculated to be 13.1 %. Therefore, the 
value of 1062 M-1cm-1 was further corrected by the following factor of 1.157 and the 
new extinction coefficient was calculated for the complex as 1229 M-1cm-1 (see 
Appendix). 
In order to calculate the dissociation constant of the copper-tobramycin complex and 
therefore examine the ability of tobramycin to bind copper, a range of tobramycin 
concentrations was titrated to the constant concentration of copper sulphate. Figure 
2.11 (over) shows a wavelength scan of this complex, made by mixing tobramycin at 
0.0244 – 0.7813 mM concentration with 0.7813 mM copper sulphate.   
The UV part of the copper-tobramycin spectrum (Figure 2.11A) was used for further 
calculations of dissociation constant. Indeed, the absorbance values in UV spectrum 
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are much higher and therefore more accurate compared to the same values in VIS 
range of the spectrum. 
A dissociation constant (KD) and pKD value was calculated by using the following 
formulas: 
KD = 
      
    
 , where [M] –metal, [L] – ligand, [ML] – complex and pKD = - log KD 
KD for copper-tobramycin complex was calculated to be 0.05
 mM and pKD was 4.301 
(see Appendix). 
 
 
 
Figure 2.11. Tobramycin binds copper. UV-VIS spectrum of a range of tobramycin (0.3906 – 6.25 mM) 
additions to a constant concentration of copper sulphate (6.25 mM) at 37
0
C. A) UV spectrum; B) VIS 
spectrum. 
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It was previously reported that copper binds to HEPES (Hegerschweiler & Saltman, 
1986). Moreover, the research of Patwardhan et al (2011) showed different values of 
copper-to ram cin ε and KD, what may be related to their use of HEPES buffer. 
Therefore, the effect of HEPES buffer systems was examined for copper sulphate 
(3.125 mM) as a source of copper (Figure 2.12). Because HBSS (+ Ca/Mg) containing    
20 mM HEPES, pH 7.4 was chosen in some further experiments reported here, 
separate components of this buffer were tested. The solvents were: water, HBSS (+ 
Ca/Mg), 20 mM HEPES, HBSS (+ Ca/Mg) containing 20 mM HEPES. The pH of the 
solutions was adjusted to 7.4.  
 
 
Figure 2.12. The effect of buffer systems on wavelength scan of copper sulphate at 37
0
C. A) Copper 
sulphate at the UV range. B) Copper sulphate at the VIS range. 
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Copper sulphate dissolved in water gave a very little absorbance at both wavelengths, 
λ  50 and λ 706 nm,  hich  ere 0.09  and 0.009, respectively, which was 
comparable to the previous results presented in Figure 2.9. (0.126 and 0.002, 
respectively). HBSS buffer increased the copper sulphate absorption maxima to     
0.512 nm at λ  50 of the spectrum. HEPES buffer was observed to have a large effect 
on absorbance, increasing values at λ  50 nm, which were: 2.187 for HEPES buffer 
alone and 2.514 for HEPES addition to HBSS buffer (Table 2.4). At the VIS range the 
absorbance signal increase gave values of 0.254 and 0.109, respectively. These results 
suggest a non specific interference of HBSS buffer, which was increased on addition of 
HEPES. These results also confirm that water was the best solvent used in the 
examination of UV-VIS spectrum in the conditions tested. 
Buffer system λ  50 nm λ 706 nm 
Water 0.092 0.009 
HBSS (+ Ca/Mg) 0.512 0.011 
20 mM HEPES 2.187 0.254 
HBSS (+ Ca/Mg) + 20 mM HEPES 2.514 0.109 
 
Table 2.4. The summary of the absorbance values of buffer systems at different wavelength. 
 
Copper sulphate at the concentration of 6.25 mM and higher was not fully dissolved in 
the buffer systems including HBSS (+ Ca/Mg), 20 mM HEPES and HBSS (+ Ca/Mg) 
containing 20 mM HEPES. Furthermore, it precipitated once left in the reaction tube or 
cuvette. 
2.5.4. SOD-LIKE AND CATALASE ACTIVITIES ASSOCIATED WITH COPPER-TOBRAMYCIN 
As mentioned earlier in this chapter (Section 2.1.3), copper-drug complexes have SOD 
or SOD and catalase activity. It was therefore crucial to examine the SOD-like activity of 
copper-tobramycin. 
Superoxide anions have a very short half life and, accordingly, they must be produced 
continuously. In a cell- and enzyme-free colorimetric assay, superoxide ions are 
generated via the ability of an aerobic mixture of NADH and PMS to produce 
superoxide anions, which converts NBT to formazan, a coloured product absorbing 
light at 560 nm. SOD activity reduces the superoxide ion concentration and thereby 
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lowers the rate of formazan formation. In the SOD-like activity test, the copper-
tobramycin and other compounds compete with nitro NBT for reaction with the 
generated superoxide ions. The more efficient the complex, the lower complex 
concentration that corresponds to 50 % inhibition of NBT reduction (IC50). 
Nitro blue tetrazolium reduction was inhibited dose dependently by copper-
tobramycin. Figure 2.13 represents the percentage inhibition of NBT reduction with an 
increasing concentration of copper-tobramycin (0.001 – 500 µM) with the best fit of 
r=0.999. IC50 was calculated to be 200 nm for this complex. EC SOD served as a positive 
control. A single concentration of 200 U/ml SOD inhibited NBT reduction by 60 %. 
However, tobramycin alone had no inhibitory effect at concentrations up to 500 µM. 
This result clearly indicates SOD-like activity of copper-tobramycin and no such activity 
of tobramycin itself. 
 
Figure 2.13. Superoxide dismutative activity of copper-tobramycin measured as inhibition of the rate of 
nitro blue tetrazolium reduction.  Copper-tobramycin potently inhibited NBT reduction with an IC50  of 
200 nM, n=3. 
SOD-mimetics are often divided into distinct classes, compounds with SOD-like activity 
only and compounds with additional activity of catalase that allows them to dismutate 
hydrogen peroxide generated by SOD. Therefore, it was of interest to examine the 
catalase activity of the copper-tobramycin complex. The Amplex Red Neuraminidase 
assay utilizes Amplex Red to detect H2O2, which, in the presence of horseradish 
peroxidase (HRP), reacts with a 1:1 stoichiometry with Amplex Red reagent to 
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generate the red-fluorescent oxidation product, resorufin. Resorufin can be detected 
by measuring absorbance at 550 nm or fluorescence. The above described reaction is 
shown in Figure 2.14. 
 
Figure 2.14. Principle of coupled enzymatic assays using Amplex Red reagent. Oxidation of glucose by 
glucose oxidase results in generation of H2O2, which is coupled to conversion of the Amplex Red reagent 
to fluorescent resorufin by HRP. 
 
Figure 2.15 illustrates no ability of copper-tobramycin to dismutate hydrogen peroxide 
in the concentration range between 0.01 to 0.5 mM after 15 minutes pre-incubation. 
For comparison, the same concentrations of copper chloride and tobramycin were 
tested. Those results clearly show that copper chloride and tobramycin do not have 
catalase activity in the range of 0.01 – 0.5 mM, concentrations that were used in most 
experimental procedures. 
 
Figure 2.15. Hydrogen peroxide dismutation by tobramycin, copper-tobramycin and copper chloride in 
the range of 0.01 – 2 mM at the wavelength 550 nm. The experiment was performed in triplicate and 
the data points show the mean ± SEM. 
0 
20 
40 
60 
80 
100 
0 0.01 0.1 0.5 1 2 
Tobramycin 
Copper-tobramycin 
Copper chloride 
H
yd
ro
ge
n
 p
er
o
xi
d
e 
[%
] 
Drug [µM] 
77 
 
To confirm that copper-tobramycin had no catalase activity at the concentrations used 
in cell based assays, a rapid kinetic assay for catalase activity was performed by 
measuring absorbance of H2O2 at λ  40.  
To evaluate the assay sensitivity and accuracy, decomposition of H2O2 was measured 
over time with 1 – 10 U/ml catalase (Figure 2.16). Hydrogen peroxide was shown to be 
stable and it was decomposed by catalase dose dependently. As predicted, higher 
concentrations of catalase lowered the absorbance values. 
 
Figure 2.16. Decomposition of hydrogen peroxide (10 mM) over time by varing concentrations of 
catalase. The change of concentration of hydrogen peroxide is proportional to the decrease in 
a sor ance at λ  40 nm. 
Different compounds were then examined for their catalase activity (Figure 2.17, 
over). Tobramycin clearly did not possess catalase activity by showing no difference 
from the hydrogen peroxide baseline. Copper-tobramycin and copper sulphate also did 
not dissociate hydrogen peroxide. However, copper maximal absorption at 250 nm 
effectively interferes in the assay, resulting in a high absorbance values, ranging from 
0.74 to 0.77 for copper-tobramycin complex and 0.82 for copper sulphate. To double 
check the copper interference in the assay 10 mM hydrogen peroxide and 0.5 mM 
copper-tobramycin absorbance were measured at λ  40 separately, followed by the 
absorbance reading of hydrogen peroxide mixed with copper-tobramycin. There were 
0.15, 0.52 and 0.68, respectively and the results were additive. 
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Figure 2.17. Evaluation of hydrogen peroxide decomposition in the presence of tobramycin, copper-
tobramycin and copper sulphate (0.5 mM). 
Finally, MnTBAP, which was reported to posses both superoxide dismutase and 
catalase activity (Ferret et al, 2001), was examined for its ability to decompose 
hydrogen peroxide. MnTBAP had a negligible effect up to the concentration of 50 µM. 
2.6. SUMMARY OF RESULTS 
Copper is present in cell culture medium and buffers as well as neutrophils, platelets 
and HLMVEC, cells used in the model of neutrophil transendothelial migration, 
described in Chapter 5. Tobramycin in the presence of copper immediately and 
spontaneously becomes a copper-tobramycin complex, which is stable over time. 
Copper-tobramycin was shown to have SOD-like activity but no catalase activity in the 
concentration range up to 0.5 mM. 
2.7. DISCUSSION 
Cell culture medium and buffers used in the experimental procedures in this 
investigation were shown to contain copper. Percival et al (1993) had reported that 
cell culture media (RPMI containing HEPES buffer, 10 % (v/v) fetal bovine serum, 2 
mmol/l glutamine, antibiotics and the insulin-transferrin-selenium supplement) are 
relatively low in copper, giving the value of 0.5 µM, which corresponds to 31.5 µg/l 
copper concentration. Here, RPMI 1640 supplemented with 2.5 % (v/v) FBS, HBSS (- 
Ca/Mg) and PBS (- Ca/Mg) contain 23.11 ± 1 .98 µg/l, 24.85 ± 1 .84 µg/l and 29.30 ± 
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6.00 µg/l copper concentration, respectively. Full growth medium for HLMVEC 
contains almost 1.5 times more copper compared to the other medium and buffers, 
presumable because it contains 5 % (v/v) fetal bovine serum. Moreover, in plasma or 
serum, most of the copper is firmly bound to the ceruloplasmin (Gubler et al, 1953) 
and this protein contains 8 atoms of copper per molecule (Holmberg & Laurell, 1948). 
Copper ions are essential for proliferation of human endothelial cells under culture 
conditions (Hu, 1998). Ceruloplasmin maintains enzymes activity during cell 
differentiation and if not supplied in the medium, the cells may acquire copper from an 
intracellular source, namely Cu/Zn-SOD. Moreover, copper supplementation resulted 
in an increase in intracellular Cu/Zn-SOD activity, but had no effect on the level of 
Cu/Zn-SOD protein (Percival et al, 1993). 
Cellular copper uptake in mammals is accomplished primarily by the copper importer, 
CTR1 (Wang et al, 2011) previously described in Section 1.8.2. CTR1 was suggested to 
be expressed in multiple tissues in selected cell types, including the endothelial cells of 
the capillary small blood vessel in the brain (Kuo et al, 2006). HLMVEC were found to 
contain the highest copper concentration compared to other cells used in the current 
study, namely 23.37 ± 1.11 ng/106 cells. In the cell culture conditions, HLMVEC could 
take up copper from FBS present in the culture medium presumably via CTR1. 
Polymorphonuclear cells were previously reported to contain 1.65 ± 0.22 ng 
copper/mg cell protein (Percival et al, 1999). However, copper was not detected in 
neutrophils in the study reported here. Similarly, another study by Schmitt (1997) also 
reported the level of copper in neutrophils to be below the detection limit. The results 
of White et al (2009) suggest that the inflammatory response of macrophages 
stimulates CTR1-mediated copper uptake. Moreover, marginal copper deficiency 
results in impaired function of rat neutrophils with 60 % decrease in superoxide anion 
production in comparison to control (Percivall et al, 1998). It suggests that copper is 
stored in unactivated neutrophils mainly as superoxide dismutase, which is also true 
for hepatocytes (Osterberg, 1980). 
Platelets also contain micromolar concentrations of copper (Lind et al, 1993). Milne & 
Nielsen (1996) found 24.4 ± 10.7 ng copper/109 cells. In the current study, platelets 
were found to contain 14.33 ± 2.49 ng copper/109 cells. Schmitt (1997) detected 
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304.29 ± 240 ng copper/109 cells, although these results are marked by a large 
variance (standard deviation). The studies of O`Sullivan et al (2005) suggested a link 
between platelet activation and progressive impairment of CF lung function. Platelets 
were therefore suspected to release copper under thrombin stimulation. However, 
release of copper from thrombin-activated platelets was below the limit of detection 
in the current study. A more sensitive method of analysis, inductively coupled plasma 
mass spectrometry (ICP-MS) could be applied in future experiments to detect release 
of copper. It was however possible to calculate the amount of copper in one platelet to 
be approximately 14 x 10-18 g copper/cell. 
Platelet size range from 1 – 2 µm diameter (Dopheide et al, 2002). Activated platelets 
could be considered as a sphere and it is possible to calculate platelet volume, based 
on a mathematical formula: 
   
 
 
        , where R is a radius of a sphere.
 
MPV (mean platelet volume) was reported to be 7.9 – 11.7 µm3 (Demirin et al, 2011; 
Tuncell et al, 2011; Vagdatli et al, 2010; Bansal et al, 2002). Interestingly, the study of 
Uysal et al (2011) shown lower MPV values of pediatric CF patients compared to 
healthy donors and suggests that the platelet volume is associated with exacerbations. 
This study indicates that MPV might be used as a diagnostic, predictive indicator for 
platelet activation in pediatric CF patients related to chronic inflammation, which 
might be helpful to discriminate or estimate exacerbation.  
Normal plasma copper level was determined previously to be approximately 790 – 
1090 µg/l as measured by AAS (Khorasani et al, 2008; Percival et al, 1999; Schmitt, 
1997; Milne & Nielsen (1996); Hatano et al, 1982 and Inutsuka & Araki, 1978). The 
copper concentration in plasma of healthy volunteers in this study was similar, 991.08 
± 229.01 µg/l, which validates the analytical procedure used in the current study. 
Normal serum copper level, measured at 1262.78 ± 211.16 µg/l, was also comparable 
to previously published values, determined by AAS, in the range of 977 – 1203 µg/l 
(Strecker, 2005; Gonzales et al, 1999; Carpentieri et al, 1986).  
In general, plasma values were lower than serum concentrations, but these differences 
were not statistically significant. Frank and colleagues (2001) found the same 
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dependence without statistically significant difference. Rosenthal & Blackburn (1974) 
also found serum copper levels to be higher compared to plasma. Foley et al (1968) 
had similar observations for zinc and he attributed this difference to a possibility that 
copper might be released from platelets, leukocytes, or erythrocytes during 
coagulation and clot retraction. However, the release of copper from platelets during 
their isolation could decrease cell copper and make the released copper hard to 
detect. 
Moreover, blood collection, processing and storage before analysis are critical for 
accurate trace element analysis. Anticoagulants and blood collection containers may 
affect albumin, copper and zinc levels. Frank et al (2001) reported that copper 
concentrations measured in EDTA plasma were lower than copper measured in any 
other collection container. Based on their experience and recommendation, here, 
plasma samples were collected into lithum-heparin tubes and serum samples were 
collected into serum clot activator tubes for trace element testing. However, chelation 
of copper in the specimen by EDTA should not substantially affect the copper 
concentration measured by ICP-MS (Frank et al, 2001). It could be explained by the 
greater tolerance of ICP-MS over GF-AAS to the sample matrix. 
ICP-MS has many advantages over other elemental analysis techniques, including high 
speed, precision and sensitivity. ICP-MS is capable of the determination of a range of 
metals at concentrations below one part per trillion (1012), whereas the limit of GF-AAS 
used in the current study is one part per billion (109). ICP-MS could therefore be 
helpful in detecting copper release by thrombin-activated platelets. 
The role of transition metal ions in the biological activity of aminoglycoside antibiotics 
has not been previously reported (Jezowska-Bojczuk et al, 1998). Among 
aminoglycoside complexes with metal, the properties of copper-tobramycin complex 
has been investigated, since aminoglycosides form the most stable complexes with 
Cu(II) ions compared to both toxic and basic metal ions, such as iron(III), nickel(II), 
cobalt(II) and zinc(II) (Szczepanik et al, 2004a). Indeed, tobramycin in the presence of 
copper sulphate forms a stable copper-tobramycin complex. In vitro, this complex was 
formed immediately and presented the same spectrum over time, suggesting its 
stability. Additionally, the blue colour of the copper complex remains the same even 
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after months of keeping the solution at 40C. Moreover, Szczepanik et al (2004a) also 
suggest that copper(II) complexes of aminoglycosides can easily be formed in vivo, i.e. 
in blood plasma by withdrawing of the metal bound to human serum albumin. 
Cu2+ coordination by aminoglycosides is pH dependent and CuL (copper-ligand) species 
dominates at the physiological pH (Jezowska-Bojczuk et al, 1998) (Figure 2.18).  
 
Figure 2.18. A species distribution diagram of tobramycin (L) complexes of Cu(II) for concentrations used 
in spectroscopic studies (2 mM L, 1 mM Cu(II)); (---) stochiometric species; (—) spectroscopic species: I – 
complex I (CuH3L and CuH2L), II - complex II (CuHL and CuL), III – complex III (CuH-1L and CuH-2L)  
(Jezowska-Bojczuk et al, 1998). 
Even over a wide pH range, copper(II)-aminoglycoside complexes are often isolated as 
monomeric species. The coordination complex is usually formed in 1:1 metal:ligand 
stoichiometry (Kozlowski et al, 2005). Also, in the present study, it is assumed that 
copper binding to tobramycin resulted in 1:1 metal ligand complex formation at mM 
concentration in water. This ratio was suggested in the method for synthesis of 
copper-aminoglycoside complexes by Sreedhara, Freed & Cowan (2000) and further 
confirmed for kanamycin A (Szczepanik et al, 2003) vancomycin (Swiatek et al, 2005) 
and tobramycin (Patwardhan & Cowan, 2011; Jezowska-Bojczuk et al, 1998). 
Moreover, complexes of 1:2 metal:ligand stechiometry are rare and are typically 
formed at higher pH (Kozlowski et at, 2005). 
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An extinction coefficient was calculated for copper-tobramycin complex only at the 
wavelength λ  50. The complex at the wavelength λ 706 nm showed very low 
absorbance values, that resulted in a poor fit of 0.8650. The molar extinction 
coefficient equalled 1229 M-1cm-1. In general, all ionic compounds, including 
complexes dissociate, when dissolved in water into smaller particles or ions. Indeed, 
aqueous solutions of strong electrolytes are characterised by non ideal properties, due 
to their partial dissociation and hydration (Heyrovska, 1996). Patwardhan & Cowan 
(2011) calculated the  a  e o  ε of copper-tobramycin to be slightly higher,     1453 M-
1cm-1. Moreover, KD of copper-tobramycin, prepared by a titration of a range of 
tobramycin concentrations (0.0244 – 0.7813 mM) to a constant, 0.7813 mM copper 
sulphate, was calculated to be 0.05 mM (pKD 4.301). In comparison, Patwardhan & 
Cowan (2011) calculated KD of their copper-tobramycin complex to be 0.1 mM (pKD 
5.000). Additionally, they titrated a range of copper sulphate to a constant 
concentration of tobramycin, prepared the samples in 100 mM HEPES buffer, pH 7.4 
and performed UV-VIS spectroscopy at 250C. There are however two possible 
explanations for different values obtained for the same complex. 
The first one could be related to the different solutes used in the assay, HEPES and 
water. HEPES is one of the zwitterionic N-substituted aminosulphonic buffers first 
introduced by Good and coworkers (1966). Hegetschweiler & Saltman (1986) reported 
a weak but significant interaction between HEPES and Cu(II). Their conclusion was 
based on indirect evidence gained from the increased reduction rates of Cu2+ to Cu+ in 
a series of alcohols and heme proteins in the presence of HEPES. Also, Vascenocelos et 
al (1996) observed that HEPES at pH 8.0 had the ability to complex copper(II). 
Vascenocelos et al (1998) noted the aggregation between buffer molecules that 
decrease the value of the stability constant with increased buffer concentrations. 
Moreover, the level of contamination in Good`s buffers with metal binding ligands, 
such as 4-(2-hydroxyethyl)piperazine-1-propanesulphonic acid (HEPPS) and N-(2-
hydroxyethyl)piperazine-N`-(2-hydroxy-propanesulphonic acid) (HEPPSO) appears to 
be highly variable with the greatest amount in HEPES (Mash et al, 2003). In the current 
work, the preparation of copper sulphate in HEPES, especially in high concentrations, 
indicated aggregation. Additionally, Vascenocelos et al (1996) suggested that Cu-HEPES 
complexes might be responsible for the rise of copper toxicity in cell culture 
experiments. However, the presence in cell culture media, of a high concentration of 
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HEPES buffer, enhances the rate of copper(II) binding to ligands on the algal surfaces, 
thus increasing metal bioavailability (Vascenocelos et al, 1996). However, HEPES does 
not form ternary complexes with copper and therefore it can still be recommended for 
copper studies, if metal binding characteristic of tested substances is determined prior 
to use (Sokolowska & Bal, 2005; Mash et al, 2003). 
Another difference could be related to the solution pH. Patwardhan & Cowan (2011) 
conducted their experiments at pH 7.4, whereas the pH in the current study was 6.0. 
Lower pH and hyperacidification has been reported in CF airway surface fluid and 
organelles of CF respiratory epithelial cells, such as trans-Golgi and endosomes, as a 
result of CFTR defect (Poschet et al, 2002). Therefore, pH 6.0, not physiological pH 7.4, 
better reflects the CF lung environment. Moreover, kanamycin B, amikacin and 
tobramycin complexes with Cu(II) are more stable in lower pH, demonstrating lower 
pKD (Gokhale et al, 2007). Copper-tobramycin complex in the current study                 
(KD = 0.05 mM) was therefore twice as stable as the complex in the study of 
Patwardhan & Cowan (2011) (KD = 0.1 mM). 
The difference in the assay temperature, 250C (Patwardhan & Cowan, 2011) versus 
370C, here, should not influence the results. 
Many SOD mimetics reported are copper(II) complexes (Lapluye, 1990). Indeed, the 
copper(II) ion is the most active SOD catalyst known. In the pH range, excluding 
hydrolysis of copper(II) complex, copper(II) ion activity is four times higher than that of 
the Cu/Zn SOD at identical copper concentrations. Moreover, hydrated Cu(II) ions are 
easily complexable and possess a short life-time in biological media containing many 
potential soluble or immobilised ligands. The complexes formed may or may not 
possess the SOD activity (Lapluye, 1990).  
Copper-tobramycin was shown to have SOD-like activity, unlike tobramycin and 
therefore, this activity is due to the presence of copper. Many other copper complexes 
have been previously reported to have SOD-like activity. Mixed-ligand bipyridyl Cu(II) 
complexes demonstrated high SOD-like activity in a chemical superoxide anion-
generating system (NBT system), with IC50  values in the low micromolar range (0.8 - 
1.7 µM). These bipyridyl complexes were also effective scavengers of ROS generated 
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by phagocytes ex vivo. Thus, they represent a promising class of SOD mimetics for 
future development (Potapov et al, 2009).  
Copper-tobramycin was demonstrated to be more efficient as a SOD-like complex than 
mixed-ligand bipyridyl Cu(II) complexes. Copper-tobramycin potently inhibited NBT 
reduction with a lower IC50 of 200 nM. Copper-tobramycin was also shown not to have 
a catalase activity up to 0.5 mM, a top concentration used in most experimental 
procedures. This is therefore crucial to further investigate the role of copper-
tobramycin complex in relation to its SOD-like activity in a model of neutrophil 
transendothelial migration described. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
86 
 
CHAPTER 3 
THE ROLE OF HEPARAN SULPHATE IN THE UPTAKE 
OF TOBRAMYCIN AND COPPER-TOBRAMYCIN BY 
HLMVEC 
 
3.1. INTRODUCTION 
3.1.1. MIMICKING CF ENDOTHELIUM 
Human lung microvascular endothelial cells (HLMVEC) are a useful tool for studying 
various aspects of the pathology and biology of the pulmonary microvasculature in 
vitro. HLMVEC form tight junctions and are known to express adhesion molecules 
including ELAM, P-selectin, ICAM and VCAM. They stain positive for vWF antigen and 
PECAM and negative for smooth muscle α-actin (Hewett & Murray, 1993b). This cell 
line was therefore chosen to study pulmonary inflammation present in respiratory 
disorders, such as CF. 
Additionally, the lack of a CF endothelial cell line, entailed the use of a specific inhibitor 
of CFTR, CFTRinh-172 [3-[(3-trifluoromethyl)phenyl]-5-[(4-carboxyphenyl)methylene]-
2-thioxo-4thiazolidinone] to model CF endothelium. Human endothelial cells also 
express CFTR (Tousson et al, 1998). As CFTR is a low-conductance cyclic, nucleotide-
regulated Cl- channel, its mutation may affect ion transport and pH regulation, ATP 
transport, vascular tone and signalling pathways within EC. In the effect, CFTR 
inhibition is expected to mimic CF inflammatory profile (Perez et al, 2007). 
3.1.2. GLYCOSAMINOGLYCANS AND PROTEOGLYCANS IN NORMAL AND CF LUNG 
A glycosaminoglycan (GAG) is a linear and negatively charged heteropolysaccharide 
possessing a characteristic disaccharide repeat sequence. One monosaccharide of the 
disaccharide repeat is an aminosugar with D-glucosamine or galactosamine and the 
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other unit is typically an uronic acid residue of either D-glucuronic acid or L-iduronic 
acid. Both units are variably N- and O-sulphated, which adds to the heterogeneity of 
these complex macromolecules (Jackson et al, 1991). The chain lengths can vary hugely 
and the molar weight of roughly 10 – 100 kDa allows these chains to have a great 
variance in structure and size. GAGs are divided into two principal types. Non-
sulphated GAGs consist of hyaluronic acid (HA), whereas sulphated GAGs include 
chondroitin sulphate (CS), dermatan sulphate (DS), keratan sulphate (KS), heparan 
sulphate (HS) and heparin  (Ghanghi & Mancera, 2008) (Figure 3.1). With the 
exceptions of heparin and HA, GAGs chains are covalently attached at their reducing 
end through an O-glycosidic linkage to a serine residue or N-linked to aspargine in the 
core protein; the resulting molecule is termed proteoglycan. Proteoglycans contain 
one of the major GAGs thus are termed chondroitin sulphate proteoglycan (CSPG), 
heparan sulphate proteoglycan (HSPG), keratan sulphate proteoglycan (KSPG) and 
dermatan sulphate proteoglycan (DSPG) (Jackson et al, 1991).
 
 
Figure 3.1. Major types of glycosaminoglycans. Glycosaminoglycans consist of repeating disaccharide 
units. With the exception of hyaluronan, the sugars frequently contain sulfate. Heparan sulfate is similar 
to heparin except that it contains fewer sulfate groups (Cooper, 2000). 
Proteoglycans are present in the intracellular granules, extracellular spaces and occur 
as integral components of BMs in probably all mammalian tissues (Jackson et al, 1991). 
However, Proteoglycans are not only structural components, but are now recognized 
to play an important role in controlling the inflammatory response (Wight, 2008; 
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Parish, 2006; Day & de la Motte, 2005; Gotte, 2003). Studies of Jiang et al (2005), 
Schaefer et al (2005) and Taylor et al (2004) show that fragments of GAGs and soluble 
proteoglycans initiate the inflammatory process through activation of TLRs. 
Proteoglycans in the extracellular matrix (ECM) also interact and modify the function 
of cytokines, chemokines, adhesion molecules and proteases to influence immune cell 
phenotype. Proteoglycans and GAGs play a crucial role in leukocyte adhesion and 
subsequent migration into tissues (Parish, 2006, Taylor & Gallo, 2006; Gotte, 2003). 
Migrating leukocytes also enzymatically modify the ECM microenvironment to drive 
further the inflammatory response (Schor et al, 2000). Moreover, proteoglycans may 
interact with matrix metalloproteinases (MMPs) and increase their activity (McCawley 
& Matrisian, 2001). 
In the lung, GAGs are distributed in the ECM, including the interstitial space between 
the capillary endothelium and alveolar epithelium, the subepithelial tissue, bronchial 
walls, and airway secretions (Reeves et al, 2011). All classes of GAGs are found in 
normal lungs, where HS is the predominant one (40 – 60 %), followed by CS/DS (31 %), 
HA (14 %) and heparin (5 %) (Sampson et al, 1984). 
HS is the most ubiquitous GAG, which is expressed on practically every cell in the body 
and comprises 50 – 90 % of the total endothelial proteoglycans (Ihrcke et al, 1993). 
Although HS is synthesized in a cell-bound form, it can also be shed in a soluble form 
(Ihrcke & Plat, 1996). HS proteoglycans expressed in the ECM include perlecan, agrin 
and collagen type XVIII, which are found in normal lungs. The transmembrane 
syndecans and the glycosylophosphoinositide (GPI)-linked glypicans are two HSPG 
families localised to cell surfaces (Bernfield et al, 1999) (Figure 3.2, over). In the lungs, 
syndecan-1 is expressed primarily on the basolateral surface of airway epithelial cells 
and localised to specific cells in the alveolar septa. Syndecan-2 is expressed on 
endothelial cells and human lung fibroblasts. Syndecan-3 is not found in normal lung 
tissue, while syndecan-4 is ubiquitously expressed in a number of tissues, including the 
lungs, and found on both stromal cells and leukocytes (Kim et al, 1994). 
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Figure 3.2. Cell surface proteoglycans. Proteoglycans consist of a protein core (brown) and one or more 
covalently attached glycosaminoglycan chains [(blue) HS; (yellow) CS/DS]. Membrane proteoglycans 
either span the plasma membrane or are linked by a GPI anchor (Varki et al, 2009).
 
HS by binding to laminin, supports BM structure (Battaglia et al, 1992) and by binding 
to collagen V plays an important role in cell substrate adhesion (LeBaron et al, 1989). A 
strong charge of HS, influences its interaction non-covalently with basic proteins and 
involvement in cell-matrix interactions, activation of cytokines, enzymes and growth 
factors (Whitelock & Iozzo, 2005). HS reversibly interacts with the following cytokines, 
IL-5, IL-6, IL-8, IL-10, TNF-α and PF-4 (Menart et al, 2002; Mummery & Rider, 2000; 
Salek-Adrakani et al, 2000; Lipsocombe et al, 1998; Spillmann et al, 1998, Stringer & 
Gallagher, 1997). Binding of IL-8 to HSPGs, including syndecan-1, renders IL-8 resistant 
to proteolysis, thus increasing the half-life and activity of the chemokine of the site of 
inflammation within the airways (Solic et al, 2005, Marshall et al, 2003; Kuschert et al, 
1999). In CF, increased expression of HS and subsequent binding to IL-8 has been 
related to the sustained inflammatory response and continued recruitment of 
neutrophils in CF bronchial tissue. Intact HS was significantly more abundant in 
epithelial and endothelial BMs in CF than COPD patients. These authors concluded that 
sustained neutrophil recruitment in the CF airway may therefore arise from not only 
increased IL-8 expression, but also from the increased stability, prolonged activity and 
retention of IL-8 bound to elevated levels of HS in CF bronchial tissue (Solic et al, 
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2005). Studies by Reeves et al (2010) identified the potential of IL-8 to determine the 
fate of other inflammatory molecules, such as IL-18, within the inflammatory milieu of 
the CF lung. Moreover, Plotkowsky et al (2001) suggested that HSPGs are potential 
receptors for Pseudomonas aeruginosa adherence to epithelial respiratory cells. 
3.1.3. HEPARANASES 
Heparanase is an endoglycosidase cleaving cell surface HS and therefore participating 
in degradation and remodeling of the ECM (Nakajima et al, 1983). It has been directly 
implicated in the promotion of tumor invasiveness and angiogenesis (Vlodavsky et al, 
1988). Heparanase may regulate growth factor action by releasing HS-bound growth 
factors, such as basic fibroblast growth factor (bFGF) from cell surfaces or from the 
ECM (Ishai-Michaeli et al, 1990).  
Human heparanase has an important housekeeping function within the late endosome 
and lysosomal organelles in cancer and inflammatory cells. This location determinates 
its role in the processing and recycling of HS from internalized HSPGs. However, the 
heparanase protein is also present in the nucleus, perinuclear regions and plasma 
membrane (Goldshmidt et al, 2002a; Goldshmidt et al, 2002b). Activation of 
macrophages by PMA induced HS degradation of endothelium-derived ECM and re-
distribution of heparanase to the cell surface (Sasaki et al, 2004). Additionally, HS 
secretion was augmented by treatment of human microvascular endothelial cells with 
TNF-α and IL-1β as well as human peripheral T cells with TNF-α (Chen et al, 2004, 
Sotnikov et al, 2004). 
Heparanase activity has been detected in activated leukocytes, such as neutrophils, 
monocytes and T cells mediating extravasation and traffic to inflammatory sites (Vaday 
& Lider, 2000). Platelets are also recognised as a very rich source of heparanase and 
their aggregation with tumor cells is believed to facilitate tumor cell metastases and 
ECM disassembly following platelet degranulation (Freeman & Parish, 1998). Indeed, 
platelet heparanase activity derives from CTAP III and other amino terminal deletion 
isoforms, isolated from human platelets and characterized. Interestingly, highly 
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purified native CTAP III from platelets was shown to be completely devoid of 
heparanase activity (Castor et al, 2002). 
Based on biochemical studies, an occurrence of several distinct heparanases has been 
reported (Bame et al, 2002; Bame et al, 1998). However, cloning the enzyme from 
different human tissues revealed a single gene (Hulett et al, 1999; Toyoshima & 
Nakajima, 1999; Vlodavsky et al, 1999), suggesting that mammalian cells express 
primarily one heparanase (Vlodavsky et al, 2002). Heparanase is synthesized as a 65 
kDa inactive precursor, which is proteolytically cleavage to 8 and 50 kDa protein 
subunits that form an active enzyme by heterodimerization (Levy-Adam et al, 2003).  
Three forms of heparinase (heparitinase) enzymes or heparin lyase from 
Flavobacterium heparinum, involved in degradation of heparin have been isolated and 
characterised (Figure 3.3) (Silva & Dietrich, 1974). Heparinase I cleaves heparin and HS 
at the linkages between hexosamines and O-sulfated iduronic acids. Additionally, 
heparinise I showed activity against the saccharide sequence of antithrombin binding 
region in heparin. Heparinase II cleaves HS, and to a lesser extent heparin, at the 1 – 4 
linkages between hexosamines and uronic acid residues (both glucuronic and 
iduronic). Heparinase III cleaves at the 1 – 4 linkages between hexosamine and 
glucuronic acid residues in HS. The enzyme is not active towards heparin or low 
molecular weight heparins (Desai et al, 1993; Linhardt et al, 1990; Nader et al, 1990). 
 
Figure 3.3. Substrate specificities of the heparin lyases (Yamada et al, 1998). 
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3.1.4. GAG – Cu(II) INTERACTIONS 
Heparin complexes with transition metal ions have been studied previously (Singh & 
Bhattacharya, 1965). The ability of heparin to form complexes with cobalt ions and a 
high cobalt affinity was associated with a high biological activity of heparin (Mathews, 
1964). Also, the presence of zinc greatly augmented the binding of histamine 
molecules by heparin (Kerp, 1963; Kerp & Steinhaeuser, 1961). Liberti and Stivala 
(1967) reported a positive correlation between copper binding of heparin and heparin 
biological activity. The sites for this cooperative binding may be the ionized carboxyl 
groups and additional binding of a smaller number of copper ions occurs initially, 
probably with the N-sulphate groups (Lages & Stivala, 1973). Mukherjee et al (1978) 
demonstrated that all GAGs, except KS, were capable of binding copper(II), affording a 
complex of an absorbance maxima near 237 nm. They hence suggested that this 
absorbance was a result of a charge transfer complex between copper(II) ions and 
carboxylate groups in the GAG. 
Previous reports have shown that ROS are able to degrade proteoglycan core proteins, 
and GAGs, including HS and heparin or can inhibit de novo synthesis of proteoglycans 
(Moseley et al, 1995; Liu & Perlin, 1994; Panasyuk et al, 1994; Klebanoff et al, 1993). 
The results of Moseley et al (1995) suggest that the presence of sulphate on the GAG 
chain may protect the molecule against ROS attack. Heparin affects leukocyte function 
by inhibiting the generation of ROS (Dadona et al, 1999). Moreover, heparin enhances 
the activity of SOD, in addition to releasing it from human umbilical veins, which 
suggests that heparin itself may have some superoxide dismutase activity in vitro (Gill 
et al, 1999). Also, glycosaminoglycans were reported to reduce oxidative damage 
induced by copper (Cu2+), iron (Fe3+) and hydrogen peroxide (H2O2) in human fibroblast 
cultures (Campo et al, 2004). 
3.1.5. THE UPTAKE OF AMINOGLYCOSIDES 
Aminoglycoside antibiotics are indicated in the treatment of acute exacerbations of CF, 
to control chronic infection, and to eradicate Pseudomonas aeruginosa after recent 
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acquisition (reviewed by Prayle & Smyth, 2010). Aminoglycosides have been associated 
with high clinical effectiveness and their uptake by bacteria has been well 
characterised. However, the action of aminoglycoside on human cells results in 
nephro- and oto-toxicity (Section 1.9.2). There are at least two characterized 
mechanisms for aminoglycoside entry into human cells. 
A receptor-mediated endocytosis at the apical membrane of sensory hair cells of the 
inner ear determines one mechanism of aminoglycoside uptake (Hashino & Shero, 
1995). Internalized aminoglycosides are transported via vesicular traffic into 
lysosomes, where they accumulate over time and eventually disrupt lysosomes 
(Hashino et al, 1997). In kidney cells, aminoglycosides are also transported through the 
endoplasmic reticulum (ER) and the Golgi complex in a retrograde manner, and are 
subsequently released into the cytosol from the ER (Sandoval & Molitoris, 2004).  
Another mechanism of aminoglycoside entry is ion channel permeation into cells. In 
cochlear sensory hair cells, aminoglycosides penetrate through the mechanosensitive 
transduction channels, which are located at the tips of individual stereocilia comprising 
the hair bundle (Marcotti et al, 2005). In cultured kidney cells, chemical agonists of the 
transient receptor potential vanilloid type 1, low extracellular Ca2+ levels, negative 
cellular potentials or acidic extracellular pH, increase the cellular uptake of 
aminoglycosides, further suggesting that they permeate through cation channels 
(Myrdal & Steyger, 2005; Meyers et al, 2003). 
In spite of the fact that aminoglycoside toxicity occurs via multiple pathways in a both 
a drug- and time course-specific manner, divalent cations, such as Ca2+ and Mg2+, have 
been shown to provide protection from aminoglycoside antibiotics (Coffin et al, 2009; 
Humes et al, 1984; Ramirez-Ronda et al, 1975). 
Also, acidic phospholipids have been implicated as integral binding components for the 
energy-dependent aminoglycoside transporter of bacterial membranes (Dickie et al, 
1978). The interaction between aminoglycosides and phosphatidylinositol could be an 
alternative mechanism of the otoxicity of this class of drugs (Orsulakowa et al, 1976). 
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3.1.6. THE ROLE OF PROTEOGLYCANS IN AMINOGLYCOSIDE UPTAKE 
Fluorescent aminoglycosides (1 and 3, Figure 3.4, over) were reported to exhibit poor 
cellular uptake (Luedtke et al, 2003), unlike to their derivatives, in which the amino 
groups of naturally occurring aminoglycoside antibiotics were converted to 
guanidinum groups, as described by Luedke et al (2000). Indeed, upon guanidinylation, 
the cellular uptake of tobramycin is enhanced by approximately 10-fold and the 
enhancement of neomycin B is approximately 20-fold (Luedtke et al, 2003). To 
examine how the cellular uptake of guanoglycosides is affected by gunanidinylation, 
Luedtke et al (2003) have synthesized a series of boron dipyrromethene (BODIPY)-
tagged aminoglycosides and guanidinoglycosides based upon tobramycin and 
neomycin B. BODIPY is a fluorescent probe, claimed to be insenstive to the changes in 
local environment. Guanidino-tobra-BODIPY (2) has four fewer guanidinum groups 
than BODIPY-Cys(Arg)9 (5), but shows approximately the same transport efficiency. 
Importantly, guanidine-neo-BODIPY (4) consistently has a better cellular uptake as 
compared to the poly-Arg peptide BODIPY-Cys(Arg)9 (5). Moreover, guanidino-
neomycin B (6) effectively inhibits the transport of BODIPY-Cys(Arg)9 into cells, 
suggesting a common pathway responsible for the uptake of both compounds. 
Microscopy experiments carried out by the same authors indicates that approximately 
one-half of HeLa cells incubated with guanidinoglycosides or fluorescein-labelled 
conjugates exhibit a highly diffuse, cytoplasmic, and nuclear distribution of these 
compounds, while the other one-half exhibit more localized nucleolar staining, similar 
to that reported for poly-Arg peptides (Luedtke et al, 2003).  Moreover, Elson-Schwab 
et al (2007) demonstrated that a derivative of the aminoglycoside antibiotic neomycin, 
in which all of the ammonium groups have been converted into guanidinum groups 
(guanidinoneomycin), can carry large (over 300 kDa) bioactive molecules across cell 
membranes. Delivery occurs at nanomolar transporter concentrations and under these 
conditions depends entirely on cell surface HSPGs. In contrast, arginine-rich peptides 
show both HS-dependent and HS-independent cellular pathway (Elson-Schwab et al, 
2007; Suzuki et al, 2002). 
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Figure 3.4. Aminoglycosides and guanidinoglycosides evaluated for cellular uptake (Luedtke et al, 2003). 
3.2. HYPOTHESIS, AIMS AND OBJECTIVES 
The hypothesis of the study was that tobramycin and copper-tobramycin are taken up 
by human endothelial cells.  
The aim was to investigate tobramycin and copper-tobramycin complex uptake by the 
host  cells, such as HLMVEC and neutrophils in order to analyse the role of HS and CFTR 
in tobramycin uptake by endothelial cells using immunocytochemistry. 
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3.3. MATERIALS 
 
Lab-TekTM II Chamber SlideTM System was purchased from Thermo Fisher Scientific 
(Waltham, MA, USA). Fisher Scientific (Loughborough, Leicestershire, UK) provided 
methanol, ethanol, Tween-20 and TRIS base. 
Collagen IV from human placenta, heparitinase II from Flavobacterium heparinum, 
bovine serum albumin (BSA), inactivated fetal bovine serum (FBS), Hoechst blue
 
and 
Poly-L-Lysine solution 0.1 % (w/v) in water were from Sigma-Aldrich Inc. (Poole, 
Dorset, UK). Streptavidin-HRP conjugate and normal rabbit serum was obtained from 
Vector Laboratories, Inc. (Burlingame, CA, USA). Complete, mini, protease inhibitor 
cocktail tablets were from Roche Ltd. (Wewlyn Garden City, Hertfordshire, UK). 
Peprotech EC (London, UK) provided recombinant human TNF-α and recombinant 
human IL-8. Invitrogen Ltd. (Paisley, UK) supplied Phosphate Buffered Saline (PBS), 
donkey anti-sheep Alexa Fluor 594, Alexa Fluor 488® F(ab`)2 fragment of rabbit anti-
mouse IgG (H+L) and Alexa Fluor 555® F(ab`) fragment of goat anti-rabbit IgG (H+L). 
Anti-HS Hepss-1 mouse was from Seikagaku Corporation (Tokyo, Japan). A polyclonal 
antibody raised against NBD1, with three prominent epitopes in NBD1 rabbit (Mr. Pink) 
and 10B6.2 Mab mouse CFTR antibody was purchased from Sorscher Lab (Birmingham, 
Alabama, USA). Goat, anti-mouse polyclonal biotinylated antibody was from Dako UK 
Ltd. (Ely, Cambridgeshire, UK). 
BDH/Merck (Poole, Dorset, UK) supplied paraformaldehyde. FluorPreserveTM Reagent, 
unfractioned heparin and CFTR inhibitor-172, 3-[(3-Trifluoromethyl)phenyl]-5-[(4-
carboxyphenyl)methylene]-2-thioxo-4-thiazolidinone were from Calbiochem/Merck 
(Nottingham, Nottinghamshire, UK).  
Randox Laboratories Ltd. (Crumlin, Co. Antrim, UK) provided competitive ELISA kit for 
tobramycin evaluation, which also included sheep anti-tobramycin. 
Cyto Tox-GloTM Cytotoxicyty Assay was from Promega
 
Inc. (Rocky Hill, NJ). 
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3.4. METHODS 
3.4.1. COLLAGEN IV COATING OF CELL CULTURE DISHES 
The method was adapted from Sigma, as supplied with product. Lyophilised collagen IV 
(Sigma Aldrich Inc., Poole, Dorset, UK) was reconstituted to 0.1 mg/ml in 3 % (v/v) 
acetic acid and left to dissolve for half an hour at room temperature on the roller 
mixer. Different volumes of collagen solution were added into appropriate cell culture 
dishes: 100 µl/well of a 96-well plate or 250 µl/well of a chamber slide for 1 to 2 hours 
incubation at room temperature. Then, the excess of collagen IV was removed and 
wells allowed to dry for 1 hour at room temperature. Wells of cell culture dishes were 
washed with HBSS (- Ca/Mg) containing phenol red and this was repeated at least 3 
times. To ensure all acid was removed, the wells were also washed with RPMI 1640, 
followed by a final rinsing with 70 % (v/v) ethanol to sterilize. The dishes were allowed 
to air dry and they were stored at 2 – 80C before use, maintaining sterility. 
3.4.2. SUBCULTURING OF HLMVEC INTO 8-WELL CHAMBER SLIDES 
250 µl fresh and warmed growth medium was added per well of a collagen IV coated 
8-well chamber slide to allow better cell distribution. It was followed by an addition of 
250 µl of cell suspension at 0.7 x 105/ml (0.175 x 105/well).  
3.4.3. TREATMENT OF HLMVEC IN 8-WELL CHAMBER SLIDES 
50 mM tobramycin/copper-tobramycin stock and appropriate dilutions were prepared 
in water. The drugs were added to cell cultures (0.01 – 0.5 mM final concentrations) 
and incubated for 3.5 hours or 24 hours at 370C and 5 % CO2.         
To investigate the role of HS, the HLMVEC cultures were treated with 5 U/ml  
heparitinase II from Flavobacterium heparinum (Sigma Aldrich) 1/20 dilution from 100 
U/ml stock) for 4 hours, followed by incubation with tobramycin and copper-
tobramycin (0.01 – 0.5 mM) for 3.5 hours at 370C and 5 % CO2.  
In order to model CF endothelium, confluent HLMVEC were treated with 20 µM 
CFTRinh-172 for 30 hours, 6 hours before the 24-hour incubation with 10 ng/ml TNF-α 
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at final concentrations. The CFTRinh-172 stock of 20 mM was prepared in DMSO and 
the TNF-α stock of 100 µg/ml was prepared in 1 % (w/v) BSA/PBS. Both, CFTRinh-172 
and TNF-α dilutions were carried out in full growth medium. CFTRinh-172 was also 
added to unactivated cells for 24 hours or in the presence of 5 U/ml heparitinase II for 
4 hours. Tobramycin and copper-tobramycin were added at the concentration of 0.01 
– 0.5 mM to cell cultures for last 3.5 hours incubation after heparitinase II treatment. 
Also, NAC (20 mM from 500 mM stock) and CuSO4 (0.5 mM from 50 mM stock) were 
tested on CFTRinh-172-treated endothelium in the absence and presence of TNF-α     
(10 ng/ml) for 3.5 hours. 
All experiments, including 8-well chamber slides, were carried out in full growth 
medium, which was added to every well in the total volume of 250 µl.
 
3.4.4. IMMUNOCYTOCHEMICAL STAINING OF HLMVEC FOR GAGs 
HLMVEC at were cultured at 0.7 x 105/ml (0.175 x 105/well, 0.25 ml) on collagen IV 
coated Microtek 8-well chamber slides (Thermo Fisher) in full EGM and challenged 
with drugs when confluent (1 – 2 days). The supernatants were removed and the cells 
were washed using 500 µl/well warm PBS (- Ca/Mg). The cells were then fixed by 
adding 500 µl/well of 1 % (w/v) PFA dissolved in 15 % (v/v) picric acid for 30 minutes at 
room temperature. The cells were washed 3 x by adding 500 µl/well of PBS (- Ca/Mg). 
The cells were permeabilised by adding 500 µl/well ice-cold methanol (100 %) for 5 
minutes at -200C or this step was omitted. The cells were washed 3 x by adding 500 
µl/well of PBS (- Ca/Mg) and incubated with 500 µl/well of 2 % (w/v) BSA/PBS plus 10 
% (v/v) rabbit serum at 40C overnight (16 hours) to block non-specific binding sites. The 
primary antibody, anti HS-mouse IgM at 1 mg/ml was diluted 1/1000 in 1 % (w/v) 
BSA/PBS, resulting in 1 µg/ml final concentration and 100 µl added per well for 1 hour 
incubation at room temperature. The cells were washed 5 x using 0.02 % (v/v) Tween-
20/PBS for 5 minutes. The secondary antibody, rabbit anti-mouse Alexa Fluor 488, 
F(ab`)2 2 mg/ml was diluted 1/800 in 1 % (w/v) BSA/PBS, resulting in 5 µg/ml final 
concentration. The cells were washed 5 x with 0.02 % (v/v) Tween-20/PBS for 5 
minutes. The chamber scaffold and the gasket were removed and the slide was 
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mounted in Fluor Preserve Reagent (Calbiochem). The cells were viewed using a Zeiss 
LSM 710 confocal microscope (ex. 488 nm, em. 540 nm). 
3.4.5. IMMUNOCYTOCHEMICAL STAINING OF HLMVEC FOR TOBRAMYCIN 
HLMVEC were subcultured for Microtek 8-well chamber slides (Thermo Fisher) at 0.7 x 
105/ml (0.175 x 105/well, 0.25 ml). The cells were cultured until confluency (at least 48 
hours). The supernatants were removed and the cells washed with 500 µl of PBS (- 
Ca/Mg) per well. The cells were fixed by adding 500 µl/well 4 % (w/v) PFA/PBS for 30 
minutes at room temperature. The slides were washed 3 x by adding 500 µl PBS (– 
Ca/Mg) per well. The cells were permeabilised by adding 500 µl per well of ice-cold 
methanol (100 %) for 5 minutes at -200C. The slides were washed 3 x as before. The 
cells were incubated with in PBS containing 1 % (w/v) BSA at 40C for 16 hours to block 
non specific binding sites. The primary antibody, sheep anti-tobramycin (Randox) was 
diluted from the stock concentration of 5.84 mg/ml to the final concentration of 10 
µg/ml in 1 % (w/v) BSA/PBS. 100 µl/well primary antibody was incubated for 1 hour at 
room temperature. The cells were washed 5 x 5 minutes with 500 µl of 0.02 % (v/v) 
Tween-20/PBS (- Ca/Mg) per well. The stock concentration of 2 mg/ml of the 
secondary antibody, donkey anti-sheep Alexa Fluor 594 (Molecular Probes) was diluted 
1/400 in 1 % (w/v) BSA/PBS (- Ca/Mg) and 100 µl of diluted secondary antibody was 
added per well for 1 hour incubation at room temperature. Each well of the slide was 
washed 5 x 5 minutes using 500 µl/well 0.02 % (v/v) Tween-20/PBS (- Ca/Mg). The 
chamber scaffold and the gasket were removed and the slide was mounted using Fluor 
Preserve Reagent (Calbiochem). The cells were viewed on a Zeiss LSM 710 confocal 
microscope (ex. 591 nm, em. 618 nm). 
3.4.6. IMMUNOHISTOCHEMICAL STAINING OF HLMVEC FOR CFTR 
HLMVEC were cultured on collagen IV coated Microtek 8-well chamber slides chamber 
slides (Thermo Fisher) in full EGM until confluent (1 – 2 days) and challenged with 
drugs. After drug treatment, the cells were washed 2 x 5 minutes using PBS (+ Ca/Mg), 
500 µl/well. The cells were fixed for 30 minutes using 1 % (w/v) PFA dissolved in 15 % 
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(v/v) picric acid in PBS (+ Ca/Mg) and washed again. They were then permeabilised by 
incubating for 10 minutes in 0.1 % (v/v) Triton X-100/PBS (+ Ca/Mg). The cells were 
washed 3 x 5 minutes using PBS (+ Ca/Mg) and incubated in 2 % (w/v) BSA/PBS (+ 
Ca/Mg) overnight at 40C. The primary antibody, Mr Pink (against purified NBD1 domain 
of human CFTR in rabbit) was diluted from 1 mg/ml stock 1/500 dilution in 0.2 % (w/v) 
BSA/PBS (+ Ca/Mg) and incubated for 1 hour at room temperature (100 µl/well). The 
cells were washed 3 x 5 minutes using PBS (+ Ca/Mg). The secondary antibody, goat 
anti-rabbit-555 was diluted 1/400 in 0.2 % (w/v) BSA/PBS (+ Ca/Mg) and incubated for 
40 minutes at room temperature (100 µl/well). The cells were washed 3 x 5 minutes 
using PBS (+ Ca/Mg), followed by removal of the chamber scaffold and the gasket. The 
slide was mounted using Fluor Preserve Reagent (Calbiochem) and the cells examined 
using a Zeiss LSM 710 confocal microscope (ex. 544, em. 590 nm). 
3.4.7. TOBRAMYCIN UPTAKE BY NEUTROPHILS 
Neutrophils were isolated according to the procedure described previously (Section 
2.4.1), re-suspended in RPMI 1640 + 2.5 % (v/v) FBS and diluted to 1 x 107 cells/ml. The 
cells were pre-incubated with tobramycin or copper-tobramycin (0.5 mM) for 30 
minutes at 370C, followed by treatment with IL-8 (6.25 x 10-8 M) for 3 hours. The final 
concentration of IL-8, 6.25 x 10-8 M, was obtained from 1.25 x 10-5 M IL-8 stock by 
1/200 dilution in  RPMI 1640 + 2.5 % (v/v) FBS. The experiment was performed in 
duplicate in the reaction volume of 100 µl. After 3.5 hours incubation time, the 
reaction was stopped on ice and cytospins on neutrophil suspensions were prepared 
by centrifugation at 450 x g for 5 minutes. The glass slides used for cytospins were 
coated with poly-L-lysine solution (Sigma) for 5 minutes and stored dry before use. 
Other experiments included 5, 15 and 30 minutes incubation of neutrophils at 1 x 107 
cells/ml at 370C without further activation, followed by cytospins. 
3.4.8. IMMUNOCYTOCHEMICAL STAINING OF NEUTROPHILS FOR TOBRAMYCIN 
Dried slides were fixed by adding 500 µl/slide of 4 % (w/v) PFA/PBS for 30 minutes at 
room temperature, followed by 3 washes with 500 µl PBS (- Ca/Mg) per slide. The cells 
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were permeabilised by adding 500 µl per slide of ice-cold methanol (100 %) for 5 
minutes at -200C and washed 3 x by adding 500 µl PBS (- Ca/Mg) per slide. They were 
then blocked overnight with 1 % (w/v) BSA/PBS (- Ca/Mg) at 40C. The slides were 
washed with PBS (- Ca/Mg). The primary antibody, sheep anti-tobramycin (Randox) 
was diluted from the stock concentration of 5.84 mg/ml to 10 µg/ml final 
concentration in 1 % (w/v) BSA/PBS and incubated on slides for 1 hour at room 
temperature (100 µl/slide). The slides were washed 5 x 5 minutes with 500 µl of 0.02 % 
(v/v) Tween-20/PBS (- Ca/Mg) per slide. The stock concentration of 2 mg/ml of the 
secondary antibody, donkey anti-sheep Alexa Fluor 594 (Molecular Probes) was diluted 
1/400 in 1 % (w/v) BSA/PBS (- Ca/Mg) and added for 1 hour incubation at room 
temperature (100 µl/well). Each slide was washed 5 x 5 minutes using 500 µl/well 0.02 
% (v/v) Tween-20/PBS (- Ca/Mg) and eventually mounted using Fluor Preserve Reagent 
(Calbiochem) before proceeding for confocal microscopy. 
3.4.9.  SUBCULTURING OF HLMVEC INTO COLLAGEN IV COATED 96-WELL PLATES FOR A         
            VIABILITY ASSAY 
Collagen IV coated 96-well plates were incubated for few minutes at 370C and 5 % CO2 
before using for subculturing. An aliquot of 100 µl growth medium was dispensed per 
well for better cell distribution. HLMVEC were diluted to 2 x 105/ml in growth medium 
and 100 µl cell suspension was dispensed per well of each 96-well plate. The plates 
were incubated for at least 48 hours at 370C and 5 % CO2 until confluent. The cells 
were fed with 100 µl of fresh and warmed medium. 
3.4.10.  TREATMENT  OF  HLMVEC  IN  COLLAGEN  IV  COATED  96-WELL PLATES  FOR  A  
              VIABILITY ASSAY 
Confluent HLMVEC grown on collagen IV coated 96-well plates were treated with the 
following compounds: tobramycin, copper-tobramycin and copper sulphate            
(0.01 – 0.5 mM), TNF-α (10 ng/ml) and CFTRinh-172 (20 µM) for 24 hours at 370C and 5 
% CO2. 
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3.4.11. ENDOTHELIAL CELL VIABILITY ASSESSMENT 
The endothelial cell viability was assessed by using the CytoTox-Glo™ assay (Promega). 
This assay measures a distinct protease activity, released from cells that have lost 
membrane integrity and therefore associated with cytotoxicity. A luminogenic peptide 
substrate (alanyl-alanylphenylalanyl-aminoluciferin; AAF-Glo™ Substrate) is here 
cleaved by a dead-cell protease activity. Following cleavage, a substrate for luciferase 
(aminoluciferin) is released, resulting in the luciferase-mediated production of light. 
The CytoTox-Glo™ Cytotoxicity Assay Reagent was prepared by transferring the 
contents of one bottle of Assay Buffer to the AAF-Glo™ Substrate bottle. The Lysis 
Reagent was prepared by transferring Digitonin to the Assay Buffer and mixed well to 
ensure homogeneity. 
Confluent HLMVEC set up on collagen IV coated 96-well plate were treated with test 
drugs for 24 hours in a total volume of 100 µl. 50 μl of CytoTox-Glo™ Cytotoxicity Assay 
Reagent was added to all wells of a plate, mixed briefly by orbital shaking and 
incubated for 15 minutes at room temperature. The total luminescence was measured 
on a Wallac Victor2 plate reader (Perkin Elmer Life Sciences, Wallac Oy, Turku, Finland). 
Then, 50 μl of Lysis Reagent was added to all wells of a plate, mixed and incubated at 
room temperature for 15 minutes. The dead luminescence was measured. The 
luminescent contribution of previously viable cells (after lysis) was calculated by 
subtracting the luminescent signal resulting from experimental cell death from total 
luminescence death according to the following formula: 
Viable cell luminescence = Total luminescence – Experimental dead cell luminescence 
The experiment was performed once in duplicate. 
3.4.12. STATISTICAL ANALYSIS 
The results were analysed by using Graph Pad Prism 4.0. Two-tailed unpaired t-test 
and one-way ANOVA with Dunnett`s multiple comparison test were performed on the 
data. The results were expressed as average plus/minus SEM and p<0.05 were 
considered as significant.
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3.5. RESULTS 
3.5.1. THE  PRESENCE OF  HS  ON  ENDOTHELIAL  CELL  SURFACE  AND  THE  EFFECT  OF  
            TNF-α, CFTRinh-172 AND HEPARITINASE II ON GAGs EXPRESSION 
The presence of HS on the surface of endothelial cells was examined by using two 
methods of slide preparation, including both fixation and permeabilization (Figure 3.5, 
page 104) or fixation step only (Figure 3.6, page 105). Fixation should immobilize the 
antigens, while retaining authentic cellular and subcellular structure. Fixation can be 
done using crosslinking reagents, such as paraformaldehyde. It forms intermolecular 
bridges, normally through free amino groups, thus creating a network of linked 
antigens. Cross-linkers preserve cell structure better than organic solvents, but may 
reduce the antigenicity of some cell components and require the addition of a 
permeabilization step, to allow access of the antibody to the specimen. Organic 
solvents such as alcohols and acetone remove lipids and dehydrate the cells, while 
precipitating the proteins on the cellular architecture. Methanol or acetone could also 
be used for permeabilization. Permeabilization should only be required for intracellular 
epitopes when the antibody required has access to the inside of the cell to detect the 
protein. However, it will also be required for detection of transmembrane proteins if 
the epitope is in the cytoplasmic region. As shown here (Figure 3.5 and Figure 3.6), 
fixed and permeabilized cells ensured free access of the antibody to the antigen, 
resulting in better surface staining, compared to cell fixation only. Moreover, the 
overall quality of staining is better, when the cells were both fixed and permeabilized. 
The surface of endothelial cells is decorated with a wide variety of membrane-bound 
macromolecules, including glycoproteins, proteoglycans, and their associated 
glycosaminoglycan (GAG) side chains that constitute the glycocalyx. Heparan sulfates 
are the most common endothelial cell-surface GAG, comprising 50 % to 90 % of the 
GAG pool (Ihrcke et al, 1993). Therefore, a specific HS monoclonal antibody was used 
to detect HS on HLMVEC surface and intracellularly in both fixed and permeabilized 
cells. Untreated HLMVEC (Figure 3.5, panel 1AB) expressed low level of HS, which was 
located mainly in the cell nucleus and the cytoplasm. Membrane staining was 
negligible. TNF-α (panel 2AB), CFTRinh-172 (panel 3AB) and the combination of TNF-α 
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and CFTRinh-172 (panel 4AB) treatment increased HS expression on the endothelial 
cell surface compared to untreated control (panel 1AB). TNF-α induced low, whereas 
CFTRinh-172, especially in the presence of TNF-α-induced, high endothelial HS 
expression. Additionally, membrane staining was observed in the presence of CFTRinh-
172 plus TNF-α. 
 
 
 
 
Figure 3.5. HS on HLMVEC, fixed and permeabilised. Cells were stained with anti-HS Hepss-1 antibody. 
1AB) control cells, no stimulus; 2AB) 10 ng/ml TNF-α; 2CD) 10 ng/ml TNF-α plus heparitinase II; 3AB) 20 
µM CFTRinh-172; 3CD) 20 µM CFTRinh-172 plus heparitinase II; 4AB) TNF-α + CFTRinh-172; 4CD) TNF-α + 
CFTRinh-172 plus heparitinase II. Scale bar 100 µm. These represent typical results from two 
independent experiments. 
Heparitinase II from Flavobacterium heparinum was used to demonstrate degradation 
of HS on the cell surface. Indeed, HLMVEC following heparitinase treatment (panel 
2CD, 3CD, 4CD) expressed less HS compared to treatment with TNF-α, CFTRinh-172 or 
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TNF-α plus CFTRinh-172. However, heparitinase reduced the amount of HS  to the level 
similar as presented by untreated cells.  
 
 
 
 
Figure 3.6. HS on HLMVEC, fixed, not permeabilised. Cells were stained with anti-HS Hepss-1 antibody. 
1AB) no treatment; 2AB) 10 ng/ml TNF-α; 2CD) 10 ng/ml TNF-α plus heparitinase II; 3AB) 20 µM 
CFTRinh-172; 3CD) 20 µM CFTRinh-172 plus heparitinase II; 4AB) TNF-α + CFTRinh-172; 4CD) TNF-α + 
CFTRinh-172 plus heparitinase II. Scale bar 100 µm, n=1. 
3.5.2. TOBRAMYCIN UPTAKE BY ENDOTHELIUM 
The aminoglycoside tobramycin and the copper-tobramycin complex were incubated 
with HLMVEC at 370C and 5 % CO2 in different time frames in order to examine 
whether these drugs are taken up by endothelial cell cultures. Figure 3.7 and 3.8 (over) 
show tobramycin and copper-tobramycin uptake by HLMVEC for 3.5 hours, 
respectively. Tobramycin and copper-tobramycin uptake by HLMVEC for 24 hours is 
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presented on Figure 3.9 and 3.10 (page 107), respectively. All images presented at 
each panel were captured at the same confocal microscopy settings and therefore 
could be directly compared.  
 
 
Figure 3.7. Tobramycin uptake of HLMVEC for 3.5 hours. 1 – 4) no primary anti-tobramycin antibody; 1 
and 5) untreated HLMVEC; 2 and 6) 0.01 mM tobramycin; 3 and 7) 0.1 mM tobramycin; 4 and 8) 0.5 mM 
tobramycin, Scale bar 100 µm. Microscope magnification 200x. These represent typical results from at 
least seven independent experiments. 
 
 
Figure 3.8. Copper-tobramycin uptake of HLMVEC for 3.5 hours. 1 – 4) no primary anti-tobramycin 
antibody; 1 and 5) untreated HLMVEC; 2 and 6) 0.01 mM tobramycin; 3 and 7) 0.1 mM tobramycin; 4 
and 8) 0.5 mM tobramycin, Scale 100 µm. Microscope magnification 200x. These represent typical 
results from at least four independent experiments. 
 
1 
7 6 5 
3 2 
8 
4 
1 
8 
4 
7 6 
3 
5 
2 
107 
 
 
 
Figure 3.9. Tobramycin uptake of HLMVEC for 24 hours. 1 – 4) no primary anti-tobramycin antibody; 1 
and 5) untreated HLMVEC; 2 and 6) 0.01 mM tobramycn; 3 and 7) 0.1 mM tobramycin; 4 and 8) 0.5 mM 
tobramycin, Scale 100 µm. Microscope magnification 200x. These represent typical results from at least 
two independent experiments. 
 
 
Figure 3.10. Copper-tobramycin uptake of HLMVEC for 24 hours. 1 – 4) no primary anti-tobramycin 
antibody; 1 and 5) untreated HLMVEC; 2 and 6) 0.01 mM tobramycn; 3 and 7) 0.1 mM tobramycin; 4 and 
8) 0.5 mM tobramycin, Scale 100 µm. Microscope magnification 200x. These represent typical results 
from at least four independent experiments. 
There was no cell staining observed in the absence of primary antibody (panel 1 – 4) 
and very little background staining of untreated cells (panel 5). Both tobramycin and 
copper-tobramycin were taken up by unactivated human endothelium and this uptake 
was dose dependent, increasing with increasing concentration of the drugs (panel 6 – 
8). 
1 
8 
4 
7 
3 2 
6 5 
1 
8 7 6 5 
4 3 2 
108 
 
It was also of interest to find out in which cell compartment tobramycin and copper-
tobramycin are located following the uptake by human endothelium. For this reason, 
400 x microscope magnification was used accompanied by a z-stack with the slice 
thickness of 1 µm. Figure 3.11 showed localisation of tobramycin within HLMVEC. 
Tobramycin is located mostly in the cell cytoplasm and in perinuclear area of the cells. 
There is little nuclear staining, as the nucleus remained dark on the scan. This is also 
true for copper-tobramycin. 
 
 
 
Figure 3.11. Tobramycin localization in HLMVEC. HLMVEC were incubated with 0.5 mM tobramycin for 
3.5 hours and 1 µm z-stack was performed. Scale bar 100 µm. Microscope magnification 400x. 
HLMVEC were treated with 0.5 mM of both tobramycin or copper-tobramycin and as 
an additional control, HLMVEC were counterstained with Hoechst blue to visualise cell 
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nuclei (Figure 3.12). The split and merged channels of tobramycin and Hoechst blue 
are shown. 
 
 
 
 
Figure 3.12. HLMVEC stained for tobramycin (anti-tobramycin antibody) with counterstained nucleus 
(Hoechst blue) under tobramycin and copper-tobramycin. 1) no primary anitbody; 2) no treatment; 3) 
0.5 mM tobramycin; 4) 0.5 mM copper-tobramycin. A) nucleus stain; B) tobramycin stain, C) both. Scale 
bar 25 µm. 
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Although confocal fluorescence allows demonstration of the precise location of 
fluorophores, confocal images are not suitable for quantification because they have 
high levels of background noise. In order to quantify tobramycin and copper-
tobramycin uptake by HLMVEC for 3.5 hours incubation, a background correction was 
applied in a manual mode, as described by Zinchuk & Zinchuk (2008) and an online 
guide: http://www.macbiophotonics.ca/imagej/image_intensity_proce.htm by using 
ImageJ 1.42q software. Manual mode is much more sensitive and customizable than 
auto mode and more importantly, it allows performance of background correction 
using the unique pixel profile of analysed images. 
The background correction is exemplified by Figure 3.13. 
 
 
 
Figure 3.13. Background correction. A) Original immunocytochemical image of HLMVEC stained for 
tobramycin. B) The same image after applying threshold, which removes the black bacground. Note, the 
edges of the cells must be seen. Scale bar 100 µm. C) Histogram. The highest peak on the left hand side 
representing the background was removed by applying a threshold at the intensity 8 that is showed by a  
vertical blue line. 
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The background was relatively even across the image (panel A) and it was corrected 
using a threshold value, which was moved from the minimum 0 value until most of the 
background displayed blue, however, with visible cell edges (panel B). The background 
removal was controlled by the image histogram (panel C), which displays both the 
number and intensity of pixels. The low intensity peak accounted for the background, 
whereas the other peak represented the red fluorescent endothelial stain. The 
threshold at the value 8 (blue vertical line) succesfully removed the background peak 
from the total intensity of the image area by changing the mean intensity from 42.825 
to 45.188. 
The mean intensity, calculated as the relationship between the total intensity and the 
pixel count, was used to express each tobramycin and copper-tobramycin stain. Figure 
3.14 confirmed that HLMVEC uptake of both tobramycin and copper-tobramycin is 
concentration dependent.
 
 
Figure 3.14. Immunocytochemical quantitative analysis of tobramycin and copper-tobramycin uptake by 
HLMVEC for 3.5 hours, following subtracting of baseline. The data is expressed by mean ± SEM of n=3 or 
4 separate experiments and analysed using unpaired two-tailed t-test. **<0.01, ***p<0.001. 
3.5.3. THE ROLE OF HS IN TOBRAMYCIN AND COPPER-TOBRAMYCIN UPTAKE 
The next step was to examine the mechanism of tobramycin and copper-tobramycin 
uptake by HLMVEC over 3.5 hours. Heparitinase II was used to degrade heparan 
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sulphate present on the surfaces of HLMVEC, as described in Section 3.4.3. and in 
Figure 3.5. The effect of heparitinase II on the uptake of tobramycin and its complex 
with copper was evaluated (Figure 3.15). Tobramycin and copper-tobramycin (0.01 – 
0.5 mM) (panels 2 – 4 and 6 – 8, respectively) were taken up in a dose dependent way 
as shown previously (Figure 3.7 & 3.8). Heparinase treatment (5 U/ml) reduced the 
uptake of the 0.5 mM concentration of both tobramycin (panel 5) and copper 
tobramycin (panel 9) by HLMVEC compared to appropriate drug treatment alone 
(panel 4 and 8, respectively). These results suggest that binding of positively charged 
aminoglycosides to negatively charged heparan sulphate could be a mechanism of 
tobramycin and copper-tobramycin uptake by HLMVEC. However, the fluorescence 
reduction introduced by heparitinase II was not complete, as the cell stain did not 
return to the baseline (panel 1). 
 
 
 
Figure 3.15. The effect of heparitinase II on tobramycin and copper-tobramycin uptake by HLMVEC. The 
cells were stained with anti-tobramycin antibody. 1) negative control; 2) 0.01 mM tobramycin; 3) 0.1 
mM tobramycin; 4) 0.5 mM tobramycin; 5) 0.5 mM tobramycin plus 5 U/ml heparitinase II; 6) 0.01 mM 
copper-tobramycin; 7) 0.1 mM copper-tobramycin; 8) 0.5 mM copper-tobramycin; 9) 0.5 mM copper-
tobramycin plus 5 U/ml heparitinase II. Scale bar 100 µm. These results are typical from at least two 
independent experiments. 
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3.5.4. TOBRAMYCIN UPTAKE BY NEUTROPHILS
 
Neutrophils were also examined for tobramycin and copper-tobramycin uptake. Figure 
3.16 showed tobramycin and copper-tobramycin treatment of both resting and IL-8-
activated normal neutrophils. In respect of the negative controls used in this 
experiment, which were the absence of primary antibody (panel 1) and no drug 
treatment (panel 2), tobramycin and copper-tobramycin (0.5 mM) were not taken up 
by unactivated (panel 3 and 4, respectively) or IL-8 (5 x 108 M)-activated neutrophils 
(panel 5 and 6, respectively). 
 
 
 
Figure 3.16. Tobramycin and copper-tobramycin is not taken up by resting or IL-8 activated neutrophils. 
The cells were stained with anti-tobramycin antibody. Neutrophils (1 x 10
7
/ml) untreated or  treated 
with tobramycin and copper-tobramycin (0.5 mM) for 3.5 hours and stained for tobramycin, 200x. 1) 
Control PMN, no primary
 
antibody; 2) Untreated PMN; 3) PMN + 0.5 mM Tob; 4) PMN + 0.5 mM Cu-Tob; 
5) PMN + 0.5 mM Tob + IL-8; 6) PMN + 0.5 mM Cu-Tob + IL-8. Bar scale 100 µm, n=1. 
3.5.5. THE EFFECT OF CFTRinh-172 ON TOBRAMYCIN UPTAKE BY ENDOTHELIUM 
HLMVEC pre-treated for at least 24 hours with 20 µM CFTRinh-172 was used to model 
CF endothelium. Normal and CF endothelium were then tested with a range of 
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tobramycin and copper-tobramycin concentrations (0.01 mM – 0.5 mM) for 3.5 hours 
at 370C and 5 % CO2. Figure 3.17 showed tobramycin uptake by HLMVEC (panels 2 – 4) 
compared to untreated endothelium (panel 5). No primary antibody control was also 
presented (panel 1). CFTR-inh172 did not increase or decrease tobramycin uptake by 
HLMVEC (panel 6 – 8).  
 
 
Figure 3.17. The effect of CFTRinh-172 on tobramycin uptake. HLMVEC were incubated for 24 hours with 
CFTRinh-172 and treated with tobramycin (0.01 - 0.5 mM) for 3.5 hours. 1) no anti-tobramycin primary 
antibody; 2) 0.01 mM tobramycin; 3) 0.1 mM tobramycin; 4) 0.5 mM tobramycin; 5) no treatment; 6) 
0.01 mM tobramycin plus 20 µM CFTRinh-172; 7) 0.1 mM tobramycin plus 20 µM CFTRinh-172; 8) 0.5 
mM tobramycin plus 20 µM CFTRinh-172. Scale bar 100 µM. These represent typical results from at least 
two independent experiments. 
Figure 3.18 (over) shows an effect of CFTRinh-172 on copper-tobramycin uptake of 
endothelium compared to normal (panels 6 – 8 versus 2 – 4) with respect to the 
appropriate controls (panels 1 and 5). Copper-tobramycin, similarly to tobramycin was 
taken up by both normal and CF endothelium without visible differences seen in 
confocal microscopy due to CFTRinh-172.
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Figure 3.18. The effect of CFTRinh-172 on copper-tobramycin uptake. HLMVEC were incubated for 24 
hours with CFTRinh-172 and treated with copper-tobramycin (0.01 - 0.5 mM) for 3.5 hours. 1) no anti-
tobramycin primary antibody; 2) 0.01 mM copper-tobramycin; 3) 0.1 mM copper-tobramycin; 4) 0.5 mM 
copper-tobramycin; 5) no treatment; 6) 0.01 mM copper-tobramycin plus 20 µM CFTRinh-172; 7) 0.1 
mM copper-tobramycin plus 20 µM CFTRinh-172; 8) 0.5 mM copper-tobramycin plus 20 µM CFTRinh-
172. Scale bar 100 µM.  These represent typical results from at least two independent experiments. 
As shown in Section 3.5.1, CFTRinh-172, especially in the presence of TNF-α, increased 
HS expression on the surface of human endothelium. It was therefore interesting to 
check whether this effect was dependent on the surface heparan sulphate. For this 
reason CF endothelium stimulated with TNF-α, was incubated with heparitinase II for 4 
hours prior the addition of tobramycin at 0.01 mM - 0.5 mM final concentration for 3.5 
hours (Figure 3.19, over). CFTRinh-172 in the presence of TNF-α could be considered as 
a better model of CF because, beside inactive CFTR, it presents a pro-inflammatory 
profile, generated by TNF-α. It would be also expected that the uptake of tobramycin is 
greater in this condition compared to normal EC, hence, it was impossible to make a 
direct comparison of different experiments. CFTRinh-172 plus TNF-α in the absence of 
tobramycin (panel 5) did not affect HLMVEC in comparison to untreated control (panel 
1). EC endothelium presented a dose dependent pattern of tobramycin uptake (panel 
2 – 4). In presence of heparitinase II, tobramycin uptake was slightly reduced also dose 
dependently (panel 6 – 8). This results indicate that heparitinase II might affect 
tobramycin and copper-tobramycin uptake by CF endothelium and suggest again a role 
of HS it this uptake.
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Figure 3.19. Tobramycin stain showing the effect of heparitinase II on HLMVEC incubated with 
tobramycin in the presence of CFTRinh-172 and TNF-α. The cells were stained with anti-tobramycin 
antibody. 1) no drug; 2 – 8) 10 ng/ml TNF-α plus 20 µM CFTRinh-172; 2) 0.01 mM tobramycin; 3) 0.1 mM 
tobramycin; 4) 0.5 mM tobramycin; 5) no drug; 6) 0.01 mM tobramycin plus 5 U/ml heparitinase II; 7) 
0.1 mM tobramycin plus 5 U/ml heparitinase II; 8) 0.5 mM tobramycin plus 5 U/ml heparitinase II. Scale 
bar 25 µm. 
3.5.6.  THE  EFFECT OF  TOBRAMYCIN,  COPPER-TOBRAMYCIN, COPPER-SULPHATE AND  
            N-ACETYLCYSTEINE ON ENDOTHELIAL CFTR 
CFTR protein is localized on the plasma membrane of CFTR-expressing cells. However, 
it could also be inserted into the membrane of intracellular organelles, including the ER 
(Pasyk & Fosket et al, 1997). The presence of CFTR within HLMVEC has previously been 
indicated and verified in HLMVEC by immunocytochemistry (Tousson et al, 1998). The 
effect of tobramycin, copper-tobramycin, N-acetylcysteine (NAC) and copper sulphate 
on endothelial CFTR was examined. Figure 3.20 (over) clearly shows that CFTR protein 
is present and expressed in endothelial cell cultured in vitro. Without any additional 
treatment, CFTR levels are low in HLMVEC and CFTR is mostly located in the 
perinuclear area and cytoplasm, possibly ER (panel 2). Both tobramycin and copper-
tobramycin increased the expression of intracellular CFTR (panels 3 and 4, 
respectively). NAC, a known mucolytic and antioxidant drug and indirect precursor of 
glutathione, increases CFTR expression (Varelogianni et al, 2010). Indeed, NAC 
increased intracellular CFTR expression in HLMVEC (panel 5). However, no visible 
membrane expression of CFTR protein might suggest that this protein is not functional. 
1 4 
8 
3 2 
5 7 6 
117 
 
Copper sulphate had no effect of endothelial CFTR (panel 6) compared to the 
untreated control (panel 2). Additionally, HLMVEC was incubated with the absence of 
primary antibody and displayed no background detection (panel 1). 
 
 
 
Figure 3.20. The effect of tobramycin, copper-tobramycin, NAC and copper sulphate on CFTR expression 
in HLMVEC. 1AB) No primary antibody (Mr. Pink); 2AB) No treatment; 3AB) 0.5 mM tobramycin; 4AB) 
0.5 mM copper-tobramycin; 5AB) 20 mM NAC; 6AB) 0.5 mM CuSO4. Scale bar 25 µm, n=3 
HLMVEC were also treated with tobramycin, copper-tobramycin, NAC and CuSO4 in the 
presence of CFTRinh-172 alone or the pro-inflammatory cytokine, TNF-α (Figure 3.21, 
over). Appropriate controls of no primary antibody (panel 1) and no drug treatment (2) 
were included. CFTRinh-172 (panel 3) and TNF-α (panel 4) had an equal effect on 
endothelial CFTR, they increased mostly perinuclear and cytoplasmic CFTR protein 
expression. The combination of CFTRinh-172 and TNF-α, which better reflects the CF 
condition, had additive effect on intracellular CFTR level (panel 5). Tobramycin in the 
presence of CFTR-inh172 increased not only intracellular but also membrane CFTR 
expression (panel 6). These results suggest that tobramycin might increase the amount 
of functional membrane CFTR, especially since NAC had a similar effect (panel 8). 
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Figure 3.21. The effect of tobramycin, copper-tobramycin, NAC and copper sulphate on CFTR expression 
in HLMVEC activated with TNF-α in the presence or absence of CFTRinh-172. 1AB) No primary antibody 
(Mr. Pink); 2AB) No drug; 3AB, 6AB – 9AB) 20 µM CFTR-inh172; 4AB) 10 ng/ml TNF-α; 5AB, 10AB – 12AB) 
20 µM CFTRinh-172 plus 10 ng/ml TNF-α; 6AB and 10AB) 0.5 mM tobramycin; 7AB and 11AB) 0.5 mM 
copper-tobramycin; 8AB and 12 AB) 20 mM NAC; 9AB) 0.5 mM CuSO4. Scale bar 25 um, n=2. 
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Copper-tobramycin increased perinuclear and cytoplasmic levels of detectable CFTR 
protein (panel 7), however membrane CFTR was increased to a lesser extent compared 
to tobramycin and NAC. Copper sulphate in the presence of CFTR-inh172 (panel 9) had 
no effect on CFTR expression, alike to copper sulphate alone. Both tobramycin and 
copper-tobramycin in the presence of CFTRinh-172 and TNF-α induced increased 
intracellular expression of endothelial CFTR. The membrane was stained  weakly  
(panels 10 and 11). NAC highly up-regulated the CFTR expression only inside the cell 
(panel 12). 
To confirm the exact location of CFTR within HLMVEC, a z-stack with 1 µm interval was 
performed on untreated control (Figure 3.22). 
 
 
 
 
Figure 3.22. Z-stack of untreated HLMVEC control stained for CFTR. 1 µm intervals. Scale bar 50 µm.  
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CFTR protein was located in the central part of the cell. It wass mainly associated with 
the perinulcear membrane and the perinuclear area corresponding to the location of 
the ER. Moreover, CFTR protein was abundantly present in the cell cytoplasm. No CFTR 
was seen on the cell membrane. 
Figure 3.23 presents the effect of tobramycin in CFTRinh-172-treated HLMVEC. 
Tobramycin or CFTR-inh172 were already shown to increase the intracellular 
expression of CFTR protein (Figure 3.20 and 3.21, respectively). Tobramycin in the 
presence of CFTRinh-172 increased the intracellular expression of CFTR, especially in 
the area close to the nucleus. Interestingly, tobramycin in the presence of CFTRinh-172 
caused the appearance of CFTR on the cell membrane.  
 
 
 
Figure 3.23. Z-stack of tobramycin-treated HLMVEC in the presence of CFTRinh-172 and stained for 
CFTR. 1 µm intervals. Scale bar 50 µm.  
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It can be noted not only on the central image of Figure 3.23, but also on the first and 
last slides, indicating the apical and basal cell membrane.
 
3.5.7. ENDOTHELIAL VIABILITY 
The viability of HLMVEC during 24 hour experiments in the presence of tobramycin, 
copper-tobramycin, copper sulphate, TNF-α and CFTRinh-172 was assessed 
luminometrically by measuring the percentage of cell viability. None of the drugs used 
were toxic to HLMVEC in full growth medium (Figure 3.24A and 3.24B). 
 
 
Figure 3.24. HLMVEC viability in full growth medium during 24 hours incubation. A) HLMVEC were 
incubated with tobramycin, copper-tobramycin (0.01 – 0.5 mM) and copper sulphate (0.5 mM); B) 
HLMVEC were incubated with 10 ng/ml TNF-α and 20 µM CFTRinh-172. The cell viability was assessed by 
using CytoTox-Glo
TM
 Cytotoxicity Assay (Promega), n=1, in duplicate. 
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3.6. SUMMARY OF RESULTS 
CFTR-inh172, especially in the presence of TNF-α, increased HS expression in HLMVEC. 
Tobramycin and copper-tobramycin were taken up by normal and CF-induced EC in the 
culture and accumulated in the cell cytoplasm and in the perinuclear area. This uptake 
is at least, partly dependent on an interaction between positively charged 
aminoglycosides and negatively charged HS on the cell surface.  
There was a low level of CFTR expression in untreated HLMVEC, expressed mainly in 
perinuclear membrane, ER and cytoplasm with no plasma membrane stain, suggesting 
non functional protein. However, upon tobramycin, copper-tobramycin and NAC 
treatment CFTR expression was increased and in presence of CFTR-inh172 appeared on 
the endothelial cell surface.  
3.7. DISCUSSION 
Under non-inflamed conditions, the endothelial surface is covered with a relatively 
thick sheath of glycosylated molecules, referred to as the glycocalyx. HS is the most 
abundant GAG within the glycocalyx, although CS/DSPGs and HA are also present, but 
their levels vary between different endothelial cells preparations. HSPGs are partly 
responsible for the negative charge to the glycocalyx (Reitsma et al, 2007; Weinbaum 
et al, 2007). Here, untreated HLMVEC were also shown to express HS. They were 
detected with HepSS-1, which specifically recognizes an epitope present in HS-GAG, 
closely related to O-sulfated and N-acetylated glucosamine, but not other types of 
GAG, such as hyaluronic acid, heparin, chondroitin, chondroitin 4-sulfate, chondroitin 
6-sulfate, dermatan sulfate, and keratan sulfate (Kure & Yoshie, 1986). In the current 
study, HS in HLMVEC was mostly located in the nucleus and the cell cytoplasm. Indeed, 
endothelial HSPGs may be found at the intracellular level, associated with the plasma 
membrane and ECM, or present in a soluble form. Syndecan 1 is the major HSPG in 
microvascular endothelial cells and it is mainly stored inside the cell, while a small 
portion is located at the basal surface (Rusnati et al, 2002). 
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Significant changes occur in the concentration and composition of GAGs at sites of 
inflammation. Increased concentrations of GAGs have been found in BALF from 
children with CF (Hilliard et al, 2010) and the secretion of heparan sulphate, 
chondroitin sulphate and hyaluronic acid is markedly increased in bronchial cells and 
CF tissues (Solic et al, 2005; Wyatt at al, 2002; Rahmoune et al, 1991). Moreover, Solic 
et al (2005) reported endothelial activation in CF patients, beside increased HS 
expression. This might not be due to defective CFTR, but to the inflammatory response 
(Solic et al, 2005), which is characterised by increased number of pro-inflammatory 
cytokines, including TNF-α. However, lung proteoglycans are susceptible to 
degradation by TNF-α-stimulated neutrophils (Shum et al, 2000). TNF-α reduced the 
amount of syndecan-1 protein in EA.hy 926 endothelial cells (Kainulainen et al, 1996) 
and increased release of HSPGs in HUVEC to the medium (Reine et al, 2012). On the 
contrary, mouse and human glomerular endothelial cells activated by TNF-α or IL-1β 
increased expression of inflammatory N- and 6-O-sulfated HS domains (Rops et al, 
2008), recognised by HepSS-1, used in the discussed study. CFTRinh-172 was here 
employed as a pharmacological tool to create a model of the CF endothelium. This 
approach was previously used by Perez et al (2007) in lung epithelial cells. CFTRinh-172 
treatment of HLMVEC increased the level of HS on the cell surface. This expression was 
hence further increased in the presence of TNF-α, in the agreement to the studies 
mentioned above. 
Injection of heparitinase I, which specifically degrades HS, into mouse cremaster 
muscle venules increased the number of adherent leukocytes, indicating that HS in 
non-inflammed venules is anti-adhesive (Constantinescu et al, 2003). Heparitinase II 
was also shown to degrade HS. Indeed, it cleaves heparan sulphate and heparin at the 
1 - 4 linkages between hexosamines and both glucuronic and iduronic acid residues
 
(Desai et al, 1993; Linhardt et al, 1990; Nader et al, 1990). Here, heparitinase II 
treatment of HLMVEC inhibited tobramycin and copper-tobramycin complex uptake, 
confirming the involvement of HS and more importantly proposing the role of HS in 
aminoglycoside uptake by human endothelial cells. However, uptake was not 
completely inhibited following heparitinase II treatment which could be due to either 
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incomplete removal of surface HS or the presence of other mechanisms of 
aminoglycoside uptake, which will now be considered here. 
Charged molecules with a molecular weight over 500 typically exhibit poor availability 
(Lipinski et al, 1997). Also, aminoglycosides cannot diffuse passively through the 
eukaryotic cell membrane because of their large size and positive charge (Tulkens, 
1990). Tulkens (1990) suggested that cell uptake of aminoglycosides corresponds to an 
active mechanism of pinocytosis by the eukaryotic cell, which explains the slow 
intracellular accumulation of these drugs and is only detectable after 48 to 72 hours of 
antibiotic exposure. In the present study, the uptake and subsequent accumulation of 
aminoglycosides within human endothelium appeared within 3.5 hours, but after 24 
hours of incubation, more staining was observed, suggesting an alternative mechanism 
of uptake other than pinocytosis. 
Schmitz et al (2001) proposed that renal epithelial cell accumulation of gentamicin is 
due to endocytosis via a giant endocytic complex formed by megalin and cubilin, which 
is restricted to the proximal tubule. Aminoglycosides then traffic through the 
endosomal compartment and accumulate mostly in lysosomes, the Golgi and 
endoplasmic reticulum (Silverblatt & Kuechn, 1979). Gentamicin binds to membrane 
phospholipids, however this binding is also a requirement for gentamicin endocytosis 
(Frommer et al, 1983).  
Phospholipid mediated aminoglycoside uptake may occur in addition to the HS binding 
mechanism. Previous reports have suggested that acidic phospholipids may be binding 
sites for aminoglycosides and that this binding was due to a charged interaction. The 
polyphosphoinisitides, a group of acidic phospholipids, have been shown to bind 
neomycin with high affinity (Schacht, 1978). Indeed, Sastrasinh et al (1982) identified 
acidic phospholipids as the renal brush border membrane binding site for 
aminoglycosides with the order of affinity being neomycin > netilmicin ≥ tobramycin ≥ 
gentamycin > amikacin ≥ kanamycin. The competitive binding studies demonstrated 
that kanamycin and amikacin, each with four ionisable groups, had relatively similar 
affinities for the brush border membranes binding site, whereas netlimicin, tobramycin 
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and gentamycin, each with five ionisable amino groups, were more avid than 
kanamycin and amikacin. Neomycin, with six ionisable amino groups, was the most 
avid aminoglycoside in the tested group. These results, therefore, demonstrate that 
the ability of aminoglycosides to interact with the anionic components of biological 
membranes is importantly influenced by the number of ionisable primary and 
secondary amino groups present within the molecule, that contribute to the overall 
molecule charge. 
Lipsky and co-workers (1980) observed that gentamycin uptake was biphasic, with an 
initial rapid uptake followed by a prolonged slower phase. Approximately half of the 
total uptake represented binding and the other half represented transport into an 
intravesicular space. Presumably, aminoglycoside binding to phospholipids was 
responsible for the faster phase of aminoglycoside uptake, followed by a slower 
endocytosis. 
There is a limited number of techniques aiming to quantify tobramycin concentrations. 
Gupta (1988) developed a calorimetric method for the determination of tobramycin in 
parenteral solutions. Kimura & Mukaida (1996) proposed a method for the 
quantitation of tobramycin concentration by laser microscopy in epithelial cells of the 
renal tubule, which was based on the reaction between tobramycin and colloidal gold. 
However, an ELISA based method for tobramycin determination was thought to be the 
most accurate way for quantitative analysis and it could be used in further 
experiments. 
BODIPY-tagged aminoglycosides, such as tobramycin and neomycin B, introduced by 
Luedtke et al (2003) were shown to display poor cellular uptake. This research group 
claimed that BODIPY was an excellent fluorescent probe for cellular uptake studies, 
because its fluorescence is relatively insensitive to changes in the local environment. 
However, their results are opposite to the ones presented here. It is possible that 
BODIPY inhibits aminoglycoside uptake into HeLa cells. Alternatively aminoglycosides 
are not taken up by HeLa (human epithelial carcinoma) cells, as they are by HLMVEC. 
126 
 
Bonventre et al (1967) first reported that streptomycin was unable to penetrate 
mouse peritoneal macrophages. However, a prolonged incubation of these 
macrophages with streptomycin up to one week resulted in a linear accumulation of 
the drug within cells (Bonventre & Imhorff, 1970). These observations were confirmed 
by Prokes & Hand (1982) and Johnson et al (1980), who respectively demonstrated 
that aminoglycosides did not accumulate within human PMNs and rabbit alveolar 
macrophages when incubated for 2 hours. In agreement, here, resting and IL-8-
activated human neutrophils did not take up tobramycin or copper-tobramycin up to 
3.5 hours incubation. 
In CF patients the pharmacokinetics of antibiotics are known to be abnormal. Lower 
blood concentrations and higher clearance rates have been found for many antibiotics, 
including the aminoglycosides: gentamycin, tobramycin and amikacin (Kearns et al, 
1982; Kelly et al, 1982; Vogelstein et al, 1977). In vitro data suggests that gentamycin 
accumulation in non-CF cells (human nasal polyp tissue) is under regulation by 
effectors and inhibitors of the CFTR channel. In CF cells with ΔF508 mutations, this 
regulation is lost with an inhibition of exocytosis since the CFTR channel is inoperable. 
As a result, aminoglycosides accumulate within the affected cells. For instance, CF cells 
accumulate over twice as much gentamycin as non-CF cells (Quesnel et al, 1998). 
Santos et al (2007) suggests an adverse drug reaction of a CF patient after 
administration of tobramycin solution for inhalation or tobramycin intravenously, 
which results from a significant tissue accumulation of tobramycin. Additionally, Al-
Aloul and coworkers (2005) hypothesized that long-term use of intravenous 
nephrotoxic antibiotics (aminoglycosides and colistin sulphomethate) may contribute 
to renal disease in CF patients. In the present study, tobramycin and copper-
tobramycin uptake by HLMVEC was higher after 24 hours than 3.5 hours. There was no 
analysis done comparing normal with CF uptake of tobramycin and copper-tobramycin. 
Anyway, this uptake was not associated with cytotoxicity. 
CFTR protein as integral membrane glycoprotein is mainly expressed at the apical 
membrane of epithelial cells (Collins, 1992). HUVEC and HLMVEC were also 
demonstrated to express CFTR protein as determined via RT-PCR (real time 
polymerase chain reaction) and immunohistochemical and immunoprecipitation 
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analyses (Tousson et al, 1998). CFTR is considered to be held on the plasma membrane 
and can also be inserted into the membrane of intracellular organelles, including the 
ER (Pasyk & Fosket et al, 1997). Moreover, Bertrand & Frizzell (2003) suggested that 
CFTR could be distributed in the Golgi apparatus or secretory vesicles in normal 
epithelial cells. Therefore, the CFTR endocytosis and exocytosis are based on CFTR 
interactions with proteins involved in membrane trafficking. 
There are a number of available monoclonal and polyclonal antibodies to CFTR 
(Kartner & Riordan, 1998). Tousson et al (1998) stained endothelial cells (HUVEC and 
HLMVEC) with antibodies directed against different domains of human CFTR, including 
the R-domain, COOH terminus, nucleotide binding domain (NBD)-1 or the first 
extracellular loop and obtained positive results. Cells analyzed with antibodies directed 
against the R-domain or the first extracellular loop displayed a punctate staining 
pattern around the nucleus and along cellular processes. In addition, the antibody 
against the first extracellular loop of CFTR stained the plasma membrane positively and 
exhibited intense perinuclear staining. Endothelial cells analyzed with antibodies that 
recognized NBD-1 or the COOH terminus of CFTR yielded a diffuse staining pattern 
throughout the cytoplasm and also stained the plasma membrane. Here, an anti-CFTR 
antibody that recognises NBD-1 was used and CFTR was mainly found in the nuclear 
membrane, perinuclear area, thought to be ER, and in the cytoplasm on resting 
HLMVEC. There was no CFTR protein detected on the plasma membrane. The 
differences could be a result of distinct staining methods. For NBD-1 detection Tousson 
et al (1998) fixed the cells with absolute methanol only and postfixed with 
formaldehyde. Here, 1 % (w/v) PFA dissolved in 15 % (v/v) picric acid in PBS preceded 
the 0.1 % (v/v) Triton X-100/PBS permeabilization step. 
In the present study, TNF-α and/or CFTRinh-172 increased the level of intracellular 
CFTR protein over a 24 hour incubation. TNF-α was shown to decrease CFTR mRNA in 
human colon epithelial cell lines (HT-29), but not in airway epithelial cell lines (Calu-3). 
Additionally, CFTR mRNA is increased in mast cells at TNF-α treatment (Baudouin-
Legros et al, 2004). However, TNF-α had no effect on CFTR-mediated chloride 
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transport activity (Estell et al, 2003). The main function of CFTRinh-172 and other CFTR 
inhibitors such as glycine hydrazide GlyH-101 is to cause inhibition of Cl- conductance. 
Both inhibitors, CFTRinh-172 and GlyH-101, are additionally able to induce a rapid 
increase in ROS levels and depolarize mitochondria, suggesting that these effects are 
independent of CFTR inhibition (Kelly et al, 2010). It was previously shown that 
CFTRinh-172 also significantly elevated the total protein content of gland fluid 
secretions, which may also be due to ROS (Thiagarajah et al, 2004).  
It was reported that defective CFTR induces upregulation of ROS (Luciani et al, 2010). 
Moreover, NO and reactive oxygen nitrogen species (RONS) decrease wild type CFTR 
protein levels in airway epithelial cell monolayers, which is related to the loss of CFTR 
function. Decreased CFTR expression may results partly from nitration of nascent CFTR, 
and its subsequent degradation by the proteasome (Bebok et al, 2002). 
Indeed, several lines of evidence suggest that misfolded CFTR chains are substrates for 
the ubiquitin-proteasome pathway. For instance, treatment of cells expressing CFTR or 
ΔF508 with proteasome inhibitors, such as lactacystin, results in the accumulation of 
multiubiquitinated forms of CFTR, pointing out proteasome degradation of CFTR and 
ΔF508. Also, in proteasome-inhibited cells, CFTR antibodies immunoprecipitate is 
recognized with antibodies to ubiquitin or to an epitope tag on ubiquitin, suggesting 
that CFTR is modified by ubiquitin (rewieved by Kopito, 1999). 
Tobramycin, copper-tobramycin and NAC in the presence of CFTRinh-172 restored 
CFTR expression on the HLMVEC surface. Tobramycin and copper-tobramycin may 
elicit antioxidant activity that allows the stabilisation of the CFTR protein via protection 
from ROS, similar to the effect elicited by NAC.
 
Indeed, NAC has been used for many years as a mucolytic and antioxidant agent in 
biomedical research (Atkuri et al, 2007) and in clinical practice (Millea, 2009). NAC is 
deacetylated to cysteine on the cell surface or inside the cell and therefore promote 
the formation of glutathione, which provides antioxidant activity in the cytoplasm. 
NAC can also have a reducing and antioxidant role by directly scavenging free radicals, 
including the hydroxyl radical, superoxide ion and hydrogen peroxide (Aruoma et al, 
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1989). It was also shown to protect against oxygen toxicity in the lung (Erzurum et al, 
1993). Finally, NAC was demonstrated to increase CFTR expression by stimulating Cl- 
efflux in CF airway epithelial cells (Varelogianni et al, 2010). NAC was also shown to 
prevent the cadmium-induced suppression of CFTR (Rennolds et al, 2010). 
Alternatively, tobramycin and copper-tobramycin may act in the similar manner to 
COMMD1 (Copper Metabolism gene MURR1 domains). COMMD1, which regulates 
hepatic copper excretion and sodium uptake via ENaC, has the ability to interact with 
CFTR. It was suggested that COMMD1 may function as a scaffold for protein 
ubiquitination and therefore regulate intracellular protein trafficking (Drevillon et al, 
2011).  
Additionally, the CFTR form in HLMVEC at tobramycin and copper-tobramycin 
treatment may be deciphered by further Western blotting experiments.
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CHAPTER 4 
THE EFFECT OF TOBRAMYCIN AND COPPER-
TOBRAMYCIN ON OXIDATIVE STRESS IN 
NEUTROPHILS AND ENDOTHELIUM 
 
4.1. INTRODUCTION 
4.1.1. OXIDATIVE STRESS IN THE LUNG 
Although all cells are exposed to oxidative stress during normal metabolism (Foronjy 
RF et al, 2006), the lungs are directly exposed to high oxygen tensions. Indeed, the 
local oxygen partial pressure at the alveolar level is much higher than in other vital 
organs including heart, liver and brain. Oxygen exposure in inhaled air, 150 mmHg, 
equals 100 mmHg at the alveolus, decreasing to 45 mmHg in venous blood, whereas in 
some sites within other organs it may be only 1 mmHg. Lung cells experience 
enhanced oxidant stress by environmental irritants and air pollutants including 
oxidants, such as cigarette smoke, ozone and free radical-generating environmental 
carcinogens. In addition, inflammation and activation of inflammatory cells with 
consequent free radical generation is characteristic of most lung disorders and lung 
infections (Kinnula & Crapo, 2003). 
Most living cells, including lung cells, generate free radicals under normal conditions 
nonenzymatically via autooxidation (Kinnula & Crapo, 2003). During homeostasis, ROS 
are released in noncytotoxic quantities and act as mediators and regulators of cell 
metabolism (Valko et al, 2007). ROS initiate cell differentiation and apoptosis, 
influence synthesis, release or inactivation of NO and induce transport of glucose into 
the cells. ROS affect the inflammatory process by enhancing permeability of capillary 
vessels. One of the most important roles of ROS is regulation of cell signalling (Droge, 
2002). Superoxide and hydrogen peroxide are considered to be secondary signal 
transducers, beause of their low reactivity and high selectivity and cell abundance 
(Valko et al, 2007; Droge, 2002). Most thiol proteins are inactivated via ROS; however 
the activity of some proteins increases in the presence of ROS. These proteins include 
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guanyl cyclase and particular transport proteins, such as 5-lipoxygenase, which is a 
source of T-cell generated ROS. 5-lipoxygenase oxidises polyunsaturated fatty acids 
and derived metabolites maintain intracellular redox balance by activating signalling 
pathways and gene expression (Bonzzi et al, 2000; Los et al, 1995b). Phagocytes, such 
as granulocytes, monocytes or macrophages, use ROS to eliminate pathogens in the 
process called respiratory burst, which involves generation of superoxide (Hampton et 
al, 1998). ROS were also shown to upregulate T cell activity and induce adhesion of 
leukocytes to endothelium, which determines their migration to the site of 
inflammation (Los et al, 1995a). In addition, a regulatory activity of low H2O2 
concentrations manifests in the activation of NF-κB, which induces expression of genes 
that encode cytokines (IL-1β or IL-6), immunity proteins, thioredoxin or SOD (Li & 
Karin, 1999). Finally, the activation of transcription factors via low levels of ROS 
induces cell differentiation and enables their adjustment to different conditions, while 
the exposure to higher ROS levels results in cell apoptosis, which is crucial in the 
elimination of damaged and potentially dangerous cells (Valko et al, 2007). 
In contrast, overproduction of ROS, arising either from the mitochondrial electron 
transport chain or excessive stimulation of NADPH oxidase, results in oxidative stress, 
which could be responsible for damage to cell structures and tissue destruction. The  
negative impact of ROS depends on their concentration and time of exposure (Valko et 
al, 2007). The harmful effects of ROS manifest by their ability to oxidise proteins with 
the generation of ROS via xanthine oxidase, mitochondrial respiratory chain or 
activated phagocytes. Proteins that undergo irreversible changes are selectively 
degraded by proteases (Du & Gebicki, 2004; Stadtman & Lewine, 2003; Stadtman & 
Lewine, 2000). Protein oxidation could lead to polypeptide chain disruption, 
appearance of modified aminoacid residues and formation of dimers or protein 
aggregates. In consequence, these changes cause loss of functional activity of 
enzymes, regulatory proteins and membrane transporters (Lushchak, 2007; Hensley et 
al, 2000). The hydroxyl radical, a toxic metabolite of the superoxide anion, is usually 
the mediator of protein breakdown. Superoxide anion and hydrogen peroxide could in 
particular elicit oxidation of –SH groups. Peroxynitrite, which if formed from a reaction 
of NO and O2
.-, is responsible for the oxidative damage of amino acids. It is highly 
reactive and able to form its derivative, 3-nitrotyrosine (Valko et al, 2007; Alvarez & 
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Radi, 2003). Moreover, peroxinitrite could react with free intracellular sulphydryl 
groups. It has been demonstrated that oxidative stress resulting from the action of 
peroxynitrite inhibits the activity of fibrinogen and tissue factor (Ischiropoulos, 2003; 
Gow et al, 1996).  
The reactions of hydroxyl radical and singlet oxygen with nucleic acids may lead to the 
breakdown of purine and pyrimidine bases, sugar residues or the breakdown of 
phosphodiester  bonds that connect nucleotides (Nunomura et al, 2004; Higuchi, 
2003). This further leads to the break of nucleic acid strands. Some of the products of 
the oxidative modification of nucleic acids are 8-hydroxy-2-deoxyguanine and 8-
hydroxyguanine, compounds which are recognized as markers of intracellular nucleic 
acid oxidation. Additionally, mitochondrial DNA is more susceptible to oxidative 
damage, regarding its proximity to the mitochondrial respiratory chain (Higuchi, 2004; 
Cookie et al, 2003; Mecocci et al, 1994). 
ROS are also involved in the process of lipid peroxidation, which could be divided into 
three stages: initiation, propagation and termination. Initiation of lipid peroxidation 
relies on detachment of hydrogen from the unsaturated fatty acid, a compartment of 
phospholipids that are the main compounds of the cell membrane and it is started by 
the following radicals: hydroxyl (OH.), superoxide (ROO.), alkyl (RO.) as well as nitric 
oxide and nitric dioxide. In propagation, alkyl radicals react with oxygen resulting in 
peroxide radicals (ROO.) and eventually in free fatty acids. This reaction could be 
repeated many times until it is terminated with a result of modified and damaged lipid 
molecules. Free radicals formed during lipid peroxidation could react with proteins 
giving free protein radicals. Such products of lipid peroxidation change the physical 
properties of cell membranes, leading to the inhibition of the activity of membrane 
enzymes and transport proteins (Gutteridge, 1995). Moreover, they could induce the 
expression of cyclooxygenase-2 (COX-2) in macrophages and activate a pro-
inflammatory potential of these cells (Kumagai et al, 2004). 
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4.1.2. MAIN CONTRIBUTORS TO OXIDATIVE STRESS 
4.1.2.1. NADPH OXIDASE 
The reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase was first 
described and characterized in professional phagocytes, such as neutrophils, 
monocytes, macrophages and eosinophils. It is however not restricted to leukocytes, 
because similar NADPH oxidases are present in a wide variety of non-phagocytic cells 
and tissues (Quinn  & Gauss, 2004).  
The phagocytic NADPH oxidase is a multiprotein enzyme complex composed of an 
integral membrane protein as well as cytosolic proteins. Two  essential membrane-
associated proteins, gp91phox and p22phox, form a non-covalent heterodimer, known as 
flavocytochrome b558, which is responsible for conducting electron transport across 
the membrane. The cytosolic NADPH oxidase proteins include p40phox, p47phox, p67phox 
and Rac2, a member of Rho family of small GTPases, associated with GDP-dissociation 
inhibitor, RhoGDI (Quinn  & Gauss, 2004). Upon activation, p47phox undergoes 
stimulation on multiple serine residues and translocates, along with p67phox and 
p40phox, to the membrane. Rac2 undergoes GDP-GTP exchange, with subsequent 
translocation of prenylated Rac2 to the membrane. At the membrane, the assembled 
oxidase complex shuttles electrons from cytosolic NADPH, across the stacked heme 
groups in gp91phox to molecular oxygen, thereby generating superoxide anion (Figure 
4.1, over) (Nauseef, 2007). 
NADPH is activated upon phagocytosis by most microorganisms to generate 
superoxide radical, O2
.-. O2
.- can further dismutate to form H2O2 and both can form 
other ROS, which are bactericidal (Figure 1.5) (Root & Cohen, 1981, Badwey & 
Karnowsky, 1980, Babior, 1978). In addition, Klebanoff (2005) demonstrated that 
microbicidal activity of NADPH-oxidide-derived ROS is significantly augmented by 
MPO. 
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Figure 4.1. Model of NADPH oxidase activation. Cytosolic phox proteins and Rac translocate to the 
phagosomal or plasma membrane, where they assemble with flavocytochrome b 558 to form the active 
O2-generating complex (Quinn et al, 2006).
 
4.1.2.2. MYELOPEROXIDASE 
Myeloperoxidase (MPO) is a haem peroxidase extensively present in azurophilic 
granules of neutrophils and monocytes and released upon cell activation into the 
phagolysosome or into the extracellular space (Schultz et al, 1965). Myeloperoxidase 
uses hydrogen peroxide to oxidize a variety of aromatic compounds by a 1-electron 
mechanism and produce reactive intermediates (Hampton et al, 1998). It oxidizes 
chloride ions to hypochlorous acid (HOCl), the major product of MPO and the most 
potent bactericidal oxidant to be produced by the neutrophil (Klebanoff, 1968). MPO 
has a wide range of substrates leading to a wide variety of by-products. Chloramines, 
long-lived oxidants, which are generated indirectly through the reaction                         
of HOCl with amines, are bactericidal (Forman & Thomas, 1986). The 
myeloperoxidase/H2O2/chloride system forms tyrosyl radical and chlorination 
products, generates tyrosine peroxide, reactive aldehydes (Hazen et al, 1998) and 
contributes to the oxidation of serum proteins (Leeuwenburgh et al, 1997) and 
lipoproteins (Daugherty et al, 1994). MPO can utilize nitrite and hydrogen peroxide as 
substrates to catalyze tyrosine nitration in proteins (Sampson et al, 1998) and can 
react with peroxynitrite (Floris et al, 1993). 
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Moreover, the myeloperoxidase/H2O2/chloride system contributes to the termination 
of NADPH oxidase activity (Jandl et al, 1978). 
4.1.2.3. NEUTROPHIL ELASTASE 
Neutrophil elastase (NE), together with other neutrophil-derived serine proteases, 
such as cathepsin G (Salvesen & Enghild, 1990), proteinase 3 (Bories et al, 1989) and 
enzymatically inactive azurocidin or CAP-37 (Morgan et al, 1991), is a highly cationic 
glycoprotein. Approximately 67,000 NE molecules are stored in the primary granules of 
neutrophils at a mean concentration of 5.33 mM (Liou & Campbell, 1995).  
NE is capable of cleaving insoluble elastin and other ECM proteins, including laminin, 
fibronectin, vitronectin and collagens (Janoff & Scherer, 1968). The degradation of 
elastin generates elastin-derived fragments, which exhibit potent chemotactic activity 
for other leukocytes, stimulate fibroblast and smooth muscle cell proliferation, and 
display proangiogenic activity as potent as VEGF (Antonicelli et al, 2007).
  
NE could interact in a variety of ways with cytokines, including: the release of active 
cytokines from their inactive precursors (IL-1β, TNF-α, TGF-β, IL-8); proteolytic 
cleavage and inactivation of active cytokines (TNF-α, IL-6, IL-2); cleavage of cell-surface 
bound cytokine receptors (TNF-α, IL-6, IL-2); proteolysis of the cytokine binding 
proteins (TGF-β, IGF); and activation of specific cell surface receptors (PARs, TLR4) 
(Bank & Ansorge, 2001). In particular, NE is capable of degrading various 
proinflammatory cytokines such as TNF-α (van Kessel et al, 1991), IL-2 (Ariel et al, 
1998), IL-6 (Bank et al, 1999) and IL-8 (Witherden et al, 2004). NE upregulates IL-8 
expression and secretion in bronchial epithelium via Toll-like receptor-4 (TLR-4) 
(Devaney et al, 2003). Moreover, neutrophil proteinases released in inflamed tissues 
convert IL-8 to more potent, N-terminally truncated forms, which tend to enhance IL-8 
activity (Padrines et al, 1994). 
In addition, NE can cleave coagulation factors (fibrinogen and factors V, VII, XII and XIII) 
(Samis et al, 2004), digest platelet IIb/IIIa receptor (Bykowska et al, 1990), cleave 
complement receptors (C3 and C5) (Berger et al, 1989) and plasminogen in the process 
of converting it into active plasmin (Gombas et al, 2004). NE inactivates endothelial 
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thrombomodulin (Abe et al, 1994), degrades immunoglobulin G (IgG), IgA and IgM 
(Doring et al, 1986) and lung surfactant proteins (Liau et al, 1996). 
NE was shown to have a role in neutrophil adhesion, as it binds to MAC-1 (Cai & 
Wright, 1996) and cleaves ICAM-1 (Champagne et al, 1998) and endothelial cadherins 
(Carden et al, 1998). 
NE contributes to chronic inflammatory airway diseases by inducing mucin production 
in airway epithelial cells (Fisher & Voynow, 2000). NE can also induce apoptosis of 
human lung epithelial cells mediated via PAR-1 (Suzuki et al, 2005). Additionally, NE 
upregulates LTB4 secretion from activated macrophages (Hubbard et al, 1991). 
However, neutrophils also store α1-AT, the major inhibitor of NE, which is secreted 
following stimulation concordantly with NE. Moreover, some of the secreted α1-AT is 
capable of forming complexes with NE in order to maintain tissue homeostasis (Paako 
et al, 1996; du Bois et al, 1991). 
4.1.3. OXIDATIVE STRESS IN CYSTIC FIBROSIS 
Cystic fibrosis lung disease is characterised by a substantial oxidative stress, since the 
airway infection and inflammatory processes in the CF lung are potential sources of 
oxidants. An oxidative environment influences multiple intracellular signalling events, 
leading to increased synthesis and secretion of mucins (Takeyama et al, 2000), 
defective apoptosis (Yalcin et al, 2009), and alterations in ion transport, including 
chloride secretion (Cowley & Lindsell, 2002). Moreover, oxidant stress could also 
suppress CFTR expression (Qu et al, 2008; Cantin et al, 2006). 
It is well established that activated neutrophils are the major generator of free radicals 
due to their NADPH oxidase inolvement in bacterial phagocytosis (Babior, 1984). 
Neutrophils represent 70 % of the ELF (epithelial lining fluid) inflammatory cells (Birrer 
at al, 1994). BALF from children with CF has an increased concentration of neutrophil-
derived protease, myeloperoxidase and 3-chlorotyrosine, a biomarker of the potent 
oxidant hypochlorous acid, which is formed by myeloperoxidase, compared to the 
control subjects (Kettle et al, 2004). The neutrophil in individuals with CF is considered 
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by some researchers to be abnormal and secretes more NE than non-CF neutrophils in 
response to IL-8, TNF and LPS, all of which are found in abundance in the CF lung. This 
further brings more neutrophils onto the epithelial surface and therefore creates an 
NE-induced inflammation cycle (Taggard et al, 2000).  
Although CF patients have normal or high serum and ELF levels of anti-NE compounds, 
such as α1-AT, SLPI and elafin, they are completely inactive as they are complexed with 
or cleaved by NE (Birrer et al, 1994; McEvaney et al, 1992). Also, they are inactivated 
by oxidative stress. Moreover, CF patients have decreased levels of GSH to 5 – 10 % of 
normal in ELF and to 50 % of normal in plasma (Roum et al, 1993). Poor nutritional 
status, vitamin E deficiency (Farrell et al, 1997) and decreased levels of carotenoid and 
retinol (Homnick et al, 1993) may contribute to low GSH levels in CF. 
Total elemental zinc and iron concentrations are elevated in sputum from subjects 
with CF and non-CF bronchiectasis compared with healthy control subjects (Gray et al, 
2000). Individuals with CF have also altered copper distribution compared to control 
individuals (Percival et al, 1999). Indeed, transition metals may contribute to oxidative 
stress in CF via Fenton chemistry. 
The increased oxidative stress in CF patients could be detected by markers of oxidative 
damage to lipids (malondialdehyde-like substances and lipid hydroxyperoxides) and 
proteins (protein carbonyls) (Brown & Kelly, 1994). 
4.1.4. ANTIOXIDANT DEFENCE OF THE LUNG 
Lung cells contain different types of antioxidants with a specific localization and 
expression (Figure 4.2, over). Among them, superoxide dismutases, previously 
described in Section 2.1.1, are hypothesized to play a significant role against oxidative 
stress especially in the lung (Kinnula et al, 1995; Crapo, 1975). Extracellular SOD3 
(Cu/Zn-SOD) is the major lung SOD and accounts for approximately 80 % of SOD 
activity. This enzyme is located primarily in the bronchial epithelium, alveolar 
epithelium, mesenchymal cells, arterioles and capillary endothelial cells of the lung 
(Foronjy et al, 2006, Kinnula & Crapo, 2003; Foronjy et al, 2006). 
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Figure 4.2. Major antioxidant pathways in the lung. Antioxidant pathways in scavenging superoxide and 
hydrogen peroxide in the intracellular and extracellular spaces. CAT - catalase; ECSOD - extracellular 
superoxide dismutase; GPXc - classic (intracellular) glutathione peroxidase; GPXe - extracellular 
glutathione peroxidase; GR - glutathione reductase; GRXs - glutaredoxins; GSH - reduced glutathione; 
GSSG - oxidized glutathione; PRXs- peroxiredoxins (thiortoedoxin peroxidase); TRXs - thioredoxins 
(Kinnula & Crapo, 2003). 
H2O2 a product of the dismutation of superoxide can be further destroyed by catalase 
and glutathione peroxidase, a selenium-containing enzyme requiring glutathione 
(GSH). Interestingly, the total concentration of GSH in normal ELF is 140-fold higher 
than in plasma and moreover, these concentrations are sufficient to protect lung cells 
against the burden of H2O2 released by alveolar macrophages removed from the lower 
respiratory tract (Cantin et al, 1987). Other redox-regulating proteins able to 
decompose hydrogen peroxide have been described as thioredoxins, glutaredoxins 
(Holmgren, 2000) and peroxideroxins (Rhee et al, 2001), localized in both cytoplasmic 
and nuclear compartments of lung cells (Kinnula et al, 2002; Soini et al, 2001). 
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Additionally, storage and transport proteins, including ceruloplasmin, ferritin, 
transferrin, can sequester transition metals and further prevent the formation of 
highly reactive radicals (Valko et al, 2005). Plasma contains a variety of redox active 
low molecular weight antioxidant molecules, such as vitamin E, uric acid, bilirubin, 
ascorbic acid, and thiol groups (Frei et al, 1988). 
 
4.2. HYPOTHESIS, AIMS AND OBJECTIVES 
The hypothesis of the study is that tobramycin and copper-tobramycin have anti-
oxidant properties. 
Neutrophils, platelets and endothelium actively contribute to the inflammatory 
response. An important aspect was to determine the role of each cell type in the 
oxidative stress. The predominant aim was to investigate the antioxidant activity of 
tobramycin and copper-tobramycin on neutrophil respiratory burst by measuring 
superoxide and hydrogen peroxide release  and on neutrophil elastase activity in the 
absence or presence of α1-antitrypsin. This antioxidant activity was further examined 
on intracellular EC ROS generation by immunocytochemistry. 
4.3. MATERIALS 
Zymosan A from Saccharomyces cerevisiae, PMA (phorbol 12-myristate 13-acetate), 
cytochrome C from equine heart, hydrogen peroxide 30 %, sodium azide (SA), NE 
substrate, N-methoxysuccinyl-ala-ala-pro-val-p-nitroanilide, protamine sulphate salt 
from salmon and DCF-DA (2`,7`-dichlorofluorescein diacetate) were purchased from 
Sigma-Aldrich Inc. (Poole, Dorset, UK). 
Zemaira α1-AT was a gift from CSL Behring Ltd. (Melbourne, Australia). 
4.4. METHODS 
4.4.1. OPSONIZATION OF ZYMOSAN 
The method was adapted from Petreccia, Nauseaf & Clark (1987) and the preparation 
of OPZ was made fresh daily. Serum was prepared from normal venous blood collected 
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into Vacuette clot activator tubes (Greiner-Bio-One) and allowed to clot for 10 minutes 
at room temperature and centrifuged at 1500 x g for 10 minutes. 
Zymosan A from Saccharomyces cerevisae (Sigma) was prepared at 10 mg in 1 ml of 
water. Particles were centrifuged at 900 x g for 10 minutes at 40C, washed in 10 ml of 
water and centrifuged again. Zymosan A was opsonised in fresh human serum (2 ml) at 
5 mg/ml for 60 minutes at 370C with gentle shaking. The reaction was stopped by 
placing on ice. Opsonised zymosan (OPZ) was washed twice with ice-cold water and 
centrifuged at 1500 x g for 10 minutes at 40C. A final re-suspension was made in HBSS 
(+ Ca/Mg) containing 20 mM HEPES, pH 7.4 at 10 mg/ml. 
4.4.2. SUPEROXIDE ASSAY 
Superoxide ion release from neutrophils was measured by the reduction of 
cytochrome C. The experiment was carried out in assay buffer, HBSS (+ Ca/Mg) 
containing 20 mM HEPES, pH 7.4 in triplicate. Neutrophils were isolated according to 
the procedure in Section 2.4.1 and diluted in assay buffer. Neutrophils (1 x 107 
cells/ml, 200 µl) were incubated with tobramycin, copper-tobramycin, copper sulphate 
(0.001 – 0.5 mM) and SOD (3.125 – 100 U/ml) in the presence of cytochrome C (40 
µM) and with OPZ-activation (1 mg/ml final concentration) at 370C for 15 minutes with 
gentle shaking in a final volume of 250 µl. The reactions were stopped on ice and the 
samples were centrifuged at 1100 x g for 5 min at 40C. 200 µl of cleared supernatant 
was transferred into a 96-well plate and the absorbance measured at 550 nm. 
4.4.3. HYDROGEN PEROXIDE RELEASE OF NEUTROPHILS 
Hydrogen peroxide release from neutrophils was detected using the Amplex Red 
Neuraminidase (Sialidase) Assay (Molecular Probes) as previously described in Section 
2.4.9. Hydrogen peroxide consumption by neutrophil myeloperoxidase was inhibited 
by using 1 mM sodium azide (Sigma). The experiment was carried out in HBSS (+ 
Ca/Mg) containing 20 mM HEPES, pH 7.4 in duplicate. Neutrophils (1 x 107 cells/ml, 
100 µl) were incubated with tobramycin, copper-tobramycin (0.01 – 0.5 mM) and SOD 
(100 U/ml) upon OPZ-activation (1 mg/ml) or PMA (1 µg/ml) at 370C for 15 minutes 
with gentle shaking. The reactions were stopped on ice and the samples were cleared 
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by centrifugation at 1100 x g for 5 minutes at 40C. 100 µM Amplex Red reagent 
containing 0.2 U/ml HRP in 50 µl was added to each 50 µl supernatant sample in a 96-
well plate. The plate was incubated at 370C for 30 minutes, whilst protected from light. 
The absorbance was measured at 550 nm and the hydrogen peroxide concentration of 
samples was calculated from a hydrogen peroxide standard curve, carried out in the 
range 0 - 100 µM H2O2. 
4.4.4. NEUTROPHIL ELASTASE ACTIVITY 
Neutrophil elasatase activity was measured using the specific NE substrate, N-
methoxysuccinyl-ala-ala-pro-val-p-nitroanilide (Sigma). The experiment was carried out 
in HBSS (+ Ca/Mg) containing 20 mM HEPES, pH 7.4 in duplicate. Neutrophils (1 x 107 
cells/ml, 200 µl) were pre-incubated with tobramycin, copper-tobramycin (0.01 –       
0.5 mM) and α1-AT (2 mg/ml) for 15 minutes in a final volume of 250 µl, followed by 
OPZ-activation (1 mg/ml) for 60 minutes at 370C with gentle shaking. The reactions 
were stopped on ice and the samples were centrifuged at 1100 x g for 5 min at 40C. 
The cell pellets were lysed in an equal volume of 1 % (v/v) Triton X-100 in water. Both, 
supernatants and cell pellets were incubated for 1 minute at 370C with gentle shaking 
and the absorbance at 405 nm was read over time in the presence of 0.555 mM NE 
substrate.  
4.4.5.   ASSESSMENT   OF   INTERFERENCE    IN     THE    IL-8    ELISA    WITH    DIFFERENT  
             COMPONENTS 
To assess the interference of components in neutrophil incubations in the IL-8 ELISA, 
IL-8 (500 pg/ml) was incubated with tobramycin, copper-tobramycin, copper sulphate 
(0.5 mM), copper chloride (0.4 mM) or protamine sulphate (0.1 mg/ml). The 
incubation was carried out in 0.1 % (w/v) BSA/PBS (- Ca/Mg) containing 0.05 % (v/v) 
Tween-20 in a reaction volume of 200 µl for 90 minutes at 370C. Additionally, these 
compounds were incubated in the absence of IL-8. The experiment was performed 
once in duplicate or triplicate. 
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4.4.6. IL-8 ELISA 
IL-8 samples from the experiments described in Section 4.4.4 and 4.4.5 were 
subsequently analysed by ELISA (PeproTech) according to the manufacturer`s 
instructions (PeproTech). 
4.4.7. PMN VIABILITY ASSESSEMENT 
TACSTM annexin V-biotin apoptosis detection kit (Trevigen) was used to assess the 
cytotoxicity of tested drugs on PMN. The assay was performed on a FACS Calibur 
Immunocytometry System.  
Neutrophils were isolated as indicated in Section 2.4.1, re-suspended in 1 x HBSS (+ 
Ca/Mg) containing 20 mM HEPES, pH 7.4 and diluted to 5 x 106 cells/ml. Neutrophils 
were then challenged with the following drugs: tobramycin, copper-tobramycin, 
copper sulphate (0.01 – 0.5 mM), SOD (3.125 – 100 U/ml) in a total volume of 250 µl 
for 0.5 – 3 hours at 370C. According to the flow cytometry instruction manual provided 
by TACSTM Annexin V-Biotin kit (Trevigen), after the incubation time the samples were 
placed on ice and collected by centrifugation at 300 x g for 10 minutes at room 
temperature. The cells were washed by re-suspending in 500 µl of cold PBS (- Ca/Mg) 
and collected again. 100 µl Annexin V Incubation Reagent was prepared per sample by 
mixing: 10 µl 10 x Binding Buffer, 10 µl propidium iodide, 1 µl Annexin V-biotin and 79 
µl distilled water. The cells were gently re-suspended in the Annexin V Incubation 
Reagent and incubated in the dark for 15 minutes at room temperature. The cells were 
collected by centrifugation at 300 x g for 10 minutes at room temperature. 1 x Binding 
Buffer was prepared from a 10 x stock by 1/10 dilution. The cells were re-suspended in 
100 µl 1 x Binding Buffer containing AlexaFluor 488 streptavidin conjugate (1 mg/ml 
diluted 1/200) and incubated for further 15 minutes in the dark at room temperature. 
400 µl 1 x Binding Buffer was added per 100 µl reaction and the fluorescence was 
measured using flow cytometry. 
Before proceeding, 3 control samples were used to calibrate the instrument: PMNs re-
suspended in Binding Buffer to evaluate the level of autofluorescence and PMNs 
stained separately with Annexin V and Propidium Iodide to define the boundaries of 
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each population. Additionally, a negative (PMNs with no drug treatment) and positive 
(PMNs treated for 24 hours with 1 µM staurosporine from Streptomyces sp.) apoptosis 
controls were used. 
4.4.8. IMMUNOCYTOCHEMICAL STAINING OF HLMVEC FOR ROS 
HLMVEC were cultured in collagen IV-coated Microtek 8-well chamber slide (Thermo 
Fisher) at 0.7 x 105/ml (250 µl/well) and grown to confluency for at least 48 hours. On 
the day of the experiment, 50 mM tobramycin and copper-tobramycin stock solution 
were prepared and diluted to obtain 10 mM and 1 mM working concentrations. 100 x 
concentrated drug stocks were added to the cell culture (0.01, 0.1 and 0.5 mM final 
concentration) and incubated for 3 hours at 370C and 5 % CO2. Fresh, 100 mM DCF-DA 
stock solution in DMSO was prepared and diluted to final concentration of 10 µM. 
Supernatants were removed and the cells washed with 500 µl/well of 1 x HBSS (-
Ca/Mg). The experiment was carried out in full growth medium. The cells were  
incubated with or without DCF-DA (Sigma) for 30 minutes at 370C and 5 % CO2, 
protected from light, then washed again and post-incubated  for further 10 minutes in 
the absence of the dye to remove its excess. The cells were washed with 500 µl/well 1 
x HBSS (- Ca/Mg). A TNF-α working concentration of 1 µg/ml was prepared and used to 
activate the cells in full medium (10 ng/ml final concentration) for 15 minutes at 370C 
and 5 % CO2. CFTRinh-172 was also prepared fro 2 mM stock to the final concentration 
of 20 µM and added to the cells for 30 minutes incubation. Tobramycin and copper-
tobramycin were present throughout. The cells underwent fixation, permeabilisation 
and the blocking step described in Section 3.4.5 for the tobramycin and copper-
tobramycin uptake experiment. The slide was finally mounted in FluorPreserveTM 
Reagent (Calbiochem) and viewed on a Zeiss LSM 710 Confocal Microscope (green 
fluorescent stain ex. 488 nm, em. 540 nm). 
ROS generation was quantified by counting total fluorescence units in 3 – 5 fields of 
view from two independent experiments. 
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4.4.9. HLMVEC VIABILITY ASSESSEMENT 
HLMVEC viability was assessed using Caspase-Glo® 3/7 Assay (Promega). This assay 
measures caspase-3 and -7 activities. The addition of Caspase-Glo® 3/7 Reagent results 
in cell lysis, followed by caspase cleavage of the substrate and generation of a 
luminescent signal, produced by luciferase. Luminescence is proportional to the 
amount of caspase activity present in the sample. 
HLMVEC were grown in collagen IV coated 96-well plates until confluency. They were 
then treated with drugs of interest for either 3 or 24 hours at 370C and 5% CO2. 
Caspase-Glo® Reagent was prepared by transferring the content of Caspase-Glo® 
Buffer to Caspase-Glo® Substrate. 100 μl of Caspase-Glo 3/7 ®Reagent was added to 
each well of a 96-well plate containing 100 μl of cells treated with appropriate drugs in 
a culture medium. The content of wells was mixed gently using a plate shaker (Mini 
orbital shaker SSM1, Bibby Scientific Ltd., Stone, Staffordshire, UK) at 300 – 500 rpm 
for 30 seconds. The plate was incubated for 30 minutes at room temperature and 
eventually the luminescence of each sample was measured on Wallac Victor2 (Perkin 
Elmer Life Sciences, Wallac Oy, Turku, Finland). 
Another luminometric assay assessing the viability of HLMVEC was previously 
described in Section 3.4.11. 
4.4.10. STATISTICAL ANALYSIS 
All statistical analyses were performed using GraphPad Prism 4 version 4. The results 
were expressed as mean ± SEM. Two-tailed paired or unpaired Student`s t-test and 
one-way ANOVA with Dunnett`s multiple comparison poc hoc test were performed as 
required. The p values less than 0.05 were considered as statistically significant. 
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4.5. RESULTS 
4.5.1.  SUPEROXIDE  ANION  DETECTION   FROM   NEUTROPHILS  AND  THE   EFFECT  OF    
             OF TOBRAMYCIN, COPPER-TOBRAMYCIN, SOD AND COPPER SUPLHATE 
The superoxide radical is the major ROS released by activated neutrophils. Indeed, 
neutrophils were demonstrated to undergo a significant (p<0.05) spontaneous and 
further significant (p<0.001) OPZ-stimulated respiratory burst compared to a reagent 
control (Figure 4.3). The values, expressed by optical density (OD) at 550 nm, were 
0.259 ±  0.002 for the reagent control, 0.308 ± 0.010, when cells were present and 
0.596 ± 0.013, when cells were activated, respectively. Moreover, significantly 
(p<0.001) more superoxide was released from activated than unactivated neutrophils. 
 
Figure 4.3. OPZ-stimulated neutrophil respiratory burst in comparison to a spontaneous respiratory 
burst and reagent control. The data is expressed as mean ± SEM, n=3, in triplicates. One-way ANOVA 
with Tukey`s post hoc test was used to analyse the data, * p<0.05, *** p<0.001. 
Other stimuli, such as fMLP and PMA were also used. However, OPZ was the strongest 
stimulus and it was used to test the effect of tobramycin, copper-tobramycin, SOD and 
copper sulphate on the level of superoxide detected from neutrophils. 
Tobramycin unlike copper-tobramycin did not significantly influence superoxide anion 
detection from OPZ-stimulated neutrophils (Figure 4.4, over). However, copper-
tobramycin significantly (p<0.01) reduced the OPZ-stimulated respiratory burst of 
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neutrophils in the concentration range 0.005 – 0.5 mM. Interestingly, 0.05 – 0.5 mM 
copper-tobramycin concentration reduced the detectable level of superoxide from 
OPZ-stimulated neutrophils below the level of spontaneous superoxide release. It 
could mean that copper-tobramycin inhibits release or scavenging of activated and 
spontaneous superoxide release. Indeed, the decrease in the amount of O2
- detected 
in the presence of copper-tobramycin potentially reflects inhibition of the NADPH 
oxidase, scavenging of O2
- ions or dismutation of O2
- to H2O2. 
 
 
Figure 4.4. The effect of tobramycin and copper-tobramycin on OPZ-stimulated neutrophil respiratory 
burst. Tobramycin (A) and copper-tobramycin (B) effect on neutrophil respiratory burst stimulated by 
OPZ. The data is expressed as mean ± SEM, n=3, each experiment carried in triplicates. One-way ANOVA 
with Dunnett`s post hoc test was used to analyse the data, ** p<0.01. 
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As copper-tobramycin was shown to possess SOD-like activity, SOD was tested in the 
same experimental settings (Figure 4.5). As low as 3.125 U/ml of SOD potently and 
significantly (p<0.01) inhibited or dismutated the O2
- that was detected from OPZ-
stimulated neutrophils. SOD was tested at concentrations up to 100 U/ml, but this top 
concentration of SOD did not reduce detectable superoxide below the untreated cell 
control and did not inhibit spontateous detection. 
 
Figure 4.5. The effect of SOD on OPZ-stimulated neutrophil respiratory burst. The data is expressed as 
mean ± SEM, n=3, in triplicates. One-way ANOVA with Dunnett`s post hoc test was used to analyse the 
data, ** p<0.01. 
Copper sulphate was also tested for its effect on the neutrophil respiratory burst 
(Figure. 4.6, over). Copper sulphate in the range of 0.001 – 0.5 mM significantly 
(p<0.05) inhibited OPZ-stimulated neutrophil detection of superoxide ion, which 
suggests that the effect of copper-tobramycin was due to the presence of copper in 
the copper-tobramycin complex. The detection of stimulated O2
- was completely 
inhibited by 0.005 mM CuSO4 and high concentrations inhibited detection of 
spontaneous O2
- release, as seen for copper-tobramycin (Figure 4.4B). 
In addition, preliminary data demonstrated that platelets or HLMVEC stimulated with 
thrombin (2 U/ml), PAF (10-5 M), PMA (1 µg/ml) and OPZ (1 mg/ml) on normal and 
collagen I- or collagen IV-coated 96-well plates did not undergo a significant 
respiratory burst.  
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Figure 4.6. The effect of copper sulphate on OPZ-stimulated neutrophil respiratory burst. The data is 
expressed as mean ± SEM, n=3, in triplicates. One-way ANOVA with Dunnett`s post hoc test was used to 
analyse the data, ** p<0.01. 
4.5.2.    HYDROGEN    PEROXIDE   RELEASE   BY   NEUTROPHILS   AND   THE   EFFECT   OF  
              TOBRAMYCIN, COPPER-TOBRAMYCIN AND SOD 
Hydrogen peroxide release was measured from OPZ- and PMA-stimulated neutrophils 
in the presence of 1 mM of sodium azide (SA) (Figure 4.7, over). The use of SA was 
crucial to inhibit myeloperoxidase, which is released during cell activation and which 
consumes H2O2. 
OPZ in the presence of SA stimulated a significant (p<0.05) amount of H2O2, 57.90 ±        
5.81 µM, measured from neutrophils, compared to 2.42 ± 1.58 µM, in the absence of 
SA (Figure 4.7A, over). Tobramycin in the range of 0.01 – 0.5 mM did not significantly 
affect the detection of H2O2 from OPZ-activated neutrophils in the presence of SA. 
However, copper-tobramycin at 0.1 mM and 0.5 mM significantly (p<0.05 and p<0.01) 
reduced the H2O2 level detected in PMN supernatants from 57.90 ± 5.81 µM to 19.31 ± 
7.60 and 1.80 ± 0.36 µM, respectively. Copper-tobramycin at 0.01 mM, similarly to 
SOD at 100 U/ml was not effective. 
There was no statistically significant difference between the H2O2 level detected in 
OPZ- and PMA-stimulated PMN supernatants in the presence of SA. The amount of 
hydrogen peroxide released from PMA-stimulated neutrophils in the presence of SA 
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was significantly (p<0.05) higher, 42.77 ± 6.89 µM in comparison to the H2O2 level in 
supernatants from PMNs stimulated by PMA in the absence of SA (Figure 4.7B). Again, 
tobramycin (0.01 - 0.5 mM), SOD (100 U/ml) and copper-tobramycin at 0.01 mM 
concentration did not affect the H2O2 level. Copper-tobramycin at 0.01 mM and 0.5 
mM significantly (p<0.01) reduced the amount of H2O2 detected from PMA-stimulated 
PMN in presence of SA to 8.69 ± 3.21 and 1.37 ± 0.44 µM compared to OPZ plus SA 
control. 
These results suggest that copper-tobramycin is not acting as SOD to produce H2O2, 
but may be a scavenger or an inhibitor of NADPH oxidase. 
 
 
Figure 4.7. The effect of tobramycin, copper-tobramycin and extracellular SOD on hydrogen peroxide 
release from OPZ- and PMA-activated neutrophils at 1 x 10
7
 cells/ml. A) Hydrogen peroxide release from 
OPZ-stimulated neutrophils. B) Hydrogen peroxide release from PMA-stimulated neutrophils, n=3, in 
duplicates. One-way ANOVA with Dunnett`s post hoc test was used to analyse the data expressed as 
mean ± SEM, * p<0.05, ** p<0.01. 
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4.5.3. VIABILITY OF NEUTROPHILS DURING THE RESPIRATORY BURST 
The viability of neutrophils incubated with tobramycin, copper-tobramycin, copper-
sulphate (0.001 – 0.5 m M) and SOD (3.125 – 100 U/ml) in HBSS (+ Ca/Mg) containing 
20 mM HEPES, pH 7.4 for 30 minutes at 370C was assessed by annexin V binding and 
measured by flow cytometry. In the untreated control cells, 88.74 ± 3.60 % were live, 
5.11 ± 1.80 % apoptotic and 6.15 ± 1.98 % nectotic neutrophils.  
Tobramycin in the range of 0.001 – 0.5 mM was not toxic to neutrophils in the 
conditions of the respiratory burst experiment (Figure 4.8). 
 
Figure 4.8. The effect of tobramycin on neutrophil viability at HBSS (+ Ca/Mg) containing 20 mM HEPES, 
pH 7.4 for 30 minutes incubation at 37
0
C. The data expressed as mean ± SEM, n=3 independent 
experiments. The apoptosis data was analysed using one-way ANOVA and Dunnett`s post hoc test. 
Copper-tobramycin in the range of 0.001 – 0.01 mM was also not toxic to neutrophils 
during 30 minutes incubation in HBSS (+ Ca/Mg) containing 20 mM HEPES, pH 7.4 
(Figure 4.9, over), however at 0.05, 0.1 and 0.5 mM, the pool of live neutrophils 
significantly (p<0.01) decreased in  favour of apoptotic cells, 27.26 ± 8.27, 59.51 ± 2.54 
and 98.96 ± 0.15 %, respectively. The effect of copper sulphate was very similar (Figure 
4.10, over), suggesting a role of copper in inducing neutrophil apoptosis in these 
settings. 
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Figure 4.9. The effect of copper-tobramycin on neutrophil viability at HBSS (+ Ca/Mg) containing 20 mM 
HEPES, pH 7.4 for 30 minutes incubation at 37
0
C. The data expressed as mean ± SEM, n=3 independent 
expeiments. The apoptosis data was analysed using one-way ANOVA and Dunnett`s post hoc test. 
 
Figure 4.10. The effect of copper sulphate on neutrophil viability at HBSS (+ Ca/Mg) containing 20 mM 
HEPES, pH 7.4 for 30 minutes incubation at 37
0
C. The data expressed as mean ± SEM, n=3 independent 
experiments. The apoptosis data was analysed using one-way ANOVA and Dunnett`s post hoc test. 
SOD did not induce toxicity of neutrophils in the range of concentration of 3.125 –  100 
U/ml in the same condititions (Figure 4.11, over). 
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Figure 4.11. The effect of SOD on neutrophil viability at HBSS (+ Ca/Mg) containing 20 mM HEPES, pH 7.4 
for 30 minutes incubation at 37
0
C, n=3 independent experiments. The apoptosis data was analysed 
using one-way ANOVA and Dunnett`s post hoc test. 
There was no time-dependent effect of tobramycin, copper-tobramycin, copper 
sulphate (0.001 – 0.5 mM) and SOD (3.125 – 100 U/ml) on neutrophil viability, when 
they were incubated over 0.5 – 3 hours in  HBSS (+ Ca/Mg) containing 20 mM HEPES, 
pH 7.4, n=3 independent experiments (data not shown).  
4.5.4. NEUTROPHIL ELASTASE ACTIVITY AND THE EFFECT OF α1-ANTITRYPSIN 
Upon activation, neutrophil elastase (NE) is abundantly released from granules of 
normal neutrophils to the neutrophil cell sufrace, where it is active and protected from 
natural inhibitors. However, in the CF airways NE is also released by necrotic 
neutrophils into the extracellular space and therefore plays a central role in chronic 
inflammation. The effect of tobramycin, copper-tobramycin and copper sulphate in the 
concentration range 0.01 – 0.5 mM was tested on NE activity in cells and supernatants 
of neutrophils stimulated with OPZ. Also, the effect of protamine sulphate, which is 
positively charged and may therefore have a similar effect to copper-tobramycin,  was 
used at 10 – 100 µg/ml. 
Release of NE activity was induced by OPZ (1 mg/ml) and compared to the 
spontaneously released NE activity and measured as the rate of cleavage of N-
methoxysuccinyl-ala-ala-pro-val-p-nitroanilide (mOD/min). NE activity was not 
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released spontaneously (Spont) and the rate was not statistically different to the 
spontaneous hydrolysis of the substrate in the reagent control (Reag). However, OPZ 
induced significantly (p<0.05) higher NE activity in supernatants (2.17 ± 0.44 mOD/min) 
compared to both reagent control (0.50 ± 0.29 mOD/min) and spontaneously released 
NE activity (0.83 ± 1.67 mOD/min) (Figure 4.12 – 4.15).  
Tobramycin at 0.5 mM significantly (p<0.01) increased NE activity in supernatants to 
5.17 ± 0.73 mOD/min compared to the OPZ-stimulated neutrophil control (Figure 
4.12). 
 
Figure 4.12. The effect of tobramycin on NE activity in supernatants of OPZ-stimulated PMNs measured 
over 30 minutes at λ=405 nm and expressed as NE rate mOD/min. Mean ± SEM results were calculated 
using one-way ANOVA and Dunnett` s post hoc test to compare the effect of tobramycin or Tukey`s post 
hoc test to compare controls, n=3, in duplicate. Reag – reagent control; Spont – spontaneously released 
NE activity; 0 – OPZ-stimulated NE activity. 
Copper-tobramycin at 0.1 and 0.5 mM significantly (p<0.01) increased NE activity in 
supernatants to 18.00 ± 4.31 and 53.00 ± 6.51 mOD/min, respectively in comparison to 
the OPZ-stimulated neutrophil control (Figure 4.13, over). Importantly, NE activity in 
the presence of copper-tobramycin was approximately 10 times higher than in the 
presence of tobramycin. While at first glance this appears to be a pro-inflammatory 
effect, subsequent experiments (Figure 4.20) shows that this renders NE susceptible to 
inhibition by α1-antitrypsin. 
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Also CuSO4 at 0.1 and 0.5 mM significantly (p<0.01) increased NE activity to 15.33 ± 
4.87 and 16.50 ± 5.62 mOD/min, respectively compared to the OPZ-stimulated PMN 
(Figure 4.14, over). NE activity released by copper sulphate was higher than NE activity 
in the presence of tobramycin and lower than in the presence of copper-tobramycin.
 
 
Figure 4.13. The effect of copper-tobramycin on NE activity in supernatants of OPZ-stimulated PMNs 
measured over 30 minutes at λ=405 nm and expressed as NE rate mOD/min. Mean ± SEM results were 
calculated using one-way ANOVA and Dunnett` s post hoc test to compare the effect of copper-
tobramycin or Tukey`s post hoc test to compare controls, n=3, in duplicate. Reag – reagent control; 
Spont – spontaneously released NE activity; 0 – OPZ-stmulated NE activity. 
 
Figure 4.14. The effect of copper sulphate on NE activity in supernatants of OPZ-stimulated PMNs 
measured over 30 minutes at λ=405 nm and expressed as NE rate mOD/min. Mean ± SEM results were 
calculated using one-way ANOVA and Dunnett` s post hoc test to compare the effect of copper sulphate 
or Tukey`s post hoc test to compare controls, n=3, in duplicate. Reag – reagent control; Spont – 
spontaneously released NE activity; 0 – OPZ-stmulated NE activity. 
0 
10 
20 
30 
40 
50 
60 
70 
Reag Spont 0 0.01 0.025 0.05 0.1 0.5 
Cu-Tob [mM] 
N
E 
ra
te
 [
∆
m
O
D
/m
in
] 
* 
* 
* 
OPZ 
** 
** 
0 
5 
10 
15 
20 
25 
Reag Spont 0 0.01 0.025 0.05 0.1 0.5 
CuSO4 [mM] 
N
E 
ra
te
 [
∆
m
O
D
/m
in
] 
* 
* 
* 
OPZ 
** 
** 
155 
 
Figure 4.15 shows that NE activity was significantly (p<0.05 and p<0.01) increased 
upon protamine sulphate incubation at 50 and 100 µg/ml to 19.50 ± 7.42 and 24.83 ± 
4.57 OD/min, respectively.
 
 
Figure 4.15. The effect of protamine sulphate on NE activity in supernatants of OPZ-stimulated PMNs 
measured over 30 minutes at λ=405 nm and expressed as NE rate mOD/min. Mean ± SEM results were 
calculated using one-way ANOVA and Dunnett` s post hoc test to compare the effect of protamine 
sulphate or Tukey`s post hoc test to compare controls, n=3, in duplicate. Reag – reagent control; Spont – 
spontaneously released NE activity; 0 – OPZ-stmulated NE activity. 
Analysis of NE activity in cell pellets showed that most is mostly associated with cell 
pellets, 96.79 ± 4.92 %, while released NE activity is minimal. OPZ-stimulated NE 
activity in the cell pellet, 55.50 ± 1.53 mOD/min, was not significantly lower than the 
NE activity in unstimulated cells, 65.50 ± 3.04 mOD/min (Figure 4.16 – 4.19), 
tobramycin (0.01 – 0.5 mM) did not influence cell-bound NE activity stimulated by OPZ 
(Figure 4.16, over).  
However, in parallel with the significantly increased release of NE activity, copper-
tobramycin in the concentration range 0.01 – 0.5 mM significantly (p<0.01) decreased 
the cell pellet-associated NE activity to 20.50 ± 0.87 mOD/min at 0.5 mM copper-
tobramycin concentration (Figure 4.17, over). 
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Figure 4.16. The effect of tobramycin on NE activity in cell pellets of OPZ-stimulated PMNs measured 
over 30 minutes at λ=405 nm and expressed as NE rate mOD/min. Mean ± SEM results were calculated 
using one-way ANOVA and Dunnett` s post hoc test to compare the effect of tobramycin or Tukey`s post 
hoc test to compare controls, n=3, in duplicate. Reag – reagent control equals 0; Spont – NE activity in 
unstimulated cells; 0 – OPZ-stmulated NE activity. 
 
Figure 4.17. The effect of copper-tobramycin on NE activity in cell pellets of OPZ-stimulated PMNs 
measured over 30 minutes at λ=405 nm and expressed as NE rate mOD/min. Mean ± SEM results were 
calculated using one-way ANOVA and Dunnett` s post hoc test to compare the effect of copper-
tobramycin or Tukey`s post hoc test to compare controls, n=3, in duplicate. Reag – reagent control 
equals 0; Spont – NE activity in unstimulated cells; 0 – OPZ-stmulated NE activity. 
Only 0.025 mM copper sulphate significantly (p<0.05) reduced the cell pellet-
associated NE activity, 45.00 ± 3.50 mOD/min, but other concentrations did not elicit 
any significant effect (Figure 4.18, over). 
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Figure 4.18. The effect of copper sulphate on NE activity in cell pellets of OPZ-stimulated PMNs 
measured over 30 minutes at λ=405 nm and expressed as NE rate mOD/min. Mean ± SEM results were 
calculated using one-way ANOVA and Dunnett` s post hoc test to compare the effect of copper sulphate 
or Tukey`s post hoc test to compare controls, n=3, in duplicate. Reag – reagent control equals 0; Spont – 
NE activity in unstimulated cells; 0 – OPZ-stmulated NE activity. 
Protamine sulphate in any concentration tested, similarly to tobramycin, was 
ineffective in changing the cell-associated NE activity (Figure 4.19). 
 
Figure 4.19. The effect of promamine sulphate on NE activity in cell pellets of OPZ-stimulated PMNs 
measured over 30 minutes at λ=405 nm and expressed as NE rate mOD/min. Mean ± SEM results were 
calculated using one-way ANOVA and Dunnett` s post hoc test to compare the effect of protamine 
sulphate or Tukey`s post hoc test to compare controls, n=3, in duplicate. Reag – reagent control equals 
0; Spont – NE activity in unstimulated cells; 0 – OPZ-stmulated NE activity. 
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Additionally, NE activity was measured in both the supernatant and cell pellet of OPZ-
stimulated neutrophils treated with 0.5 mM tobramycin and copper-tobramycin, in the 
presence and absence of α1-AT (Figure 4.20).  
 
 
Figure 4.20. The effect of tobramycin and copper-tobramycin on NE activity in supernatants (A) and cell 
lysates (B) of OPZ-stimulated PMN and the effect of α1-AT. The data is expressed as mean ± SEM and 
analysed using two-tailed, paired t-test, all assays were carried out in duplicate in 3 independent 
experiments, * p<0.05, **p<0.01, ***p<0.001. 
As before, tobramycin and copper-tobramycin significantly (p<0.01 and p<0.05) 
increased NE activity in the supernatants. Released NE was inhibited by α1-AT at 
physiological plasma concentration (2 mg/ml). This inhibition was significant (p<0.05) 
in the presence of tobramycin, copper-tobramycin and OPZ-stimulated control. 
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Moreover, copper-tobramycin, but not tobramycin significantly (p<0.001) reduced cell-
associated NE activity, which was further significantly (p<0.01) inhibited by α1-AT. NE 
activity in the cell pellet was not significantly inhibited by α1-AT in the presence of 
tobramycin or the OPZ-stimulated control. 
Since both NE and IL-8 have previously been reported to bind to HS or CS, 
supernatants and cell pellets from the above described experiments were also 
assessed in relation to the level of IL-8. 
Unstimulated neutrophils released a small amount of IL-8 (8.49 ± 3.88 pg/ml) and IL-8 
release from OPZ-stimulated neutrophils was not significantly higher at 29.91 ± 13.77 
pg/ml (Figure 4.21 – 4.24).  
Only 0.05 mM tobramycin elicited significantly (p<0.01) more IL-8 release, 71.53 ± 
22.39 pg/ml, from OPZ-stimulated neutrophils than in the absence of tobramycin 
(Figure 4.21). IL-8 release at any other tobramycin concentration was not different to 
the OPZ-stimulated neutrophil control IL-8 release. 
 
Figure 4.21. IL-8 level released from OPZ-stimulated neutrophils treated with tobramycin. The data 
expressed as mean ± SEM was analysed using one-way ANOVA and Dunnett`s multiple comparison test 
to compare drug treated and OPZ-stimulated IL-8 release. Additionally, two-tailed, paired t-test was 
applied to analyse OPZ-stimulated versus unstimulated IL-8 release, n=3, ns – not significant, **p<0.01. 
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Copper-tobramycin at 0.05 and 0.1 mM significantly (p<0.01 and p<0.05) reduced the 
concentration of IL-8 released from OPZ-stimulated neutrophils to 6.20 ± 3.37 and 
10.93 ± 4.76 pg/ml, respectively, compared to the IL-8 level released from OPZ-
stimulated neutrophils without copper-tobramycin treatment (Figure 4.22).  
 
Figure 4.22. The level of IL-8 released from OPZ-stimulated neutrophils incubated with copper-
tobramycin. The data expressed as mean ± SEM was analysed using one-way ANOVA and Dunnett`s post 
hoc test regarding to IL-8 of released of OPZ-stimulated PMNs. Two-tailed, paired t-test was used to 
analyse OPZ-stimulated versus unstimulated IL-8 release, n=3, ns – not significant, * p<0.05, **p<0.01. 
Also, both copper sulphate and protamine sulphate had similar effects to copper-
tobramycin on IL-8 released from OPZ-stimulated PMNs. Copper sulphate significantly 
(p<0.05) decreased IL-8 released to the supernatant in the concentration 0.025 – 0.1 
mM; however 0.5 mM of copper sulphate was the most effective and significantly 
(p<0.01) decreased IL-8 level to 5.59 ± 3.65 pg/ml compared to the IL-8 concentration 
in the absence of the copper sulphate (Figure 4.23, over). IL-8 released from OPZ-
stimulated neutrophils was significantly (p<0.05) diminished by incubation with 
protamine sulphate at 25 –  100 µg/ml (Figure 4.24, over). 
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Figure 4.23. The effect of copper-sulphate on IL-8 level released from OPZ-stimulated neutrophils. The 
data expressed as mean ± SEM was analysed using one-way ANOVA and Dunnett`s post hoc test to 
compare drug treated and OPZ-stimulated IL-8 release. Two-tailed, paired t-test was used to analyse 
OPZ-stimulated versus unstimulated IL-8 release, n=3, ns – not significant, * p< 0.05, **p<0.01. 
 
Figure 4.24. The effect of protamine sulphate on IL-8 level released from OPZ-stimulated neutrophils. 
The data expressed as mean ± SEM was analysed using one-way ANOVA and Dunnett`s multiple 
comparison test to compare drug treated and OPZ-stimulated IL-8 release. Two-tailed, paired t-test was 
applied to analyse OPZ-stimulated versus unstimulated IL-8 release, n=3, ns – not significant, *p<0.05. 
Cell pellet-associated IL-8 was approximately 30 times higher than IL-8 released to the 
supernatant. IL-8 detected in the cell pellet of OPZ-stimulated neutrophils was not 
significantly lower than unstimulated IL-8, 850.4 ± 225.6 versus 395.9 ± 121.4 pg/ml 
(Figure 4.25 – 4.28).  
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After tobramycin (0.01 – 0.5 mM) treatment, IL-8 was unchanged compared to cell-
associated IL-8 from stimulated PMNs (Figure 4.25). 
 
Figure 4.25. Cell pellet-associated IL-8 of OPZ-stimulated neutrophils treated with tobramycin. The data 
expressed as mean ± SEM was analysed using one-way ANOVA and Dunnett`s multiple comparison test 
in comparison to untreated OPZ-stimulated control. Also, two-tailed, paired t-test was applied to 
analyse cell-associated OPZ-stimulated versus unstimulated IL-8, n=3, ns – not significant. 
The incubation of OPZ-stimulated neutrophils with copper-tobramycin at 0.05, 0.1 and 
0.5 µM concentration significantly (p<0.01) decreased IL-8 concentration measured in 
the cell pellet compared to the untreated OPZ-stimulated neutrophil control to 116.7 ± 
54.26, 61.82 ± 7.75 and 50.68 ± 20.76 pg/ml, respectively (Figure 4.26, over). 
The IL-8 level from copper-sulphate treated OPZ-stimulated neutrophils was also 
significantly (p<0.01) decreased in the range of 0.025 – 0.5 mM from 29.91 ±            
13.77 pg/ml to 46.41 ± 5.40 to 22.16 ± 13.42 pg/ml in comparison to OPZ-stimulated 
neutrophils in the absence of the drug (Figure 4.27, over). 
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Figure 4.26. The effect of copper-tobramycin on IL-8 levels in the cell pellet of OPZ-stimulated PMNs. 
The data expressed as mean ± SEM was analysed using one-way ANOVA and Dunnett`s multiple 
comparison test in comparison to cell-associated IL-8 from OPZ-stimulated control. Two-tailed, paired t-
test was used to analyse OPZ-stimulated versus unstimulated IL-8 level in the cell pellet, n=3, ns – not 
significant, **p<0.01. 
 
Figure 4.27. IL-8 level from OPZ-stimulated neutrophils incubated with copper sulphate in the cell pellet. 
The data expressed as mean ± SEM was analysed using one-way ANOVA and Dunnett`s post hoc test to 
compare drug treated and OPZ-stimulated cell-associated IL-8 level. Also, two-tailed, paired t-test was 
applied to analyse OPZ-stimulated versus unstimulated IL-8 in the cell pellet, n=3, ns – not significant, 
**p<0.01. 
Additionally, protamine sulphate at 100 µg/ml significantly (p<0.05) diminished IL-8 
concentration measured in the cell pellet from 850.4 ± 225.6 to 61.19 ± 21.54 pg/ml 
(Figure 4.28, over). 
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Figure 4.28. The effect of protamine sulphate in OPZ-stimulated PMN on IL-8 level in the cell pellet. The 
data expressed as mean ± SEM was analysed using one-way ANOVA and Dunnett`s post hoc test in 
comparison to IL-8 level in OPZ-stimulated PMNs in the cell pellet. Two-tailed, paired t-test was used to 
analyse OPZ-stimulated versus unstimulated cell pellet-associated IL-8, n=3, ns – not significant, 
*p<0.05. 
Figure 4.29 (over) shows the effect of α1-AT on the IL-8 level in both supernatants and 
cell pellets of OPZ-stimulated PMNs incubated with tobramycin and copper-
tobramycin (0.5 mM). Tobramycin or copper-tobramycin at 0.5 mM concentration did 
not change the IL-8 released to the supernatant in comparison to the untreated 
control. However, tobramycin in the presence of α1-AT significantly (p<0.05) increased 
this level from 43.73 ± 18.56 to 124.1 ± 34.52 pg/ml, while copper-tobramycin in the 
presence of α1-AT was ineffective compared to the appropriate control. The presence 
of α1-AT significantly (p<0.05) increased the concentration of IL-8 measured in the 
supernatant only in the presence of tobramycin (Figure 4.29A). Moreover, tobramycin 
or copper-tobramycin (0.5 mM) did not change significantly cell pellet-associated IL-8 
level compared to the OPZ-stimulated PMNs control in the absence or the presence of 
α1-AT.  α1-AT was also ineffective on IL-8 concentrations measured in the cell pellet of 
PMN-stimulated with OPZ and treated or untreated with tobramycin and copper-
tobramycin (Figure 4.29B). 
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Figure 4.29. The effect of α1-AT on the level of IL-8 in supernatants (A) and cell pellets (B) of OPZ-
stimulated neutrophils treated with tobramycin and copper-tobramycin (0.5 mM). The data expressed 
as mean ± SEM was analysed using two-tailed, paired t-test, n=3 independent experiments, ns – not 
significant, *p<0.05. 
4.5.5.   VIABILITY    OF    NEUTROPHILS    DURING    NEUTROPHIL    ELASTASE    ACTIVITY  
              MEASUREMENT 
α1-AT at 2 mg/ml was not toxic to PMNs over 1 hour incubation in HBSS (+ Ca/Mg) 
containing 20 mM HEPES, pH 7.4 compared to the untreated control, which contained 
85.70 ± 0.20 % live, 0.07 ± 0.02 % apoptotic and 14.24 ± 0.20 % necrotic cells (Figure 
4.30, over). However, protamine sulphate diminished the population of live 
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neutrophils concentration-dependently and 100 mg/ml protamine sulphate decreased 
the live cell pool by 15.66 ± 2.84 % (Figure 4.31).  
 
Figure 4.30. The effect of α1-AT (2 mg/ml) on neutrophil viability during 1 hour incubation in HBSS (+ 
Ca/Mg) containing 20 mM HEPES, pH 7.4, n=1, in triplicate. 
 
 
Figure 4.31. Neutrophil viability during 1 hour incubation with protamine sulphate in HBSS (+ Ca/Mg) 
containing 20 mM HEPES, pH 7.4, n=1, in triplicate. 
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The effect of tobramycin, copper-tobramycin and copper sulphate on neutrophil 
viability during neutrophil elastase activity measurements was not different to the 
effect elicited after 3 hour incubation with the assay buffer, HBSS (+ Ca/Mg) containing 
20 mM HEPES, pH 7.4 (results not shown). 
4.5.6. THE EFFECT OF DIFFERENT COMPOUNDS ON IL-8 LEVEL DETECTED BY ELISA 
In the view of the apparent loss of IL-8 from both cell supernatants and pellets on 
treatment with copper-tobramycin, copper sulphate and protamine sulphate, the 
compounds were tested for their interference in the ELISA. 
Tobramycin, copper-tobramycin, copper sulphate (0.5 mM), copper chloride (0.4 mM) 
and protamine sulphate (0.1 mg/ml) were tested either alone for a false positive effect 
(Table 4.1) or in the presence of a constant IL-8 concentration (500 pg/ml)  for IL-8 
degradation (Table 4.2).  
Compound IL-8 detected in compound [pg/ml] 
0.5 mM Tob 7.84 ± 0.11 
0.5 mM Cu-Tob Non detected 
0.5 mM CuSO4 35.66 ± 3.83 
0.4 mM CuCl2 42.25 ± 20.40 
0.1 mM Protamine sulphate 13.587 ± 0.200 
 
Table 4.1. IL-8 detected in different compounds measured by ELISA. The data showing the effect of 
compound alone on IL-8 level is subtracted from the buffer control [pg/ml] and shown as mean ± SEM, 
n=1 in triplicate. Tob – tobramycin,   Cu-Tob – copper-tobramycin. 
Compound + IL-8 (500 pg/ml) % of IL-8 control 
0.5 mM Tob 101.53 ± 17.34 
0.5 mM Cu-Tob 69.90 ± 7.34 
0.5 mM CuSO4 73.33 ± 8.16 
0.4 mM CuCl2 91.78 ± 14.38 
0.1 mM Protamine sulphate 78.54 ± 24.50 
 
Table 4.2. The effect of different compounds on IL-8 level detected by ELISA. The data showing the 
effect of compound in the presence of IL-8 (500 pg/ml) is expressed as a percentage of the control. The 
data is shown as mean ± SEM, n=1 in triplicate. Tob – tobramycin,   Cu-Tob – copper-tobramycin. 
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IL-8 detected in samples containing tobramycin, copper-sulphate, copper chloride or 
protamine sulphate alone may indicate the assay limitation or sample contamination.  
Tobramycin and copper chloride did not reduce the level of IL-8 detected in the 
sample, however other compounds did. Among them, copper-tobramycin had the 
strongest effect and decreased IL-8 by 30.10 ± 7.34 %, while copper sulphate and 
protamine sulphate decreased IL-8 by 26.66 ± 8.16 % and 21.46 ± 24.50 %, 
respectively. 
4.5.7. OXIDATIVE STRESS IS NOT INDUCED IN HLMVEC BY COPPER AND/OR HYDROGEN     
            PEROXIDE 
2`,7`-Dichlorodihydrofluorescein diacetate (H2DCF-DA) at 10 µM was used as an 
indicator of intracellular ROS generation in HLMVEC. It is a cell permeable probe that 
enters the cell and is deacetylated to a nonfluorescent product, 2`,7`-
dichlorodihydrofluorescein (H2-DCF) by cellular esterases and oxidised by ROS to a 
fluorescent product, 2`,7`-dichlorofluorescein (DCF). 
In order to find a stimulus to induce intracellular ROS generation (Figure 5.32, B, over) 
in a layer of confluent HLMVEC, they were treated with CuCl2 (400 µM) alone, H2O2 (50 
µM) alone or with a combination of CuCl2 (400 µM) and H2O2 (50 µM) for 30 minutes in 
full growth medium. Then tobramycin and copper-tobramycin (0.5 mM) in the 
presence of these stimuli were tested to check whether they have any anti-oxidant 
properties. A nuclear stain (Hoechst) was used as an additional control to visualize the 
cell nucleus (Figure 5.32, A, over). CuCl2 alone (panel 2), H2O2 alone (panel 5) as well as 
CuCl2 plus H2O2 (panel 6) induce a minimal level of ROS generation in HLMVEC 
compared to a negative control (panel 1). This induced ROS level was not high enough 
to observe an effect of tobramycin (panel 3 and 7) or copper-tobramycin (panel 4 and 
8). 
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Figure 4.32. The effect of copper chloride and hydrogen peroxide on ROS generation in HLMVEC. A) 
Nuclear stain (Hoechst blue) ; B) ROS stain (DCF-DA); 1) Negative control ; 2) 400 µM CuCl2 ; 3) 400 µM 
CuCl2 + 0.5 mM Tob ; 4) 400 µM CuCl2 + 0.5 mM Cu-Tob ; 5) 100 µM H2O2 ; 6) 50 µM CuCl2 + 100 µM 
H2O2 ; 7) 50 µM CuCl2 + 100 µM H2O2 + 0.5 mM Tob ; 8) 50 µM CuCl2 + 100 µM H2O2 + 0.5 mM Cu-Tob. 
Scale bar 100 µm, n=1. 
4.5.8. TNF-α-INDUCED ROS GENERATION IN HLMVEC AND THE PROTECTIVE ROLE OF  
           TOBRAMYCIN AND COPPER-TOBRAMYCIN 
TNF-α was used to generate oxidative stress in the same cells. TNF-α in a 
concentration range of 1 – 10 ng/ml was tested on the oxidative stress generated in 
HLMVEC for 15 minutes (Figure 4.33, over). TNF-α at 10 ng/ml (panel 8) induced more 
ROS than 1 and 5 ng/ml (panel 6 and 7) compared to the absence of TNF-α (panel 5) or 
DCF-DA (panel 1 – 4). The effect of 10 ng/ml TNF-α was then tested in the time-course 
experiment. 
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Figure 4.33. TNF-α concentration curve of HLMVEC stained for ROS using DCF-DA. 1. no TNF- α, no DCF-
DA; 2. 1 ng/ml TNF- α, no DCF-DA, 3. 5 ng/ml TNF- α, no DCF-DA; 4. 10 ng/ml TNF- α, no DCF-DA; 5. no 
TNF- α, 10 uM DCF-DA; 6. 1 ng/ml TNF- α, 10 uM DCF-DA; 7. 5 ng/ml TNF- α, 10 uM DCF-DA, 8. 10 ng/ml 
TNF- α, 10 uM DCF-DA. Scale bar 100 µm. 
TNF-α-treatment (10 ng/ml) of HLMVEC for 15 minutes triggered the most intense ROS 
generation (Figure 4.34, panel 7) compared to the same treatment for 5 (panel 6) and 
30 minutes (panel 8). ROS were generated at a minimal level in the absence of TNF-α 
(panel 5) and not detected in the absence of DCF-DA (panel 1 – 4), respectively.  
 
 
Figure 4.34. TNF-α time course  of ROS generation in HLMVEC. 1) no TNF-α; no DCF-DA; 2) 10 ng/ml TNF-
α for 5 minutes, no DCF-DA; 3) 10 ng/ml TNF-α for 15 minutes, no DCF-DA; 4) 10 ng/ml TNF-α for 30 
minutes, no DCF-DA; 5) no TNF-α, 10 µM DCF-DA; 6) 10 ng/ml TNF-α for 5 minutes, 10 µM DCF-DA; 7) 10 
ng/ml TNF-α for 15 minutes, 10 µM DCF-DA, 8) 10 ng/ml TNF-α, for 30 minutes, 10 µM DCF-DA. Scale 
bar 100 µm. 
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Figure 4.35 confirms that TNF-α at 10 ng/ml incubated on HLMVEC for 15 minutes at 
370C was the best stimulus to induce oxidative stress in EC. ROS were most likely  
generated predominantly in mitochondria and cytoplasmic organelles, rather than the 
nucleus. 
 
 
 
 
Figure 4.35. Z-stack of HLMVEC stained for ROS. HLMVEC were treated with 10 ng/ml TNF-α for 15 
minutes and stained with DCF-DA (positive control). Z-stack was performed with 1 µm interval, Scale bar 
100 µm. 
Having established optimum conditions for intracellular ROS generation in HLMVEC, 
the anti-oxidative capacity of tobramycin and copper-tobramycin in a concentration 
range of 0.01 – 0.5 mM was tested (Figure 4.36, over). Copper-tobramycin at 0.5 mM 
concentration completely reduced oxidative stress induced by TNF-α treatment in 
HLMVEC. Tobramycin also reduced ROS generation, but was less effective than copper-
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tobramycin. The effect of both copper-tobramycin and tobramycin was concentration 
dependent. 
 
 
 
Figure 4.36.The effect of tobramycin and copper-tobramycin (0.01 – 0.5 mM) on TNF-α-induced ROS 
generation in HLMVEC. HLMVEC were incubated with tobramycin and copper-tobramycin for 3.5 hours, 
treated with 10 uM DCF-DA for 30`, activated with TNF-α for 15` and fixed with 4 % (w/v) PFA/PBS. 1. 
Negative control (no drug, no DCF-DA); 2. Positive control (no drug, TNF-α activation); 3-8 TNF-α 
activation , DCF-DA; 3. 0.01 mM Tob; 4. 0.1 mM Tob; 5. 0.5 mM Tob; 6. 0.01 mM Cu-Tob; 7. 0.1 mM Cu-
Tob; 8. 0.5 mM Cu-Tob. These represent typical results from three independent experiments. 
 
The anti-oxidant effect of tobramycin and copper-tobramycin was analysed 
quantitatively (Figure 4.37, over). TNF-α induced a significant (p<0.001) oxidative 
stress in EC compared to the untreated control, 20.64 ± 1.66 versus 7.54 ± 0.75 mean 
intensity units. Tobramycin reduced ROS level generated by TNF-α, however only 0.01 
and 0.5 mM tobramycin elicited a significant (p<0.5 and 0.01) effect. In comparison, 
ROS level was significantly (p<0.01) reduced concentration-dependently by copper-
tobramycin over the whole concentration range, 0.01 – 0.5 mM.  There was no 
statistically significant difference between the effect of 0.01 mM tobramycin and 0.01 
mM copper-tobramycin concentration, 14.45 ± 1.43 versus 11.96 ± 1.06 mean intensity 
units. However, the effect of copper-tobramycin was significantly greater than that of 
tobramycin at 0.1 mM (8.98 ± 0.39 versus 15.97 ± 1.38 mean intensity units, p<0.001) 
and 0.5 mM (7.77 ± 0.53 versus 13.28 ± 1.59 mean intensity units, p<0.01), 
respectively. 
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Figure 4.37. The effect of tobramycin and copper-tobramycin on reducing TNF-α-induced ROS 
generation in HLMVEC. The data is expressed as mean ± SEM and was analysed using one-way ANOVA 
with Dunett`s post hoc test and two-way, unpaired t-test. The mean intensity is quantified from at least 
3 fields of view of two independent experiments. 
4.5.8. THE EFFECT OF CFTRinh-172 ON ROS GENERATION IN HLMVEC AND THE ROLE   
            OF TOBRAMYCIN   AND COPPER-TOBRAMYCIN 
The CFTR inhibitor, CFTRinh-172 was reported to induce oxidative stress in epithelial 
cell lines (Kelly et al, 2010). The pro-oxidant ability of CFTRinh-172 on endothelial cells 
was investigated in the absence and presence of TNF-α (Figure 4.38, over). TNF-α (10 
ng/ml) incubated on HLMVEC for 15 minutes was shown to induce oxidative stress 
(panel 7) and 30 minutes-treatment of HLMVEC with CFTRinh-172 (20 µM) induced a 
similar level of ROS generation in those cells (panel 5), while the presence of CFTRinh-
172 for 5, 15 or 60 minutes had a smaller effect (panel 3, 4 and 6). The highest degree 
of ROS was generated by a combination of TNF-α and CFTRinh-172, when TNF-α was 
present on HLMVEC for 15 minutes and CFTRinh-172 for 30 minutes (panel 9). Shorter 
(15 minutes, panel 8) or longer (60 minutes, panel 10) treatment of EC with CFTRinh-
172 in the presence of TNF-α was less effective. Moreover, ROS were not detected in 
the presence of TNF-α or CFTRinh-172 alone without DCF-DA (panel 1 and 2, 
respectively). 
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Figure 4.38. The effect of CFTRinh-172 in the absence and presence of TNF-α on ROS generation in 
HLMVEC. 1) Negative control, 10 ng/ml TNF-α for 15 minutes, no DCF-DA; 2) Negative control, 20 µM 
CFTRinh-172 for 30 minutes, no DCF-DA; 3) CFTRinh-172 for 5 minutes; 4) CFTRinh-172 for 15 minutes; 
5) CFTRinh-172 for 30 minutes; 6) CFTRinh-172 for 60 minutes; 7) 10 ng/ml TNF-α for 15 minutes; 8) 20 
µM CFTRinh-172 for 15 minutes + TNF-α for 15 minutes; 9) 20 µM CFTRinh-172 for 30 minutes + TNF-α 
for 15 minutes; 10) 20 µM CFTRinh-172 for 60 minutes + TNF-α for 15 minutes. Scale bar 100 µm. 
The contribution of CFTRinh-172 to endothelial ROS generation was previously 
reported, therefore CFTRinh-172 alone was used as an oxidative stress inducer in 
HLMVEC. Furthermore, the anti-oxidative effect of tobramycin and copper-tobramycin 
in the concentration range of 0.01 – 0.5 mM and NAC (1 – 20 mM) on CFTRinh-172-
treated endothelium was investigated (Figure 4.39, over). Tobramycin and copper-
tobramycin reduced oxidative stress concentration-dependently (panel 3 – 5 and 6 – 8, 
respectively), in regard to the positive effect of CFTRinh alone (panel 2). However 
copper-tobramycin was more effective in terms of maximal effect, than tobramycin. 
NAC also reduced ROS level, but its effect was not dose dependent (panel 9 – 11). 
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Figure 4.39. The effect of tobramycin, copper-tobramycin (0.01 – 0.5 mM) and NAC (1 – 20 mM) on 
oxidative stress generated by CFTRinh-172 (20 µM, 30 minutes). 1) Negative control, no CFTRinh-172, no 
drug; 2) Positive control, CFTRinh-172, no drug; 3 – 11) CFTRinh-172; 3) 0.01 mM Tob; 4) 0.1 mM Tob; 5) 
0.5 mM Tob; 6) 0.01 mM Cu-Tob; 7) 0.1 mM Cu-Tob; 8) 0.5 mM Cu-Tob; 9) 1 mM NAC; 10) 10 mM NAC; 
11) 20 mM NAC. Scale bar 100 µm. 
4.6. SUMMARY OF RESULTS 
Copper-tobramycin was demonstrated to have anti-oxidant properties, as it 
significantly decreased the detection of both superoxide anion and hydrogen peroxide 
(extracellular oxidative stress) from OPZ- and PMA-activated neutrophils at 
concentrations which did not induce apoptosis, while tobramycin was without any 
effect. Also, copper-tobramycin reduced ROS generated in HLMVEC (intracellular 
oxidative stress) by TNF-α or CFTRinh-172. Tobramycin had the same qualitative 
inhibitory effect on endothelial ROS as copper-tobramycin, but it was less efficacious. 
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Moreover, both tobramycin and copper-tobramycin increased released NE activity, 
which was inhibitable by α1-AT, while cell-associated NE activity was reduced by 
copper-tobramycin and was inhibited by α1-AT.  
4.7. DISCUSSION 
PMNs can participate in host defence through their ability to metabolize oxygen to 
ROS through NADPH oxidase (Lambeth, 2004). The importance of this process is 
exemplified in patients suffering from chronic granulomatous disease, a disorder of 
non functioning oxidase due to a deficiency of gp91 phox, resulting in recurrent 
bacterial and fungal infections (Segal et al, 1978). The stimulation of leukocyte 
oxidative metabolism takes place during direct contact with the pathogen and 
subsequent phagocytosis. Indeed, the respiratory burst can be induced by a variety of 
stimuli, including chemoattractants (fMLP, C5a and C3a complement fragments), 
cytokines (TNF-α, TNF-β, GM-CSF, G-CSF), nonchemotactic stimuli (IgG, PMA, 
ionophore A23187), lectins (concanavalin A) or opsonised crystals (monosodium urate 
crystals, calcium pyrophosphate dehydrate, zymosan) (Burt & Jackson, 1993; 
Hoogewerf et al, 1990; Nathan et al, 1989; Balsinde & Mollinedo, 1988; McPhail & 
Snyderman, 1983; Simchowitz et al, 1982).  
Unopsonised zymosan was shown to be a poor activator of PMN respiratory burst, but 
human PMN that express CR3 (CD11/CD18) bind and ingest zymosan after exogenous 
opsonization (Ezekowitz et al, 1985). In the current study, zymosan particles were 
opsonised with normal human serum. Moreover, the OPZ-stimulated respiratory burst 
of neutrophils was significantly higher compared to the spontaneous production of O2
-. 
Also, OPZ elicited a stronger effect compared to other stimuli, such as PMA or fMLP. 
Others also reported OPZ to be the strongest and the most physiological activator of 
the neutrophil respiratory burst (Ramasamy et al, 2010; Azuma et al, 1993). 
Importantly, the activation of the respiratory burst in neutrophils could be elicited in 
independent ways. Both, OPZ and fMLP activates the respiratory burst through a 
receptor-dependent pathway, whereas PMA is a direct activator of protein kinase C 
(Azuma et al, 1993, Ezekowitz et al, 1985).  
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Hydrogen peroxide release was only detectable in the presence of the MPO and 
catalase inhibitor, sodium azide (Nakagawara et al, 1981), in agreement with the 
current study.  Also, Nahum et al (1990) reported using sodium azide to allow 
detection of H2O2 from OPZ-activated PMNs and to improve sensitivity and 
reproducibility of H2O2 measurement. No H2O2 was detected in the absence of SA. 
Hydrogen peroxide is an unusual oxidant. It reacts slowly with organic substrates and 
thus can diffuse large distances in biological systems. Its small size and lack of charge 
facilitate its movement across plasma membranes. Although H2O2 is not a free radical, 
it is detectable by DCF-DA. Moreover, its intracellular concentration is decreased by 
several enzymes (Test & Weiss, 1984). In contrast to hydrogen peroxide, superoxide is 
not transported across the cell membrane. Superoxide is a poorly reactive oxide radical 
made from the reaction of molecular oxygen with catecholamines, tetrahydrofolates 
and some constituents of mitochondrial and other electron-transport chains. 
Additionally, activated phagocytes generate large amounts of superoxide as part of 
bacterial phagocytosis (Halliwell, 1994). 
During chronic inflammation, this normal and protective mechanism of killing foreign 
microorganisms could be damaging. Therefore, the inhibition of NADPH oxidase may 
be necessary.  
Many antibiotics have been shown to interfere with various aspects of host defence, 
including phagocytic ingestion and killing (Gemmel, 1984; Mandell, 1982; Milatovic, 
1982) by either up- or down-regulating phagocyte function. Tobramycin sulphate (2 – 
12 µg/ml) alone and in a combination with pencillin G sodium and metronidazole 
hydrochloride was previously reported to significantly and dose-dependently reduce 
NADPH oxidase activity in human PMNs stimulated with fMLP (Moon et al, 1986). 
However, tobramycin in the concentration range 1 – 500 µM, approximately 0.5 – 250 
µg/ml, was unable to decrease superoxide anion detected from OPZ-stimulated 
neutrophils. Also, tobramycin at 10 – 500 µM (5 – 250 µg/ml) was ineffective in the 
inhibition of H2O2 release in the same experimental settings. Likewise, Ottonello and 
co-workers (1991) showed that penicillin G, ceftazidime, cephotaxime, cephoperazon, 
ampicillin and piperacillin did not inhibit superoxide generation by neutrophils. 
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Moreover, these drugs were capable of inhibiting the neutrophil cytolytic activity by 
inactivating HOCl generated extracellularly by MPO, crucial to the cell lysis of 
lymphoblastoid Daudi target cells. No effect of tobramycin on the respiratory burst of 
neutrophils may be due to the fact that tobramycin was demonstrated not to bind or 
to be taken up by resting or activated neutrophils (Chapter 3). 
Copper-tobramycin, as opposed to tobramycin, reduced superoxide detection from 
OPZ-stimulated PMNs. This effect was seen at non-cytotoxic concentrations of copper-
tobramycin. This could be due to the SOD-like activity of copper-tobramycin complex 
(Chapter 2), since SOD is a superoxide scavenging enzyme. The same superoxide 
reducing effect was however also observed for copper sulphate, which could indicate a 
role for copper. Copper-tobramycin, but not SOD, was also shown to significantly 
decrease H2O2 detected from both OPZ- and PMA-stimulated neutrophils. SOD as an 
enzyme catalysing dismutation of superoxide to hydrogen peroxide, may be expected 
to increase the level of detectable hydrogen peroxide, but this is not always the case 
(Liochev & Fridovich, 2007). However, large proteins such as SOD do not penetrate cell 
membranes and are therefore ineffective against intracellular ROS (Szeto, 2006). This 
experiment raises the possibility that H2O2 is made intracellularly. Since copper-
tobramycin does not have catalase activity (Chapter 2), this result might indicate an 
inhibitory effect on NADPH oxidase. Copper-tobramycin could also act as a pericellular 
agent (not taken up by neutrophils), while no substantial SOD enzyme activity was 
observed in the membranous fraction (Rest & Spitznagel, 1977). However, the most 
probable explanation of the copper-tobramycin effect in reducing detectable hydrogen 
peroxide and superoxide from activated neutrophils at high concentrations is its ability 
to elicit neutrophil apoptosis in the same concentration range in assays lacking the 
protective effect of FBS. Importantly, these results indicate that copper-tobramycin 
has SOD-like activity in both cell-based and cell-free (Chapter 2) systems. 
Copper complexes with amino acids, such as Cu(Lys)2, Cu(His)2 and CuTyr, were shown 
to inhibit O2
--dependent NADPH oxidation (Joester et al, 1972; Klug et al, 1972). 
Additionally, commonly used chelating agents, by interacting with available copper, 
may artificially increase NADPH oxidation in xanthine oxidase and other superoxide 
generating systems (Bidwell Goetz & Proctor, 1984). The effect of copper-tobramycin 
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and, in comparison, copper sulphate on NADPH oxidase could be further investigated 
after isolation of neutrophil cytoplasts, adapting the method presented by 
Yazdabakhsh and co-workers (1987) for eosinoplast preparation. Indeed, cytoplasts are 
granules and internal organelles of neutrophils that contain a fully competent 
stimulatable NADPH oxidase activity (Henderson et al, 1988). However, as neutrophils 
do not take up tobramycin or copper-tobramycin (Chapter 3), copper-tobramycin, 
unlike tobramycin, was demonstrated here to have potent extracellular anti-
inflammatory properties. 
Neutrophil degranulation is a consequence of neutrophil stimulation with the same 
activators over time (Bentwood & Henson, 1980). Turner et al (1994) reported that 
OPZ is a poor stimulus for NE release. Also here, released NE was minimal, whereas the 
majority (96.76 ± 4.92 %) of NE was bound to the cell surface. Although NE is released 
to the local environment, human neutrophils express persistently active cell-surface 
bound human leukocyte elastase (Owen et al, 1995). Moreover, the sulphate groups of 
HS/CS proteoglycans have been identified as the PMN binding sites for human 
leukocyte elastase and cathepsin G (CG). HS/CS-containing proteoglycans are low 
affinity, high volume PMN surface binding sites for NE and CG, which are well suited to 
bind high concentrations of active serine proteinases released from degranulating 
PMN and protecting them from inactivation (Campbell & Owen, 2007). Neutrophil 
elastase, proteinase 3 (PR3) and cathepsin G bound to bronchoalveolar proteoglycans 
are also active (Shum et al, 2000). Moreover, the active serine proteases in CF sputum 
were shown to bind to NETs secreted by the activated neutrophils and genomic DNA 
released from senescent and dead neutrophils. Due to this binding, NE was resistant in 
part inhibition by exogenous protease inhibitors (Dubois et al, 2012). 
In the current study, tobramycin significantly increased the released NE level up to 3-
fold. However, copper-tobramycin induced a 30-fold increase in free NE and 
additionally, CuSO4 increased NE release by 9 fold. In agreement, copper ions were 
shown to stimulate neutrophils to degranulate in a concentration-dependent manner 
(Hunt et al, 1992). Although the effects on NE were seen at concentrations of copper-
tobramycin and copper sulphate that induce apoptosis, apoptosis is independent of 
degranulation (Hebert et al, 1996). Moreover, only copper-tobramycin significantly 
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decreased cell pellet-associated NE activity, which suggests displacing elastase from its 
HS binding sites, while the released NE was protected by copper-tobramycin. 
α1-AT is the major inhibitor of serine proteases, including NE, which is secreted by the 
liver and accesses the local inflammatory site by simple diffusion from plasma. Indeed, 
during an inflammatory response, there is plasma exudation into the airway tissue and 
lumen (Persson, 1991) and α1-AT is measured in airway BAL or sputum (Hilliard et al, 
2002). More importantly, α1-AT is synthesised and secreted by neutrophils (du Bois et 
al, 1991), like two other low-molecular weight inhibitors, SLPI and elafin, which were 
also shown to be synthesized locally in the lung (Sallenave et al, 1997). Thus, 
neutrophils respond to the surface stimulation not only by secreting NE, but also by 
secreting its inhibitor, α1-AT, suggesting that these cells have an inherent mechanism 
for suppressing the local effects of NE (Paakko et al, 1996). However, the rate of α1-AT 
synthesis within neutrophils is low compared with that of hepatocytes and in the 
current experiment α1-AT was supplemented at the concentrations found in human 
plasma, 2 mg/ml (Fregonese & Stolk, 2008). α1-AT inhibits free NE, but catalytically 
active cell surface-bound human NE is remarkably resistant to inhibition by serine 
proteinase inhibitors, such as α1-AT (Owen et al, 1995). This membrane-bound 
leukocyte elastase activity may have potent pro-inflammatory effects (Owen et al, 
1997). Interestingly, α1-AT in the presence of copper-tobramycin was able to inhibit 
both free and cell-associated NE. These results suggest that copper-tobramycin not 
only releases NE from HS/CS binding sites on neutrophils, but also protects α1-AT from 
degradation by NE and ROS. 
NE was demonstrated to bind to the cell surface by a charge-dependent mechanism, 
since incubation of cells with cationic molecules (protamine and L-lysine) 
downregulates membrane-bound elastase (Owen et al, 1997). Protamine sulphate, 
similar to aminoglycoside antibiotics, is a positively-charged molecule at pH 7.4 and 
here mirrored the effects of tobramycin, copper-tobramycin and copper sulphate in 
increasing the release of NE activity. Protamine sulphate also induced a degree of 
neutrophil necrosis, not apoptosis. However, necrotic neutrophils will release IL-8 and 
NE and here they did not. 
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Although OPZ stimulation of neutrophils released a small percentage of NE, it had no 
significant effect on IL-8. IL-8, similarly to NE was mostly associated with the cell pellet. 
Indeed, the level of cell-bound IL-8 was 40 times higher compared to the IL-8 
concentration in the supernatant. Tobramycin at 50 µM increased the level of detected 
released IL-8, but had no effect on cell-bound IL-8. In contrast, the IL-8 concentration 
was diminished in both supernatants and cell pellets of neutrophils stimulated with 
OPZ in the presence of copper-tobramycin, copper sulphate and protamine sulphate.  
Neutrophils release the content of the granules in the reverse order to the 
biosynthesis of their characteristic proteins. Indeed, IL-8 stored in neutrophil secretory 
vesicles is released long before NE from the primary granules (Borregaard & Cowland, 
1997). During that time IL-8 could be degraded by extracellular ROS generated by OPZ-
activated neutrophils, but this explanation is not probable. Copper chloride and 
hydrogen peroxide, a known ROS-generating system, induced a low level of 
intracellular ROS detected within HLMVEC in a full growth medium. Copper chloride 
and hydrogen peroxide were also shown to have no effect on IL-8, when incubated in 
medium deprived of antioxidants, such as FBS or ascorbic acid (results not shown). 
Also, MMPs were not shown so far to degrade IL-8. For instance, gelatinase B was 
found to truncate six amino acids from the aminoterminus of IL-8 converting it into 10 
- 20 times more potent chemokine that the full length chemokine (Opdenakker et al, 
2001). However, NE could degrade a variety of proinflammatory cytokines including IL-
8 (Witherden et al, 2004), or the protein could be destroyed by other proteases, such 
as CG or PR3. Copper-tobramycin and copper sulphate could also interfere slightly with 
the IL-8 ELISA, as those treatments diminished the detectable IL-8 concentration by 
approximately 30 %, whereas protamine sulphate diminished IL-8 level by 
approximately 20 %. Alternatively a recognition site of IL-8 antibody detection had 
been affected by those treatments. 
In vivo, HS functions as an antioxidant in the basement membrane, protecting different 
molecules from degradation by ROS (Raats et al, 1997). This antioxidant effect has also 
been shown for heparin and hyaluronic acid (Hiebert & Liu, 1990, Sato et al, 1990). 
Recently, HS was demonstrated to protect the chemokine from oxidative damage, 
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promoting dityrosine cross-links and multimer formation under oxidative conditions 
(MacGregor et al, 2011). 
α1-AT was demonstrated to bind IL-8 and thus prevented its interaction with CXCR1, 
eliciting an anti-inflammatory effect (Bergin et al, 2010). Importantly, the IL-8 level was 
increased in supernatants from OPZ-stimulated neutrophils in the presence of 
tobramycin and α1-AT compared to the absence of this inhibitor. However, α1-AT had 
no effect on neutrophil IL-8 in the presence of copper-tobramycin. α1-AT does not 
appear to protect IL-8 from degradation, therefore it is not an effect of NE, CG or PR3. 
Previous studies have identified abnormalities in the oxidative responses of the 
neutrophil in CF (Witko-Sarsat et al, 1996, Vaisman et al, 1994). In contrast, McKeon 
(2010) reported that CF neutrophils have normal intrinsic ROS generation and the 
expression of NADPH oxidase components is identical in the CF and non-CF 
neutrophils. Hence, CF neutrophils in BALF respond abnormally to TNF-α and IL-8 and 
react to opsonised bacteria by releasing increased amounts of NE (Taggard et al, 2000). 
More importantly, peripheral circulating neutrophils in CF have been characterized by 
delayed apoptosis. Defective apoptosis, which is suggested to be related to primary 
innate factors rather than infectious state or CFTR mutation, may explain PMN 
persistence at the inflammation site (Moriceau et al, 2010). Blood neutrophils have 
been shown to have reduced expression of Fas and FasL, and thus delayed apoptosis, 
due to intravenous administration of antibiotics (Downey et al, 2007). Moreover, 
reduced expression of the tumor necrosis factor receptor 1 (TNF-R1), which is a 
prerequisite for TNF-α-induced neutrophil apoptosis (Gon et al, 1996), was observed 
on purified circulating neutrophils (Downey et al, 2007). Also, defective airway 
clearance of apoptotic cells by macrophages in CF may be due to elastase-mediated 
cleavage of the phosphatidylserine receptor on phagocytes and may contribute to 
ongoing airway inflammation (Vandivier et al, 2002). CF neutrophils may therefore not 
respond to tobramycin and copper-tobramyicn treatment in the same way as normal 
neutrophils. It should therefore be investigated further. 
Copper-tobramycin and copper sulphate at 0.5 mM concentration induced nearly 100 
% apoptosis in neutrophils in the absence of FBS, ie in HBSS (+ Ca/Mg) containing 20 
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mM HEPES, pH 7.4 within 30 minutes incubation. However, no neutrophil apoptosis 
was induced by those drugs at any concentration tested (0.01 – 0.5 mM) in RPMI 1640 
supplemented by 2.5 % FBS (Chapter 5). It therefore indicates the deleterious effect of 
non physiological HBSS buffer with no addition of FBS. FBS could not be used in the 
assay to measure superoxide and hydrogen peroxide release from neutrophils or NE 
activity, because bovine serum albumin, the major component of FBS, exerts some 
important anti-oxidant activities (Wayner et al, 1985). In vivo, phagocytic clearance of 
intact apoptotic cells is a safe disposal route for the organism (Ren & Savill, 1998). 
Therefore, apoptosis triggered by copper-tobramycin and copper sulphate would have 
a favourable effect. However, this effect would not happen in vivo, as neutrophils are 
not in plasma-free conditions. 
Platelets were reported to undergo a respiratory burst by releasing superoxide and 
hydrogen peroxide (Del Principle et al, 1983; Finazzi-Agro et al, 1982) or augment the 
respiratory burst of neutrophils (Miedzybrodzki et al, 2008). Also NADPH oxidase 
appears to be the major source of ROS in ECs (Frey et al, 2009). However, the level of 
superoxide and hydrogen peroxide released from activated platelets and HLMVEC 
were not statistically significant upon stimulation in comparison to an untreated 
control. Also, the co-cultures of HLMVEC with platelets and/or neutrophils 
demonstrated neutrophils to be the main source of superoxide and hydrogen 
peroxide. 
The current research showed that TNF-α generates intracellular ROS in HLMVEC, 
confirming the observations of Rahman and coworkers (1998) that TNF-α generates 
intracellular ROS in human pulmonary artery endothelial cells. Intracellular ROS are 
here involved in signal transduction after binding of TNF-R1 (Shen & Pervaiz, 2006). In 
most cells and tissues mitochondria are the major generators of ROS (Boveris, 1984). 
TNF-α may stimulate ROS production by mitochondria (Chandel et al, 2001), but the 
major source of ROS is a phagocyte-type NADPH oxidase that is constitutively 
expressed in EC (Gu et al, 2002; Bayraktutan et al, 2000; Gorlach et al, 2000). In the 
current study, TNF-α induced intracellular oxidative stress in HLMVEC, which was 
located mainly in the mitochondria and cytoplasmic organelles, presumably ER (Zhang 
& Kaufman, 2008). It was however impossible to identify the exact ROS location.  
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CFTRinh-172 as well as another highly potent CFTR inhibitor, GlyH-101 was able to 
induce a rapid increase in ROS levels and depolarise mitochondria in epithelial cells 
and those effects were independent of their CFTR inhibition (Chen et al, 2008; Maiuri 
et al, 2008). Also here, CFTRinh-172 induced ROS generation to a level similar to TNF-α 
in HLMVEC. A combination of CFTRinh-172 and TNF-α elicited a stronger response in 
comparison to CFTRinh-172 or TNF-α alone. 
On the contrary, copper in the absence or presence of hydrogen peroxide did not 
stimulate ROS generation in HLMVEC, although it is known that, in the presence of 
heavy metals, H2O2 undergoes the Fenton reaction to form the highly reactive hydroxyl 
radical (Biaglow et al, 1997). It is therefore possible that these reactions require longer 
incubation times and/or higher concentrations of both copper chloride and hydrogen 
peroxide. Moreover, the CuCl2/H2O2 effect was not receptor-mediated. 
Importantly, tobramycin and copper-tobramycin were shown to concentration-
dependently reduce intracellular oxidative stress generated in HLMVEC by TNF-α or 
CFTRinh-172, and copper-tobramycin was more effective than tobramycin. Another 
antioxidant, NAC, de-acetylated to cysteine on the cell surface or inside of the cell, 
promotes glutathione formation, while intracellular cysteine limits and/or enhances 
the antioxidant activity of the cytoplasm (Arakawa & Ito, 2007). Also here, NAC 
reduced oxidative stress induced by CFTRinh-172, however its effect was not 
concentration-dependent. Even though NAC is an efficient antioxidant and an anti-
inflammatory agent, known to protect lung (Moldeus et al, 1986) and used in the 
treatment of CF and COPD (Sadowska et al, 2007; Duijvestijn & Brand, 1999), great 
care has to be taken, because under certain circumstances, anti-oxidants, such as NAC 
may also serve as pro-oxidants (Childs et al, 2001; Oikawa et al, 1999; Sprong et al, 
1998). 
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CHAPTER 5 
THE EFFECT OF TOBRAMYCIN AND COPPER-
TOBRAMYCIN ON NEUTROPHIL  
TRANSENDOTHELIAL MIGRATION 
 
5.1. INTRODUCTION 
5.1.1. NEUTROPHIL-PLATELET-ENDOTHELIAL CELL INTERACTIONS 
CF patients have increased levels of circulating activated platelets. Since the plasma 
level of ATP is increased in CF, the platelet hyperactivation may be due to ATP. ATP is 
both transported by CFTR and acts as an agonist of platelets (Birk et al, 2002; Lader et 
al, 2000). Enhanced lipid peroxidation is an important feature of CF that may also 
contribute to the persistent platelet activation. The urinary excretion of 11-
dehydrothromboxane B2, a marker of in vivo platelet activation, was shown to be 
significantly higher in CF patients than controls. Moreover, the supplementation of 
vitamin E, which is also deficient in CF, reduces 11-dehydrothromboxane B2 excretion 
(Ciabattoni et al, 2000). The platelet reactivity has been determined by greater 
aggregability with monocytes and neutrophils as well as increased expression of 
surface P-selectin in response to agonists than in normal platelets. Also increased 
release of platelet-derived mediators could play an important role in the pathogenesis 
of CF lung disease (O`Sullivan et al, 2005). 
In normal physiologic conditions, circulating platelets do not interact with 
nonactivated endothelium, but endothelial denudation induces immediate platelet 
adhesion and aggregation at the site of injury (Clementson, 1999). Platelet-endothelial 
cell interactions are comprised of an initial platelet tethering, followed by rolling and 
subsequent firm adhesion of platelets, mediated by selectins, integrins and adhesion 
molecules. 
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Two platelet receptors for endothelial P-selectin were identified to be PSGL-1 and a 
glycoprotein GPIbα to mediate platelet rolling on the endothelial cell layer (Frenette et 
al, 2000; Romo et al, 1999). Also, vWF, which is stored in Webel-Palade bodies, 
similarly to P-selectin, was shown to be an important ligand for platelet GPIbα (Wagner 
et al, 1982). Platelets may also loosely interact with E-selectin expressed on activated 
endothelial cells, but the counter-ligand on the platelet surface is unknown (Frenette 
et al, 1998).  
The adhesion of activated platelets to activated endothelium involves platelet integrin 
αIIbβ3 and endothelial αVβ3 and ICAM-1 (Bombeli et al, 1998; Li et al, 1996). Platelet 
adhesion to post-ischaemic walls of endothelial cells in vitro revealed a contribution of 
fibrinogen that bridges endothelial ICAM-1 with αIIbβ3 on platelets (Massberg et al, 
1999). Moreover, studies of Lagadec and coworkers (2003) shown that CD47 expressed 
on human and mouse platelets significantly contributes to platelet adhesion on TNF-α-
stimulated vascular endothelial cells by binding of thrombospondin-1 on EC surface. 
Also, PECAM sites on the endothelium are involved and may be exposed by the injury 
to promote platelet adhesion and aggregation (Rosenblum et al, 1996). 
Platelet firm adhesion induces signalling pathways, which promotes the secretion of 
platelet-derived mediators from their dense α-granules, such as RANTES and IL-1β 
(Schober et al, 2002; Lindemann et al, 2001). ADP-activated platelets were shown to 
induce both endothelial MCP-1 secretion and ICAM-1 surface expression via an NF-κB-
dependent mechanism (Gawaz et al, 1998). Additionally, CD40L expression on platelets 
induces ECs to secrete chemokines and to express adhesion molecules, thereby 
generating signals for the recruitment and extravasation of leukocytes at the site of 
injury (Henn et al, 1998). 
The above discussed interactions are summarised in Table 5.1 (over). 
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 Rolling Firm adhesion 
Resting Activated 
Platelet receptor GPIbα PSGL-1 P-
selectin 
αIIbβ3 CD47 PECAM-
1 
Endothelial 
ligand/counter-
receptor 
vWF     
P-
selectin 
E-selectin 
P-selectin 
? αVβ3     
ICAM-1 via 
fibrynogen 
TSP-1 PECAM-
1 
 
Table 5.1. Adhesion molecules involved in platelet rolling along activated or inflamed endothelium and 
firm adhesion to inflamed endothelium. The endothelial ligand mediating rolling of activated platelets is 
unknown. ICAM-1 – intracellular adhesion molecule-1; PECAM-1 – platelet-endothelial  cell adhesion 
molecule 1; PSGL-1 – P-selectin glycoprotein ligand-1; TPS-1 – thrombospondin-1; vWF – von Willebrand 
factor (Bergmeier & Wagner, 2007). 
Activated platelets can bind to leukocytes to form platelet–leukocyte aggregates and 
therefore potentiate inflammation. The initial adhesion step is mediated by platelet P-
selectin (formerly termed GMP-140 or PADGEM) and leukocyte PSGL-1 (Rinder et al, 
1992; Hamburger & McEver, 1990). Also rolling of neutrophils on immobilized platelets 
is selectin-dependent (Buttrum et al, 1993). These interactions increase firm adhesion, 
mediated by leukocyte integrins, LFA-1 and MAC-1. Moreover, cell surface expression 
of MAC-1 increased upon cross-linking of PSGL-1 (Blanks et al, 1998). Weber & 
Springer (1997) demonstrated that a stable arrest and adhesion strengthening of PMN 
on thrombin-stimulated, surface-adherent platelets in flow required interactions of 
MAC-1 with fibrinogen, which was bound to platelets via αIIbβ3. Also, JAM-3 and 
GPIbα serve as a counter-receptor for MAC-1 mediating leukocyte-platelet interactions 
(Wang et al, 2005; Ehlers et al, 2003; Santoso et al, 2002). ICAM-2, highly expressed on 
platelets and endothelium was shown to be a counter-receptor for the leukocyte 
integrin LFA-1 (Table 5.2) (Weber et al, 2004). 
 Rolling Firm adhesion 
Leukocyte receptor PSGL-1 LFA-1 MAC-1 
Platelet counter-
receptor 
P-selectin ICAM-2 αIIbβ3 via fibrinogen             
ICAM-2 via fibrinogen             
JAM-2 
 
Table 5.2. Adhesion molecules involved in leukocyte adhesion to activated platelets (Bergmeir & 
Wagner, 2007). 
188 
 
Platelet-leukocyte aggregates lead to endothelial activation and the leukocyte 
migration cascade (Figure 5.3) (Dole et al, 2005). However, vice versa, Weissmuller et 
al (2008) reported that PMNs facilitated translocation of platelets across human and 
mouse epithelium. 
Platelet-neutrophil complexes represent a large subpopulation of neutrophils with 
higher expression of adhesion molecules, greater capacity of production of reactive 
oxygen metabolites and phagocytosis (Peters et al, 1999). After leukocytes are 
recruited to tissue, platelets intensify the inflammatory process by inhibiting apoptosis 
of PMNs, monocytes and eosinophils (Raiden et al, 2003; Brunetti et al, 2000; 
Andonegui et al, 1997).  
 
Figure 5.1. Platelets enhance leukocyte rolling on the endothelium. Formation of platelet–leukocyte 
aggregates (far left) in the circulation enhances recruitment of polymorphonuclear cells (and other 
leukocytes) to the endothelial surface. There, platelet and endothelial surface P-selectin bind P-selectin 
glycoprotein ligand-1 (PSGL-1), which is constitutively expressed on the leukocyte surface. This leads to 
margination and rolling of leukocytes, the first step in leukocyte recruitment. P-selectin/PSGL-1 
engagement, via leukocyte signaling pathways, up-regulates integrin adhesion molecule expression on 
leukocytes (not shown), leading to firm adhesion and diapedesis (O` Sullivan & Michelson, 2006). 
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5.1.2. AN IN VITRO MODEL OF LEUKOCYTE TRANSENDOTHELIAL MIGRATION (TEM) 
Boyden (1961) originally described an in vitro assay technique, which uses a chamber 
separated into two compartments by a porous filter membrane to allow the study of 
the chemotactic activity of soluble substances on motile cells. In this assay, the cells 
are seeded on one side of the membrane, while a solution to be tested for chemotactic 
activity is placed on the opposing side. After an incubation period, the membrane is 
fixed and stained. The number of cells which have migrated through the pores to the 
underside of the membrane in response to the chemotactic agent is counted 
microscopically. Antal Rot showed, in fact, cells were migrating in response to 
membrane-bound chemotactic stimulus in the process called haptotaxis (Rot, 1993). 
The Boyden chamber technique subsequently underwent many modifications 
(Richards & McCullough, 1984; Harvath et al, 1980). For example, a membrane insert 
was used to establish two compartments in the wells of 24- or 96-well tissue culture 
plates. Assay options also included coating the membrane with a variety of matrix 
proteins (Eccles et al, 2005). One of them is collagen IV, which is the most abundant in 
basement membrane (Timpl et al, 1979). 
However, new drug discovery methods measure the ability of motile cells to traverse 
physiological barriers, such as endothelium and epithelium (Eccles et al, 2005). A 
growing number of studies on the mechanism of leukocyte transendothelial migration 
and leukocyte-endothelial interactions use ECs grown on microporous filters as an in 
vitro model of endothelium (Mackarel et al, 1999). The transendothelial assay was first 
established by Huber and Weiss (1989). Their data indicated that neutrophil 
extravasation and reversible basement membrane disruption are coordinated events 
that occur as a consequence of vessel wall transmigration. 
ECs line the blood vessels of the entire circulatory system, ranging from the aorta to 
capillaries, and act as the barrier between circulating blood and the rest of the vessel 
wall. While large veins and arteries remain a quick and convenient source of ECs, the 
great morphological, biochemical and functional heterogeneity that ECs express has 
necessitated the development of techniques to isolate microvessel ECs from different 
tissues to create more realistic in vitro models (Hewett & Murray, 1993a).  
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Although, neutrophil migration in CF takes place mainly in bronchial tissue, there is 
some evidence of alveolar CF inflammation (Ulrich et al, 2010). In the pulmonary 
circulation, leukocytes marginate and transmigrate in alveolar capillaries, rather than 
postcapillary venule, as in the bronchial circulation. Many leukocyte-EC interactions 
take place in the pulmonary capillary bed, which generally contain many more 
leukocytes compared to other tissue vascular beds. In fact, the concentration of 
leukocytes in the pulmonary capillary blood is 35 to 100 times more than that of 
systemic vessels (Shepro, 2006). 
Key studies have demonstrated that neutrophilic inflammation is a hallmark of CF lung 
disease. However, the exact mechanism of neutrophilic inflammation remains unclear 
(Tirouvanziam, 2006). Although the genetic basis of CF as well as the molecular 
structure of CFTR have been well defined, a clear relationship between the genetic 
defect and the pulmonary pathophysiology, has not been established (Witko-Sarsat et 
al, 1999). Interestingly, human platelets were found to express a biologically active 
CFTR and thus platelets from CF patients are affected by the molecular defect of CFTR 
(Mattoscio et al, 2010). Therefore, platelets are an important, albeit generally 
underappreciated, component of the inflammatory cascade. Moreover, platelet 
dysfunction in CF could contribute to pulmonary inflammation and tissue destruction 
(O`Sullivan & Michelson, 2006). Therefore, to investigate neutrophil-endothelium-
platelet interaction, a novel cell culture model of transendothelial migration (TEM) of 
neutrophils towards thrombin-activated platelets has been developed. Platelets have 
not previously been used as a source of neutrophil chemoattractant, however they 
were used before in a model of T cell TEM (Shute et al, 2011, abstract). In the current 
model, HLMVEC (Figure 5.2, over) were grown on an uncoated polyethylene 
terephthalate (PET) microporous membrane until confluency over 14 days during, 
which time they are expected to lay down a basement membrane (Huber & Weiss, 
1989). Platelets isolated from healthy donors were activated with a potent platelet 
stimulus, thrombin and added to the lower compartment of the Transwell. Neutrophil 
TEM started when neutrophils isolated from healthy donors were added to the upper 
compartment. After incubation, neutrophils were collected from the lower 
compartment and counted microscopically. The outline of a transwell chamber is 
schematically presented in Figure 5.3 (over).  
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Aminoglycosides are commonly used for the treatment of CF infection, especially 
tobramycin, which has the highest in vitro activity against Pseudomonas aeruginosa 
strains among all aminoglycosides (Laxer et al, 1975). Tobramycin has been suggested 
to have anti-inflammatory properties beyond its anti-pseudomonal effect (Ramsey et 
al, 1999). Additionally, it was shown to effectively inhibit T-cell migration (McGregor et 
al, 2009, abstract). Therefore, the anti-inflammatory effect of tobramycin and copper-
tobramycin, a derivative with antioxidant properties (Chapter 4), was tested in this 
novel neutrophil TEM model.  
 
  Figure 5.2. HLMVEC (400 x).                                  Figure 5.3. The outline of a Transwell.   
 
5.2. HYPOTHESIS, AIMS AND OBJECTIVES 
It was hypothesized that tobramycin and its complex with copper have anti-
inflammatory properties. 
In order to investigate platelet-neutrophil-endothelial cell interactions, an in vitro 
model of neutrophils migrated across TNF-α-stimulated endothelium towards 
thrombin-activated platelets was created. To mimic neutrophilic inflammation in CF, 
CFTRinh-172 was used. A further objective was to test the effect of tobramycin and a 
copper-tobramycin complex on transendothelial migration of neutrophils in the PMN 
TEM model and decipher the mechanism of action of these drugs. 
The aim was to investigate the anti-inflammatory effect of tobramycin and copper-
tobramycin. 
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5.3. MATERIALS  
Multiwell 24-well companion plates and biotin-FITC conjugate were from Becton 
Dickinson Biosciences (Oxford, Oxfordshire, UK) and 3 µM culture inserts (PET) were 
supplied from Marathon Labs Supplies (London, UK). 
Anti-human IL-8 and NAP-2 antigen affinity purified polyclonal antibodies, TNF-α as 
well as human IL-8, PAI-1 and NAP-2 development kit were purchased from Peprotech 
EC (London, UK). DuoSet® ELISA development system for human CCL5/RANTES and 
human ICAM-1/CD54 was from R&D Systems Ltd. (Abingdon, Oxfordshire, UK). PAI-1 
activity assay was from Hyphen BioMed (Neuville-sur-Oise, France). 
Nunc MaxiSorb 96-well ELISA plates and ethylenediaminetetraacetic acid (EDTA) were 
provided by Fisher Scientific (Loughborough, Leicestershire, UK). Superoxide dismutase 
(SOD), catalase, fetal bovine serum (FBS) heat inactivated and Triton-X100 were from 
Sigma Aldrich (Dorset, UK). Complete mini® protease inhibitor (double strength) was 
purchased from Roche Ltd. (Wewlyn Garden City, Hertfordshire, UK). 
Calbiochem/Merck (Nottingham, Nottinghamshire, UK) provided MnTBAP 
(Mn(III)tetrakis(4-benzoic acid)porphyrin chloride), staurosporine from Streptomyces 
sp., XR5118, PAI-1 inhibitor was a gift from Xenova, UK. WEB 2086 was from 
Boehringer Ingelheim Inc. (Bracknell, Berkshire, UK). Plasmin substrate was from 
Chromogenix (Lexington, MA, USA). 
Trevigen Inc. (Helgerman City, Gaithersburg, MD, USA) supplied TACSTM annexin V kit 
and Promega
 
Inc. (Rocky Hill, NJ) supplied Caspase-Glo® 3/7 assay.  
5.4. METHODS 
5.4.1. SUBCULTURING INTO TRANSWELLS 
Polyethylene terephthalate (PET) 3 μM uncoated Transwells cell culture inserts were 
used to grow HLMVEC for transmigration experiments. The inserts were placed in wells 
of 24-well companion plates, containing 800 µl of growth medium underneath. 250 µl 
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of HLMVEC suspension (2 x 105/ml) was added per transwell (5 x 104/well) and topped 
up to 300 µl with growth medium. The plates were covered and incubated at 370C and 
5 % CO2. 
5.4.2.  A   CELL  CULTURE  MODEL  OF  NEUTROPHIL  TRANSENDOTHELIAL   MIGRATION       
            (TEM) 
Primary HLMVEC were cultured in monolayers on PET, 3 μM uncoated Transwells cell 
culture inserts for two weeks to confluency (Figure 5.2 & 5.3). EGM-2MV (300 μl in 
upper well and 800 μl in lower well) was changed every other day.         
Where indicated, HLMVEC were stimulated overnight with 10 ng/ml TNF-α and/or pre-
treated overnight (16 hours) prior to the migration assay with tobramycin, copper-
tobramycin and copper-sulphate at 0.01 – 0.5 mM, catalase (250 U/ml), SOD (500 – 
2000 U/ml) and MnTBAP (1 – 50 µM). The compounds were added to both top and 
bottom compartments at the same concentrations. 
On the day of experiment, full growth medium was removed and replaced with RPMI 
1640 containing 25 mM HEPES and 2 mM L-glutamine supplemented with 2.5 % (v/v) 
FBS.  
Platelets   were    isolated   as previously described in Section 2.4.2, re-suspended in 
RPMI 1640 containing 25 mM HEPES and 2 mM L-glutamine and 2.5 % (v/v) FBS, 
diluted to 1 x 108 cells/ml and applied to the basal compartment of Transwells 
with/without 2 U/ml thrombin or with/without 100 ng/ml LPS for 30 minutes 
preincubation at 370C and 5 % CO2. The volume of platelets in the bottom 
compartment of Transwells was 800 µl (0.8 x 108 cells/well). 
Where indicated, TNF-α, copper chelators and antioxidants were refreshed before the 
experiment. Copper chelators, antioxidants, PAI-1 inhibitor (XR5118) (1, 10, 100 µM) 
anti-IL-8 and anti-NAP-2 (100 µg/ml) were also added to both top and bottom 
compartment for 30 minutes or 16 hours pre-incubation. Where indicated, IL-8 (6.25 x 
10-8 M) was also pre-incubated with endothelial cells in the bottom compartment for 
30 minutes before neutrophils were added to start the migration assay. 
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Neutrophils were isolated as previously described in Section 2.4.1, re-suspended in 
RPMI 1640 containing 25 mM HEPES and 2 mM L-glutamine and 2.5 % (v/v) FBS, 
diluted to 2 x 106 cells/ml and applied to the apical compartment of Transwells. The 
volume PMNs in the top compartment of Transwells was 300 µl (0.66 x106 cells/well). 
Following 3 hours incubation at 370C and 5 % CO2, the plate was placed on ice for 10 
minutes. 80 µl 100 mM EDTA (Sigma, UK) was added to every bottom well, resulting in 
a 10 mM final concentration. The inserts were shaken gently to loosen adherent cells. 
The plate was placed into the incubator for 10 – 15 minutes, followed by another 
gentle shake of the inserts. The apical supernatant was collected into separate 
microcentrifuge tubes and cleared by centrifugation at 900 x g for 10 minutes at 40C. 
HLMVEC on cell culture inserts were washed two times with 200 µl ice-cold PBS (- 
Ca/Mg), followed by cell lysis with 300 µl 1 % (v/v) Triton X-100 containing double 
strength protease inhibitors (Roche). The cell lysates were placed at -800C and were 
subjected to 3 freeze-thaw cycles. Basal supernatants containing migrated neutrophils 
were collected into separate microcentrifuge tubes. The bottom wells were washed 
with 320 µl RMPI 1640 containing 25 mM HEPES and 2 mM L-glutamine and 2.5 % (v/v) 
FBS to wash off any cells left behind and added to the recovered cells (the total volume 
of 1200 µl). Basal supernatants were centrifuged at 450 x g for 10 minutes at 40C. All 
supernatant samples were stored at -800C for further analysis. The remaining cell 
pellets were re-suspended in 100 µl PBS (- Ca/Mg) and diluted 1/10 in Trypan blue. At 
least two aliquots were counted using a haemocytometer. The cell number was 
calculated in two 25-square fields using x 40 microscope magnification and then 
averaged. 
5.4.3. OBTAINING A DOSE RESPONSE CURVE TO TNF-α AND IL-8 IN PMN TEM 
To obtain a dose response curve for TNF-α, HLMVEC were stimulated for 16 hours with 
TNF-α at the final concentration range 1 – 10 ng/ml. For this purpose, TNF-α was 
added to the upper (3 µl/300 µl) and to the lower (8 µl/800 µl) compartment of 
Transwells at 0.1 – 1 µg/ml working concentrations. On the day of experiment, TNF-α 
was refreshed. 
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In another set of experiments, IL-8 in the concentration range 1.25 x 10-9 – 1.25 x      
10-7 M was prepared in RPMI 1640 containing 25 mM HEPES and 2 mM L-glutamine 
and 2.5 % (v/v) FBS and added to the lower compartment for 30 minutes pre-
incubation before starting the experiment. 
5.4.4. SETTING UP A CF MODEL OF PMN TEM USING CFTRinh-172 
CFTRinh-172 was added to the top (3 µl/300 µl) and bottom (8 µl/800 µl) compartment 
of Transwells at 20 µM final concentration prepared from 2 mM working concentration 
6 hours before the overnight addition of TNF-α. It was refreshed 30 minutes before the 
experiment. Thrombin-stimulated platelet and neutrophils were added to appropriate 
compartments as described earlier in Section 5.4.2. 
5.4.5. THROMBIN PLATELET ACTIVATION 
Platelets were isolated according to the procedure shown in Section 2.4.2, re-
suspended in PBS (+ Ca/Mg) and diluted to 2 x 108/ml. 1250 U/ml thrombin stock 
(Sigma) was used to obtain 0.1 – 3 U/ml final concentrations of thrombin by 1/100 
dilution of its working concentration. Platelets were incubated for 30 minutes at 370C 
with or without thrombin stimulation. The material was then centrifuged at 2500 x g 
for 15 minutes at 40C. The supernatant was removed and the cell pellet was lysed in an 
equal volume of 1 % (v/v) Triton X-100 containing double strength protease inhibitor 
(Roche). The supernatant and cell pellets were stored at -800C before ELISA analysis. 
5.4.6. ELISA
  
IL-8, PAI-1 and NAP-2 were measured using human IL-8, PAI-1 and NAP-2 ELISA 
Development Kit (PeproTech), respectively and human CCL5/RANTES and sICAM-1 
were measured by Duo Set ELISA development systems (R&D Systems) according to 
the manufacturer’s instructions. 
5.4.7. PLASMIN ACTIVITY ASSAY 
This assay is based on data in the Chromogenix catalogue. 3 mM plasmin substrate 
stock solution (Chomogenix) was made by dissolving 25 mg in 11.33 ml distilled water. 
Assay buffer was 50 mM TRIS-HCl containing 130 mM NaCl, pH 8.5. Standard enzyme, 
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0.5 mg plasmin from human plasma (Sigma) was dissolved in 0.5 ml assay buffer to the 
concentration of 1 mg/ml. Standards were diluted from the 1 mg/ml stock for the 
assay in the range: 0 – 100 µg/ml using assay buffer. The reaction well of a 96-well 
plate contained: 75 µl of TRIS buffer, pH 8.5, 25 µl standard enzyme/sample and 25 µl 
substrate (0.8 mM final concentration). The reaction was started by the addition of the 
substrate to all wells of the plate, which was incubated at 370C for 30 minutes before 
reading on a Dynex plate reader at 405 nm. 
5.4.8. PMN VIABILITY ASSESSMENT 
A FACS Calibur Immunocytometry System was used to assess neutrophil apoptosis by 
using TACSTM annexin V-biotin apoptosis detection kit (Trevigen) and biotin-FITC 
conjugate (Becton Dickinson Biosciences) (Section 4.4.6). Isolated neutrophils were re-
suspended in RPMI 1640 supplemented with 2.5 % (v/v) FBS and diluted to 5 x 106 
cells/ml. Neutrophils were then challenged with tobramycin, copper-tobramycin and 
copper sulphate (0.01 – 0.5 mM) and SOD (500 – 2000 U/ml), catalase (250 U/ml), 
MnTBAP (1 – 50 µM), XR5118 (1 – 100 µM), TNF-α (10 ng/ml) and CFTRinh-172 (20 
µM) in the total volume of 250 µl for 3.5 hours at 370C. 
5.4.9. HLMVEC VIABILITY ASSESSMENT 
Apoptosis of HLMVEC was assessed using a CytoTox-Glo™ assay and Caspase-Glo® 3/7 
assay (Promega) (Section 3.4.16 and 4.4.19, respectively).  
5.4.10. STATISTICAL ANALYSIS 
Graph Pad Prism 4.0 Software was used to analyse the results. One-way ANOVA with 
Dunnett`s multiple comparison test as a post hoc test was performed on the data. 
Where appropriate, two-tailed unpaired t-test was used. The results were expressed as 
average plus/minus SEM. p<0.05 was the minimum accepted level of significance. 
 
 
197 
 
5.5. RESULTS 
5.5.1. NEUTROPHIL TEM TOWARDS IL-8 ACROSS UNACTIVATED ENDOTHELIUM 
IL-8 in the concentration range 1.25 x 10-9 – 1.25 x 10-7 M added to the lower 
compartment of Transwells attracted PMN to migrate across HLMVEC in a dose-
dependent manner (Figure 5.4). IL-8 in the range 6.25 x 10-9 – 1.25 x 10-7 M induced a 
significant (p<0.01) neutrophil TEM. 6.25 x 10-8 M IL-8 concentration induced the 
highest level of neutrophil migration and 86.65 ± 5.60 % of the neutrophils added to 
the upper chamber migrated. This concentration was therefore chosen as an optimum 
concentration to use in further experiments to test the effect of drugs on TEM of PMN. 
Neutrophil migration was considered in regard to spontaneous migration in the 
absence of added IL-8, which was 5.15 ± 0.49 %. 
 
Figure 5.4. Dose response curve for IL-8 induced neutrophil TEM. Results are presented as neutrophils 
migrated as % of those added to upper well (mean ± SEM, n=4). Data was analysed using one-way 
ANOVA and Dunnett`s multiple comparison test, ** p<0.01. 
5.5.2. NEUTROPHIL TEM ON TNF-α-ACTIVATED ENDOTHELIUM 
There was a low level of spontaneous neutrophil migration, 3.06 ± 1.21 %, across 
unactivated endothelium (Figure 5.5, over). EC stimulated with TNF-α in a 
concentration range of 1 – 10 ng/ml were found to induce a significantly higher PMN 
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TEM compared with the unstimulated control. The neutrophil response was not dose-
dependent and there was no significant difference between the response to any 
concentration of TNF-α tested. The response to 10 ng/ml TNF-α was 27.94 ± 6.18 % 
and 10 ng/ml TNF-α was chosen as an optimum concentration to induce TEM of PMN 
in further drug testing experiments, based on literature values for comparison. 
Additionally, TNF-α (10 ng/ml) was a significantly (p<0.001) weaker stimulus for PMN 
migration across HLMVEC in comparison to IL-8 (6.25 x 10-8 M) (Figure 5.4), 27.94 ± 
6.18 % versus 86.65 ± 5.60 %. 
 
Figure 5.5. Dose response curve for TNF-α-induced neutrophil TEM. Results are presented as neutrophils 
migrated as % of cells added to the upper chamber (mean ± SEM, n=3). Data was analysed using one-
way ANOVA and Dunnett`s multiple comparison test, * p<0.05, ** p<0.01. 
5.5.3.  NEUTROPHIL   TEM   TOWARDS   THROMBIN-ACTIVATED   PLATELETS  THROUGH  
            TNF-α-STIMULATED ENDOTHELIUM COMPARED TO SUBENDOTHELIAL IL-8 
Platelets (1 x 108/ml, 300 µl) added to the top compartment of Transwells did not 
stimulate, but rather inhibited neutrophil TEM, both upon thrombin and LPS 
stimulation in the absence and presence of TNF-α activation of EC (data not shown). 
Neutrophil TEM was observed only when platelets were added to the lower 
compartment (1 x 108/ml, 800 µl) (Figure 5.6, over). A low level of spontaneous 
neutrophil migration (2.03 ± 0.92 %) was observed over monolayers of unactivated EC 
control. The addition of unstimulated platelets induced a non-significant increase to 
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4.90 ± 1.02 %, whereas thrombin (2 U/ml)-activated platelet induced a significant 
(p<0.01) increase in PMN TEM to 10.98 ± 1.76 %, compared to spontaneous PMN 
migration. This increase was due to thrombin acting on the platelets, as thrombin 
alone, acting on EC, did not induce a significant neutrophil TEM.  
Stimulation of endothelial cell layers with TNF-α (10 ng/ml) induced a significant 
(p<0.001) increase in the level of migrating neutrophils to 23.63 ± 3.53 % compared to 
no stimulus control. A similar result was obtained in a previous set of experiments with 
TNF-α at 10 ng/ml (Figure 5.5). The addition of platelets, alone, to the lower 
compartment induced a further significant (p<0.05) increase in neutrophil TEM, 50.25 
± 8.46 %, across TNF-α-stimulated endothelium. Thrombin activation of platelets 
induced a neutrophil response on activated endothelium (74.96 ± 5.71 %) that was not 
significantly different to the response to IL-8 on unactivated EC (86.65 ± 5.6 %). IL-8 is a 
well known and potent neutrophil chemoattractant, therefore the novel contribution 
of platelets to PMN TEM is the subject of this study.  
 
Figure 5.6. The effect of activated platelets on neutrophil transendothelial migration on unactivated and 
TNF-α-activated HLMVEC. Transendothelial migration of neutrophils was measured in response to 
subendothelial platelets to thrombin alone and thrombin-stimulated platelets in the absence or 
presence of TNF-α (10 ng/ml) compared with the response to IL-8 over 3 hours (n≥3). The data is 
expressed as mean ± SEM and was analysed using unpaired two-tailed t-test. * represents comparison 
to control, + represents comparison to TNF-α alone, # represents comparison between bars, * p<0.05, 
** p<0.01, *** p<0.001.
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Since the effect of thrombin on platelet-induced neutrophil TEM across unactivated 
(10.98 ± 1.76 %) or TNF-α-activated (74.96 ± 5.71 %) endothelium was significant, it 
was compared to the effect of LPS activation of platelets on PMN TEM across HLMVEC 
(Figure 5.7). However, platelets activated with LPS (100 ng/ml) did not induce a 
significant effect on neutrophil migration across unactivated endothelium (5.33 ± 2.52 
%), but did (p<0.05) across TNF-α-activated EC (33.51 ± 7.72 %). Moreover, platelets 
activated with LPS induced significantly (p<0.01) smaller neutrophil migration across 
activated HLMVEC than platelets stimulated with thrombin.  
 
Figure 5.7. TEM of neutrophils induced by platelets ± thrombin (2 U/ml) and LPS (100 ng/ml), n≥3. The 
data is expressed as a mean ± SEM and was analysed using unpaired two-tailed t-test. * represents 
comparison to control, + represents comparison to TNF-α, # represents comparison between bars, * 
p<0.05, ** p<0.01, *** p<0.001. 
To investigate further the PMN TEM driving force, IL-8 in both apical and basal 
supernatants was measured in experiments, where platelets were absent or present in 
the basal compartment (Figure 5.8, over). IL-8 is the major neutrophil chemoattractant 
known to be released by activated HLMVEC. Here, IL-8 was mostly detected in the 
basal compartment of Transwells, confirming endothelial polarisation. IL-8 was 
negligible in the absence of TNF-α activation. However, even unactivated platelets 
induced a small, but not significant, increase in IL-8 level in basal supernatant to 
191.79 ± 96.82 pg/ml. The presence of thrombin-activated platelets induced a further 
non-significant increase to 308.11 ± 186.96 pg/ml. LPS was without any effect. TNF-α 
not-significantly stimulated HLMVEC to release IL-8 to the apical (829.47 ± 316.00 
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pg/ml) or to the basal (1957.73 ± 916.98 pg/ml) compartment of the Transwells in 
comparison to the unstimulated control, 1.85 ± 1.85 pg/ml. The addition of platelets in 
the absence of thrombin on TNF-α-stimulated EC did not increase the level of IL-8 in 
the apical or basal supernatant, while the presence of thrombin elicited a significant 
(p<0.05) effect only in the apical supernatant. No further increase with LPS-activated 
platelets on stimulated or unstimulated HLMVEC was observed. The concentration of 
IL-8 in Transwells with TNF-α-activated EC was not significantly higher in the basal 
compartment, because of high data variability between experiments. 
 
Figure 5.8. IL-8 measurement in TEM of neutrophils induced by thrombin- or LPS-activated platelets with 
TNF-α-stimulated or unstimulated HLMVEC. The data is expressed as a mean ± SEM and was analysed 
using two-tailed paired t-test. + indicates p<0.05 compared to TNF-α, where, n=3. 
Because PAI-1 is pro-inflammatory and supports IL-8-driven PMN TEM, the active form 
of PAI-1 was measured in both apical and basal supernatants collected after TEM of 
PMN (Figure 5.9, over). Unlike IL-8, the majority of PAI-1 activity was found in the 
apical compartment. PAI-1 activity released from unactivated EC was higher in the 
apical (0.41 ± 0.13 ng/ml) than the basal (0.04 ± 0.02 ng/ml) compartment, although 
the difference was not significant. The addition of unactivated or thrombin- or LPS-
activated platelets did not affect the level of PAI-1 activity. However, TNF-α induced a 
significant (p<0.01) increase in active PAI-1 release to the apical supernatant, 2.36 ± 
0.30 ng/ml. In the presence of platelets, in the absence or presence of thrombin, a 
non-significant decrease in the apical level of active PAI-1 compared to the TNF-α 
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control was seen. LPS-activated platelets underneath TNF-α-stimulated EC induced a 
further non-significant decrease in PAI-1 activity in apical supernatants compared to 
TNF-α control. The active form of PAI-1 released to the basal supernatant was not 
significantly different to the unactivated control in any condition tested.  
 
Figure 5.9. PAI-1 activity measurement in TEM of neutrophils induced by thrombin- or LPS-activated 
platelets with TNF-α-stimulated or unstimulated HLMVEC. The data is expressed as a mean ± SEM and 
was analysed using two-tailed paired t-test. * represents comparison to control, # represents 
comparison between bars, * p<0.05, ** p<0.01, n=3. 
It was of interest to analyse the role of chemoattractants involved in TEM of PMN 
towards thrombin-activated platelets in the presence of TNF-α. The response was 
normalised in every experiment to 100 % and the effect of antibodies was compared to 
this value. IL-8 was released from TNF-α-activated HLMVEC (Figure 5.8) and NAP-2 is 
one of the main neutrophil chemoattractants found in platelets. Therefore, the effects 
of neutralizing antibodies to IL-8 and NAP-2 were tested (Figure 5.10, over). Neutrophil 
migration was significantly (p<0.05) inhibited by anti-IL-8 (17.15 ± 2.06 %, n=4) and by 
anti-NAP-2 (30.04 ± 5.91 %, n=5). In addition, the anti-IL-8 effect on PMN TEM was not 
statistically different to the effect of anti-NAP-2. However, IL-8 and NAP-2 antibodies 
together inhibited only approximately 50 % of TEM of PMN, indicating a contribution 
of other chemokines, such as ENA-78 or PF-4 or neutrophil attracting lipids such as 
PAF. 
0.0 
0.5 
1.0 
1.5 
2.0 
2.5 
3.0 
3.5 
control plts plts + 
thr 
plts + 
LPS 
control plts plts + 
thr 
plts + 
LPS 
Apical s/n 
Basal s/n 
P
A
I-
1
 a
ct
iv
it
y 
[n
g/
m
l]
 
TNF-α 
** 
# 
## 
## 
203 
 
However, a specific PAF antagonist, WEB2086, used at a final concentration of 10 µM 
was not effective in limiting neutrophil migration across HLMVEC stimulated with TNF-
α towards thrombin-activated platelets, as it reduced the migration only by 8.32 ± 5.77 
%. This result suggests no role of PAF in the tested model of PMN TEM.  
 
Figure 5.10. The effect of anti-IL-8, anti-NAP-2 and PAF antagonist, WEB2086 on neutrophil TEM across 
TNF-α-stimulated HLMVEC towards thrombin-activated platelets. 100 µg/ml of anti-IL-8 and anti-NAP-2 
significantly inhibited TEM of neutrophils in the conditions tested. The data is expressed as a % of 
control, mean ± SEM and was analysed using unpaired two-tailed t-test. * indicates p<0.05. 100 % value 
represents % neutrophils migrated of those in the upper well, 78.64 ± 6.65 %. 
5.5.4. IL-8, NAP-2 AND RANTES RELEASE BY THROMBIN-ACTIVATED PLATELETS 
In order to evaluate the role of platelets in PMN TEM, platelets were activated with a 
range of thrombin concentrations (0.1 – 3 U/ml) for 30 minutes at 370C. The 30 
minutes incubation time reflected the pre-incubation time of platelets with thrombin 
in the neutrophil transmigration experiment. 
Platelets were shown to release very small amounts of IL-8, detected at pg/ml levels 
(Figure 5.11, over). Unactivated platelets released 1.73 ± 0.34 pg/ml IL-8, while 2.91 ± 
0.55 pg/ml IL-8 was still associated with the cell pellet. However, 1, 2 and 2.5 U/ml 
thrombin induced a significant (p<0.01) IL-8 release of 4.74 ± 0.67, 4.81 ± 0.46 and 5.31 
± 0.28 pg/ml IL-8, respectively compared to the unactivated platelets. Thrombin at 3 
U/ml had no significant effect on IL-8 release from platelets. Additionally, reduced 
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levels of IL-8 were measured in association with the cell pellet following thrombin 
stimulation. 1 U/ml thrombin significantly (p<0.01) decreased the level of IL-8 bound 
to the cell pellet to 0.81 ± 0.31 pg/ml in comparison to the untreated control.  
 
 
Figure 5.11. Platelet dose response curve to thrombin, IL-8. A) IL-8 released from platelets in the 
absence and presence of thrombin was measured by ELISA in supernatant. B) IL-8 remaining in the cell 
pellet in the absence and presence of thrombin was measured by ELISA. Results are presented as mean 
± SEM, n=7. ** indicates p<0.01 compared to unstimulated control. 
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Platelets were shown to be a rich source of NAP-2, which was detected in µg/ml levels 
(Figure 5.12). Unactivated platelets released 6.41 ± 4.23 µg/ml of NAP-2, while 9.05 ± 
1.18 µg/ml NAP-2 was still associated with the cell pellet. Thrombin-stimulation 
increased the level of released NAP-2, however only 2 U/ml thrombin concentration 
induced a significant (p<0.05) effect in releasing 18.97 ± 3.13 µg/ml NAP-2 compared 
to the untreated control. A non-significant trend towards a decreasing NAP-2 level in 
the pellet with increasing concentrations of thrombin was also observed. 
 
 
Figure 5.12. Platelet dose response curve to thrombin, NAP-2. A) NAP-2 released from platelets in the 
absence and presence of thrombin was measured by ELISA in supernatant. B) NAP-2 remaining in the 
absence and presence of thrombin was measured by ELISA in cell pellet. Results are presented as mean 
± SEM, n=3. * indicates p<0.05 compared to unstimulated control. 
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Platelets also contained ng/ml concentrations of RANTES (Figure 5.13). Unactivated 
platelets released RANTES (9.16 ± 2.04 ng/ml) into supernatants, but most was 
retained in the cell pellet (19.87 ± 2.92 ng/ml). 1 U/ml thrombin non-significantly 
increased RANTES release, but significantly (P<0.05) decreased cell-associated RANTES. 
2 and 3 U/ml thrombin significantly (p<0.05) increased release of RANTES to 20.85 ± 
4.55 and 20.77 ± 3.69 ng/ml, respectively and significantly (p<0.01) decreased cell 
associated RANTES to 13.44 ± 2.50 and 12.79 ± 2.67 ng/ml, respectively in comparison 
to the appropriate non-activated platelet control. 
 
 
Figure 5.13. Platelet dose response curve to thrombin, RANTES. A) RANTES released from platelets in 
cell pellet in the absence and presence of thrombin was measured by ELISA in supernatant. B) RANTES 
remaining in the absence and presence of thrombin was measured by ELISA. Results are presented as 
mean ± SEM, n=4. * indicates p<0.05 and ** indicates p<0.01 compared to unstimulated control. 
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5.5.5. THE EFFECT OF TOBRAMYCIN AND COPPER-TOBRAMYCIN ON PMN TEM 
One of the main objectives of this thesis was to investigate the anti-inflammatory 
effects of tobramycin. Therefore, tobramycin was tested in models of neutrophil 
transendothelial migration, as this may be a process affected by intravenous 
tobramycin. Tobramycin was tested in three in vitro models of neutrophil migration. 
Firstly, the response of neutrophils to IL-8 added underneath an unactivated 
endothelium, secondly, the response of neutrophils to TNF-α-activated endothelium, 
and thirdly, the response of neutrophils to thrombin-activated platelets underneath a 
TNF-α-activated endothelium. Tobramycin has been shown to bind copper and to have 
SOD-like properties (Chapter 2), therefore the anti-inflammatory properties of copper-
tobramycin were also investigated in the same settings. 
Table 5.3 presents an overview of the results of experiments in which the effect of 
tobramycin and copper-tobramycin in 3 models of PMN TEM was investigated. Only 
statistically significant data is present in the figures that follow. 
The effect of tobramycin and copper-tobramycin were tested in the TEM experiments 
(3 hours) and following pre-treatment of HLMVEC for 30 minutes or 16 hours. 
Stimulus HLMVEC 
activator 
Total time of 
drug 
treatment 
Tobramycin 
(0.01 – 0.5 
mM) 
n Copper-
tobramycin  
(0.01 – 0.5 mM) 
n 
IL-8 - 3.5 h ns 4 ↑* (0.5 mM) 3 
- TNF-α 3.5 h ns 3 ns 4 
Platelets + 
thrombin 
TNF-α 3.5 h ns 3 ns 4 
Platelets + 
thrombin  
TNF-α 19 h ↓** (0.01 
and 0.1 mM) 
5 ↓* (0.5 mM) 5 
 
Table 5.3. The effect of tobramycin and copper-tobramycin on TEM of PMN. ns – non-significant effect; 
↑ - increased cell migration; ↓ - decrease cell migration, * indicates p<0.05; ** indicates p<0.01. 
In the short-term, tobramycin in the concentration range of 0.01 – 0.5 mM had no 
significant effect on neutrophil migration across unstimulated HLMVEC towards IL-8 or 
across TNF-α-stimulated endothelium, in the absence or presence of thrombin-
208 
 
activated platelets. However, pre-treatment of TNF-α-stimulated HLMVEC for 16 hours 
with tobramycin, significantly decreased neutrophil migration towards thrombin-
activated platelets (Figure 5.14). Indeed, tobramycin (0.01 mM) significantly (p<0.01) 
reduced PMN TEM by 23.33 ± 3.63 %. PMN TEM was also significantly (p<0.05) 
reduced by 12.29 ± 5.23 % by 0.1 mM tobramycin treatment compared to an 
untreated control. However, 0.5 mM tobramycin concentration did not have a 
significant effect on TEM of PMN in the conditions tested. 
 
Figure 5.14. The effect of tobramycin pre-treatment for 16 hours of HLMVEC stimulated with 10 ng/ml 
TNF-α on TEM of neutrophils towards thrombin-activated platelets for 3 hours. Results are expressed as 
% of control ± SEM, n=5. The data was analysed using one-way ANOVA and Dunnett`s multiple 
comparison test. 100 % = 74.96 ± 5.71 % neutrophils migrated of those added added to the upper well. 
To understand the mechanisms of tobramycin inhibition of PMN TEM in the conditions 
tested, the levels of IL-8, PAI-1 and sICAM-1 as markers of the inflammatory response 
were measured by ELISA in supernatants from both apical and basal compartments 
collected after each experiment, n=5. 
There were significantly higher levels of IL-8 measured in the basal supernatants 
compared to the apical ones (Figure 5.15, over). The control apical IL-8 concentration 
was 1.48 ± 0.25 ng/ml, while the control basal supernatant contained 3.88 ± 0.96 
ng/ml IL-8. However, tobramycin had no significant effect on IL-8 concentration at any 
dose tested.  
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Figure 5.15. IL-8 measurement in supernatants from PMN TEM across TNF-α-stimulated HLMVEC 
towards thrombin-activated platelets following tobramycin pre-treatment for 16 hours. Results are 
expressed as mean ± SEM, n=5. The data was analysed using one-way ANOVA and Dunnett`s multiple 
comparison test and paired two-tailed t-test to compare IL-8 level in apical versus basal supernatant. # 
indicates p<0.05 and ## indicates p<0.01 as a comparison between apical and basal supernatant IL-8 
values. 
The total PAI-1 was measured and, unlike active PAI-1 (Figure 5.9), was found to be in 
greater concentration in basal compartments. The total PAI-1 concentration in the 
apical Transwell compartment of the control was 11.47 ± 2.68 ng/ml when thrombin-
activated platelets were present underneath the TNF-α-stimulated HLMVEC (Figure 
5.16, over). In comparison, the active form of PAI-1 in the apical supernatant for the 
same condition was 1.75 ± 0.34 ng/ml (Figure 5.9), suggesting that the major part of 
PAI-1 was inactive. PAI-1 in the apical supernatant of the control was significantly 
(p<0.001) lower than in the basal compartment, which was 45.47 ± 3.50 ng/ml (Figure 
5.16). Under the same conditions, the active form of PAI-1 in the basal compartment 
was only 0.62 ± 0.14 ng/ml (Figure 5.9). Tobramycin pre-treatment for 16 hours did not 
change the level of total PAI-1 in apical supernatants. However, tobramycin (0.01 mM 
and 0.5 mM) significantly decreased the total PAI-1 in the basal supernatants 
compared to the untreated control to 25.52 ± 3.80 ng/ml (p<0.05) and 21.49 ± 7.36 
ng/ml (p<0.01), respectively. Although, 0.1 mM tobramycin reduced the total PAI-1 in 
the basal supernatant, the effect was non significant. 
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Figure 5.16. Measurement of PAI-1 in PMN TEM across TNF-α-stimulated HLMVEC towards thrombin-
activated platelets in the presence of tobramycin treatment for 16 hours. Results are expressed as mean 
± SEM, n=5. The data was analysed using one-way ANOVA and Dunnett`s multiple comparison test and 
paired two-tailed t-test to compare IL-8 level in apical versus basal supernatant. * represents 
comparison with untreated control, # represents comparison between the apical and basal supernatant. 
* indicates p<0.05 and ** indicates p<0.01. 
ICAM-1 is shed during HLMVEC activation and neutrophil migration and therefore 
soluble ICAM-1 was measured in supernatants. Figure 5.17 presents the level of 
sICAM-1 measured in both apical and basal supernatants from the same experiments.  
 
Figure 5.17. sICAM-1 measurement in PMN TEM across TNF-α-stimutaled HLMVEC towards thrombin-
activated platelets following tobramycin pre-treatment for 16 hours. Results are expressed as mean ± 
SEM, n=5. The data was analysed using one-way ANOVA and Dunnett`s multiple comparison test and 
paired two-tailed t-test to compare IL-8 level in apical versus basal supernatant. # indicates p<0.05 and 
## indicates p<0.05 as compared between the apical and basal supernatant.  
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For the control, this was 769.55 ± 137.10 pg/ml in the apical and 1870.73 ± 314.08 
pg/ml in the basal compartment. Moreover, sICAM-1 was significantly (p<0.05 or 
p<0.01) lower in the apical supernatant compared to the basal supernatant, not only 
for the untreated control, but also for tobramycin-treated samples. sICAM-1 
concentration was significantly (p<0.05) decreased in the apical supernatant after 
addition of 0.5 mM tobramycin compared to the sICAM-1 concentration in untreated 
control. Tobramycin-treatment did not affect sICAM-1 level in the basal supernatants, 
however at 0.1 mM it showed a tendency to lower sICAM-1, which may reflect the 
inhibitory effect of tobramycin on PMN TEM. 
Since tobramycin binds copper, which is elevated in the blood and sputum in CF (Gray 
et al, 2010; Percival et al, 1999), it is conceivable that tobramycin binds copper 
spontaneously to form a copper-tobramycin complex. Therefore, the anti-
inflammatory effect of copper-tobramycin was tested in all 3 in vitro models of 
neutrophil migration. 
Interestingly, copper-tobramycin present with HLMVEC for 3.5 hours demonstrated a 
tendency to inhibit TEM of PMN. 0.5 mM copper-tobramycin concentration reduced 
neutrophil migration by 19.05 ± 7.6 %, however this effect was not statistically 
significant (Figure 5.18, over). This effect became significant when copper-tobramycin 
was added to HLMVEC 0.5 hour before TNF-α and then each drug was present for 16 
hours before TEM. Indeed, 0.5 mM copper-tobramycin concentration significantly 
(p<0.05) reduced neutrophil migration by 33.78 ± 10.37 % in comparison to the 
untreated control in the conditions tested. 
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Figure 5.18. Copper-tobramycin (0.01 – 0.5 mM) effect on neutrophil TEM in the presence of 1 x 10
8
 
platelets/ml stimulated with 2 U/ml thrombin across EC stimulated with 10 ng/ml TNF-α. A) Copper-
tobramycin was present for 3.5 hours, n=4. B) Copper-tobramycin was present overnight and was added 
0.5 hour before TNF-α, n=5. Results are presented as % of control ± SEM. * indicates p<0.05 compared 
to unstimulated control. 100 % = 74.96 ± 5.71 % cells migrated of those added to the upper well. 
 
Again, IL-8, PAI-1 and sICAM-1 concentrations were measured in apical and basal 
supernatants from the above experiments, n=5.  
IL-8 was detected in the apical supernatants of control well at 1.04 ± 0.10 ng/ml and 
0.5 mM copper-tobramycin induced a small, but significant (p<0.05) increase in IL-8 
level to 1.22 ± 0.13 ng/ml, compared to the untreated control (Figure 5.19, over). The 
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control basal supernatant contained 2.23 ± 0.61 ng/ml IL-8, which was not statistically 
different with copper-tobramycin treatment. 
 
Figure 5.19. IL-8 concentration in PMN TEM across TNF-α-stimulated HLMVEC towards subendothelial 
thrombin-activated platelets in the presence of copper-tobramycin. Results are expressed as mean ± 
SEM, n=5. The data was analysed using one-way ANOVA and Dunnett`s multiple comparison test and 
paired two-tailed t-test to compare IL-8 level in apical versus basal supernatant. * indicates p<0.05. 
The PAI-1 concentration in the apical supernatant of control experiment was 9.05 ± 
1.31 ng/ml, while significantly higher levels were measured in the basal supernatant 
was 37.65 ±4.21 ng/ml (Figure 5.20, over). However, the drug treatment did not affect 
the amount of total PAI-1 level in the basal supernatant. 
The level of sICAM-1 measured in the apical and basal compartment of control wells 
was 534.42 ± 141.68 pg/ml and 1382.13 ± 359.04 pg/ml, respectively and drug 
treatment did not influence these values, however it tended to decrease in basal 
supernatant (Figure 5.21, over), possibly reflecting the decrease in neutrophil TEM 
under these conditions. 
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Figure 5.20. PAI-1 concentration in PMN TEM across TNF-α-stimulated HLMVEC towards subendothelial 
thrombin-activated platelets in the presence of copper-tobramycin. Results are expressed as mean ± 
SEM, n=5. The data was analysed using one-way ANOVA and Dunnett`s multiple comparison test and 
paired two-tailed t-test to compare IL-8 level in apical versus basal supernatant. ## - p<0.01 and ### - 
p<0.001. 
 
Figure 5.21. sICAM-1 level in PMN TEM across TNF-α-stimulated HLMVEC towards subendothelial 
thrombin-activated platelets in the presence of copper-tobramycin. Results are expressed as mean ± 
SEM, n=5. The data was analysed using one-way ANOVA and Dunnett`s multiple comparison test and 
paired two-tailed t-test to compare IL-8 level in apical versus basal supernatant.
 
Tobramycin had no effect on neutrophil TEM towards subepithelial IL-8 (Figure 5.22A, 
over). Unlike the effect on neutrophil TEM across TNF-α-stimulated endothelium 
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opposite, stimulatory effect on neutrophil TEM with recombinant IL-8 as the 
chemoattractant, (Figure 5.22B). Indeed, when IL-8 was the chemoattractant, a short-
term exposure to copper-tobramycin (0.5 mM) induced a significant (p<0.05) increase 
in TEM of neutrophils to 116.79 ± 6.02 %. It suggests that all neutrophils have migrated 
from the upper to the lower compartment of the Transwells. 
 
 
Figure 5.22. The effect of tobramycin and copper-tobramycin (0.01 – 0.5 mM) on PMN TEM across 
unstimulated HLMVEC towards IL-8. A) The effect of tobramycin, n=4. B) The effect of copper-
tobramycin, n=3. Results are presented as % of control ± SEM. The data was analysed in comparison to 
the untreated control. 100 % = 86.65 ± 5.60 % of cells added to the apical compartment that migrated to 
the lower compartment. 
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To understand the mechanism of the effect of copper-tobramycin on neutrophil 
migration towards subendothelial IL-8, the levels of IL-8, PAI-1, sICAM-1 and plasmin 
activity were measured in apical and basal supernatants of the above experiments, 
n=3. 
IL-8 in control apical and basal supernatant was 6.80 ± 0.32 ng/ml and 490.76 ± 21.74 
ng/ml, respectively (Figure 5.23), reflecting the addition of IL-8 to the basal 
compartment. IL-8 levels were unchanged in either apical or basal supernatant after 
3.5 hour incubation with a range of copper-tobramycin (0.01 – 0.5 mM). 
 
Figure 5.23. IL-8 measurement in PMN TEM towards subendothelial IL-8 in the presence of copper-
tobramycin. Results are expressed as mean ± SEM, n=3. The data was analysed using one-way ANOVA 
and Dunnett`s post hoc test and paired two-tailed t-test to compare IL-8 level in apical versus basal 
supernatant. # indicates p<0.05 and ## indicates p<0.01. 
The level of control PAI-1 was  4.02 ± 1.42 ng/ml in apical supernatant and 6.32 ± 1.30 
ng/ml in basal supernatant (Figure 5.24, over) and the concentrations were not 
significantly different in the presence of copper-tobramycin (0.01 – 0.5 mM). 
In parallel with the lack of effect of copper-tobramycin on PAI-1 levels, plasmin activity 
was also not statistically different upon copper-tobramycin treatment compared to 
control values of plasmin in apical and basal supernatants (Figure 25, over). The values 
were 1.09 ± 0.08 µg/ml and 0.99 ± 0.6 µg/ml, respectively.
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Figure 5.24. Total PAI-1 level in PMN TEM towards subendothelial IL-8 in the presence of copper-
tobramycin. Results are expressed as mean ± SEM, n=3. The data was analysed using one-way ANOVA 
and Dunnett`s multiple comparison test and paired two-tailed t-test to compare IL-8 level in apical 
versus basal supernatant. 
 
Figure 5.25. Plasmin activity in PMN TEM towards subendothelial IL-8 in the presence of copper-
tobramycin. Results are expressed as mean ± SEM, n=5. The data was analysed using one-way ANOVA 
and Dunnett`s multiple comparison test and paired two-tailed t-test to compare IL-8 level in apical 
versus basal supernatant. 
The level of sICAM-1 was also measured in apical and basal supernatants (Figure 5.26, 
over). The apical supernatant from control wells contained 26.64 ± 13.33 pg/ml sICAM-
1. This level was unchanged in the presence of copper-tobramycin (0.01 – 0.5 mM). 
The sICAM-1 in the basal supernatant of the control was 27.93 ± 15.69 pg/ml and both 
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0.1 and 0.5 mM copper-tobramycin increased sICAM-1 level more than 5 times and 
p=0.08 for 0.5 mM copper-tobramycin (162.57 ± 44.48 pg/ml), possibly reflecting the 
increase in TEM under these conditions with IL-8 as the chemoattractant. 
 
Figure 5.26. sICAM-1 level in PMN TEM towards subendothelial IL-8 in the presence of copper-
tobramycin. Results are expressed as mean ± SEM, n=3. The data was analysed using one-way ANOVA 
and Dunnett`s multiple comparison test and paired two-tailed t-test to compare IL-8 level in apical 
versus basal supernatant. 
5.5.6. THE EFFECT OF CATALASE AND SOD ON NEUTROPHIL TEM 
Since tobramycin and copper-tobramycin inhibited TEM without effects on IL-8, PAI-1 
or ICAM-1, an effect on ROS production either by migrating cells or EC was 
hypothesized. Copper-tobramycin was previously shown to have SOD-like activity 
without catalase activity in the range of concentration 0.01 – 0.5 mM (Section 2.2.4). 
To understand the effect of copper-tobramycin on PMN TEM across TNF-α-stimulated 
HLMVEC towards thrombin-activated platelets, SOD alone and in the presence of 
catalase was tested in this model (Figure 5.27, over). SOD in the range 500 – 2000 U/ml 
clearly had no effect on TEM of PMN across TNF-α-stimulated HLMVEC across platelets 
activated by thrombin, and neither did catalase alone at 250 U/ml. Also SOD alone was 
not effective in TEM of PMN when IL-8 was added underneath (n=3) or across TNF-α-
activated HLMVEC (n=5) (results not shown). However, 2000 U/ml SOD in combination 
with 250 U/ml catalase induced a significant (p<0.05) decrease in the level of migrating 
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neutrophils by 25.73 ± 11.00 % compared to untreated control. This effect was 
dependent not solely on SOD. It had to be due to a combination of SOD and catalase 
activities, that can be found in the Mn(III)tetrakis(4-benzoic acid)porphyrin chloride 
(MnTBAP) complex. 
 
 
Figure 5.27. The effect of SOD in the absence and presence of catalase on PMN TEM across HLMVEC 
stimulated with 10 ng/ml TNF-α towards thrombin-activated platelets. A) The effect of SOD alone (500 – 
2000 U/ml), n=3. B) The effect of SOD in the presence of 250 U/ml catalase, n=4. Results are 
represented as % of control ± SEM, n=5. The data was analysed using one-way ANOVA and Dunnett`s 
multiple comparision test. 100 % = 74.96 ± 5.71 % cells migrated of those added to the upper well. 
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5.5.7. THE EFFECT OF MnTBAP ON TEM OF NEUTROPHILS 
MnTBAP is a cell permeable SOD mimetic, which also has catalase activity. MnTBAP 
was used in the following range of concentrations, 1 – 50 µM in the model of PMN 
TEM, where neutrophils migrated towards thrombin-activated platelets in the 
presence of TNF-α (Figure 5.28).  
 
 
Figure 5.28. The effect of MnTBAP (1 – 50 µM) on neutrophil TEM across TNF-α-stimulated endothelium 
towards thrombin-activated platelets. A) MnTBAP was present on HLMVEC for 3.5 hours, n=3. B) 
MnTBAP was added to the upper and lower compartment of Transwells 0.5 hour before the addition of 
TNF-α and was present overnight, n=3. The data is expressed as a % of a control ± SEM and were 
analysed using one-way ANOVA and Dunnett`s as a post hoc test. * indicates p<0.05. 100 % = 74.96 ± 
5.71 % cells migrated of those added to the upper well. 
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MnTBAP (50 µM) present with TNF-α-stimulated HLMVEC for 3.5 hours significantly 
(p<0.05) reduced PMN TEM by 43.46 ± 15.32 % towards thrombin-activated platelets 
(A). Additionally, when MnTBAP was present overnight (B), 50 µM MnTBAP also 
significantly (p<0.05) reduced PMN TEM by 37.37 ± 5.68 %. 
The level of IL-8, PAI-1, sICAM-1 was measured in both apical and basal supernatant 
collected from PMN TEM in presence of MnTBAP for 16 hours to understand the 
mechanism of inhibition of neutrophil migration through EC in presence of 50 µM 
MnTBAP. 
The level of IL-8 found in the control apical and basal compartment of Transwells was 
1.28 ± 0.92 ng/ml and 1.33 ± 0.41 pg/ml, respectively (Figure 5.29). IL-8 concentration 
tended to decrease in a dose-dependent manner with increasing concentrations of 
MnTBAP, although this effect was not statistically significant. 
 
Figure 5.29. IL-8 level in PMN TEM across TNF-α-stimulated HLMVEC towards subendothelial thrombin-
activated platelets in the presence of MnTBAP. Results are expressed as mean ± SEM, n=3. The data was 
analysed using one-way ANOVA and Dunnett`s multiple comparison test and paired two-tailed t-test to 
compare IL-8 level in apical versus basal supernatant. 
PAI-1 concentration in the apical supernatant of the control well was 3.69 ± 0.81 
ng/ml. PAI-1 level was significantly (p<0.01 and p<0.05) increased in the apical 
supernatant by incubation with 1 and 10 µM MnTBAP to 6.41 ± 0.29 ng/ml and 5.49 ± 
0.34 ng/ml, respectively, but not significantly increased with 50 µM MnTBAP 
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treatment (Figure 5.30). In the basal supernatant of control wells PAI-1 was 18.76 ± 
1.97 ng/ml and was unchanged upon incubation with MnTBAP. Moreover, the amount 
of PAI-1 measured in apical supernatant was significantly (p<0.05 or p<0.01) lower 
compared to PAI-1 concentration in basal supernatant. 
 
Figure 5.30. PAI-1 level in PMN TEM across TNF-α-stimulated HLMVEC towards subendothelial 
thrombin-activated platelets in the presence of MnTBAP. Results are expressed as mean ± SEM, n=3. 
The data was analysed using one-way ANOVA and Dunnett`s post hoc test and paired two-tailed t-test 
to compare IL-8 level in apical versus basal supernatant. # - p<0.05 and ## - p<0.01. 
In control wells the level of sICAM-1 was 485.74 ± 156.19 and 1511.09 ± 302.15 pg/ml 
in apical and basal Transwell compartment, respectively (Figure 5.31, over).  
MnTBAP at 50 µM significantly (p<0.05) increased sICAM-1 concentration in apical 
supernatant, while MnTBAP at 10 µM significantly (p<0.05) decreased sICAM-1 
concentration in the basal supernatant compared to the untreated control. Moreover, 
significantly (p<0.05) more sICAM-1 was detected in basal than in apical supernatant in 
the untreated control and following 50 µM MnTBAP treatment. 
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Figure 5.31. sICAM-1 level in PMN TEM across TNF-α-stimulated HLMVEC towards subendothelial 
thrombin-activated platelets in the presence of MnTBAP. Results are expressed as mean ± SEM, n=3. 
The data was analysed using one-way ANOVA and Dunnett`s post hoc test and paired two-tailed t-test 
to compare IL-8 level in apical versus basal supernatant. * and # indicates p<0.05. 
5.5.8. THE EFFECT OF COPPER SULPHATE ON TEM OF NEUTROPHILS 
To test whether the effect of copper-tobramycin on PMN TEM was due to copper, 
CuSO4 was tested in the same way as copper-tobramycin. Copper-tobramycin 
increased the level of neutrophils migrated towards subendothelial IL-8 (Figure 5.22), 
but there was no effect of copper sulphate in the same concentration range (0.01 – 0.5 
mM) (Figure 5.32, over). Also, no effect of copper sulphate was observed on PMN 
migration across the layer of TNF-α-stimulated ECs towards platelets activated with 
thrombin (Figure 5.33, over), in comparison to copper-tobramycin (0.01 – 0.5 mM) 
(Figure 5.18). 
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Figure 5.32. The effect of copper sulphate on neutrophil TEM towards subendothelial IL-8. The results 
are expressed as % of control ± SEM. The data was analysed in comparison to the untreated control, 
n=4. 100 % = 86.65 ± 5.60 % cells migrated of those added to the upper well. 
 
 
Figure 5.33. The effect of copper sulphate on neutrophil TEM on TNF-α-stimulated HLMVEC towards 
thrombin-activated platelets. The data is expressed as a % of a control and was analysed in comparison 
to the untreated control, n=5. 100 % = 74.96 ± 5.71 % cells migrated of those added to the upper well. 
5.5.9. THE EFFECT OF PAI-1 INHIBITOR (XR5118) ON TEM OF NEUTROPHILS 
PAI-1 inhibitor, XR5118, was used to investigate the role of PAI-1 in TEM of PMN in the 
presence of TNF-α and activated platelets. XR5118 (100 µM) induced a significant 
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(p<0.01) inhibition of cell migration by 72.00 ± 10.90 %, while lower XR5118 
concentrations (1 and 10 µM) had no effect (Figure 5.34).  
 
Figure 5.34. XR5118 effect on neutrophil TEM in response to platelet activated with thrombin across 
stimulated EC. Results are presented as mean ± SEM. ** indicates p<0.01 compared to unstimulated 
control, n=4. 100 % = 74.96 ± 5.71 % neutrophils migrated of those added to the upper well. ** - p<0.01. 
5.5.10. THE EFFECT OF CFTRinh-172 ON NEUTROPHIL TRANSENDOTHELIAL MIGRATION 
As a new in vitro model of neutrophil transendothelial migration across TNF-α-
stimulated endothelial cell layer towards thrombin-activated platetets was established, 
it was of interest to examine the role of CFTR, using the CFTR inhibitor, CFTRinh-172 to 
mimic vascular inflammation in CF.  
In order to set up an in vitro CF model of PMN TEM, the effect of pre-treatment with 
CFTRinh-172 (20 µM) for 20 hours was tested on neutrophil migration in the absence 
of any stimuli or with platelets (1 x 108/ml) activated with thrombin, with or without 
endothelial stimulation of HLMVEC with TNF-α (10 ng/ml) or subendothelial IL-8 (6.25 
x 10 -8 M) (Figure 5.35, over).  
In experiments where the CFTR inhibitor was tested (Figure 5.35, over), the neutrophil 
response in control wells in the absence of inhibitor (A) was similar to that reported in 
previous experiments (Figure 5.6). The spontaneous response of PMN across 
unactivated EC was the same in the absence (A) or presence (B) of the inhibitor. 
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CFTRinh-172 did not have a significant effect on PMN TEM. However, CFTRinh-172 
significantly (p<0.05) decreased PMN TEM across unactivated HLMVEC in the presence 
of platelets activated with thrombin from 11.15 ± 2.71 % to 2.92 ± 0.92 %. Moreover, 
the significantly increased neutrophil response to thrombin-activated platelets 
compared to TNF-α-activated endothelium alone (A) was not seen in the presence of 
CFTRinh-172 (B). 
 
 
Figure 5.35. The effect of CFTRinh-172 on neutrophil transendothelial migration. A) PMN TEM in the 
absence of CFTRinh-172. B) PMN TEM in the presence of 20 µM CFTRinh-172. The results are presented 
as an average % of migrating neutrophils ± SEM and analysed by comparison to the appropriate 
experiment control and by using paired, two-tailed t-test, n=4. * is comparing to the control and # is 
comparing ± CFTRinh-172 under the same conditions. * - p<0.05 and ** p<0.01. 
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To understand why CFTRinh-172 did not cause the expected pro-inflammatory profile 
of CF endothelium with increased PMN TEM, the cytokine level in both apical and basal 
supernatant was measured.  
Figure 5.36 (over) presents the apical IL-8 concentration from the above experiment in 
the absence (A) and presence (B) of CFTRinh-172. A low level of IL-8 measured in the 
apical supernatant of the untreated control was significantly increased to 2.86 ± 0.73 
ng/ml in the presence of subendothelial thrombin-activated platelets plus TNF-α 
(p<0.05) or IL-8, 3.30 ± 1.40 ng/ml (p<0.05). The addition of CFTRinh-172 significantly 
(p<0.05) increased apical IL-8 levels only in the presence of thrombin-activated 
platelets plus TNF-α. There was no statistically significant difference in IL-8 
concentration measured in the apical supernatant in the absence versus the presence 
of CFTRinh-172. 
 
The basal IL-8 concentration in the absence (A) and presence (B) of CFTRinh-172 is 
shown in Figure 5.37 (page 229). IL-8 levels detected in the basal compartment was 
much higher than IL-8 in the apical compartment, but not significantly different. IL-8 
detected in the basal compartment of Transwells containing already approximately 
7500 ng/ml IL-8 added as a neutrophil chemoattractant, was significantly (p<0.01) 
higher compared to the untreated control both in the absence and presence of the 
CFTRinh-172, 5704.14 ± 1367.95 ng/ml and 8792.78 ± 3369.87 ng/ml, respectively and 
not significantly different between each other. When thrombin-activated platelets 
were present on unactivated endothelium, IL-8 was significantly lower in the presence 
of the inhibitor. 
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Figure 5.36. The level of IL-8 in neutrophil transendothelial migration in the absence and presence of 
CFTRinh-172 measured in apical supernatants. A) IL-8 level in PMN TEM upon different conditions. B) IL-
8 level in PMN TEM upon different conditions in the presence of 20 µM CFTRinh-172. The results are 
expressed as a mean ± SEM and analysed by comparing to appropriate untreated experiment control 
and by using paired, two-tailed t-test, n=4. * indicated p<0.05 and ** indicates p<0.01. 
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Figure 5.37. The level of IL-8 on neutrophil transendothelial migration in the absence and presence of 
CFTRinh-172 measured in basal supernatants. A) IL-8 level in PMN TEM upon different conditions. B) IL-8 
level in PMN TEM upon different conditions in the presence of 20 µM CFTRinh-172. The results are 
expressed as a mean ± SEM and analysed by comparison to appropriate untreated experiment control 
and by using paired, two-tailed t-test, n=4. 
Also, total PAI-1 levels were measured in the apical and basal compartments of 
Transwells in the absence and presence of the CFTRinh-172. Additionally, PAI-1 was 
measured in endothelial cell pellets collected after each of 4 experiments. 
PAI-1 detected in the apical supernatant from PMN TEM did not differ significantly 
from apical PAI-1 level in the presence of CFTRinh-172 in PMN TEM with one exception 
(Figure 5.38, over). Under TNF-α-activation of HLMVEC and in the presence of 
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platelets, the PAI-1 level was significantly (p<0.05) lower in the presence of CFTRinh-
172, 31.20 ± 6.93 ng/ml versus 36.59 ± 7.62 ng/ml, while in the absence of platelets 
the p value was 0.067. 
 
 
Figure 5.38. The level of PAI-1 on neutrophil transendothelial migration in the absence and presence of 
CFTRinh-172 measured in apical supernatants. A) PAI-1 in PMN TEM upon different conditions. B) PAI-1 
in PMN TEM upon different conditions in the presence of 20 µM CFTRinh-172. The results are expressed 
as a mean ± SEM and analysed by comparison to appropriate untreated experiment control and by using 
paired, two-tailed t-test, n=4. * represents comparison to control and # is comparing ± CFTRinh-172 
under the same conditions. * indicates p<0.05. 
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significant difference between PAI-1 detected in the basal supernatant in the absence 
and presence of CFTRinh-172 (Figure 5.39). 
i 
 
i 
 
Figure 5.39. The level of PAI-1 on neutrophil transendothelial migration in the absence and presence of 
CFTRinh-172 measured in basal supernatants. A) PAI-1 in PMN TEM upon different conditions. B) PAI-1 
in PMN TEM upon different conditions in the presence of 20 µM CFTRinh-172. The results are expressed 
as a mean ± SEM and analysed by comparison to appropriate untreated experiment control and by using 
paired, two-tailed t-test, n=4. 
 
 
Moreover, the absence and presence of CFTRinh-172 did not show any statistically 
significant difference in PAI-1 measured in endothelial cell pellets (Figure 5.40, over). 
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Figure 5.40. The effect of PAI-1 on neutrophil transendothelial migration in the absence and presence of 
CFTRinh-172 measured in endothelial cell pellets. A) PAI-1 in PMN TEM upon different conditions. B) 
PAI-1 in PMN TEM upon different conditions in the presence of 20 µM CFTRinh-172. The results are 
expressed as a mean ± SEM and analysed by comparison to appropriate untreated experiment control 
and by using paired, two-tailed t-test, n=4. 
Plasmin activity was measured in the apical supernatant of PMN TEM in the absence 
and presence of CFTRinh-172 (Figure 5.41, over). The untreated control had                        
1.31 ± 0.08 µg/ml and 1.50 ± 0.13 µg/ml plasmin, depending on the absence or 
presence of the inhibitor, respectively. The plasmin activity was higher in the apical 
supernatant upon CFTRinh-72 treatment and reached significance (p<0.05) in the case 
of thrombin-activated platelets, platelets in the presence of TNF-α and subendothelial 
IL-8 as neutrophil chemoattractant.  
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Figure 5.41. The plasmin activity in neutrophil TEM in the absence and presence of CFTRinh-172 
measured in apical supernatants. A) Plasmin activity in PMN TEM upon different conditions. B) Plasmin 
activity in PMN TEM upon different conditions in the presence of 20 µM CFTRinh-172. The results are 
expressed as a mean ± SEM and analysed by using unpaired two-tailed t-test, n=4. 
 
 
There was approximately 5 times more plasmin activity detected in basal Transwell 
compartment than apical compartment (Figure 5.42, over). Plasmin activity in the 
basal control supernatant was 5.44 ± 1.45 µg/ml and this activity was significantly 
(p<0.01) increased in PMN TEM towards thrombin-activated platelets across TNF-α 
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CFTRinh-172 enhanced plasmin activity in the basal control supernatant to 7.39 ± 1.79 
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µg/ml, which was significantly (p<0.05 and 0<0.01) increased with thrombin-activated 
platelets on unstimulated or stimulated endothelium 9.90 ± 2.05 µg/ml or 11.17 ± 1.03 
µg/ml, respectively, in comparison to the untreated control.  
i 
 
i 
 
Figure 5.42. The effect of plasmin on neutrophil transendothelial migration in the absence and presence 
of CFTRinh-172 measured in basal supernatants. A) Plasmin in PMN TEM upon different conditions. B) 
Plasmin in PMN TEM upon different conditions in the presence of 20 µM CFTRinh-172. The results are 
expressed as a mean ± SEM and analysed by using unpaired two-tailed t-test, n=4. 
Interestingly, plasmin activity detected in the basal supernatant upon CFTRinh-172-
treatment was statistically (p<0.05) higher in the untreated control, platelets plus TNF-
α, thrombin-activated platelets in the presence of TNF-α and subendothelial IL-8, than 
in the absence of this inhibitor. 
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In addition, correlations between the measured parameters were assessed in the 
previous experiments (Figure 5.35 – 5.42). Only significant correlations are presented 
in the graphs below. There was a significant (p=0.0002 and p=0.0391) correlation 
found between the level of both IL-8 and PAI-1 detected in basal supernatants of PMN 
TEM and the percentage of neutrophils migrated through HLMVEC (R2=0.8293 and 
R2=0.4314, respectively) (Figure 5.43 and 5.44).  
 
Figure 5.43. The correlation between a percentage of migrated neutrophils and IL-8 level detected in the 
basal supernatant of PMN TEM. 
 
Figure 5.44. The correlation between a percentage of migrated neutrophils and PAI-1 level detected in 
the basal supernatant of PMN TEM. 
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A significant positive correlation was also found between plasmin activity in the apical 
supernatants versus the percentage of PMN migrated transendothelially, IL-8 and    
PAI-1 levels measured in the basal compartments (results not shown). 
Additionally, Figure 5.45 presents a significant (p=0.0420) correlation between the 
level of basal IL-8 and PAI-1, where R2 equal 0.4223.  
 
Figure 5.45. The correlation between IL-8 and PAI-1 level measured in the basal supernatant of PMN 
TEM. 
5.5.11. VIABILITY OF NEUTROPHILS 
The cytotoxic effect of drugs on neutrophil viability was tested in separate 
experiments, in which freshly isolated neutrophils were exposed to the drugs for 3.5 
hours to mimic the effect of the drugs in TEM experiments. The viability of neutrophils 
was examined by annexin V-biotin assay and measured by flow cytometry. This 
technique allows analysis of neutrophil populations into 3 groups, such as necrotic, 
apoptotic and live cells. Every experiment had its own control of untreated neutrophils 
for comparison with drug-treated cellls. The assay was done once in triplicate or three 
times in single measurements, as indicated on the graphs.  
The following drugs were incubated with freshly isolated neutrophils for 3.5 hours in 
RPMI 1640 supplemented with 2.5 % (v/v) FBS medium for TEM experiments: 
tobramycin, copper-tobramycin and copper-sulphate (0.01 – 0.5 mM), SOD (500 – 
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2000 U/ml), catalase (250 U/ml), MnTBAP (1 – 50 µM), PAI-1 inhibitor, XR5118 (1 – 100 
µM) and CFTRinh-172 (20 µM).  
Tobramycin (Figure 5.46), copper-tobramycin (Figure 5.47) and copper sulphate (Figure 
5.48, over) were shown to be non-toxic for neutrophils in the conditions tested. 
 
Figure 5.46. Viability of neutrophils in 3.5 hours in RPMI 1640 + 2.5 % (v/v) FBS with tobramycin 
treatment (0.01 - 0.5 mM), n=1, in triplicate. 
 
Figure 5.47. Viability of neutrophils in 3.5 hours in RPMI 1640 + 2.5 % (v/v) FBS in the presence of 
copper-tobramycin (0.01 – 0.5 mM), n=3, independent experiments. 
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Figure 5.48. Viability of neutrophils during 3.5 hours in RPMI 1640 + 2.5 % (v/v) FBS in the presence of 
copper sulphate (0.01 – 0.5 mM), n=3, independent experiments. 
None of the antioxidants used in neutrophil transmigration experiments were harmful 
to neutrophils. Among them were SOD (Figure 5.49), catalase (Figure 5.50, over) and 
MnTBAP (Figure 5.51, over). 
 
Figure 5.49. The effect of SOD (500 – 2000 U/ml) on viability of neutrophils during 3.5 hours in RPMI 
1640 + 2.5 % (v/v) FBS, n=3, independent experiments. 
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Figure 5.50. The effect of catalase (250 U/ml) on neutrophil viability during 3.5 hours in RPMI 1640 + 2.5 
% (v/v) FBS, n=1, in triplicate. 
 
 
Figure 5.51. Viability of neutrophils during 3.5 hours incubation of PMN with MnTBAP (1- 50 µM) in 
RPMI 1640 + 2.5 % (v/v) FBS, n=1, in triplicate. 
Only XR5118 at the highest concentration of 100 µM diminished the population of live 
neutrophils from 95.86 ± 0.96 % to 55.76 ± 3.87 %, increasing the amount of both 
apoptotic (from 2.41 ± 0.25 % to 34.33 ± 2.93 %) and necrotic (from 1.73 ± 0.72 % to 
9.91 ± 1.60 %) cells (Figure 5.52, over). 
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Figure 5.52. Viability of neutrophils after 3.5 hours incubation of PMN with XR5118 (1 – 100 µM) in RPMI 
1640 + 2.5 % (v/v) FBS, n=3, independent experiments. 
CFTRinh-172 had no effect on neutrophil viability in the conditions tested (Figure 5.53). 
 
Figure 5.53. The effect of CFTRinh-172 on viability of neutrophils during 3.5 hours treatment in RPMI 
1640 + 2.5 % (v/v) FBS, n=1, in triplicate. 
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5.5.12. VIABILITY OF HLMVEC 
The viability of HLMVEC after 3.5 hours incubation in RPMI 1640 supplemented with    
2.5 % (v/v) FBS with drugs used in PMN TEM was assessed luminometrically. The 
results were compared to the following controls, a negative control of apoptosis, 
which was untreated HLMVEC and a positive control of apoptosis, HLMVEC treated 
with 1 µM staurosporine concentration for 24 hours. The negative and positive 
apoptosis controls were 25,046 and 102,303 CPS (count per second) luminescence 
units, respectively.  
Tobramycin, copper-tobramycin and copper sulphate in the range of 0.01 – 0.5 mM 
were not found to be toxic (Figure 5.54). Also, extracellular SOD in the concentration 
range 500 – 2000 U/ml (Figure 5.55, over) and XR5118 at 1 – 100 U/ml (Figure 5.56, 
over) were not toxic to HLMVEC for 3.5 hours incubation in RPMI 1640 supplemented 
with 2.5 % (v/v) FBS. 
 
Figure 5.54. Viability of HLMVEC at 3.5 hours incubation with tobramycin, copper-tobramycin and 
copper sulphate (0.01 – 0.5 mM) in RPMI 1640 + 2.5 % (v/v) FBS and a staurosporine-induced apoptosis, 
n=1, in duplicate. CPS = count per second. 
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Figure 5.55. Viability of HLMVEC at 3.5 hours incubation with SOD (500 – 2000 U/ml) in RPMI 1640 + 2.5 
% (v/v) FBS and staurosporine-induced apoptosis, n=1, in duplicate. CPS = count per second. 
 
 
Figure 5.56. Viability of HLMVEC at 3.5 hours incubation with XR5118 (1 -100 µM) in RPMI 1640 + 2.5 % 
(v/v) FBS and staurosporine-induced apoptosis, n=1, in duplicate. CPS = count per second 
Moreover, the effect of the above mentioned drugs was assessed on HLMVEC in the 
presence of 10 ng/ml TNF-α for 3.5 hours in RPMI 1640 + 2.5 % (v/v) FBS in the regard 
to the appropriate negative and positive apoptosis controls, which were measured to 
be 35,787 and 104,740 CSP luminescence units, respectively (Figure 5.57 – 5.59). None 
of the tested drugs were toxic to HLMVEC activated with TNF-α, with the exception of 
100 U/ml of XR5118, which induced apoptosis in 22.15 % of HLMVEC.  
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Figure 5.57. Viability of TNF-α-activated (10 ng/ml) HLMVEC at 3.5 hours incubation with tobramycin, 
copper-tobramycin and copper sulphate (0.01 – 0.5 mM) in RPMI 1640 + 2.5 % (v/v) FBS and a 
staurosporine-induced apoptosis, n=1, in duplicate. CPS = count per second 
 
Figure 5.58. Viability of TNF-α-activated (10 ng/ml) HLMVEC at 3.5 hours incubation with SOD (500 – 
2000 U/ml) in RPMI 1640 + 2.5 % (v/v) FBS and a staurosporine-induced apoptosis, n=1, in duplicate. CPS 
= count per second. 
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Figure 5.59. Viability of TNF-α-activated (10 ng/ml) HLMVEC at 3.5 hours incubation with XR5118 (1 – 
100 U/ml) in RPMI 1640 + 2.5 % (v/v) FBS and a staurosporine-induced apoptosis, n=1, in duplicate. CPS 
= count per second 
Some of the drugs tested in PMN TEM were incubated on HLMVEC for 24 or 16 hours. 
Therefore, the viability of HLMVEC was also measured using luminescence following 24 
hours incubation of these drugs in RPMI 1640 supplemented with 2.5 % (v/v) FBS. The 
results below are presented as a percentage of cell viability.  
Figure 5.60 (over) presents the effect of 10 ng/ml TNF-α and 20 µM CFTRinh-172 on 
HLMVEC viability after 24 hours treatment in RPMI 1640 supplemented with 2.5 % 
(v/v) FBS. Tobramycin in the range of concentrations 0.01 – 0.5 mM was not toxic to 
HLMVEC following 24 hour incubation in RPMI 1640 plus 2.5 % (v/v) FBS. Similarly, 0.01 
and 0.1 mM copper-tobramycin and copper sulphate did not decrease endothelial cell 
viability. However 0.5 mM concentration of copper-tobramycin caused 16.64 % 
cytotoxicity, whereas 0.5 mM copper sulphate caused a 41.25 % decrease (Figure 5.61, 
over). 
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Figure 5.60. Viability (%) of HLMVEC upon 24 hours incubation with TNF-α (10 ng/ml) and CFTRinh-172 
(20 µM) in RPMI 1640 + 2.5 % (v/v) FBS, n=1, in duplicate. 
 
Figure 5.61. Viability (%) of HLMVEC treated with tobramycin, copper-tobramycin and copper sulphate 
(0.01 – 0.5 mM) in RPMI 1640 + 2.5 % (v/v) FBS for 24 hours, n=1, in duplicate. 
Catalase (250 U/ml) and SOD in a range of 500 – 2000 U/ml (Figure 5.62, over) as well 
as MnTBAP  at 10 – 50 µM were not toxic to HLMVEC after 24 hours incubation in 
RPMI 1640 supplemented with 2.5 % (v/v) FBS (Figure 5.63, over). 86.39 % of HLMVEC 
were alive after treatment with 50 µM MnTBAP. 
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Figure 5.62. Viability (%) of HLMVEC treated with catalase (250 U/ml) and SOD (500 – 2000 U/ml) in 
RPMI 1640 + 2.5 % (v/v) FBS for 24 hours, n=1, in duplicate. 
 
Figure 5.63. Viability (%) of HLMVEC for 24 hours in RPMI 1640 + 2.5 % (v/v) FBS after treatment with 
MnTBAP (1 – 50 µM), n=1, in duplicate. 
5.6. SUMMARY OF RESULTS 
A new in vitro model of neutrophil migration across TNF-α-activated HLMVEC towards 
thrombin activated platelets was established. The measured response was equivalent 
to the response elicited by IL-8 added alone under inactivated EC. Neutrophil migration 
was partly IL-8- and NAP-2-dependent, however other cytokines are likely to be 
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involved. Tobramycin was more potent and copper-tobramycin was more effective in 
inhibiting PMN TEM in this model. The effect is likely to be due to the SOD-like activity 
of copper-tobramycin, since SOD plus catalase and MnTBAP also inhibited PMN TEM. 
The inhibition of PMN TEM by any drug was apparently not due to a cytotoxic effect, 
however copper-tobramycin caused a decrease in EC viability in 24 hours. Additionally, 
copper-tobramycin (0.5 mM) increased PMN TEM when IL-8 was the chemoattractant.  
An in vitro model of neutrophil migration in the presence of CFTRinh-172 was set up to 
mimic CF conditions, however no significant difference in neutrophil migration was 
observed compared to PMN TEM in the absence of this inhibitor. 
5.7. DISCUSSION 
This study introduced three independent in vitro models of neutrophil transendothelial 
migration based on the use of HLMVEC grown in culture for 14 days. This time period 
allowed EC to form their own basement membrane. Similarly, Huber & Weiss (1989) 
cultured HUVEC for 21 days and the EC monolayer displayed in vivo-like intracellular 
borders and junctions and deposited a single-layered, continuous basement 
membrane. This basement membrane was impenetrable to colloidal particles and 
supported neutrophil extravasation in a physiologic manner. 
IL-8 is the most potent known neutrophil chemoattractant and also here induced the 
maximum level of PMN TEM, 86.65 ± 5.6 % of cells added to the upper chamber 
migrated to the lower. Smart & Casale (1993) previously showed IL-8-induced 
neutrophil migration through naked filters and through both endothelial (HUVEC) and 
epithelial (A549) cells cultured on these filters. Moreover, the IL-8 concentration they 
used (1 x 10-8 M) is similar to the one reported in this study, 6.25 x 10-8 M. Rot et al 
(1996) suggested that subendothelial IL-8 is internalized by EC, transported 
transcellularly and released onto the luminal surface to be localized on membrane 
protrusions. However, IL-8 was also shown to bind to endothelial HS and this binding 
creates a chemotactic gradient and enhances neutrophil responses to IL-8 (Webb et al, 
1993). 
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TNF-α-induced TEM of PMN was reported to be dependent on TNF-α-stimulated 
production of IL-8 (Smart & Casale, 1994) and supports the suggestion that, in this 
model, TNF-α stimulates 2.38 x 10-10 M IL-8 release from EC. PAI-1 has been shown to 
support IL-8 gradients (Marshall et al, 2003) and TNF-α is known to induce release of 
both IL-8 and PAI-1 from endothelial cells (Mantovani et al, 1997; Van der Poll, 1991). 
In the model of PMN TEM, discussed in this chapter, pro-inflammatory mediators, such 
as IL-8 and PAI-1 were detected in cell culture supernatants and their levels were 
increased by TNF-α. Morover, IL-8 and PAI-1 release were polarized to the basal aspect 
of the HLMVEC layer and levels of both correlated with the extent of neutrophil 
migration. 
IL-8 was mostly released from activated HLMVEC, since activated platelets released 
only small amounts of IL-8. TNF-α-activation of non-adherent neutrophils is 
controversial. It was shown that TNF-α induces a classical respiratory burst in 
neutrophils (Dusi et al, 1996). However, neutrophil respiratory burst induced by TNF-α 
in this model is unlikely. TNF-α is a prominent priming agent (Onnhein et al, 2008) and 
in the discussed model, there is no agonist in the apical compartment of Transwells 
capable of activating neutrophils, except for soluble and apical membrane bound IL-8. 
Neutrophil activation is therefore due to apical membrane bound IL-8.  
In vitro, TNF-α-stimulated EC secrete large amounts of PAI-1 over a period of hours 
(Handt et al, 1996) and endothelium considerably contributes to release of PAI-1 
during an inflammatory process (Binder et al, 2002).  In the blood, the main storage of 
PAI-1 is platelet α-granules, where it is released to the plasma (Nordenhem & Wiman, 
1997), therefore platelets could contribute to the PAI-1 released into the basal 
compartment. However, PAI-1 released to the basal compartment of Transwells was 
mostly inactive, compared to PAI-1 in the apical compartment, which was active. PAI-1 
is known to exist in at least three different conformations, including an active, latent 
and proteolytically or oxidatively inactivated form (Edelberg et al, 1994). Low levels of 
the active form of PAI-1 in the basal supernatant suggests that ROS (He, 2010) and 
proteases (Harlan, 1985) released from migrating neutrophils may subsequently 
inactivate PAI-1. 
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The possibility that PAI-1 plays a direct role in inflammatory diseases (Arndt et al, 
2005) makes it an attractive target for small molecule drug development, such as PAI-
039, known as tiplaxtinin (Gorlatova et al, 2007). XR5118 is a low-molecular-weight 
inhibitor of PAI-1 that binds to PAI-1 at the area between amino acids 110 and 145 of 
the PAI-1 molecule or at least affecting the accessibility to this region, which contains 
the t-PA-PAI-1 interaction site (Friederich et al, 1997). XR5118 (100 µM) was shown to 
significantly reduce PMN TEM across TNF-α-stimulated HLMVEC towards thrombin-
activated platelets, suggesting a role of PAI-1 in the given PMN TEM model. However, 
XR5118 at 100 µM was found to induce a degree of apoptosis, not necrosis, of both 
neutrophils and HLMVEC. 
To understand the mechanisms of transendothelial migration of neutrophils across 
TNF-α-stimulated HLMVEC, a comparison to other, similar models was made. Casale et 
al (1998 & 1999) created an in vitro model of neutrophils migration through 
endothelial (HUVEC) monolayers grown on the top of permeable filter and epithelial 
(A549) monolayers on the underface of the filters. A sequential migration of human 
neutrophils through endothelium and epithelium was observed towards basally added 
TNF-α. Morzycki et al (1990) reported that the apical or basal exposure of HUVEC to 
TNF-α induced comparable PMN adherence. However, basal exposure alone induced 
significantly higher PMN migration than apical exposure alone. Here, TNF-α was added 
to both apical and basal compartment of Transwells, to allow TNF-α molecules to 
interact with both sides of the HLMVEC membrane as well as with neutrophils. 
An upregulation of adhesion molecules, such as ELAM-1 and ICAM-1 in the response to 
TNF-α was also reported (Morzycki et al, 1990). Indeed, TNF-α and other cytokines 
were reported to increase the expression of adhesion molecules on endothelial cells 
(Ohira et al, 2003; de Vries et al, 1998). Also, treatment of human EC with TNF-α 
results in marked changes in cell shape and cytoskeletal organization (Camussi et al, 
1991) and synthesis of cytokines, such as IL-8 (Elner et al, 1990) and mediators, such as 
PAF (Bussolino et al, 1988). Also, both endothelium and PMNs contribute to the 
generation of low levels of ROS (Lum & Roebuck, 2001).  
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Endothelial IL-8 and platelet NAP-2 were demonstrated to contribute approximately  
50 % to the neutrophil migration in this PMN TEM model, however other cytokines of 
endothelial (ENA-78, GRO-α, GCP-2) and/or platelet (NAP-2, PF-4, ENA-78) origin could 
be involved. Specific neutrophil chemokines express different chemotactic potency 
and the following pattern was observed for adult and neonatal neutrophils at 100 
ng/ml: IL-8/CXCL8 > GRO-α/CXCL1 > GCP-2/CXCL6 > NAP-2/CXCL7 > ENA-78/CXCL5 > 
GRO-γ/CXCL2 > GRO-β/CXCL3 (Fox et al, 1995). In addition, PAF, generated by various 
cells including platelets and thrombin-activated EC (Lynch et al, 1986; Ludwig et al, 
1984; Prescott et al, 1984), was reported to induce neutrophil migration (Carolan & 
Casale, 1990), however neutrophil migration in the model showed here was not due to 
PAF. 
This study introduced also an in vitro model of neutrophil transendothelial migration 
across TNF-α-stimulated HLMVEC towards thrombin activated platelets. Here, platelets 
were recognised as a source of chemokines. Indeed, platelets, in addition to a role in 
haemostasis, contribute to inflammation by secreting chemokines that attract 
neutrophils to the site of inflammation. PF-4 and β-TG, which is proteolytically cleaved 
to NAP-2, are the most abundantly expressed platelet chemokines. However platelets 
also contain MIP-1α, RANTES, MCP-3, GRO-α, ENA-78 and IL-8 (Gear & Camerini, 
2003).  
Thrombin is a potent activator of platelets (Sambrano et al, 2001) and activates G 
protein-coupled protease activated receptors, PAR-1 and PAR-4 on human platelets. 
Thrombin initiates signaling cascades leading to increases in intracellular Ca2+, 
secretion of autocrine activators, trafficking of adhesion molecules to the plasma 
membrane and shape change, which promote platelet aggregation (Brass, 2003). 
Interestingly, there is increased coagulation in CF, which generates thrombin (Komp & 
Selden, 1970). Human platelets were previously demonstrated to release NAP-2 
(Piccardoni et al, 1996) and RANTES (Kameyoshi et al, 1992) upon thrombin activation. 
Platelets from rabbit have been reported to secrete IL-8 after thrombin stimulation (Su 
et al, 1996). Here, thrombin-activated platelets were found to release high (µg/ml) 
NAP-2, moderate (ng/ml) RANTES and low (pg/ml) IL-8 levels. Among them, NAP-2 and 
IL-8 are chemotactic for neutrophils. 
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An inflammatory state, which is often a result of endothelial dysfunction, as seen in CF 
(Romano et al, 2001), predisposes platelets to interact directly with leukocytes for 
their efficient recruitment to inflamed tissue. Platelet-leukocyte aggregates have been 
observed in CF and asthmatic patients and a murine model of allergic inflammation 
and it is suggested that platelets might prime leukocytes for subsequent adhesion and 
transmigration into tissues (O`Sullivan et al, 2005; Pitchford et al, 2003). Moreover, 
Weissmuller et al (2008) reported that PMNs facilitated translocation of platelets 
across human and mouse epithelium. On the contrary, the current research indicated 
the possibility that platelets in the apical compartment of Transwells arrested the 
movement of neutrophils when platelets and neutrophils were added to the upper 
compartment of Transwells together. 
Moreover, platelets not only contribute to the migration of other cells, but actively 
participate in this process themselves. Platelets have been recognised to be activated 
in CF and asthma (O`Sullivan et al, 2005; Page et al, 1985) and accumulated within the 
guinea pig lung after PAF infusion (Morley et al, 1985). They were also found in BALF 
from asthmatic patients and allergic rabbits after allergen challenge (Metzger et al, 
1987). Platelets were also shown to participate directly in allergic tissue inflammation 
as they migrate extravascularly in response to a sensitized allergen (Pitchford et al, 
2008). 
Random migration of human platelets has been recognised as a parameter of platelet 
function (Valone et al, 1974) and platelets were reported to migrate directly to added 
collagen, which was not a result of diffusion or Brownian movement (Lowenhaupt et 
al, 1973). Metabolic inhibitors such as iodoacetic acid, sodium fluoride, and 2,4-
dinitrophenol inhibited platelet movement further proving platelet migration to be an 
energy-dependent process (Lowenhaupt et al, 1977). Czapiga and co-workers (2005) 
demonstrated gradient-driven chemotaxis of platelets toward formyl peptides, derived 
from bacteria.  
In the novel in vitro model of neutrophil migration across TNF-α-activated EC towards 
thrombin activated platelets, thrombin could also activate HLMVEC, as HLMEC and 
HUVEC express several PAR, including PAR-1, PAR-3 and thrombin independent PAR-2 
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(Kataoka et al, 2003; Molino et al, 1997). PAR-1 and PAR-2 signalling on HUVEC 
activated by thrombin was potentiated by LPS and TNF-α to release an inflammatory 
cytokine, IL-6 (Chi et al, 2001). Although TNF-α is known to induce release of IL-8 from 
endothelial cells (Mantovani et al, 1997), thrombin in the presence of TNF-α could be 
responsible for exaggerating this response. Indeed, thrombin-activated platelets 
underneath a layer of HLMVEC activated by TNF-α induced significantly higher apical 
and non-significantly basal release of IL-8 compared to unactivated endothelium. 
However, thrombin alone did not induce a significant increase of PMN TEM compared 
to spontaneous neutrophil migration.  
LPS is a major component of the outer surface of Gram-negative bacteria that forms a 
complex with LPS-binding protein (Schimann et al, 1990). This complex further binds to 
CD14, a high-affinity LPS receptor present on the surface of the immune and 
inflammatory system (Wright et al, 1990). The putative LPS signaling receptor, Toll-like 
receptor 4 (TLR4), is expressed in many cells, incuding platelets (Cognasse et al, 2005). 
LPS was shown to promote platelet activation by inducing secretion of the contents of 
both α and dense granules and thus amplifying secretion-dependent platelet 
aggregation (Zhang et al, 2009). It is still unknown whether EC TLR4 is expressed within 
the HUVEC and human coronary artery endothelial cells (HCAEC) or on the cell surface 
(Andreakos et al, 2004, Dunzendorfer et al, 2004). LPS was also reported to activate 
neutrophils via TLR2 and TLR4 (Sabroe et al, 2002). Indeed, treating peripheral PMNs 
with LPS induces the production of TNF-α mRNA (Palma et al, 1992). However, 
endothelium rather than neutrophil TLR4 was important in neutrophil sequestration 
into the lungs (Andonegui et al, 2003). Additionally, LPS increases neutrophil 
adherence mostly via an effect on HUVEC (Thomas et al, 1988). It is also known that 
LPS stimulates the interaction between platelets and neutrophils, leading to robust 
neutrophil activation via TLR4-dependent mechanisms (Clark et al, 2007; Semple et al, 
2007). In this study, LPS could act on both platelets and EC. However, thrombin was 
demonstrated to be a more potent stimulus than LPS. Indeed, thrombin-activated 
platelets significantly increased PMN TEM in the absence or presence of TNF-α, 
whereas LPS induced a small increase in PMN TEM versus TNF-α alone. 
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There are indications of a role of ICAM-1 in the discussed model of TEM of PMN.   
ICAM-1 is expressed on endothelial cells, but is greatly increased at inflammatory sites 
by stimulation with LPS and pro-inflammatory cytokines such as IL-1 and TNF-α 
(Lawrence & Springer et al, 1991). ICAM-1 engagement is involved in ROS generation 
(Wang & Doerschuk, 2000). TNF-α is known to increase ROS production and stimulates 
lung vascular barrier function by engaging TNF-α receptor-1, leading to the increased 
endothelial permeability in cultured EC (Partridge et al, 1993; Hocking et al, 1990). 
Moreover, under activation, the soluble form of ICAM-1 (sICAM-1) can be released 
from different cells including HUVEC, human saphenous vein EC, human aortic SMCs, 
melanoma cells and haematopoetic cell lines (Lawson & Wolf, 2009). In the current 
research, significantly more sICAM-1 was detected in the basal than apical supernatant 
and reflected levels of neutrophil migration. 
In the model of transendothelial migration of neutrophils with platelets activated with 
thrombin underneath TNF-α-stimulated HLMVEC, 78.64 ± 6.65 % neutrophils migrated. 
This response was not significantly different to to the response elicited by IL-8 and 
represents a more physiological model of the inflammatory response.  
Copper-tobramycin (0.5 mM) significantly potentiated PMN TEM when IL-8 was added 
subendothelially. Indeed all neutrophils added to the top well migrated through the EC 
layer. Copper-tobramycin was shown to have SOD-like activity (Chapter 2) and to bind 
to HSPGs (Chapter 3). There are number of ways in which the SOD-like activity of 
copper-tobramycin may enhance neutrophil TEM. The binding of copper-tobramycin to 
HSPGs could be responsible for protecting HSPGs from degradation by ROS (Klebanoff 
et al, 1993) or elastase released from migrating neutrophils (Heeringa et al, 1996). 
Moreover, PAI-1 supports IL-8-mediated PMN TEM by inhibition of plasmin shedding 
of IL-8/HS complexes (Marshall et al, 2003). Copper-tobramycin might therefore also 
protect PAI-1 activity, especially without changing the amount of PAI-1, as there is no 
change in the amount of PAI-1 measured in apical or basal levels in the conditions 
tested. 
However, the neutrophil migration towards IL-8 in the presence of copper-tobramycin 
could also involve adhesion molecules, such as ICAM-1. The results indicate that 
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copper-tobramycin increased neutrophil migration, which is followed by shedding of 
ICAM-1 from the endothelial cell surface. After copper-tobramycin treatment, ICAM-1 
was increased in the basal supernatant, although not significantly, due to the 
variability in results. Alternatively, copper-tobramycin may enhance actin cytoskeleton 
rearrangements to aid in neutrophil migration (Yoshida et al, 2006). Indeed, ICAM-1 is 
localized at the apical surface on EC and is organized in microdomains along with 
VCAM-1 around adherent leukocytes. The cytoplasmic C-terminus of ICAM-1 
associates to α-actin and the actin binding ezrin-moesin-radixin family of proteins 
(Carpen et al, 1992). 
Additionally, there is a possibility that early stages of HLMVEC apoptosis contributed to 
the enhancement of neutrophil migration in the presence of copper-tobramycin for 24 
hours. 
Although, copper-tobramycin is a potent anti-oxidant agent (Chapter 3 & 4), it had no 
effect on neutrophil migration when HLMVEC were stimulated with TNF-α alone. In the 
current study, stimulation of HLMVEC layers with TNF-α induced 23.63 ± 3.53 % of 
neutrophil migration. Presumably the level of neutrophil migration was too low to 
observe an effect elicited by copper-tobramycin. 
Incubation of tobramycin or copper-tobramycin on TNF-α-activated EC for 3.5 hours 
indicated a trend towards an inhibition of PMN TEM towards activated platelets. 
However, low concentrations of tobramycin (0.01 and 0.1 mM) as well as a high 
concentration of copper-tobramycin (0.5 mM) was shown to significantly inhibit PMN 
TEM in the model across TNF-α-stimulated HLMVEC towards platelets activated with 
thrombin when both drugs were present on EC for 19 hours. Moreover, these drugs 
were added 0.5 hour earlier than TNF-α. Indeed, tobramycin and copper-tobramycin 
were shown to be potent intracellular antioxidants (Chapter 4), which were believed to 
protect endothelial cells from ROS, generated by TNF-α. 
It is conceivable, in the view of the results in Chapter 2, that tobramycin binds copper 
present in the culture medium in a 1:1 metal:ligand ratio. The copper level in RPMI 
1640 supplemented with 2.5 % (v/v) FBS was measured by GF-AAS to be 23.11 ± 1.98 
ng/ml (Chapter 2), which corresponds to approximately 0.37 µM. This small amount of 
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copper may bind to tobramycin, which is in excess, by 30 and 300 fold, at 0.01 and    
0.1 mM concentration to form a copper-tobramycin complex, which significantly 
inhibited PMN TEM. Tobramycin at the concentration 500 µM was not effective in 
inhibiting PMN TEM. This may be because free tobramycin in excess competes with 
copper-tobramycin for HS binding sites for cellular uptake (Chapter 2).  
Copper-tobramycin significantly inhibited PMN TEM only at 0.5 mM, while lower 
concentrations of this complex were not effective. Moreover, the copper-tobramycin 
complex was demonstrated to have SOD-like activity without catalase activity at the 
concentration 0.01 – 0.5 mM (Section 2.5.4). SOD or catalase alone did not affect PMN 
TEM, however the combination of SOD (2000 U/ml) and catalase (250 U/ml) 
significantly inhibited neutrophil migration in the conditions tested. MnTBAP (50 µM), 
which is known to have both intracellular SOD and catalase activities (Faulkner et al, 
1994) produced a similar effect. These results may suggest that SOD plus catalase as 
well as MnTBAP are stronger antioxidants than copper-tobramycin, as they potently 
inhibited PMN TEM without overnight preincubation. Also, MnTBAP demonstrated the 
same degree of PMN TEM inhibition when present on HLMVEC for 3.5 and 19 hours. 
Oxidative stress was demonstrated to promote leukocyte transendothelial migration. 
Neutrophil activation by releasing their granular contents, containing digestive 
enzymes and producing ROS, allow their interaction with endothelium. In turn, 
neutrophil adhesion to the endothelium triggers multiple endothelial signalling events, 
including those, mediated by ROS. It then leads to widened intracellular space and 
facilitating plasma leakage and neutrophil migration (Yuan et al, 2012). Removal of 
superoxide inhibits the infiltration of neutrophils at sites of inflammation, as 
demonstrates by the use of the liposomal SOD (Niwa et al, 1985) and synthetic SOD 
mimetics M40403 and SC-55858 (Salvemini et al, 2001; Salvemini et al, 1999). 
However, SOD3 was shown to inhibit monocyte and T cell infiltration in the model of 
acute ischaemia, but have little effect on neutrophil migration (Laurila et al, 2009). 
Indeed, T-cells utilize the VCAM-1 pathway of cell adhesion to the endothelium, 
whereas neutrophils, instead of VCAM-1, use the ICAM-1-dependent pathway with no 
role for NADPH oxidase (reviewed by Cook-Mills et al, 2011). Moreover, NADPH 
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oxidase-dependent ROS have been identified as key regulators of neutrophil 
chemotactic migration (Hattori et al, 2010). 
ROS could also alter vascular permeability involving regulation of junctional protein 
phoshorylation. ROS inhibits phosphatase activity by reversible oxidation of the 
catalytic cysteine residue and the resulting increase in tyrosine phosphorylated 
junctional proteins might increase TEM as an effect of junctional disruption (Sallee et 
al, 2006). ROS may also regulate junctional permeability by affecting the organisation 
of the actin cytoskeleton (Moldovan et al, 2000). Copper-tobramycin as a potent 
intracellular anti-oxidant (taken up by HLMVEC, Chapter 3 and 4) may inhibit ROS 
generation and therefore inhibit TEM of PMN. 
Also, the extracellular anti-oxidant activity of copper-tobramycin (not taken up by 
neutrophils, Chapter 3 and 4) may contribute to the inhibition of ROS generation via a 
ROS scavenging mechanism or inhibition of NADPH oxidase and thus prevent 
neutrophil-endothelial interactions leading to TEM. Moreover, by inhibition of NADPH 
oxidase or superoxide scavenging, copper-tobramycin prevents superoxide undergoing 
further conversion into hydroxyl radical or peroxynitrate. 
NE elastase has also been demonstrated to contribute to the human PMN migration 
across basement membrane by activating pro-gelatinase B (Delclaux et al, 1996). It was 
also reported that migrating PMN localise their membrane-bound elastase to the 
migrating front, where it facilitates TEM (Cepinskas et al, 1999). Interestingly, carbon 
monoxide (CO)-releasing molecule (CORM) was reported to reduce the level of cell-
bound elastase, which contributes to the suppressed PMN TEM in a mice model of 
sepsis (Mizuguchi et al, 2009). Also, copper- tobramycin could displace NE from its cell 
surface-binding sites, where it is persistently active and cannot be inhibited by α1-AT 
(Chapter 4). This is therefore another possible mechanism of the inhibition of PMN 
TEM in the presence of copper-tobramycin. 
Copper-tobramycin was not toxic to neutrophils or HLMVEC in medium with FBS. 
Moreover, PMN were unactivated in the viability experiments, as it took place in TEM 
of PMN. Indeed, TNF-α and other inflammatory stimuli, such as IL-6 and LPS, prolong 
the neutrophil lifespan. Additionally, transmigration across the endothelium signals in 
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further delay of neutrophil apoptosis (reviewed by Mayadas & Cullere, 2005). 
Therefore, PMN viability in TEM of PMN could be greater than demonstrated in the 
actual viability experiments. These results cannot be also explained by a cytotoxic 
effect of copper-tobramycin on HLMVEC, as there was an inhibitory effect of this drug. 
Also copper sulphate elicited some cytotoxicity on HLMVEC, however copper sulphate 
had no effect on PMN TEM at any concentration tested. 
Interestingly, copper ions are known to inactivate a variety of enzymes and lactate 
dehydrogenase (LDH) is exceptionally sensitive to this metal. Moreover, NADH, found 
in neutrophil cell membranes, strongly enhances the Cu(II)-mediated loss of LDH 
activity (Pamp et al, 2005). For this reason, the LDH assay could not be used to assess 
the cytotoxicity of copper containing compounds. The cytotoxicity of test compounds 
on neutrophils and HLMVEC was assessed based on annexin V and caspase-3 and -7 
activities, which allow detection of the early stages of apoptosis.  
The quantitative measurement of inflammatory mediators, such as IL-8, PAI-1 and an 
inflammatory marker, sICAM-1 was undertaken to investigate the mechanism of action 
of tobramycin and copper-tobramycin in the inhibition of PMN TEM. More total IL-8, 
PAI-1 and sICAM-1 were detected in basal than apical supernatants collected from 
appropriate experiments with no indication for inhibition of PMN TEM. However, both 
IL-8 and PAI-1 correlate with neutrophil migration, demonstrating their involvement in 
TEM of PMN and confirming a good model of PMN TEM.  
CFTR inhibitors are so far the only known tools to mimic CF endothelium, as there is no 
CF endothelial cell line avaliable. CFTRinh-172 specifically inhibited CFTR chloride 
channel function (He et al, 2004, Thiagarajah et al, 2004). However, it expresses other 
effects, which are independent of CFTR inhibition. Indeed, CFTRinh-172 and GlyH-101 
were able to depolarize mitochondria and induce a rapid increase in ROS levels. 
CFTRinh-172 was previously shown (Chapter 3) to upregulate endothelial HS 
expression on the HLMVEC surface and generate intracellular ROS (Chapter 5). 
CFTRinh-172 significantly attenuated lung endothelial cell apoptosis induced by 
staurosporine or H2O2 (Noe et al, 2009). Furthermore, CFTRinh-172 alters the 
organization of cytoskelatal proteins, F-actin and α-tubulin, in the following epithelial 
258 
 
cell lines, 16HBE14o- and CFBE41o- (Nilsson et al, 2010). CFTRinh-172, but not GlyH-
101, induced NF-κB activation (Kelly et al, 2010; Perez et al, 2007). Additionally, 
CFTRinh-172 enhanced secretion of IL-1, IL-6 and IL-8 release from lung epithelial cells 
(Bartling & Drumm, 2009). It was therefore expected that CFTR inhibition would induce 
an exaggerated inflammmatory response, as observed in CF epithelial cells (Chen et al, 
2008; Perez et al, 2007) and subsequently increase PMN TEM. The percentage of PMNs 
migrated across HLMVEC in the presence of CFTRinh-172 tended to decrease with a 
significant effect with thrombin-activated platelets underneath unstimulated HLMVEC. 
This response was, however, too low to be further investigated. The level of IL-8, PAI-1, 
sICAM-1 and plasmin activity showed no change when compared to the absence of the 
inhibitor.  
It is also highly controversial as to whether neutrophils and platelets in CF are different 
to normal cells (Mattoscio et al, 2010, O`Sullivan et al, 2005; Witko-Sarsat et al, 1999).  
However, it is possible to improve this in vitro model of CF PMN TEM by the use of 
neutrophils and platelets from CF patients. 
 
Normal and CF neutrophils express CFTR at the mRNA and protein level and 
extracellular HOCl production by CF neutrophils is normal, however the chlorination of 
ingested P.aeruginosa is impaired (Painter et al, 2006). It may therefore indicate a lack 
of functional CFTR in neutrophils in CF. However, no role of CFTR in controlling 
neutrophil oxidative activity was suggested by McKeon et al (2010). In contrast, Witko-
Sarsat et al (1996) reported that MPO-dependent oxygenation activity and chloramine 
release were significantly increased in both CF homozygotes and heterozygotes as 
compared with controls. Also, Vaisman et al (1994) observed that neutrophils from CF 
patients exhibit increased chemiluminescence activity, not related to increased ROS 
production. Moreover, CF neutrophils release increased amounts of NE elastase 
compared to normal neutrophils upon stimulation with TNF-α, IL-8 and opsonised 
bacteria (Taggart et al, 2000). Pharmacologic inhibition and genetic mutation of CFTR 
in neutrophils facilitates production of MIP-2 and TNF-α and activates NF-κB upon LPS 
stimulation (Su et al, 2011). CF neutrophils were reported to express a reduced 
responsiveness to IL-8 (Dai et al, 1994) and to LTB4 (Lawrence & Sorrelli, 1992). 
Reduced L-selectin responsiveness could be responsible for defective adhesion of CF 
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neutrophils (Russell et al, 1998). However, CF neutrophils co-cultured with bronchial 
epithelial cells deficient with CFTR expressed increased adherence and the level of 
both IL-6 and IL-8 measured in the cell supernatants. These effects may contribute to 
the sustained and exaggerated inflammatory response in CF airways (Tabary et al, 
2006). 
The hyperactivity of CF platelets has been suggested to be a consequence of CFTR 
dysfunction, although neither the mRNA nor the CFTR protein has been found in 
platelets from CF or normal subjects (O`Sullivan et al, 2005). On the contrary, a more 
recent study of Mattoscio et al (2010) found that platelets express biologically active 
CFTR. Moreover, platelets from CF patients generated 40 % less LXA4 than platelets 
from healthy subjects. LTXA4 were shown to be involved in resolution of inflammation 
and therefore are anti-inflammatory compounds (McMahon et al, 2001). Interestingly, 
CFTR inhibition increased platelet-dependent PMN viability and suppressed nitric oxide 
generation. 
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CHAPTER 6 
PRELIMINARY DATA AND FURTHER WORK 
 
6.1. INTRODUCTION 
6.1.1. NORMAL AND CF PULMONARY EPITHELIUM  
The entire pulmonary tree is lined by a continuous layer of epithelial cells. The relative 
distributions and abundance of epithelial cell types vary significantly between airway 
regions. The epithelial cells lining the luminal surface of the proximal airway can be 
further classified as ciliated cells, non-ciliated secretory cells and basal cells. A 
characteristic pseudostratified two-layered epithelium persists through the major 
bronchi, while a multi-layered structure is seen in the more distal, narrow bronchi, 
which have fewer cartilage rings and more submucosal glands. Ciliated cells and 
secretory cells attach to the basal lamina via desmosine adhesions and to one another 
via tight junctions at the luminal surface. The underlying basal cells lie in contact with 
most of basal membrane (Jeffery, 1983; Breeze & Wheeldon, 1977). 
The pulmonary epithelium is important for maintaining the normal functions of the 
respiratory system, which include acting as a barrier for various insults (Widdicombe, 
1987b), facilitating mucociliary clearance (Sleigh et al, 1988), secreting substances, 
such as surfactant proteins, mucus and antimicrobial peptides for airway surface 
production (Widdicombe, 1987a), repairing and regenerating epithelial cells to restore 
normal airway function (Evans et al, 1976) and modulating the response of other 
airway components, such as airway smooth muscle cells and inflammatory cells 
(Flavahan et al, 1985; Holtzman et al, 1983).  
Mutations in CFTR lead to unique alterations in the microenvironment of the lung, 
including the respiratory epithelium, that facilitate bacterial infection (Smith et al, 
1996). Reported abnormalities in the CF lung manifest by altered fluid and ionic fluxes 
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across the respiratory epithelium, diminished glutathione level, excessive and 
dehydrated luminal mucus, diminished mucociliary clearance, altered patterns of 
epithelial surface molecule glycosylation and decreased activity of bacterial factors, 
such as lysozyme, lactoferrin, defensins and cathelicidins in the airway surface liquid 
(Pilewski et al, 1999; Travis et al, 1999, Matsui et al, 1998; Cheng et al, 1989). 
6.1.2. EPITHELIAL CELL LINES FOR CF RESEARCH 
The development of immortalized cell lines has been a significant benefit to the study 
of human disease, including CF (Gruenert  et al, 1995). The immortalization of cells 
from CF patients as well as cells from non-CF individuals from tissues relevant to CF has 
been critical to enhancing our understanding of the physiological, biochemical and 
genetic  mechanisms underlying CF and for the development of  therapeutic  strategies 
designed to manage CF pathology. Gruenert et al (2004) presented and discussed a 
comprehensive list of immortalized cells from various tissues and species, with an 
emphasis on epithelial cells that have played a significant role in advancing our 
knowledge of CF. Among them, two cell lines were chosen in the current study. The 
normal human bronchial epithelial cell line 16HBE 14o- was recognized as a model 
system of the airways for studying drug transport (Forbes et al, 2003). The CFBE 41o- 
cell line was generated by transformation of CF tracheo-bronchial cells with SV40 and 
has been reported to be homozygous for the ΔF508 mutation over multiple passages in 
culture. It has been recognised as useful tool for studies of CF gene transfer or 
alternative treatment with small drug molecules and for the gathering of further 
information about the disease at the cellular level, without the need for primary 
culture (Ehrhardt et al, 2006). 
 
6.2. AIMS AND OBJECTIVES 
The predominant aim in this pilot study was to evaluate the effects of the antibiotic 
tobramycin and the copper-tobramycin complex on CFTR expression in normal and CF 
epithelial cells using immunocytochemistry. 
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6.3. MATERIALS 
16HBE 14o¯ and CFBE 41o¯ cell lines were kindly gifted by Dieter Gruenert, University 
of Davis, CA. Basal MEM (minimal essential medium) was supplemented with 10 % 
(v/v) FBS, 1 % (v/v) L-glutamine and 1 % (v/v) antibiotic/antimycotic from Invitrogen 
Ltd. (Paisley, UK). Human plasma fibronectin and albumin bovine fraction V 35 % (v/v) 
were purchased from Sigma-Aldrich Inc. (Poole, Dorset, UK). BD Biosciences (Oxford, 
Oxfordshire, UK) provided collagen type I. 
6.4. METHODS 
6.4.1. EPITHELIAL CELL CULTURE 
16HBE 14o¯ and CFBE 41o¯ cell  lines  were  seeded  into  collagen I/ fibronectin  
coated   75 cm2  flasks at a seeding density of  5 x 103 cells/ cm2. Cells were grown until 
confluent in MEM containing 10 % (v/v) FBS, 1 % (v/v) L-glutamine and 1 % (v/v)  
antibiotic/antimitotic. The feeding and subculturing into 8-well chamber slides were 
the same as stated for HLMVEC line (Section 2.4.4.1, 3.4.2, respectively). 
6.4.2. COLLAGEN I/FIBRONECTIN COATING 
Fibronectin from human plasma (Sigma) was reconstituted in 1 ml sterile water to 
obtain a 1 mg/ml working concentration and stored in 100 µl aliquots at -20°C. The 
collagen I/fibronectin solution was prepared in basal MEM containing a final 
concentration of 0.1 mg/ml albumin bovine fraction V 35 % (v/v) (Sigma), 0.03 mg/ml 
collagen type I (BD biosciences) and 0.01 mg/ml fibronectin. 2ml of solution per T-75 
flask and 1 ml per well of a 6 well plate was added and incubated for 2 – 3 hours at 
37°C. Coating solution was aspirated and flasks/plates were stored maintaining sterility 
at room temperature. 
6.4.3. OTHER METHODS 
Epithelial cells were treated with tobramycin and copper-tobramycin (0.01 – 0.5 mM) 
in the same way as endothelial cells (Section 3.4.3). A method for 
immunocytochemical detection of CFTR was previously described in Chapter 3. 
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6.5. RESULTS 
6.5.1. CFTR LOCALISATION IN EPITHELIAL CELLS 
Untreated 16HBE 14o- showed intracellular CFTR detection (panel 2B, Figure 6.1). 
Tobramycin at 0.01 mM had no effect of the distribution or the amount of CFTR (panel 
3B), unlike at other tobramycin concentrations. Tobramycin at 0.1 mM highly 
upregulated the level of CFTR protein, located in the epithelial cell cytoplasm, 
excluding nucleus and big vesicles (panel 4B). CFTR was also present in the cytoplasm 
of 16HBE 14o- treated with 0.5 mM tobramycin, but to a much smaller extent 
compared to the presence of 0.1 mM tobramycin (panel 5B). Copper-tobramycin at 
0.01 mM increased the level of CFTR protein located in the cell cytoplasm and in the 
perinuclear area (panel 6B). Copper-tobramycin at 0.1 and 0.5 mM had similar effects 
on the level and distribution of CFTR in the epithelial cell line (panel 7B and 8B, 
respectively). Both concentrations highly increased the level of intracellular CFTR. The 
cells showed no autofluorescence in the absence of CFTR antibody (panel 1B).  
 
 
 
 
Figure 6.1. The effect of tobramycin and copper-tobramycin on CFTR in 16 HBE 14o
-
. A) nuclear stain 
(Hoechst blue); B) CFTR stain (Mr. Pink); C) merged image. 1) no primary antibody; 2) no treatment; 3) 
0.01 mM tobamycin; 4) 0.1 mM tobramycin; 5) 0.5 mM tobramycin; 6) 0.01 mM copper-tobamycin; 7) 
0.1 mM copper-tobramycin; 8) 0.5 mM copper-tobramycin. Scale bar 25 µm. 
1C 1A 
5A 
1B 2B 2C 
5B 
2A 
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7B 8B 7C 
4A 3B 3C 4C 4B 3A 
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A Z-stack of the untreated 16HBE 14o- revealed some surface staining of CFTR on the 
apical membrane and CFTR was detected intracellularly, especially within cell vesicles, 
presumably ER (Figure 6.2). Figures 6.3 and 6.4 (over) demonstrate the maximal 
upregulation of the CFTR level within 16HBE 14o- under treatment with tobramycin 
(0.1 mM) and copper-tobramycin (0.5 mM), respectively. Additionally both treatments 
moved CFTR presumably from the ER to the cytoplasm. There is no nuclear stain in the 
case of tobramycin at 0.1 mM, whereas copper-tobramycin (0.5 mM) intensified CFTR 
staining within all regions of the cell, including the apical cell membrane. 
 
 
 
Figure 6.2. Z-stack of the untreated control of 16HBE 14o- with 1 µm intervals. Scale bar 25 µm. 
Optical slices were obtained through the cell from the apical to the basal, adherent cell 
surface. 
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Figure 6.3. Z-stack of 16HBE 14o- treated with 0.1 mM tobramycin with 1 µm intervals. Scale 
bar 25 µm. 
 
 
 
Figure 6.4. Z-stack of 16HBE 14o- treated with 0.5 mM copper-tobramycin with 1 µm intervals. 
Scale bar 25 µm. 
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The untreated control CFBE 41o- expressed a low level of CFTR protein detected in the 
perinuclear area (panel 2B, Figure 6.5) compared to the negative control (1B). The 
incubation of CFBE 41o- with 0.01 mM tobramycin had no effect on CFTR (panel 3B). 
However, 0.1 mM tobramycin highly increased the level of CFTR located perinuclearly 
and in the cell cytoplasm (panel 4B). In the presence of 0.5 mM tobramycin the 
amount of CFTR within CFBE 41o- was decreased (panel 5B) compared to the 
treatment of 0.1 mM, but slightly enhanced compared to the untreated control. 
Copper-tobramycin at 0.01 and 0.1 mM was ineffective (panel 6B and 7B, respectively). 
In contrast, 0.5 mM copper-tobramycin upregulated CFTR levels mainly around the cell 
nucleus (panel 8B) and, additionally, a condensation of DNA was observed (panel 8A), 
suggesting an effect of top copper-tobramycin concentration on CFBE 41o- apoptosis.  
 
 
 
 
Figure 6.5. The effect of tobramycin and copper-tobramycin on CFTR in CFBE 41o-. A) nuclear stain 
(Hoechst blue); B) CFTR stain (Mr. Pink); C) merged image. 1) no primary antibody; 2) no treatment; 3) 
0.01 mM tobamycin; 4) 0.1 mM tobramycin; 5) 0.5 mM tobramycin; 6) 0.01 mM copper-tobamycin; 7) 
0.1 mM copper-tobramycin; 8) 0.5 mM copper-tobramycin. Scale bar 25 µm. 
Figure 6.6 (over) shows some degree of surface staining within CFBE 41o- treated with 
0.1 mM tobramycin, however CFTR was mostly located in the cytoplasm and around 
the nucleus and was highly upregulated. 
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Figure 6.6. Z-stack of CFBE 41o- treated with 0.1 mM tobramycin with 1 µm intervals. Scale bar 
25 µm. 
6.6. DISCUSSION 
Like other glycoproteins, CFTR is synthesized on ER-associated ribosomes and core-
oligosaccharide chains are attached to the protein co-translationally at the asparagines 
(N) residues 894 and 900 located in the 4th extracellular loop (Chang et al, 1994). A 
large portion of CFTR is degraded from the ER. Retained misfolded proteins undergo 
ER-associated degradation (ERAD) through the ubiquitin-proteasome pathway (Farinha 
& Amaral, 2005). The remaining protein fragments are transported to the Golgi. Along 
the secretory pathway, the polypeptidic chain undergoes different post-translational 
modifications at its glycidic residues to produce the fully glycosylated form. Monitoring 
the glycosylation state of CFTR allows the wild type protein to be distinquished from 
the several processing mutants. According to the glcosylation status, 3 forms of the 
CFTR can be identified: the non-glycosylated polypeptidic chain known as band A (130 
kDa), the ER core-glycosylated form of the protein known as band B (150 kDa) and the 
fully glycosylated mature form known as band C (170 – 180 kDa) (Cheng et al, 1990). 
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In normal human airway surface epithelium, CFTR is restricted to the apical plasma 
membrane of ciliated cells (Puchelle et al, 1992) and it is directly linked to cellular 
polarization (Morris et al, 1994). The deletion of the amino acid Phe 508 (ΔF508) is a 
CFTR mutation characteristed by an abnormal intracellular maturation and trafficking 
(Cheng et al, 1990). Mutated CFTR has been localized diffusely in the cytoplasm of 
epithelial respiratory cells, as a consequence of its retention in the ER. It is therefore 
unable to accumulate at normal levels at the apical plasma membranes (Dupuid et al, 
1995; Puchelle et al, 1992). 
In the current study, both 16HBE 14o- and CFBE 41o- lines were observed to express 
low levels of surface CFTR stain, similarly to HLMVEC (Chapter 3). Higher levels of 
cytoplasmic CFTR was detected within 16HBE 14o- than CFBE 41o-. Interestingly, CFTR 
was located in cell vesicles neighbouring the nucleus, indicating ER. However, to find 
out what is the exact cellular location of CFTR in the given cell lines, specific markers of 
intracellular organelles, such as ER (calnexin), trans Golgi network (58K-9), endosomes 
(Rab4) (Drevillon et al, 2011) or lysosomes (LAMP-1) (Luciani et al, 2010) should be 
used. However, mature CFTR can travel continually between the apical plasma 
membrane and the recycling endosome (Rab11 and EHD1) (Drevillon et al, 2011). 
Therefore, the protein distribution depends on conditions, such as cell type, 
differentiation and phosphorylation (Bertrand & Frizzell, 2003). Moreover, the 
epithelial cells in the current study were not polarized, which can be achieved by 
growing them on permeable filters (Denning et al, 1992a; Denning et al, 1992b). 
Indeed, epithelial and endothelial cells (Chapter 3) were grown on collagen IV-coated 
chamber slides in submerged culture. 
Stop mutations, such as G542X or W1282X, are the class I of CFTR mutations that 
consist of only about 5 % of total mutations, resulting in most severe CF phenotype 
(Chapter 1). It was previously demonstrated that, after topical gentamicin treatment, a 
significant increase in peripheral and surface staining for CFTR was observed in the 
nasal epithelial cells of patients carrying stop mutations in vivo (Wilschansky et al, 
2003). Indeed, gentamycin was proposed to reduce translation fidelity, caused mRNA 
misreading and insertion of alternative amino acids at the site of mutated codons. In 
contrast, the studies of Clancy et al (2007) indicated no difference observed in CFTR 
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expression of nasal epithelial cells obtained from both healthy and CF subjects carrying 
heterozygous CFTR stop mutations before and during aminoglycoside (tobramycin and 
gentamycin) treatment in vivo. The study of Wilschansky et al (2003) was carried out 
on homozygous epithelial cells and the local concentrations of drugs used were higher 
by using single drops (0.9 mg daily) compared to the research done using an inefficient 
spray system (1.8 mg daily) by Clancy et al (2007). These disparities could be 
responsible for the different effect of aminoglycosides on epithelial CFTR level. 
However, the nasal epithelium demonstrates different pattern of gene expression 
compared to bronchial epithelium, therefore it is not recommended for assessing the 
effect of a new treatment on inflammation in the lung (Ogilvie et al, 2011). 
In the current study, the role of tobramycin and its complex with copper was examined 
on the ΔF508 mutation in vitro. Importantly, the ΔF508 mutation is the most common 
CFTR mutation, belonging to the class II of CFTR mutations. Here, tobramycin at 0.1 
mM upregulated the level of CFTR in both normal and CF epithelial cells in one of the 
mechanisms discussed below. Also, copper-tobramycin at 0.5 mM had a similar 
enhancing effect within 16HBE 14o-, but not within CFBE 41o-. Copper-tobramycin at 
the top concentration may therefore induce CF epithelial cells apoptosis, which could 
be indicated by nuclear granularity and possible DNA condensation. However, an 
assessment of epithelial cell viability (16HBE 14o- and CFBE 41o-) in the presence of 
used drugs has to be carried out.  
Moreover, tobramycin and copper-tobramycin should be examined in terms of 
correcting CFTR function by measuring the transepithelial electric potential difference 
across ΔF508-CFTR-transfected epithelial cells and/or epithelial cells isolated from 
patients carrying the ΔF508 mutation. Also, specific CFTR inhibitors (CFTRinh-172 or 
GlyH-101) could be used to indicate that Cl- movement across the membrane is via 
CFTR. 
CFTR expression is susceptible to oxidative stress and subsequent degradation (Cantin 
et al, 2006). Epithelial cells and/or culture medium are assumed to contain copper, 
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which is exchangeable and binds tobramycin to give a copper-tobramycin complexes. 
Copper-tobramycin is therefore believed to be an antioxidant that should increase 
CFTR expression. Tobramycin and copper-tobramycin could interfere in at least two 
steps of the CFTR cycle of maturation, trafficking and plasma membrane insertion and 
degradation process (Figure 6.7).  
 
 
Figure 6.7. Intracellular locations of CFTR during maturation, plasma membrane insertion and 
degradation. Properly folded, nascent CFTR leaves the rough endoplasmic reticulum and travels through 
the Golgi, where it undergoes glycosylation to mature protein. Mature CFTR leaves the Golgi in vesicles 
that can travel directly to the apical plasma membrane or to the recycling endosome. CFTR-containing 
vesicles continually traffic between recycling endosomes and plasma membrane. CFTR eventually 
follows the late endosome-to-lysosome pathway for degradation. Misfolded CFTR mutants and 
significant wildtype nascent CFTRs are degraded by the proteosome (Bertrand & Frizzell, 2003). 
Tobramycin and copper-tobramycin could inhibit the proteosomal degradation of 
CFTR. Indeed, several copper-binding compounds have been found to spontaneously 
complex with copper and form active proteasome inhibitors and apoptosis inducers 
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(Daniel et al, 2007). For example, a copper chelator, disulfiram, induces apoptotic cell 
death in breast cancer cultures and xenografts via inhibition of the proteasome activity 
(Chen et al, 2006). Misfolded, damaged or mutant proteins are eliminated by ERAD via 
the ubiquitin proteasome system. Ubiquitination is essential for proteasome 
degradation and endosomal recycling of native CFTR from the plasma membrane 
(Belcher & Vij, 2010; Ward et al, 1995). Interestingly, ubiquitination is also inhibited by 
copper chelators and may increase intracellular and membrane-associated CFTR. 
Clioquinol (5-chloro-7-iodo-quinolin-8-ol), an anti-cancer drug, inhibits ubiquitination 
in a Cu(II)-dependent manner (Choi et al, 2006) and it is capable of directly inhibiting 
the proteasome at higher concentrations (Schimmer et al, 2011). The copper 
metabolism gene MURR1 domain 1 (COMMD1) is involved in copper metabolism and 
was suggested to inhibit proteasomal degradation, thereby affecting protein trafficking 
(Drevillon et al, 2011). Tobramycin as a copper-binding compound (Chapter 2) could 
have the same role as disulfiram, clioquinol or COMMD1 and therefore increase 
intracellular CFTR protein in the epithelial cells and restore CFTR on the HLMVEC 
membrane (Chapter 3). 
To find out whether tobramycin and copper-tobramycin inhibits the endothelial 
proteasome, immunoprecipitation of ubiquitin immunoreactive polypeptides with 
CFTR antibody could be done in a similar way to the study of Ward et al (1995), 
followed by separating and immunoblotting CFTR immunoprecipitates with a 
polyclonal ubiquitin antibody. Ward and co-workers used two potent inhibitors of the 
20S proteasome, N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal and lactacystin, which 
could be now compared with tobramycin and copper-tobramycin. 
Alternatively, tobramycin and copper-tobramycin could promote CFTR escape from ER, 
thus working as correctors. Correctors may be a useful tool in the treatment of CF 
caused by the ΔF508 mutation (Pedemonte et al, 2005). Curcumin, has also been 
described as CFTR corrector, which works by eliciting increased CFTR traffic towards 
the plasma membrane (Egan et al, 2004). Interestingly, curcumin was reported to have 
anti-inflammatory properties (Bachmeier et al, 2008; Takahashi et al, 2007). Moreover, 
curcumin binds copper and the Cu(II)-curcumin complex possesses SOD activity, free 
radical neutralizing ability and antioxidant potential (Barik et al, 2005). Therefore in 
these properties, curcumin resembles copper-tobramycin. 
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CHAPTER 7 
FROM BENCH TO BEDSIDE 
Tobramycin is a natural aminoglycoside antibiotic, isolated from Streptomyces 
tenebrarius and discovered in 1967. It has higher in vitro activity than other 
aminoglycosides against Pseudomonas aeruginosa strains (Laxer et al, 1975; Koch et al, 
1973). The study of Ramsey et al (1999) shows that long-term, intermittent 
administration of inhaled tobramycin in addition to standard therapy for CF improves 
pulmonary function, decreases P. aeruginosa colonisation and reduces the 
requirement for intravenous antipseudomonal antibiotics as well as hospital 
admissions. Tobramycin inhalation therapy is also clinically effective for severe non-
cystic fibrosis bronchiestasis patients who present with increased density of P. 
aeruginosa in expectorated sputum (Schienberg & Shore, 2005). Inhaled tobramycin 
was shown to not only reduce P. aeruginosa counts in sputum over a 28 day cycle, but 
also to reduce levels of inflammatory cytokines IL-8, IL-6, TNF-α, as a consequence. 
This study did not however rule out a direct effect of tobramycin on epithelial cells 
(Husson et al, 2005). 
In addition to its known antibacterial activity, inhaled tobramycin was suggested to 
have an anti-inflammatory effect, although the mechanism was not known (Ramsey et 
al, 1999). Also, CF patients may improve clinically, as measured by lung function, FEV1, 
even if P. areuginosa is present in their sputum and not fully sensitive to the antibiotics 
they have received (Smith et al, 2003). Subsequently, Nakamura and co-workers (2011) 
reported that high-dose tobramycin inhibits LPS-induced MUC5AC production in 
human lung epithelial cells, presumably because positively charged tobramycin binds 
negatively charged LPS and neutralises its effect. Furthermore, the results of Cantin 
and Woods (1993) indicated that tobramycin and gentamicin protected lung epithelial 
cells against MPO-dependent oxidant injury by binding to anionic cell surfaces and 
converting HOCI to hydrophilic noncytotoxic chloramines. Additionally, tobramycin 
completely inhibited epithelial cell cytotoxicity induced by CF sputum and H2O2 (Cantin 
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& Woods, 1993). Vancomycin and tobramycin at high concentrations also had relaxing 
effects on vascular smooth muscle in vitro suggesting a protective role on NO (Richter 
et al, 2010). These results clearly indicate the anti-oxidant effects of tobramycin.  
The study of Geller et al (2002) evaluated the high sputum and low serum 
concentrations of aerosolised tobramycin that were achieved when administered as 
300 mg dose in a regime of 28 days off/28 days on. Mean sputum tobramycin 
concentrations measured 10 minutes after administration of the first dose of 
tobramycin for inhalation were approximately 1237 µg/g (~2 mM), while the mean 
serum tobramycin concentration at 1 hour after the administration of aerosolised 
tobramycin for inhalation was approximately 1 µg/ml (~2 µM) (Geller et al, 2002). In 
comparison, the serum concentration of tobramycin 30 minutes after intravenous 
administration of 2.71 ± 0.38 mg/kg was 10.2 ± 1.2 µg/ml (~20 µM) (Roberts et al, 
1993). However, parenteral aminoglycosides are highly polar and penetrate poorly into 
the endobronchial space, resulting in 1.07 – 2.2 µg/ml (~2 – 4 µM) tobramycin in the 
airways (Hoogkamp-Korstanje & van der Laag, 1983). 
The clinical use of intravenous aminoglycoside antibiotics results in side effects, 
including ototoxicity and nephrotoxicity, but the participation of free radicals in the 
adverse renal and cochlear side effects of aminoglycoside antibiotics is controversial 
(Priuska & Schacht, 1995). Gentamicin was shown to enhance the production of 
hydrogen peroxide in renal mitochondria (Walker & Shah, 1987). Free radicals are also 
rapidly produced by avian hair cells in vitro after exposure to gentamicin. A number of 
studies have demonstrated a protective effect of antioxidants (Hirose et al, 1997). 
However, since chelators can enhance iron-catalyzed oxidations, it was suggested that 
gentamicin-dependent radical formation was based upon iron chelation (Priuska & 
Schacht, 1995). The ability of aminoglycosides to bind Cu(II) is also thought to be 
responsible for aminoglycoside toxicity (Gaggelli et al, 2010). 
Aminoglycosides themselves are redox-inactive. They need a specific medium to 
participate in the oxidative pathway, where metal ions are present (Sczepanik et al, 
2004b). Some unique activities of aminoglycosides depend on metal ions (Kozlowski et 
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al, 2005). The binding of iron to gentamicin has been postulated to induce free radical 
formation, responsible for the peroxidation of lipids (Priuska et al, 1998). An 
erythromycin-iron complex was observed to exhibit superoxide scavenging activity, 
which was not seen for the antibiotic without the metal (Muranaka et al, 1997). The 
Cu2+-aminoglycoside complexes are observed to exhibit oxidative activity, which can 
catalyse oxidation of nucleotides in the presence of H2O2 in vitro (Szczepanik et al, 
2003, Jezowska-Bojczuk et al, 2001a, Jezowska-Bojczuk & Lesniak, 2001). Hygromycin B 
in the presence of Cu(II) was found to damage extracellular DNA in vitro (Gaggelli et al, 
2010).  
Interestingly, tobramycin can inhibit the activity of copper-dependent enzymes. 
Indeed, tobramycin and vancomycin significantly inhibited, while their combination 
almost completely abolished copper-dependent acid sphingomyelinase activity in the 
renal cortices of rats (Beauchamp et al, 1990). Acid sphingomyelinase generates 
ceramide from sphingomyelin. It has been reported that ceramide is both increased 
(Becker et al, 2010) and decreased (Guilbault et al, 2009) in CF. Increased ceramide has 
been associated with lung inflammation in CF (Becker et al, 2010), while decreased 
ceramide has been associated with defective host defences against Pseudomonas 
(Guilbault et al, 2009). Decreased levels of ceramide in CF may also contribute to the 
known defect in neutrophil apoptosis in CF (Seumois et al, 2007). The contribution of 
tobramycin therapy to these changes in ceramide levels is unknown, but tobramycin 
may be associated with the inhibition of acid sphingomyelinase, reduced ceramide 
levels and defective apoptosis. Conversely, copper-tobramycin would not be expected 
to have these effects. 
The use of aminoglycosides is variably associated with the side effects of ototoxicity 
and nephrotoxicity (Talaska & Schacht, 2007). Oxidative stress has been suggested to 
have a key role in these processes, but the mechanism for aminoglycoside-induced 
ROS formation is not known. Several mechanisms have been suggested, including the 
binding of metal ions to aminoglycosides and, in particular, the binding of Fe2+ ions to 
gentamicin. However, several physio-chemical factors mitigate against this being a 
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likely mechanism under physiological conditions (Talaska & Schacht, 2007). Another 
mechanism, that has been proposed for ROS formation is the activation by 
aminoglycosides of Rac-1, a member of the family of Rho-GTPases with subsequent 
activation of the NADPH oxidase complex. In fact, the evidence presented in this thesis 
indicates that a copper complex of tobramycin has antioxidant properties and would 
protect against ROS formation via any mechanism and the subsequent toxic effects on 
cells of the inner ear and renal epithelial and endothelial cells (Lopez-Novoa et al, 
2011). 
Two opposite structural changes have been described in the CF lung. Firstly, 
bronchiectasis, which is a common result of an early protease/anti-protease imbalance 
in CF and, secondly, fibrotic changes, which may be associated with end-stage lung 
disease (Regamey et al, 2011). The bronchectasis changes have been related to 
inflammation and anti-inflammatory therapeutic approaches to reduce the protease 
burden in the lung are suggested (Rottner et al, 2011). This study has shown that 
copper-tobramycin can displace elastase from sites of encryption on the neutrophil 
membrane making the enzyme susceptible to inhibition by endogenous anti-proteases, 
such as α1-AT. Indirectly, therefore, copper-tobramycin may redress the 
protease/antiprotease imbalance.  
Preliminary data has shown that tobramycin can inhibit the copper-dependent enzyme 
lysyl-oxidase, which is essential for cross-linking newly synthesized elastin and collagen 
fibres and therefore the tissue matrix repair process. Thus tobramycin may limit 
bronchial tissue repair and contribute to the development of bronchiectasis. 
Similarly, decreased Cu/Zn-SOD and SOD3 activity in mononuclear and 
polymorphonuclear cells detected in CF patients (Percival et al, 1999) could be an 
effect of tobramycin use. However, due to diminished SOD3 activity in CF lung (Rottner 
et al, 2011), copper-tobramycin could be considered as a replacement therapy. 
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Moreover, tobramycin and other aminoglycoside antibiotics prescribed in CF patients 
were shown to trigger hypomagnesaemia (Adams et al, 1998), which inhibits 
magnesium-dependent DNAse I activity (Sanders et al, 2006). 
This study tested the hypothesis that tobramycin binds copper and becomes a copper-
tobramycin complex with anti-inflammatory properties. In the view of the current 
study, it appears that tobramycin chelates copper present in the cell culture medium 
and/or cells and forms a safe storage depot for copper. It is also proposed that 
tobramycin is a pro-drug for the copper-tobramycin complex, which has anti-
inflammatory and antioxidant effects not seen in tobramycin. 
 
Azithromycin, a macrolide antibiotic with anti-inflammatory activity was shown to 
chelate copper in vitro (Sher et al, 1994). The results of Szczepanik et al, (2004a) have 
shown that the aminoglycoside kanamycin A has higher affinity for Cu(II) ions than 
other metal ions, which may be available biologically or accessible following the 
contamination. Moreover, it was suggested that copper(II) complexes of 
aminoglycosides can easily be formed in vivo, in blood plasma by withdrawing of the 
metal bound to human serum albumin (Szczepanik et al, 2004a).  
Although, the blood plasma copper levels in healthy humans are 808.8 ± 80.0 µg/l 
(12.84 ± 1.27 µM), copper levels in the circulation of adult men with CF are significantly 
elevated at  1205.9 ± 255.4 µg/l (19.14 ± 4.05 µM) (Percival et al, 1999). The majority 
of copper in the human blood is bound to ceruloplasmin (65 %), while, albumin and 
transcuprein bind 18 % and 12 % of plasma copper, respectively. Cells take up copper 
from all these pools, but copper bound to albumin and transcuprein appears to be the 
primary component of the exchangeable plasma copper pool. The remaining 5 % of 
copper is associated with small peptides and amino acids (Linder & Hazegh-Azam, 
1996). 
Intravenously administered tobramycin is predicted to bind with the maximum of 30 % 
of exchangeable endogenous copper. However, the concentration and therefore 
availability of copper in the blood could be increased by wearing copper bracelets and 
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in this way increase the efficacy of tobramycin as an anti-inflammatory agent. Indeed, 
clinical trials using copper bracelets and Cu(II) salicylate complexes together showed 
efficacy in arthritis (Walker et al, 1981). Moreover, the kanamycin B, amikacin and 
tobramycin complexes with Cu(II) are more stable in lower pH (Gokhale et al, 2007), 
which is usually found in CF airway surface fluid and organelles of CF respiratory 
epithelial cells  (Poschet et al, 2002).  
Previous in vitro studies demonstrated that the complex of salicylic acid with Cu(II) 
could not exist in plasma (Arena et al, 1978), presumably because of its stability 
constant of 10.60 (Furia, 1972) similar to the one reported for Cu(II)-HSA, 11.18 
(Masuoka et al, 1993). For comparison, a pKD for copper-tobramycin equal to 7.44 was 
proposed by Jezowska-Bojczuk et al (1998) and 4.30 in the current research (Chapter 
2). Because tobramycin forms a stronger complex with copper than salicylic acid, it is 
more likely that tobramycin would pull copper from albumin, not salicylate. However, 
copper-tobramycin administered in a pre-formed complex might exert a better anti-
inflammatory effect than tobramycin alone. Conversely, a Cu(II)-salicylic acid complex 
did not have a different therapeutic effect when administered parenterally pre-formed 
or as a mixture of its individual components at equivalent concentrations, but the 
preformed complex was postulated to exhibit a greatly enhanced bioavailability (Arena 
et al, 1978).  
An intravenous route for copper-tobramycin administration in CF lung disease to 
achieve of final blood level of 20 µM, would be beneficial because TEM of PMNs takes 
place through the blood vessel wall, where the anti-inflammatory and anti-oxidant 
potential of copper-tobramycin is observed. Indeed, the IC50 for copper-tobramycin in 
neutrophil oxidative stress was calculated as 2.5 µM (Figure 4.4B) and in endothelial 
oxidative stress below 10 µM (Figure 4.37). Moreover, intravenous copper-tobramycin 
could exert its SOD-like activity in the sputum, if it achieves the same final 
concentration as tobramycin (~2 µM). Indeed, copper-tobramycin exerts its SOD-like 
activity at levels as low as 0.2 µM, as demonstrated in a cell-free system.  
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Copper-tobramycin could be also administered via inhalation and also reach 
approximately 2 µM in serum, depending on a dose. Copper levels were shown to be 
increased in CF sputum (0.3 µM) compared to healthy control (0.135 µM) (Gray et al, 
2010). The source of copper is not known, however, sputum microorganisms, such as 
P. aeruginosa (Marks et al, 2004) and Aspergillus are likely to contain copper in a small 
copper protein, azurin and in the membrane, respectively (Tsekova &Todorova, 2002). 
The inhalation approach could achieve copper-tobramycin sputum concentrations of 
about 2 mM, if administered in the same dose as tobramycin. Importantly, copper-
tobramycin was shown to be equally effective as tobramycin in inhibiting bacterial 
growth within 72 hours (unpublished results).  
Copper complexes were shown to be much more effective than their parent drugs 
(Sorenson et al, 1989). High-dose non-steroidal anti-inflammatory drugs, mainly 
ibuprofen, can slow the progression of lung damage in CF, especially in children (Lands 
& Stanojevic, 2007). Interestingly, Cu(II) complexes with NSAIDs were shown to be 
more effective and less toxic than their parent drugs (Weder et al, 2002). Indeed, 
copper-tobramycin might be devoid of the side effects characteristic for tobramycin, 
because it already contains copper within the complex and it would not inhibit copper-
dependent (SOD, lysyl oxidase, sphingomyelinase, tyrosinase) and magnesium-
dependent (DNase I) enzymes. Moreover, copper-tobramycin is an antioxidant and 
therefore protective. 
Roberts and Robinson (1984) proved that copper-conjugates of NSAIDs have SOD-like 
activity, similar to copper-tobramycin. Of them, Alcusal® is still available commercially 
(Weder et al, 2002).  
Preclinical studies revealed that endogenous EC-SOD had a protective effect in animal 
models of lung inflammation (Bowler et al, 2004), asthma (Bowler & Crapo, 2002) or 
COPD (Barnes, 2000). Also, the use of the native enzymes in clinical trials supported 
the concept that removal of superoxide had a beneficial outcome. For example, 
Orgotenin® (bovine Cu/Zn-SOD) showed promising results in human rheumatoid 
arthritis (Goebel et al, 1981). However, there were drawbacks associated with its use. 
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The main problem was the nonhuman origin of the enzyme, causing a variety of 
immunological problems (Muscoli et al, 2003). Therefore, a recombinant human 
Cu/Zn-SOD was indicated to decrease early pulmonary injury due to 
bronchopulmonary dysplasia, resulting in improved pulmonary outcome in premature 
infants (Davis et al, 2003). However, natural human Cu/Zn-SOD is a large molecule (135 
kDa) (Marklund, 1982). Its diffusibility through most living tissues is low and is almost 
negligible through cellular membranes. In the view of potential therapeutic uses, in 
which a greater ability to diffuse through tissues and capacity of intracellular uptake 
are required, low molecular weight SOD mimics might be beneficial. Such non-
enzymatic systems should reach deeper and faster their targets (Lapluye, 1990). SOD 
mimetics, such as M40403 and SC-55858 were shown to have anti-inflammatory 
properties in a rat model of inflammation (Salvemini et al, 2001; Salvemini et al, 1999). 
In addition, MnTBAP, which is a synthetic metalloporphyrin with anti-oxidant action 
prevented the generation of intracellular ROS in LPS-stimulated RAW 264.7 
macrophage cells (Tumurkhuu et al, 2007).  
Although superoxide is implicated in neutrophil migration and bacterial phagocytosis, 
it plays a central role in generating other ROS in the human body, contributing to cell 
and matrix damage and therefore to the pathogenesis of many inflammatory lung 
diseases (Rahman et al, 2006). For instance, superoxide can immediately react with 
NO, an important signal molecule and endothelial-derived vasodilator, which also 
decreases platelet aggregation, to form peroxynitrite. This reaction depletes NO 
bioactivity and peroxynitrite has detrimental effects on vascular function, by the 
oxidation of cellular proteins and lipids (Guzik et al, 2002). Therefore, copper-
tobramycin might be a better drug than tobramycin to protect the bioactivity of NO 
(Richter et al, 2010). 
In the presence of copper-tobramycin, superoxide ion cannot be converted to its toxic 
intermediates, including peroxynitrite and, especially because copper-tobramycin was 
demonstrated not to accumulate within neutrophils, it could act as extracellular ROS 
scavenger or an inhibitor of NADPH oxidase. Additionally, copper-tobramycin is not a 
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true SOD or SOD-mimetic, as it had no effect on extracellular H2O2 concentrations, 
which may be expected following dismutation of superoxide ions. However, inhaled or 
intravenous copper-tobramycin could be used as SOD3 replacement therapy in CF, 
additionally offering other multiple effects. 
Preliminary data demonstrated that copper-tobramycin degraded extracellular DNA, 
indicating another possible therapeutic application of copper-tobramycin. Similarly to 
inhaled human recombinant DNase (Fuchs et al, 1994), it could be considered as a 
useful mucolytic agent in CF.  
Importantly, this study suggested that tobramycin and copper-tobramycin entered the 
human endothelium, and presumably epithelium, via HS binding, which precedes its 
accumulation within the cell cytoplasm and in the perinuclear area. Also, both 
endothelial and epithelial cells were previously demonstrated to express CFTR 
(Tousson et al, 1998; Puchelle et al, 1992). Tobramycin and copper-tobramycin were 
shown in the current study to increase the level of epithelial and endothelial CFTR 
expression as well as endothelial surface CFTR level, which is predicted to have an anti-
inflammatory effect. A functional CFTR was demonstrated to suppress NF-κB activation 
in inflammatory signalling in epithelial cells and IL-8 expression (Verhaeghe et al, 
2007). Tobramycin and copper-tobramycin are suggested to inhibit proteasomal 
degradation of CFTR or correct defective ΔF508-CFTR folding or cellular processing, 
thus working as a CFTR corrector. Curcumin is a well known CFTR corrector (Egan et al, 
2004). Curcumin has been recognised to express anti-inflammatory properties 
(Bachmeier et al, 2008; Takahashi et al, 2007), being a free radical scavenger and 
hydrogen donor with both anti- and pro-oxidant activity, respectively. It also binds 
metals, particularly iron and copper (Hatcher et al, 2008). Moreover, Cu(II)-curcumin 
complexes possesses SOD activity, free radical neutralizing ability and antioxidant 
potential (Barik et al, 2005). Copper-tobramycin actions are therefore similar to those 
of curcumin, but copper-tobramycin is believed not to be a hydrogen donor, because it 
had no effect on extracellular H2O2. Moreover, the pro-inflammatory effects of copper-
tobramycin were not observed in this project. Importantly, rescued ΔF508-CFTR in 
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epithelial cells is less stable than wild-type CFTR (Hoelen et al, 2010). Therefore to 
maintain the effect of copper-tobramycin on CFTR, regulation of the channel gating by 
agents, small molecule CFTR potentiators, such as genistein (Hwang et al, 1997) or 
capsaicin (Ai et al, 2004) would be required together with the copper-tobramycin 
complex administered parenterally. 
Copper-tobramycin was shown to displace NE from its sites of encryption, making it 
more susceptible for inhibition by α1-AT, which could be derived from activated 
neutrophils or the serum in vitro and in vivo. Additionally, α1-AT secretion is believed 
not to be impaired in CF and functions normally (Cantin et al, 1992), but another 
report revealed that α1-AT was partly oxidized and could be proteolytically inactivated 
(Cantin & Bilodeau, 1989). Copper-tobramycin potentially protects α1-AT from 
proteolysis and ROS-mediated degradation. These actions of copper-tobramycin may 
improve the protease/antiprotease imbalance observed in CF patients (Birrer et al, 
1994). Several studies indicate a promising role of α1-AT inhalation therapy, reducing 
airway inflammation in patients with CF (Griese et al, 2007, McElvaney et al, 1991). 
Therefore, inhaled α1-AT could be used in a combination with inhaled copper-
tobramycin therapy as an important improvement of CF therapy. 
To summarise, since there is no satisfactory anti-inflammatory therapy for lung disease 
in CF, tobramycin beyond being an effective antibiotic, might fill the niche of anti-
inflammatory treatment in CF. It exerts further multiple roles, including anti-oxidant, 
anti-inflammatory and possibly anti-mucolytic due to binding with copper. 
Importantly, tobramycin may increase CFTR protein in vivo as observed in cell culture 
experiments. Intravenous tobramycin could therefore serve as a pro-drug for copper-
tobramycin, together with copper bracelets to increase the pool of available 
endogenous copper. Alternatively, pre-formed copper-tobramycin might be 
administered intravenously or via inhalation; however it should be closely monitored 
for possible toxic effects. 
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APPENDIX 
Partial dissociation of the complex “MLH” to M, LH, L- and H+ 
M – metal, LH – weakly acidic ligand 
MLH ↔ M + LH                           KD1 
       
     
                      (1) 
MLH ↔ ML- + H+                         Ka1 
         
     
                   (2) 
ML- ↔ M + L-                               KD2 
       
     
                       (3) 
LH ↔ L- + H+                                 Ka2 
        
    
                     (4) 
First calculation: Reactions 2 and 3 are ignored. The aim is to estimate the 
concentration of undissociated complex in a solution prepared from a pure sample, 
allowing for partial dissociation to free metal and partly ionised ligand: 
MLH ↔ M + LH                           KD1 
       
     
                      (1) 
LH ↔ L- + H+                                 Ka2 
        
    
                    (4) 
Second calculation: All four steps are included, but simplified: 
 Both MLH and ML- have the same molar absorbance, εcomplex 
 Ka1 = Ka2, denoted Ka and KD1 = KD2, denoted KD 
The same calculation would apply if the ligand was protonated from a weak base, i.e: 
MLH+ ↔ M + LH+                  (1a) 
LH+ ↔ L + H+                          (4a) 
Let the prepared concentration (molar) of MLH be “c” 
Let the equilibrium concentration of M be “y”  
                                  the equilibrium concentration of MLH is “c-y” 
Let the equilibrium concentration of H+ be “x” 
                                  the equilibrium concentration of L- is “x” and the equilibrium  
                                   concentration of LH is “y-x” 
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KD 
      
   
     (5)          Ka 
  
   
     (6)         
 Rearrange to: y 
  
  
             and substitute y in (5) 
    
      
   
  
 
  
  
     
  
  
      
    
  
  
    
  
   
  
  
    
      
  
  
    
      (7)   
Multiply out:              
         
  
  
         
Rearrange to:     
 
  
            
                  
Factorise:        
  
  
      +    
                      
     
  
  
           
  
  
             
 
  
  
       
                       (8) 
If we have values of Ka and KD, then the equation can be solved (in principle) for any 
chosen value c to give x, and then y is obtained by substituting back. Polynominal 
equations were here solved by making reasonable approximations: 
For example: 
Ka = 1 x 10
-6 M (pKA = 6.0) 
KD= 1 x 10
-4 M 
c = 6.25 mM = 0.00625 M 
 
  
  
       
                       (8) 
 
  
    
                                      
                                       
              and                               
                   
                
                
              M 
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y is calculated from the ionization of LH: 
   
  
   
    (6) 
Rearrange to:    y 
  
  
    
y 
           
 
    
                        M 
The percentage reduction in the concentration of MLH, and hence in the absorbance 
of the solution: 
 
 
       
           
         
            
               
    
   
           M 
Correction for ε is:   
         
         
        M-1cm-1 
Corrected ε is 1062            M-1cm-1 
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Calculating dissociation constant for the copper-tobramycin complex 
[M0] = 0.78125 x 10
-3 M 
[T]T = 0.78125 x 10
-3 M 
A0 = 0.024151 (0.78125 mM CuSO4 + 0 mM Tob) 
AT = 0.38129 (0.78125 mM CuSO4 + 0.78125 mM Tob) 
ε250 = 1229 M
-1cm-1 
 
ACuSO4+Tob = ACuSO4 + ACuT 
AT = AM + AML 
AML = AT – A0 = 0.38129 – 0.024151 = 0.357139  
[ML]` = 
   –  
   
 = 
        
          
 = 0.58119 x 10-3 M     
[M]` = [M]0 – [ML]` = 0.78125 x 10
-3 – 0.58119 x 10-3 = 0.20006 x 10-3 M 
AAL = A0 x 
   
    
 = 0.024151 x 
       
       
 = 0.0061845 (adjusted baseline) 
[ML] = 
   –  
ε  
 = 
                 
          
 = 0.610424 x 10-3 M 
[M] = [M0] – [ML]` = 0.78125 x 10
-3 – 0.610424 x 10-3 = 0.170826 x 10-3 M 
[L] = [T]T – [ML] = 0.78125 x 10
-3 – 0.610424 x 10-3 = 0.170826 x 10-3 M 
KD = 
      
    
 = 
                                 
               
 = 0.048 mM 
pKD = - log KD 
pKD = 4.301 
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